<SEC-DOCUMENT>0001043961-17-000018.txt : 20170822
<SEC-HEADER>0001043961-17-000018.hdr.sgml : 20170822
<ACCEPTANCE-DATETIME>20170821174013
ACCESSION NUMBER:		0001043961-17-000018
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20170630
FILED AS OF DATE:		20170822
DATE AS OF CHANGE:		20170821

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		171043804

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		4027385480

	MAIL ADDRESS:	
		STREET 1:		12325 EMMET STREET
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>prpo-20170630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4D80CE84B6F554F08E335EFF484B4D8E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">10-Q</font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended June 30, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">OR</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from _____ to _____</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: 001-36439</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">PRECIPIO, INC.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:83.203125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:47%;"></td><td style="width:5%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">91-1789357</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="padding-bottom:1px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4 Science Park, New Haven, CT </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">06511</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(203) 787-7888</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;_______________________________</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x </font><font style="font-family:inherit;font-size:10pt;">No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x </font><font style="font-family:inherit;font-size:10pt;">No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.5078125%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:46%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;(Do not check if a smaller reporting company)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;padding-top:4px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of August 16, 2017, the number of shares of common stock outstanding was </font><font style="font-family:inherit;font-size:10pt;">6,407,860</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s0B41536D70595A8FACE3BDDB381D9B60"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC.</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:83%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Page&#160;No.&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;I.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sB365CD2CD6105808AEAB923214D67E56"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB365CD2CD6105808AEAB923214D67E56"> 3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s93011EA8297B5BB5916ED2A8916C2E89"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s93011EA8297B5BB5916ED2A8916C2E89"> 3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDB5A7AB1013E5118B2E926D7178FBE80"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets at June 30, 2017 (Unaudited) and December 31, 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDB5A7AB1013E5118B2E926D7178FBE80"> 3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0354E3E3001259AEAAD569D5147E74B5"><font style="font-family:inherit;font-size:10pt;">Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30,&#160;2017 and 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s14A2FECF29905D9DB1B3D49F1B3DAD9D"> 4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2171DFCE863156428315A7449AC8E295"><font style="font-family:inherit;font-size:10pt;">Unaudited Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Six Months Ended June 30,&#160;2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2171DFCE863156428315A7449AC8E295"> 5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9CFEE127B03257608FC4EA461E110F7C"><font style="font-family:inherit;font-size:10pt;">Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30,&#160;2017 and 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9CFEE127B03257608FC4EA461E110F7C"> 6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AA4061B1DB4583789DD7F47A146BC5B"><font style="font-family:inherit;font-size:10pt;">Notes to Unaudited Condensed Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;2.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9824F83781BC5DED9D50BF2A5A1AEDD8"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9824F83781BC5DED9D50BF2A5A1AEDD8"> 28</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6A3C871B25CC53CD8F0C1F38D3CE8EE7"> 34</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;4.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s957689494F765D44BBBE817074D0DD7B"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s957689494F765D44BBBE817074D0DD7B"> 34</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s5FD994F1FD275EA6898AD5671EE3E65D"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5FD994F1FD275EA6898AD5671EE3E65D"> 36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s076A0F8DD2095797AABF3AE847836BE9"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s076A0F8DD2095797AABF3AE847836BE9"> 36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;1A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE6F43987BB6853A28AEB15D5BF659761"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE6F43987BB6853A28AEB15D5BF659761"> 36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item&#160;6.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4FA28EE63B8F5CF9B9C1906D06A902EC"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4FA28EE63B8F5CF9B9C1906D06A902EC"> 51</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sB790CFCABC7D58CF9FFAB0C86DFF0213"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB790CFCABC7D58CF9FFAB0C86DFF0213"> 53</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;2</font></div></div><hr style="page-break-after:always"><div><a name="sB365CD2CD6105808AEAB923214D67E56"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="s93011EA8297B5BB5916ED2A8916C2E89"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Financial Statements</font></div></td></tr></table><div><a name="sDB5A7AB1013E5118B2E926D7178FBE80"></a></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Dollars in thousands, except share data)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT ASSETS:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">154</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROPERTY AND EQUIPMENT, NET</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER ASSETS:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,832</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,010</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT LIABILITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current maturities of long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">395</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible bridge notes, less debt discounts and debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,328</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,084</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current maturities of capital leases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,521</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,528</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LONG TERM LIABILITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, less current maturities and discounts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital leases, less current maturities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY (DEFICIT):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock - $0.01 par value, 15,000,000 and 1,294,434 shares authorized at June 30, 2017 and December 31, 2016, respectively, 1,712,901 and 780,105 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.01 par value, 150,000,000 and 1,806,850 shares authorized at June 30, 2017 and December 31, 2016, respectively, 6,407,860 and 449,175 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital  </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,287</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,848</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity (deficit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,769</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,460</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,010</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;3</font></div></div><hr style="page-break-after:always"><div><a name="s14A2FECF29905D9DB1B3D49F1B3DAD9D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Dollars in thousands, except per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SALES</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patient service revenue, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">619</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,271</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">less provision for bad debts</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(56</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(229</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">508</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,042</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COST OF DIAGNOSTIC SERVICES</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">466</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">479</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OPERATING EXPENSES</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">777</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">548</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OPERATING LOSS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(801</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,398</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(513</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INCOME (EXPENSE):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(220</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(382</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(242</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant revaluation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merger advisory fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,603</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,879</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LOSS BEFORE INCOME TAXES</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,680</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(752</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INCOME TAX EXPENSE </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NET LOSS </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,680</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(444</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,439</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(752</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DEEMED DIVIDENDS ON ISSUANCE OR EXCHANGE OF PREFERRED UNITS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,248</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,248</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,422</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PREFERRED DIVIDENDS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TOTAL DIVIDENDS</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,855</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,928</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(444</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,607</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:25px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BASIC AND DILUTED LOSS PER COMMON SHARE  </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15.35</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.03</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18.77</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">581,481</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429,819</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515,968</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,217</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;4</font></div></div><hr style="page-break-after:always"><div><a name="s2171DFCE863156428315A7449AC8E295"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">Six Months Ended&#160;<br>&#160;June 30, 2017</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Dollars in thousands)</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:86.93957115009746%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:26%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding<br>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Par<br>Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Par</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional<br>Paid-in<br>Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">780,105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449,175</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,848</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,439</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of warrants into preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,542</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of warrants into common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,958,166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of preferred stock into common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(788,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">788,647</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of Senior and Junior debt into preferred stock and common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802,920</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,414,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,749</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of bridge notes into common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,639</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock for consulting services in connection with the merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">321,821</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,189</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares issued in connection with business combination</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">802,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,255,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,078</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107,056</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">399</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of warrants in conjunction with issuance of side agreement</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beneficial conversion feature on issuance of bridge notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-cash stock-based compensation and vesting of restricted units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,712,901</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,407,860</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,975</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,769</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;5</font></div></div><hr style="page-break-after:always"><div><a name="s9CFEE127B03257608FC4EA461E110F7C"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Dollars in thousands)</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended&#160;<br>&#160;June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH FLOWS USED IN OPERATING ACTIVITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,439</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash flows used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of deferred financing costs and debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on extinguishment of debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation and change in liability of stock appreciation rights</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merger advisory fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,603</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for losses on doubtful accounts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized PIK interest on convertible bridge notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrant revaluation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(340</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">290</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses and other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(897</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(390</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH FLOWS PROVIDED BY INVESTING ACTIVITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash acquired in business combination</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments on capital lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of preferred stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payment of deferred financing costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from exercise of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from convertible bridge notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,365</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">455</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments on long-term</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(345</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash flows provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,712</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">352</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NET CHANGE IN CASH AND CASH EQUIVALENTS</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CASH AND CASH EQUIVALENTS AT END OF PERIOD</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">967</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">197</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUPPLEMENTAL CASH FLOW INFORMATION</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash paid during the period for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of equipment financed through capital lease</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred unit dividend financed through exchange agreement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">433</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible bridge notes exchanged for long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A and B preferred exchanged for long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,715</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of bridges loans plus interest into common stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conversion of senior and junior notes plus interest into preferred stock and common stock</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beneficial conversion feature on issuance of bridge notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued merger cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of warrants in conjunction with issuance of side agreement</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">414</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See notes to unaudited condensed consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;7</font></div></div><hr style="page-break-after:always"><div><a name="s1AA4061B1DB4583789DD7F47A146BC5B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div><a name="sBE60082FBFD853F28BB890E00793E2E3"></a></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.  BUSINESS DESCRIPTION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Description</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio, Inc., and Subsidiary, (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Precipio&#8221;) is a cancer diagnostics company providing diagnostic products and services to the oncology market. We have built and continue to develop a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory located in New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and technologies developed within academia so that we can provide a better standard of cancer diagnostics and solve the growing problem of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development of ICE-COLD-PCR (&#8220;ICP&#8221;), the patented technology which was exclusively licensed by us from Dana-Farber Cancer Institute, Inc. (&#8220;Dana-Farber&#8221;) at Harvard University (&#8220;Harvard&#8221;). The research and development center will focus on the development of this technology, which we believe will enable us to commercialize other technologies developed by our current and future academic partners. Our platform connects patients, physicians and diagnostic experts residing within academic institutions. Launched in 2017, the platform facilitates the following relationships:</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients: patients may search for physicians in their area and consult directly with academic experts that are on the platform. Patients may also have access to new academic discoveries as they become commercially available.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Physicians: physicians can connect with academic experts to seek consultations on behalf of their patients and may also provide consultations for patients in their area seeking medical expertise in that physician&#8217;s relevant specialty. Physicians will also have access to new diagnostic solutions to help improve diagnostic accuracy.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Academic Experts: academic experts on the platform can make themselves available for patients or physicians seeking access to their expertise. Additionally, these experts have a platform available to commercialize their research discoveries.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to continue updating our platform to allow for patient-to-patient communications and allow individuals to share stories and provide support for one another, to allow physicians to consult with their peers to discuss and share challenges and solutions, and to allow academic experts to interact with others in academia on the platform to discuss their research and cross-collaborate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ICP was developed at Harvard and is licensed exclusively by us from Dana-Farber. The technology enables the detection of genetic mutations in liquid biopsies, such as blood samples. The field of liquid biopsies is a rapidly growing market, aimed at solving the challenge of obtaining genetic information on disease progression and changes from sources other than a tumor biopsy.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gene sequencing is performed on tissue biopsies taken surgically from the tumor site in order to identify potential therapies that will be more effective in treating the patient. There are several limitations to this process. First, surgical procedures have several limitations, including:</font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost: surgical procedures are usually performed in a costly hospital environment. For example, according to a recent study the mean cost of lung biopsies is greater than $14,000; surgery also involves hospitalization and recovery time.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Surgical access: various tumor sites are not always accessible (e.g. brain tumors), in which cases no biopsy is available for diagnosis.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk: patient health may not permit undergoing an invasive surgery; therefore a biopsy cannot be obtained at all.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Time: the process of scheduling and coordinating a surgical procedure often takes time, delaying the start of patient treatment.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second, there are several tumor-related limitations that provide a challenge to obtaining such genetic information from a tumor:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tumors are heterogeneous by nature: a tissue sample from one area of the tumor may not properly represent the tumor&#8217;s entire genetic composition; thus, the diagnostic results from a tumor may be incomplete and non-representative.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Metastases: in order to accurately test a patient with metastatic disease, ideally an individual biopsy sample should be taken from each site (if those sites are even known). These biopsies are very difficult to obtain; therefore physicians often rely on biopsies taken from the primary tumor site.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The advent of technologies enabling liquid biopsies as an alternative to tumor biopsy and analysis is based on the fact that tumors (both primary and metastatic) shed cells and fragments of DNA into the blood stream. These blood samples are called &#8220;liquid biopsies&#8221; that contain circulating tumor DNA, or ctDNA, which hold the same genetic information found in the tumor(s). That tumor DNA is the target of genetic analysis. However, since the quantity of tumor DNA is very small in proportion to the &#8220;normal&#8221; (or &#8220;healthy&#8221;) DNA within the blood stream, there is a need to identify and separate the tumor DNA from the normal DNA.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ICP is an enrichment technology that enables the laboratory to focus its analysis on the tumor DNA by enriching, and thereby &#8220;multiplying&#8221; the presence of, tumor DNA, while maintaining the normal DNA at its same level. Once the enrichment process has been completed, the laboratory genetic testing equipment is able to identify genetic abnormalities presented in the ctDNA, and an analysis can be conducted at a higher level of sensitivity, to enable the detection of such genetic abnormalities. The technology is encapsulated into a chemical that is provided in the form of a kit and sold to other laboratories who wish to conduct these tests in-house. The chemical within the kit is added to the specimen preparation process, enriching the sample for the tumor DNA so that the analysis will detect those genetic abnormalities.</font></div><div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Merger Transaction</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;29, 2017, the Company (then known as &#8220;Transgenomic, Inc.&#8221;, or &#8220;Transgenomic&#8221;), completed a reverse merger (the &#8220;Merger&#8221;) with Precipio Diagnostics, LLC, a privately held Delaware limited liability company (&#8220;Precipio Diagnostics&#8221;) in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated October&#160;12, 2016, as amended on February&#160;2, 2017 and June&#160;29, 2017, by and among Transgenomic, Precipio Diagnostics and New Haven Labs Inc. (&#8220;Merger Sub&#8221;) a wholly-owned subsidiary of Transgenomic. Pursuant to the Merger Agreement, Merger Sub merged with and into Precipio Diagnostics, with Precipio Diagnostics surviving the Merger as a wholly-owned subsidiary of the combined company (See Note 3 - Reverse Merger). In connection with the Merger, the Company changed its name from Transgenomic, Inc. to Precipio, Inc., relisted its common stock under Precipio, Inc. on the National Association of Securities Dealers Automated Quotations (&#8220;NASDAQ&#8221;), and effected a 1-for-30 reverse stock split of its common stock. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements. Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods. As a result of the Merger, historical preferred stock, common stock, restricted units, warrants and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the effect of the Merger exchange ratio. Pursuant to the Merger Agreement, each outstanding share of capital stock of Precipio Diagnostic was exchanged for 10.2502 pre-reverse stock split shares of Company Common Stock (the &#8220;Exchange Ratio&#8221;). See Note 3 - Reverse Merger for additional discussion of the Merger.</font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Going Concern</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. As of June 30, 2017, the Company had a net loss of </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and negative working capital of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s ability to continue as a going concern is dependent upon a combination of achieving its business plan, including generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio is currently in discussions with certain investors to raise additional capital.  There can be no assurance such capital is or will be available at terms favorable or agreeable to management, if at all, or that the Company will successfully complete the proposed capital raise. Since the outcome of these matters cannot be predicted with any certainty at this time, there is substantial doubt that the Company will be able to continue as a going concern. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company&#8217;s ability to continue as a going concern.  There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern. The accompanying financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of the outcome of this uncertainty.</font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB0376920848C5B9B8A7CC1F55D54DED7"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to June 30, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than what is disclosed in Note 12 - Subsequent Events, there were no other subsequent events that required recognition or disclosure. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto of Precipio Diagnostics for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;contained in our current report on Form 8-K/A, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 31, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Precipio, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in the healthcare industry which is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse.  Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.  Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.  See Note 10 - Fair Value for additional information.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of June 30, 2017 of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;includes prepaid assets of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and other receivables of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and consisted of primarily prepaid assets as of December 31, 2016.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Risk.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed Federal Deposit Insurance Corporation insured limits.  We have not experienced any losses on such accounts as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Service companies in the health care industry typically grant credit without collateral to patients.  The majority of these patients are insured under third-party insurance agreements. The services provided by the Company are routinely billed utilizing the Current Procedural Terminology (CPT) code set designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial, and analytical purposes. CPT codes are currently identified by the Centers for Medicare and Medicaid Services and third-party payors. The Company utilizes CPT codes for Pathology and Laboratory Services contained within codes 80000-89398.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense related to property and equipment was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Merger, the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration. See Note 3 - Reverse Merger for the amounts recorded.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Goodwill</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may impact goodwill. Impairment occurs when the carrying value is determined to be not recoverable, thereby causing the carrying value of the goodwill to exceed its fair value. If impaired, the asset&#8217;s carrying value is reduced to its fair value. No events have transpired in the six months ended June 30, 2017 that would require an impairment analysis prior to our scheduled review.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Intangibles</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group). There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impairment charges during the six months ended June 30, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development (&#8220;IPR&amp;D&#8221;) represents the fair value assigned to research and development assets that were not fully developed at the date of the Merger. Until the IPR&amp;D projects are completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. For the six months ended June 30, 2017, there was no impairment of IPR&amp;D. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended both </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2016, we recorded compensation expense for all stock awards of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;within operating expense.  As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized compensation expense related to unvested stock awards was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;year.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in our stock awards outstanding as of June 30, 2017 were fully vested stock appreciation rights (&#8220;SARs&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">to purchase </font><font style="font-family:inherit;font-size:10pt;">2,777</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock. The SARs were issued solely to a former executive officer and vested over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years from the date of grant. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our New Haven, Connecticut laboratory, we primarily recognize revenue for services rendered upon completion of the testing process.  Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payors.  Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At each of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales included in the balance sheet in deferred revenue were </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Insurance Claims and Related Insurance Recoveries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its insurance claims and related insurance recoveries at their gross values as standards for health care entities do not allow the Company to net insurance recoveries against the related claim liabilities.  There were no insurance claims or insurance recoveries recorded during the three and six months ended June 30, 2017 and 2016.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent that it is more likely than not that they will not be realized. </font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Beneficial Conversion Features.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of a beneficial conversion feature (&#8220;BCF&#8221;) inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the first conversion date using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the BCF is measured by comparing the effective </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares. When the preferred shares are non-redeemable the BCF is fully amortized into additional paid-in capital and preferred discount. If the preferred shares are redeemable, the discount is amortized from the commitment date to the first conversion date.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to </font><font style="font-family:inherit;font-size:10pt;">2,545,463</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2,771,149</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock have been excluded from the computation of diluted loss per share at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, because the effect is anti-dilutive due to the net loss.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&#8217;s financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2016, FASB issued ASU No.&#160;2016-15</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">Classification of Certain Cash Receipts and Cash Payments.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">ASU No.&#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&#160;2016-15 is effective for fiscal years beginning after December&#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&#160;2016-15 will have a material effect on our financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, FASB issued ASU No.&#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01 adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January&#160;2017, FASB issued ASU No. 2017-04, Intangibles &#8212; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which removes Step 2 from the goodwill impairment test.&#160;It is effective for annual and interim periods beginning after December&#160;15, 2019.&#160;Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after January&#160;1, 2017. The Company has adopted this standard and there was no impact on its consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, FASB issued ASU No. 2017-11, Earning Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815), which was issued in two parts, Part I, Accounting for Certain Financial Instruments with Down Round Features and Part II, Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of ASC No. 2017-11 addresses the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in Part II of ASU 2017-11 recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the codification, to a scope exception. Part II amendments do not have an accounting effect. The ASU 2017-11 is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company has early adopted this standard as of January 1, 2017 with the only impact being that the warrants with down round provisions entered into in June 2017 were treated as equity classification. (See Note 5 - Convertible Bridge Notes).</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s42325f4bac004fb58685d97556cf2cec"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.  REVERSE MERGER</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;29, 2017 (the &#8220;Closing Date&#8221;), the Company completed the Merger with Precipio Diagnostics, in accordance with the terms of the Merger Agreement. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements. Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods.</font></div><div style="line-height:120%;padding-top:9px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Closing Date, the outstanding common and preferred units of Precipio Diagnostics and certain debt of Precipio Diagnostics were converted into (i) </font><font style="font-family:inherit;font-size:10pt;">5,352,847</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock, together with cash in lieu of fractional units, and (ii) </font><font style="font-family:inherit;font-size:10pt;">802,920</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio preferred stock with an aggregate face amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:11px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, on the Closing Date, Precipio also issued promissory notes and shares of Precipio preferred and common stock in a number of transactions, whereby:</font></div><div style="line-height:120%;padding-top:11px;text-align:left;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of certain secured indebtedness of Transgenomic received in exchange for such indebtedness </font><font style="font-family:inherit;font-size:10pt;">802,925</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio preferred stock in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;stated value, and </font><font style="font-family:inherit;font-size:10pt;">352,630</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of Transgenomic preferred stock converted it into </font><font style="font-family:inherit;font-size:10pt;">7,155</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio issued </font><font style="font-family:inherit;font-size:10pt;">107,056</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio preferred stock to certain investors in exchange for </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in a private placement. Precipio also completed the sale of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$800,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of promissory notes pursuant to a securities purchase agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Consideration</font></div><div style="line-height:120%;padding-top:9px;text-align:left;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preliminary estimated purchase consideration based on the value of the equity of Transgenomic, the accounting acquiree, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.2265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:3%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legacy Transgenomic common stock</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of preferred stock converted to common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of debt converted to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of debt converted to preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,796</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of existing bridge notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase consideration</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,602</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In estimating the preliminary purchase consideration above, Transgenomic used its closing stock price of </font><font style="font-family:inherit;font-size:10pt;">$6.80</font><font style="font-family:inherit;font-size:10pt;">&#32;as of the Closing Date. Transgenomic had </font><font style="font-family:inherit;font-size:10pt;">895,334</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares outstanding prior to the Merger. In connection with the Merger, Transgenomic preferred stock converted into </font><font style="font-family:inherit;font-size:10pt;">7,155</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock and certain of Transgenomic debt and accrued interest converted into </font><font style="font-family:inherit;font-size:10pt;">352,630</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock and </font><font style="font-family:inherit;font-size:10pt;">802,925</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio preferred stock, face value </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;with an </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;">&#32;annual dividend. At the Closing Date, the preferred stock had a fair value of </font><font style="font-family:inherit;font-size:10pt;">$12.20</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Allocation of Purchase Consideration</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth an allocation of the purchase consideration to the identifiable tangible and intangible assets of Transgenomic, the accounting acquiree, based on fair values as of the Closing Date with the excess recorded as goodwill:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:4%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current and other assets  </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets  </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,604</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities  </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired  </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,602</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets consist of:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:82%;"></td><td style="width:4%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademark and trade name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Backlog</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,590</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangibles</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determined the estimated fair value of the acquired technology but using the multi-period excess earnings method of the income approach.  The estimated fair value of the remaining identifiable intangible assets acquired were determined primarily by using the income approach.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited pro forma information</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operating results of Transgenomic for the period after the Closing Date to June 30, 2017 have been included in the Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollars in thousands, except per share amounts</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss available to common stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,864</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;16</font></div></div><hr style="page-break-after:always"><div><a name="s2FE0B06B3315583B93F5DFF59482400E"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LONG-TERM DEBT</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Note debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Junior Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Connecticut Innovations - line of credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Department of Economic and Community Development (DECD)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DECD debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Webster Bank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Webster Bank debt discounts and issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible promissory notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,522</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(513</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Senior and Junior Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2016, the Company raised </font><font style="font-family:inherit;font-size:10pt;">$525,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from members through the issuance of senior notes which accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">&#32;and are payable at the sooner of the closing of a qualified public offering, as outlined in the note agreement, or five years from date of issuance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also during 2016, the Company restructured equity through a redemption and exchange agreement by exchanging Member Equity comprised of Series A and Series B Convertible Preferred Units in the amount of </font><font style="font-family:inherit;font-size:10pt;">$2,147,716</font><font style="font-family:inherit;font-size:10pt;">&#32;(members&#8217; initial investment of $</font><font style="font-family:inherit;font-size:10pt;">1,715,000</font><font style="font-family:inherit;font-size:10pt;">, plus declared dividends on these preferred units of </font><font style="font-family:inherit;font-size:10pt;">$432,716</font><font style="font-family:inherit;font-size:10pt;">), and Convertible Bridge Notes of </font><font style="font-family:inherit;font-size:10pt;">$1,120,000</font><font style="font-family:inherit;font-size:10pt;">, plus accrued interest of </font><font style="font-family:inherit;font-size:10pt;">$61,073</font><font style="font-family:inherit;font-size:10pt;">&#32;for new senior notes of </font><font style="font-family:inherit;font-size:10pt;">$2,744,968</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;Senior Notes&#8221;) and new junior notes of </font><font style="font-family:inherit;font-size:10pt;">$583,821</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;Junior Notes&#8221;). The Senior and Junior Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">, respectively, and have maturity dates ranging from March 2021 to September 2021, or earlier based on certain qualifying events as outlined in the note agreements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six months ended June 30, 2017, the Company raised </font><font style="font-family:inherit;font-size:10pt;">$315,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from members through the issuance of Senior Notes at a rate of </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;">&#32;interest that are payable at the sooner of the closing of a qualified public offering, as outlined in the note agreement, or five years from date of issuance.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Closing Date of the Merger, the outstanding balance of </font><font style="font-family:inherit;font-size:10pt;">$3,584,968</font><font style="font-family:inherit;font-size:10pt;">&#32;in Senior Notes and </font><font style="font-family:inherit;font-size:10pt;">$583,821</font><font style="font-family:inherit;font-size:10pt;">&#32;in Junior Notes, plus accrued interest of </font><font style="font-family:inherit;font-size:10pt;">$602,373</font><font style="font-family:inherit;font-size:10pt;">, were converted into </font><font style="font-family:inherit;font-size:10pt;">802,920</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio preferred stock and </font><font style="font-family:inherit;font-size:10pt;">1,414,700</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;Senior or Junior Notes outstanding as June 30, 2017. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, the outstanding balance of Senior and Junior Notes was </font><font style="font-family:inherit;font-size:10pt;">$3,269,968</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$583,821</font><font style="font-family:inherit;font-size:10pt;">, respectively, with accrued interest included within the accrued expenses on the accompanying condensed consolidated balance sheet of </font><font style="font-family:inherit;font-size:10pt;">$279,740</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$71,258</font><font style="font-family:inherit;font-size:10pt;">, respectively.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Connecticut Innovations, Incorporated</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a line of credit on April 1, 2012 with Connecticut Innovations, Incorporated (Connecticut Innovations), an entity affiliated with a director of the Company, for up to </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">&#32;with interest paid monthly at </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;">, due on </font><font style="font-family:inherit;font-size:10pt;">September&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">. Principal and interest payments began February 1, 2013 and ranged from </font><font style="font-family:inherit;font-size:10pt;">$7,436</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$12,206</font><font style="font-family:inherit;font-size:10pt;">&#32;until September 2016, when the Company entered into a forbearance agreement to 1) defer monthly principal payments until October 2017 and 2) make interest-only payments totaling </font><font style="font-family:inherit;font-size:10pt;">$1,041</font><font style="font-family:inherit;font-size:10pt;">&#32;per month through October 2017. Pursuant to the forbearance agreement, the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Company was also restricted from any additional borrowings under the line of credit. The line was secured by substantially all of the Company&#8217;s assets.  </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company was to pay in full its loan obligations with Connecticut Innovations. The outstanding balance was </font><font style="font-family:inherit;font-size:10pt;">$162,066</font><font style="font-family:inherit;font-size:10pt;">&#32;at both June 30, 2017 and December 31, 2016.  The outstanding principal and accrued interest balance was paid in full in July 2017. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Department of Economic and Community Development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year term loan with the Department of Economic and Community Development (&#8220;DECD&#8221;) on May 1, 2013 for </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">, with interest paid monthly at </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">, due on </font><font style="font-family:inherit;font-size:10pt;">April&#160;23, 2023</font><font style="font-family:inherit;font-size:10pt;">. The loan was secured by substantially all of the Company&#8217;s assets but was subordinate to the term loan with Webster Bank and the Connecticut Innovations line of credit.  In connection with the Merger, the Company was to pay in full its loan obligations with DECD. The outstanding balance was </font><font style="font-family:inherit;font-size:10pt;">$225,714</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$243,287</font><font style="font-family:inherit;font-size:10pt;">&#32;as of June 30, 2017 and December 31, 2016, respectively.  The outstanding principal and accrued interest balance was paid in full in July 2017. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Webster Bank.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a </font><font style="font-family:inherit;font-size:10pt;">3.5</font><font style="font-family:inherit;font-size:10pt;">-year term loan with Webster Bank on December 1, 2014 for </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">, with interest paid monthly at the one month LIBOR rate (</font><font style="font-family:inherit;font-size:10pt;">1.16%</font><font style="font-family:inherit;font-size:10pt;">&#32;at June 30, 2017) plus 500 basis points, due on </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The line was secured by substantially all of the Company&#8217;s assets and had first priority over all other outstanding debt. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term loan with Webster Bank was subject to financial covenants relating to maintaining adequate cash runway, as defined in the term loan agreement. As of December 31, 2016 the Company was not in compliance with these covenants and, as such, the Webster Bank debt has all been presented as current in the accompanying condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2017, the closing date of the Merger, the Company paid in full its loan obligations (including principal and interest) with Webster Bank. The outstanding balance was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$328,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as of June 30, 2017 and December 31, 2016, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and six months ended June 30, 2017, the Company incurred a loss on extinguishment of debt in the approximate amount of </font><font style="font-family:inherit;font-size:10pt;">$53,000</font><font style="font-family:inherit;font-size:10pt;">, related to the extinguishment of the Connecticut Innovations, DECD and Webster Bank loans.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Promissory Notes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company, as part of the merger, assumed an Unsecured Convertible Promissory Note (the &#8220;Note&#8221;) with an accredited investor (the &#8220;Investor&#8221;) in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$125,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and interest accrues at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year. The Note provided that two-thirds of the outstanding principal amount of the Note was due upon the earlier to occur of the close of the Merger or </font><font style="font-family:inherit;font-size:10pt;">June&#160;17, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;(such applicable date, the &#8220;Maturity Date&#8221;).&#160; The remaining one-third of the principal amount outstanding on the Note was to be paid on the six month anniversary of the Maturity Date.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Maturity Date, the then outstanding aggregate amount owed on the Note of $</font><font style="font-family:inherit;font-size:10pt;">143,041</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(</font><font style="font-family:inherit;font-size:10pt;">$125,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in principal amount and </font><font style="font-family:inherit;font-size:10pt;">$18,041</font><font style="font-family:inherit;font-size:10pt;">&#32;of accrued interest which is included within accrued expenses on the accompanying consolidated condensed balance sheet) became due. Pursuant to the terms of the Note, the Company&#8217;s failure to pay any principal or interest within 10 days of the date such payment is due will constitute an event of default (the &#8220;Prospective Event of Default&#8221;). On June 21, 2017, the Investor agreed to waive the Prospective Event of Default and agreed to further extend the Maturity Date of the Note pursuant to a side letter to the Note (the &#8220;Side Letter&#8221;). The Side Letter provides that two-thirds of the outstanding principal amount of the Note must be paid upon the earlier to occur of (1) the closing of a public offering by the Company of either common stock, convertible preferred stock or convertible preferred notes or (2) August 16, 2017 (such applicable date, the &#8220;Deferred Maturity Date&#8221;). As of August 21, 2017, the Company has not made any payment related to amounts that were due on August 16, 2017. Pursuant to the terms of the Notes, the Company&#8217;s failure to pay any principal or interest within 10 days of the date such payment is due will constitute an event of default. The Company is attempting to negotiate a resolution with the Investor so that the Company will not default on such payment; however, there is no guarantee that the Company will be able to work out a satisfactory resolution. The remaining one-third of the principal amount outstanding on the Note must be paid on the six month anniversary of the Deferred Maturity Date (the &#8220;Extended Maturity Date&#8221;). All accrued and unpaid interest on the outstanding principal amount of the Note will be due and immediately payable on the Extended Maturity Date, unless the Note is converted in which case such interest will be payable in shares of the Company&#8217;s common stock as part of the conversion.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sf5850188e8844efeb744addc89e2d5b6"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONVERTIBLE BRIDGE NOTES.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Bridge Notes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2016, the Company had outstanding </font><font style="font-family:inherit;font-size:10pt;">$695,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of unsecured convertible bridge notes.  The notes accrued interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">14%</font><font style="font-family:inherit;font-size:10pt;">&#32;and were payable on the extended maturity date of December 31, 2016. During January 2017, the holders of the convertible bridge notes agreed to waive the maturity date of December 31, 2016 and change it to payable on demand and accrue interest until paid.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The convertible bridge notes had conversion terms of (i) convertible into Series C Preferred Units of the Company (at a </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;">&#32;discount) upon a Qualified Series C Financing (as defined in the note agreement), (ii) at the option of the holders of a majority of the then-outstanding principal amount of the notes, convertible into Series C Preferred Units of the Company (at a </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;">&#32;discount) upon any other Series C Financing, or (iii) if no such Qualified Series C Financing occurs, or no such optional conversion takes place by the maturity date (as hereinafter defined), the convertible notes will be fully repaid by Company or the notes and accrued and unpaid interest shall convert into Preferred Series B Units (at a </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;">&#32;discount) of the Preferred Series B conversion Price as defined in the operating agreement provided that notice is given to the Company at least one day prior to maturity.&#160; In the event a Deemed Liquidity Event (merger, sale, IPO, or transaction with exchange of 50% or more of voting power) the holders of the notes at their sole discretion can (a) require the Company to pay an amount equal to two times the principal and accrued and unpaid interest or (b) convert all unpaid principal and interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">70%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the applicable security.&#160; These notes were subordinated to Connecticut Innovations, DECD and Webster Bank.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, on the Closing Date, convertible bridge notes of </font><font style="font-family:inherit;font-size:10pt;">$695,000</font><font style="font-family:inherit;font-size:10pt;">, plus </font><font style="font-family:inherit;font-size:10pt;">$192,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of accrued interest, were converted into </font><font style="font-family:inherit;font-size:10pt;">155,639</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 New Bridge Notes I.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the Merger, the Company (then Transgenomic) completed the sale of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of non-convertible promissory notes (the &#8220;2017 Bridge Notes&#8221;) in a bridge financing pursuant to a securities purchase agreement (the &#8220;Purchase Agreement&#8221;), for which $561,500 was then given to Precipio Diagnostics through the issuance of a promissory note and is eliminated in consolidation. The financing was intended to help facilitate the completion of the Merger. The 2017 Bridge Notes had an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;">&#32;and a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-day maturity. The 2017 Bridge Notes may be repaid by the Company at any time in cash upon payment of a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;premium. In connection with the issuance of the 2017 Bridge Notes, the Company issued warrants (the &#8220;2017 Bridge Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">40,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, subject to anti-dilution protection. The Purchase Agreement provides certain piggyback registration rights for the holders of the 2017 Bridge Warrants for a period of six months after the closing of the bridge financing. Aegis Capital Corp. acted as placement agent for the bridge financing and received a placement agent fee of </font><font style="font-family:inherit;font-size:10pt;">$84,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and warrants (the &#8220;Aegis Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">5,600</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The Aegis Warrants are identical to the 2017 Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the time of the Merger, the 2017 Bridge Notes were extinguished and replaced with convertible promissory notes (the &#8220;2017 New Bridge Notes I&#8221;) with an original principal amount of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the aggregate pursuant to an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) entered into on the Closing Date. The 2017 New Bridge Notes I have an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;and are due and payable upon the earlier to occur of (i) October 1, 2017 or (ii) the closing of a Qualified Offering (as defined in the 2017 New Bridge Notes I). The 2017 New Bridge Notes I are convertible into shares of our common stock at an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$3.736329</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, subject to adjustment, and may be convertible into shares of our preferred stock at the holder&#8217;s option if the Company does not complete a Qualified Offering (as defined in the 2017 New Bridge Notes I) by October 1, 2017. The Company may redeem the 2017 New Bridge Notes I at any time in cash upon payment of a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;premium, or </font><font style="font-family:inherit;font-size:10pt;">$240,000</font><font style="font-family:inherit;font-size:10pt;">. As the convertible promissory notes were convertible into the Company's common stock at a conversion rate lower than the fair market value of the common stock at the time of issuance, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$989,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as a beneficial conversion feature, which was recorded as a debt discount in the balance sheet. The discount will be amortized using the effective interest method through the first conversion date of the 2017 New Bridge Notes I.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Exchange Agreement, the 2017 Bridge Warrants were canceled and replaced with new warrants to acquire </font><font style="font-family:inherit;font-size:10pt;">45,600</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock (the &#8220;2017 New Bridge Warrants&#8221;). The initial exercise price of the 2017 New Bridge Warrants is </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;">&#32;(subject to adjustments). If the Company completes a Qualified Offering (as defined in the 2017 New Bridge warrants), the exercise price of the 2017 New Bridge Warrants will become the lower of (i) </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;">, or (ii) </font><font style="font-family:inherit;font-size:10pt;">110%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the per share offering price in the Qualified Offering, but in no event lower than </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, which has been considered a down round provision. At issuance, the 2017 New Bridge Warrants had a fair value of </font><font style="font-family:inherit;font-size:10pt;">$211,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and were recorded as a debt discount to the related 2017 New Bridge Notes I, with the corresponding entry to additional paid in capital as the warrants were considered classified as equity in accordance with GAAP. As discussed in Note 2 of the accompanying unaudited condensed consolidated financial statements, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Company early adopted ASU 2017-11, which allowed the Company to treat the warrants as equity classified, despite the down round provision.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 New Bridge Note II.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, on the Closing Date and pursuant to a Securities Purchase Agreement (the &#8220;Bridge Purchase Agreement&#8221;), the Company completed the sale of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$800,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of a convertible promissory note (the &#8220;2017 New Bridge Note II&#8221;). The Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$721,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from the sale of the 2017 New Bridge Note II, which will be used for working capital purposes. The 2017 New Bridge Note II has an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;and are due and payable upon the earlier to occur of (i) October 1, 2017 or (ii) the closing of a Qualified Offering (as defined in the 2017 New Bridge Note II). The 2017 New Bridge Note II is convertible into shares of our common stock at an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$3.736329</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, subject to adjustment, and may be convertible into shares of our preferred stock at the holder&#8217;s option if the Company does not complete a Qualified Offering (as defined in the 2017 New Bridge Note II) by October 1, 2017. The Company may redeem the 2017 New Bridge Note II at any time in cash upon payment of a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;">&#32;premium, or </font><font style="font-family:inherit;font-size:10pt;">$160,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the 2017 New Bridge Note II was convertible into the Company's common stock at a conversion rate lower than the fair market value of the common stock at the time of issuance, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$656,000</font><font style="font-family:inherit;font-size:10pt;">&#32;as a beneficial conversion feature, which was recorded as a debt discount in the balance sheet. The discount will be amortized using the effective interest method through the first conversion date of the 2017 New Bridge Note II.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the bridge financing and the assumption of certain obligations by an entity controlled by Mark Rimer (a director of the Company), the Company issued to that entity warrants (the &#8220;Side Warrants&#8221;) to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">91,429</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$7.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share (subject to adjustment), with a fair value of </font><font style="font-family:inherit;font-size:10pt;">$487,000</font><font style="font-family:inherit;font-size:10pt;">&#32;at the date of issuance. The Side Warrants have a term of </font><font style="font-family:inherit;font-size:10pt;">5 years</font><font style="font-family:inherit;font-size:10pt;">&#32;and are exercisable as to </font><font style="font-family:inherit;font-size:10pt;">22,857</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock upon grant and as to </font><font style="font-family:inherit;font-size:10pt;">68,572</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock upon the entity&#8217;s performance of the assumed obligations. The Company has recorded merger advisory expense of </font><font style="font-family:inherit;font-size:10pt;">$414,000</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the Side Warrants during the three and six months ended June 30, 2017. The remaining fair value of </font><font style="font-family:inherit;font-size:10pt;">$73,000</font><font style="font-family:inherit;font-size:10pt;">&#32;will be recorded as expense at the time the performance obligations are met.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, upon the Company consummating one or more rounds of equity financing following July 1, 2017, with aggregate gross proceeds of at least </font><font style="font-family:inherit;font-size:10pt;">$7 million</font><font style="font-family:inherit;font-size:10pt;">, the Company will use a portion of the proceeds from such financing to repay the principal amount of the 2017 New Bridge Notes, together with any premium and interest.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 30, 2017, the outstanding convertible notes balance was </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of debt discounts of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and debt issuance cost of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.  Accrued interest of approximately </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">&#32;is included within accrued expenses on the accompanying condensed consolidated balance sheet.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sf00ad1094d35483481dbe944bef13c8a"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ACCRUED EXPENSES.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following:</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.5859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:54%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">791</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB470C5CB171157CFB2FD36C2F97DAABE"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.  CONTINGENCIES</font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is involved in legal proceedings related to matters, which are incidental to its business. The Company has also assumed a number of claims as a result of the Merger. See below for a discussion on these matters. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The healthcare industry is subject to numerous laws and regulations of federal, state and local governments.  These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed.  Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations.  While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outcome of legal proceedings and claims brought against us are subject to significant uncertainty.  Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management&#8217;s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Claims assumed in the Merger</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assumed a number of claims as a result of the Merger. In addition to the claims described below, we are delinquent on the payment of outstanding accounts payable certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, the Board of Regents of the University of Nebraska (&#8220;UNMC&#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;owed by us to UNMC.  A </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay $0.4 million to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of the initial payment due to UNMC. A </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 13, 2016, Fox Chase Cancer Center (&#8220;Fox Chase&#8221;) filed a lawsuit against Transgenomic in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &#8220;Court of Common Pleas&#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement Transgenomic entered into with Fox Chase in August 2000, as amended (the &#8220;License Agreement&#8221;), as well as the assignment of certain of Transgenomic's rights under the License Agreement to Integrated DNA Technologies, Inc. (&#8220;IDT&#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement Transgenomic entered into with IDT effective as of July 1, 2014 (the &#8220;IDT Agreement&#8221;). Pursuant to the terms of the IDT Agreement, Transgenomic agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained Transgenomic's preliminary objections to several of Fox Chase&#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&#8217;s fees.&#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remained pending against Transgenomic. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During June 2017, prior to the Merger, Transgenomic entered into a settlement agreement with Fox Chase (the &#8220;Agreement&#8221;) which will resolve all outstanding claims in the litigation brought in April 2016 by Fox Chase against Transgenomic in the Court of Common Pleas of Philadelphia County (the &#8220;Action&#8221;). The case will remain pending with the Court until all settlement payments to Fox Chase have been made. Under the Agreement the Company will make three (</font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">) payments to Fox Chase totaling </font><font style="font-family:inherit;font-size:10pt;">$175,000</font><font style="font-family:inherit;font-size:10pt;">. The last payment is to be made on or before September 30, 2017, and once received Fox Chase is obligated to cause the Action to be formally dismissed with prejudice. Also, on July 13, 2017 the Company entered into an agreement with its co-Defendant, IDT, regarding the Company&#8217;s indemnity obligations to IDT for legal fees and expenses incurred in the Action pursuant to the terms of the IDT Agreement. The IDT Agreement provides for monthly payments of </font><font style="font-family:inherit;font-size:10pt;">$27,800</font><font style="font-family:inherit;font-size:10pt;">&#32;from the Company to IDT, in the total amount of </font><font style="font-family:inherit;font-size:10pt;">$139,000</font><font style="font-family:inherit;font-size:10pt;">, commencing on August 15, 2017 and concluding on December 15, 2017. A </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to Mount Sinai in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at June 30, 2017.  Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 19, 2016, Todd Smith (&#8220;Smith&#8221;) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties.  On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to Smith in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at June 30, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 21, 2017, XIFIN, Inc. (&#8220;XIFIN&#8221;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.27 million</font><font style="font-family:inherit;font-size:10pt;">&#32;owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;liability has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Science Park Development Corporation (&#8220;SPDC&#8221;) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the &#8220; SPDC Lease&#8221;).   In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease.  Specifically, SPDC alleges that we failed to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease.  We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CPA Global provides us with certain patent management services.  On February 6, 2017, CPA Global claimed that we owe approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for certain patent maintenance services rendered.  CPA Global has not filed claims against us in connection with this allegation.  A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 9, 2016, counsel for Edge BioSystems, Inc. (&#8220;EdgeBio&#8221;) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the &#8220;EdgeBio Agreement&#8221;). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement.  On September 13, 2016, we received a demand for payment letter from EdgeBio&#8217;s counsel alleging that the balance due to EdgeBio is approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.  A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 17, 2017, Jesse Campbell (&#8220;Campbell&#8221;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&#8217;s deal protection provisions deter superior offers.&#160; As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&#160; Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case.  Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sA89FD23010B75A4AB387AE44E1A3D228"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.  INCOME TAXES </font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;22</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We file a US federal consolidated income tax return and state income tax returns in various jurisdictions. We have statutes of limitation open for federal &amp; state income tax returns related to tax years 2014 through 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense for both the three months and six months ended June&#160;30, 2017 was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;as a result of recording a full valuation allowance against the deferred tax asset generated predominantly by net operating losses. For the three and six months ended June 30, 2016, the Company was organized as a limited liability company and operated under the default classification as a partnership until July 31, 2016. Consequently, prior to August 1, 2016, income tax expense or benefits were calculated at the members&#8217; level.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had no material interest or penalties during fiscal 2017 or fiscal 2016, and we do not anticipate any such items during the next twelve months.  Our policy is to record interest and penalties directly related to uncertain tax positions as income tax expense in the condensed consolidated statements of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the merger, there was a change in ownership as defined in IRS &#167; 382. Because of this change, use of a portion of the accumulated net operating losses and tax credit carryforwards will be limited in future periods. Further, a portion of the carryforwards will expire before being applied to reduce future income tax liabilities. Since the net deferred tax assets have a full valuation allowance recorded, any limitation generated from this calculation would not effect the current financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4365805F3B2254DC9E78BA1A27A7572E"></a></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.  STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock.</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">150,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">shares of common stock authorized for issuance.</font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company effected a 1-for-30 reverse stock split of its common stock. This reverse stock split became effective on June 13, 2017 and, unless otherwise indicated, all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying unaudited condensed consolidated financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split. Additionally, as a result of the Merger, the Company has recapitalized its stock. All historical preferred stock, common stock, restricted units, warrants and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the effect of the Merger exchange ratio. Pursuant to the Merger Agreement, each outstanding share of capital stock of Precipio Diagnostics was exchanged for </font><font style="font-family:inherit;font-size:10pt;">10.2502</font><font style="font-family:inherit;font-size:10pt;">&#32;pre-reverse stock split shares of the Company's common stock.</font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">449,175</font><font style="font-family:inherit;font-size:10pt;">&#32;share of common stock outstanding. </font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2017, restricted stock of </font><font style="font-family:inherit;font-size:10pt;">59,563</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were granted during the three and six months ended June 30, 2017, none of which vested prior to the merger, upon closing of the merger, all shares fully vested. During 2017, </font><font style="font-family:inherit;font-size:10pt;">64,593</font><font style="font-family:inherit;font-size:10pt;">&#32;shares were released to common stock. We recorded stock compensation expense of approximately </font><font style="font-family:inherit;font-size:10pt;">$28,000</font><font style="font-family:inherit;font-size:10pt;">&#32;related to restricted stock that vested during the six months ended June 30, 2017. </font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Closing Date, Precipio Diagnostics received </font><font style="font-family:inherit;font-size:10pt;">4,317,152</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock from the conversion of preferred stock, senior and junior debt, bridge notes and warrants. Also, certain advisors of Precipio Diagnostics received </font><font style="font-family:inherit;font-size:10pt;">321,821</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock related to services performed in connection with the Merger. The fair value of these advisory shares was </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at the date of the Merger and is included as a merger advisory fee expense in the accompanying financial statements.</font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the Merger, Precipio Diagnostics also received </font><font style="font-family:inherit;font-size:10pt;">200,081</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock that have not been issued yet. </font><font style="font-family:inherit;font-size:10pt;">135,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of these shares are being held for future issuance to advisors pending completion of certain performance obligations. If these performance obligations are not met, the shares will remain with Precipio Diagnostics as part of the unissued pool. For any shares that remain unissued, it is the intent of the Company to allocate these to Precipio Diagnostics shareholders on a pro rata basis. </font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also, upon completion of the Merger, Transgenomic legacy stockholders had </font><font style="font-family:inherit;font-size:10pt;">1,255,119</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock outstanding.</font></div><div style="line-height:120%;padding-top:11px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 30, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">6,407,860</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock outstanding.</font></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the merger, in connection with the line of credit with Connecticut Innovations, the Company issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">8,542</font><font style="font-family:inherit;font-size:10pt;">&#32;Series A Preferred shares of the Company, which were classified as an equity warrant, at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.93</font><font style="font-family:inherit;font-size:10pt;">&#32;per unit, subject to adjustments as defined in the warrant agreement. The warrants were valued at </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;">&#32;at the date of the grant utilizing the Black-Sholes model (volatility </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;">, expected life </font><font style="font-family:inherit;font-size:10pt;">7 years</font><font style="font-family:inherit;font-size:10pt;">, and risk free rate </font><font style="font-family:inherit;font-size:10pt;">.36%</font><font style="font-family:inherit;font-size:10pt;">). The value of the warrants were treated as a debt discount. At the Merger date, the warrants were exercised and then converted into shares of Precipio common stock.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Webster Bank agreement, the Company issued </font><font style="font-family:inherit;font-size:10pt;">7 years</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">20,000</font><font style="font-family:inherit;font-size:10pt;">&#32;Series B Preferred shares of the Company. At the Merger date, Webster Bank declined to exercise their warrants and, per the terms of the warrant agreement, the warrants were retired.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Company entered into a redemption and exchange agreement with certain member's relating to their </font><font style="font-family:inherit;font-size:10pt;">275,237</font><font style="font-family:inherit;font-size:10pt;">&#32;Preferred A Units and </font><font style="font-family:inherit;font-size:10pt;">208,087</font><font style="font-family:inherit;font-size:10pt;">&#32;Preferred B Units. Under the terms of the agreement, the unit holders would exchange their units in the Company for the issuance of debt. The aggregate purchase price per the agreement was the member's initial investment of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for Preferred A Units and </font><font style="font-family:inherit;font-size:10pt;">$965,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for Preferred B Units, along with a preferred return of </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;">, recorded as a dividend in the amount of </font><font style="font-family:inherit;font-size:10pt;">$432,716</font><font style="font-family:inherit;font-size:10pt;">. In addition to the debt issued as consideration for the member's preferred units, the Company also issued common warrant units, which allows the holders to collectively purchase common units of the Company, representing approximately </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company at the time of exercise. At the time of issuance, this represented approximately </font><font style="font-family:inherit;font-size:10pt;">1,958,204</font><font style="font-family:inherit;font-size:10pt;">&#32;common units. The common warrant units had a $0.00 exercise price with a </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;year expiration date. The common warrant units were classified as equity awards and the fair value upon issuance was calculated utilizing a discounted cash flow analysis to value the Company's equity and an option pricing method to allocate the value of the equity. The fair value of the warrants was determined directly utilizing the option pricing method as the exercise price was $0.00. The aggregate value of the common warrant units was </font><font style="font-family:inherit;font-size:10pt;">$1,421,738</font><font style="font-family:inherit;font-size:10pt;">, which was considered a deemed dividend. At the time of the Merger, these warrants were converted into </font><font style="font-family:inherit;font-size:10pt;">1,958,204</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Precipio common stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrants Assumed in Merger</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the time of the Merger, Transgenomic had a number of outstanding warrants related to various financing transactions that occurred between 2013-2016. Details related to year issued, expiration date, amount of underlying common shares and exercise price are included in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 New Bridge Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six months ended June 30, 2017, prior to the Merger, Transgenomic completed the sale of the 2017 Bridge Notes in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and the issuance of the 2017 Bridge Warrants to acquire </font><font style="font-family:inherit;font-size:10pt;">40,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, subject to anti-dilution protection. Aegis Capital Corp. acted as placement agent for the bridge financing and received Aegis Warrants to acquire </font><font style="font-family:inherit;font-size:10pt;">5,600</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Transgenomic common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The Aegis Warrants are identical to the 2017 Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection. (See Note 5 - Convertible Bridge Notes).</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the holders of the 2017 Bridge Notes, the 2017 Bridge Warrants and the Aegis Warrants agreed to exchange the 2017 Bridge Notes, the 2017 Bridge Warrants and the Aegis Warrants for 2017 New Bridge Notes and the 2017 New Bridge Warrants to acquire </font><font style="font-family:inherit;font-size:10pt;">45,600</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock. (See Note 5 - Convertible Bridge Notes). The initial exercise price of the 2017 New Bridge Warrants is </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;">&#32;(subject to adjustments). If the Company completes a Qualified Offering (as defined in the 2017 New Bridge Warrants), the exercise price of the 2017 New Bridge Warrants will become the lower of (i) </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;">&#32;or (ii) </font><font style="font-family:inherit;font-size:10pt;">110%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the per share offering price in the Qualified Offering, but in no event lower than </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At issuance, the 2017 New Bridge Warrants had a fair value of </font><font style="font-family:inherit;font-size:10pt;">$211,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and were recorded as a debt discount to the related 2017 New Bridge Notes I, with the corresponding entry to additional paid in capital as the warrants were considered classified as equity in accordance with GAAP.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Side Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the bridge financing and the assumption of certain obligations by an entity controlled by Mark Rimer (a director of the Company), the Company issued to that entity Side Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">91,429</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$7.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share (subject to adjustment), with a fair value of $487,000 at the date </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of issuance. The Side Warrants have a term of </font><font style="font-family:inherit;font-size:10pt;">5 years</font><font style="font-family:inherit;font-size:10pt;">&#32;and are exercisable as to </font><font style="font-family:inherit;font-size:10pt;">22,857</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock upon grant and as to </font><font style="font-family:inherit;font-size:10pt;">68,572</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock upon the entity&#8217;s performance of the assumed obligations. The Company has recorded merger advisory expense of </font><font style="font-family:inherit;font-size:10pt;">$414,000</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the Side Warrants during the three and six months ended June 30, 2017. The remaining fair value of </font><font style="font-family:inherit;font-size:10pt;">$73,000</font><font style="font-family:inherit;font-size:10pt;">&#32;will be recorded as expense at the time the performance obligations are met. </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a summary of the warrants outstanding as of June 30, 2017:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:5%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Warrants Assumed in Merger</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,055</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$270.00</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$120.00</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,826</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$67.20</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$49.80</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,733</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$36.30</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$36.30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Warrants</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,600</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.50</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,379</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with an offering in July 2015, and were amended in connection with an offering which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These are the 2017 New Bridge Warrants which were issued in connection with the Merger. See discussion above for additional information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These are the Side Warrants which were issued in connection with the Merger. See discussion above for additional information</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series A and Series B Preferred Stock.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had outstanding preferred units of </font><font style="font-family:inherit;font-size:10pt;">367,299</font><font style="font-family:inherit;font-size:10pt;">&#32;for Series A and </font><font style="font-family:inherit;font-size:10pt;">412,806</font><font style="font-family:inherit;font-size:10pt;">&#32;for Series B as of December 31, 2016.  These shares have been recapitalized and are included in preferred stock. On the Closing Date, the outstanding preferred units for Series A and Series B, along with the related accumulated dividends, were converted into common shares of the Company.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Board of Directors is authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;">15,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i)&#160;the number of shares; (ii)&#160;the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii)&#160;whether shares </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv)&#160;whether shares shall be convertible and, if so, the terms and provisions thereof; (v)&#160;what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi)&#160;whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends.  We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series A Senior Preferred Stock.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware on June 29, 2017, designating </font><font style="font-family:inherit;font-size:10pt;">4,100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, as Series A Senior Convertible Preferred Stock ("Series A Senior") and establishing the rights, preferences and privileges of the new preferred stock. Generally, the holders of the Series A Senior stock are entitled to vote as a single voting group with the holders of the Company's common stock, and the holders of the Series A Senior stock are generally entitled to that number of votes as is equal to the number of whole shares of the Company's common stock into which the Series A Senior stock may be converted as of the record date of such vote or consent.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">So long as the shares of Series A Senior stock are outstanding certain actions will require the separate approval of at least two-thirds of the Series A Senior stock, including: changes to the terms (requires three-fourths approval) of the Series A Senior stock, changes to the number of authorized shares of Series A Senior stock, issuing a series of preferred stock that is senior to the Series A Senior stock, changing the size of the board of directors, certain changes to the capital stock of the Company, bankruptcy proceedings and granting security interests in the Company&#8217;s assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series A Senior stock will be convertible into the Company's common stock at any time at the then applicable conversion price. The initial conversion price for the Series A Senior stock issued in connection with the Merger and the other transactions described herein is </font><font style="font-family:inherit;font-size:10pt;">$3.736329</font><font style="font-family:inherit;font-size:10pt;">, but will be subject to anti-dilution protections including adjustments for stock splits, stock dividends, other distributions, recapitalizations and the like. Additionally, each holder of the Series A Senior stock will have a right to convert such holder's Series A Senior stock into securities issued in any future private offering of the Company's securities at a </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">&#32;discount to the proposed price in such private offering.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series A Senior stock will be entitled to an annual </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;">&#32;cumulative payment in lieu of interest or dividends, payable in-kind for the first two years and in cash or in-kind thereafter, at the option of the Company. The Series A Senior stock also will be entitled to share in any dividends paid on the Company's common stock.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 3 - Reverse Merger, in connection with the Merger, the Company issued 1) to holders of certain Transgenomic secured indebtedness, </font><font style="font-family:inherit;font-size:10pt;">802,925</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Senior stock in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;">, 2) to holders of certain Precipio Diagnostic indebtedness, </font><font style="font-family:inherit;font-size:10pt;">802,920</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Senior stock in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and 3) to certain investors, </font><font style="font-family:inherit;font-size:10pt;">107,056</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Series A Senior stock in exchange for </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in a private placement. The Company had outstanding Series A Senior shares of </font><font style="font-family:inherit;font-size:10pt;">1,712,901</font><font style="font-family:inherit;font-size:10pt;">&#32;as of June 30, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determined that there was a beneficial conversion feature in connection with the issuances of the Series A Senior stock since the conversion price of  </font><font style="font-family:inherit;font-size:10pt;">$3.736329</font><font style="font-family:inherit;font-size:10pt;">&#32;was at a discount to the fair market value of the Company's common stock at issuance date. The Series A Senior stock is non-redeemable and as a result, the Company recognized the full beneficial conversion feature in the amount of </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as a deemed dividend at the time of issuance. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5E5B2EAD4F29520D8BA8FA35453C5D69"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.  FAIR VALUE</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Observable inputs other than those included in Level&#160;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&#160;and</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrant Liabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assumed the 2016 Warrant Liability in the merger and it represents the fair value of Transgenomic warrants issued in January 2016, of which, </font><font style="font-family:inherit;font-size:10pt;">25,584</font><font style="font-family:inherit;font-size:10pt;">&#32;warrants remain outstanding as of June 30, 2017. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model.  This method is well suited to valuing options with non-standard features.  Assumptions and inputs used in the valuation of the common stock warrants include: our equity value, which was estimated using our stock price of </font><font style="font-family:inherit;font-size:10pt;">$9.00</font><font style="font-family:inherit;font-size:10pt;">&#32;as of June 30, 2017; volatility of </font><font style="font-family:inherit;font-size:10pt;">121%</font><font style="font-family:inherit;font-size:10pt;">; and a risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.64%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended June 30, 2017, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:72.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at April 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions - liability assumed in the Merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC16823D600D752E0A68DD89B42C32CFC"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.  STOCK OPTIONS </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's 2006 Equity Incentive Plan (the "2006 Plan") was terminated as to future awards on July 12, 2016. The Company's 2017 Stock Option and Incentive Plan (the "2017 Plan") was adopted by the Company's stockholders on June 5, 2017 and will expire on June 5, 2027. The following table summarizes stock option activity under our plans during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRECIPIO, INC. AND SUBSIDIARY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three and Six Months Ended June 30, 2017 and 2016</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:71%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,908</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">21,713</font><font style="font-family:inherit;font-size:10pt;">&#32;options that were vested or expected to vest with an aggregate intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">6.9</font><font style="font-family:inherit;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">SARs</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2,777</font><font style="font-family:inherit;font-size:10pt;">&#32;outstanding and exercisable SARs shares were vested or expected to vest. All outstanding SARs were issued solely to a former chief executive officer. The weighted-average exercise price of these SARs was </font><font style="font-family:inherit;font-size:10pt;">$129.60</font><font style="font-family:inherit;font-size:10pt;">&#32;per share and the aggregate intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">6.25</font><font style="font-family:inherit;font-size:10pt;">&#32;years. During the six months ended June 30, 2017, the SARs liability decreased approximately </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and at June 30, 2017, a liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$7,000</font><font style="font-family:inherit;font-size:10pt;">&#32;was recorded in accrued expenses. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF34875C040235733B83469DCE3F6C5AF"></a></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.  SUBSEQUENT EVENTS </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 1, 2017, the Company announced that it was planning a public offering of common stock and warrants in an underwritten public offering. There can be no assurances as to whether the offering will be completed, or as to the size or terms of the offering. Even if the offering is completed, the Company will need to raise additional funding.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9824F83781BC5DED9D50BF2A5A1AEDD8"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div></td></tr></table><div style="line-height:120%;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1E425442BE785AEC8D8C28DA3DCD85F1"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward-Looking Information</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This Quarterly Report on Form 10-Q, including this Management&#8217;s Discussion&#160;and Analysis, contains forward-looking statements. These statements are based on management&#8217;s current views, assumptions or beliefs of future events and financial performance and are subject to uncertainty and changes in circumstances. Readers of this report should understand that these statements are not guarantees of performance or results.  Many factors could affect our actual financial results and cause them to vary materially from the expectations contained in the forward-looking statements. These factors include, among other things: our expected revenue, income (loss), receivables, operating expenses, supplier pricing, availability and prices of raw materials, insurance reimbursements, product pricing, sources of funding operations and acquisitions, our ability to raise funds, sufficiency of available liquidity, future interest costs, future economic circumstances, business strategy, industry conditions, our ability to execute our operating plans, the success of our cost savings initiatives, competitive environment and related market conditions, expected financial and other benefits from our organizational restructuring activities, actions of governments and regulatory factors affecting our business, retaining key employees and other risks as described in our reports filed with the Securities and Exchange Commission. In some cases these statements are identifiable through the use of words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative versions of these terms and other similar expressions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">You are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements we make are not guarantees of future performance and are subject to various assumptions, risks and other factors that could cause actual results to differ materially from those suggested by these forward-looking statements. Actual results may differ materially from those suggested by the forward-looking statements that we make for a number of reasons, including those described in Part II, Item 1A, &#8220;Risk Factors,&#8221; of this Quarterly Report on Form 10-Q.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion should be read together with our financial statements and related notes contained in this Quarterly Report on Form 10-Q and with the audited financial statements and notes thereto of Precipio Diagnostics for the year ended </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;contained in our current report on Form 8-K/A, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 31, 2017.  Results for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are not necessarily indicative of results that may be attained in the future.</font></div><div><a name="sF9F2F0BD847F531DBE4DEF8DD7E0D7BE"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Merger</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;29, 2017, or the Closing Date, the Company (then known as Transgenomic, Inc., or Transgenomic), completed a reverse merger, or the Merger with Precipio Diagnostics, LLC, a privately held Delaware limited liability company, or Precipio Diagnostics, in accordance with the terms of the Agreement and Plan of Merger, or the Merger Agreement, dated October&#160;12, 2016, as amended on February&#160;2, 2017 and June&#160;29, 2017, by and among Transgenomic, Precipio Diagnostics and New Haven Labs Inc., or Merger Sub, a wholly-owned subsidiary of Transgenomic. Pursuant to the Merger Agreement, Merger Sub merged with and into Precipio Diagnostics, with Precipio Diagnostics surviving the Merger as a wholly-owned subsidiary of the merged company. In connection with the Merger, the Company changed its name from Transgenomic, Inc. to Precipio, Inc and effected a 1-for-30 reverse stock split of its common stock. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements. Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio, Inc., and Subsidiary, (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Precipio&#8221;) is a cancer diagnostics company providing diagnostic products and services to the oncology market. We have built and continue to develop a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory located in New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and technologies developed within academia so that we can provide a better standard of cancer diagnostics and solve the growing problem of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development of ICE-COLD-PCR. or ICP, the patented technology which was exclusively licensed by us from Dana-Farber Cancer Institute, Inc., or Dana-Farber, at Harvard University. The research and development center will focus on the development of this technology, which we believe will enable us to commercialize other technologies developed by our current and future academic partners. Our platform connects patients, physicians and diagnostic experts residing within academic institutions. Launched in 2017, the platform facilitates the following relationships:</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients: patients may search for physicians in their area and consult directly with academic experts that are on the platform. Patients may also have access to new academic discoveries as they become commercially available.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Physicians: physicians can connect with academic experts to seek consultations on behalf of their patients and may also provide consultations for patients in their area seeking medical expertise in that physician&#8217;s relevant specialty. Physicians will also have access to new diagnostic solutions to help improve diagnostic accuracy.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Academic Experts: academic experts on the platform can make themselves available for patients or physicians seeking access to their expertise. Additionally, these experts have a platform available to commercialize their research discoveries.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to continue updating our platform to allow for patient-to-patient communications and allow individuals to share stories and provide support for one another, to allow physicians to consult with their peers to discuss and share challenges and solutions, and to allow academic experts to interact with others in academia on the platform to discuss their research and cross-collaborate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ICP was developed at Harvard and is licensed exclusively by us from Dana-Farber. The technology enables the detection of genetic mutations in liquid biopsies, such as blood samples. The field of liquid biopsies is a rapidly growing market, aimed at solving the challenge of obtaining genetic information on disease progression and changes from sources other than a tumor biopsy.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gene sequencing is performed on tissue biopsies taken surgically from the tumor site in order to identify potential therapies that will be more effective in treating the patient. There are several limitations to this process. First, surgical procedures have several limitations, including:</font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost: surgical procedures are usually performed in a costly hospital environment. For example, according to a recent study the mean cost of lung biopsies is greater than $14,000; surgery also involves hospitalization and recovery time.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Surgical access: various tumor sites are not always accessible (e.g. brain tumors), in which cases no biopsy is available for diagnosis.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk: patient health may not permit undergoing an invasive surgery; therefore a biopsy cannot be obtained at all.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Time: the process of scheduling and coordinating a surgical procedure often takes time, delaying the start of patient treatment.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second, there are several tumor-related limitations that provide a challenge to obtaining such genetic information from a tumor:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tumors are heterogeneous by nature: a tissue sample from one area of the tumor may not properly represent the tumor&#8217;s entire genetic composition; thus, the diagnostic results from a tumor may be incomplete and non-representative.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Metastases: in order to accurately test a patient with metastatic disease, ideally an individual biopsy sample should be taken from each site (if those sites are even known). These biopsies are very difficult to obtain; therefore physicians often rely on biopsies taken from the primary tumor site.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The advent of technologies enabling liquid biopsies as an alternative to tumor biopsy and analysis is based on the fact that tumors (both primary and metastatic) shed cells and fragments of DNA into the blood stream. These blood samples are called &#8220;liquid biopsies&#8221; that contain circulating tumor DNA, or ctDNA, which hold the same genetic information found in the tumor(s). That tumor DNA is the target of genetic analysis. However, since the quantity of tumor DNA is very small in proportion to the &#8220;normal&#8221; (or &#8220;healthy&#8221;) DNA within the blood stream, there is a need to identify and separate the tumor DNA from the normal DNA.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ICP is an enrichment technology that enables the laboratory to focus its analysis on the tumor DNA by enriching, and thereby &#8220;multiplying&#8221; the presence of, tumor DNA, while maintaining the normal DNA at its same level. Once the enrichment process has been completed, the laboratory genetic testing equipment is able to identify genetic abnormalities presented in the ctDNA, and an analysis can be conducted at a higher level of sensitivity, to enable the detection of such genetic abnormalities. The technology is encapsulated into a chemical that is provided in the form of a kit and sold to other laboratories who wish to conduct these tests in-house. The chemical within the kit is added to the specimen preparation process, enriching the sample for the tumor DNA so that the analysis will detect those genetic abnormalities.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following discussion should be read together with our financial statements and related notes contained in this Quarterly Report.  Results for the three and six months ended June 30, 2017 are not necessarily indicative of results that may be attained in the future.</font></div><div style="line-height:120%;text-align:justify;padding-left:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s29D913E86C1D55D5A75EDFC000E6B17D"></a></div><div style="line-height:174%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Second Quarter 2017 Overview and Recent Highlights </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2017, both Precipio Diagnostics and Transgenomic worked to prepare for the Merger. From an operation perspective, since each company had a certified CLIA lab, management determined that consolidation would both streamline company operations and reduce the regulatory burden, while significantly decreasing operating costs on a going forward basis. Both companies continued to work to integrate their various teams and related operations; the finance teams of both companies worked together to prepare for the combination of both companies financial, billing, AP and accounting systems to ensure a smooth transition upon completion of the Merger. Customer service and logistics functions also were combined to ensure that the proper efficiencies were achieved once the Merger was completed. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From a corporate governance perspective, the Company enhanced its board of directors and will further supplement its board of directors with experienced industry individuals.  In addition, the Company also formulated its scientific advisory board, to create a strong scientific backbone to support the management team, and ensure that the Company continues product development. &#160;We continue to build on our long standing relationships with Yale Medicine, Harvard, and Dana Farber.  Collaboration with academia and biopharma remains an integral component of our strategy to access advanced genetic technology and diagnostic testing in the cancer marketplace for future growth.  In April 2017, we signed a contract renewal with Yale for diagnostic pathology services and medical director leadership. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ending June 30, 2017, we expanded the diagnostic sales force and focused on product branding.  These efforts will continue through 2017 and beyond. In addition, significant resource was directed on communicating the broad technical synergies and product development capabilities created through the Merger.  We signed our first multi-national distribution agreement with Clearbridge Health, a Singaporean-based healthcare company that will be providing Precipio&#8217;s services in numerous countries throughout Asia.      </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC81DC5B075A15BDF995E876E698A4FBB"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Uncertainties</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have historically operated at a loss and have not consistently generated sufficient cash from operating activities to cover our operating and other cash expenses. We have been able to historically finance our operating losses through borrowings or from the issuance of additional equity. At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. Our ability to continue as a going concern is dependent upon a combination of generating additional revenue and raising necessary financing to meet our obligations and pay our liabilities arising from normal business operations when they come due. The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that we will be able to continue as a going concern.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s37446BD935AA5DB9955FC15E2D9BFB22"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations for the Three Months Ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales. </font><font style="font-family:inherit;font-size:10pt;">Net sales were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Net Sales</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">260</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">504</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales decreased by $0.2 million, or </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">48%</font><font style="font-family:inherit;font-size:10pt;">, during the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease is entirely due to the decrease in cases processed during the three months ended June 30, 2017 as compared to the same period in 2016.  We processed 230 cases during the three months ended June 30, 2017 as compared to 338 cases during the same period in 2016, or a 32% decrease in cases. </font><font style="font-family:inherit;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:10pt;">The decrease in volume is the result of turnover of key sales personnel.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Diagnostic Services.</font><font style="font-family:inherit;font-size:10pt;">&#32;Cost of diagnostic services includes material and supply costs for the patient tests performed and other direct costs (primarily personnel costs and rent) associated with the operations of our laboratory. Cost of diagnostic services increased by less than $0.1 million, or 19%, for the three months ended June 30, 2017 as compared to the same period in 2016.  The increase is due to increased professional fees involved with the processing of patient tests in the three months ended June 30, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Gross Profit.</font><font style="font-family:inherit;font-size:10pt;">&#32;Gross profit and gross margins were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Margin %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross (Loss) Profit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross loss was a negative </font><font style="font-family:inherit;font-size:10pt;">(10)%</font><font style="font-family:inherit;font-size:10pt;">&#32;of total net sales, during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">second</font><font style="font-family:inherit;font-size:10pt;">&#32;quarter of </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, compared </font><font style="font-family:inherit;font-size:10pt;">52%</font><font style="font-family:inherit;font-size:10pt;">&#32;of total net sales, during the same quarter of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">. The gross profit decreased by $0.3 million during the three months ended June 30, 2017 as compared to the same period of 2016 due to the decreased revenues discussed above and associated fixed costs to operate the laboratory.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;Operating expenses primarily consist of personnel costs, professional fees, travel costs, facility costs and depreciation. Our operating expenses increased by </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to $</font><font style="font-family:inherit;font-size:10pt;">0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the three months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. The increase in operating expenses reflects the increase in professional fees attributed to legal expenses related to the Merger.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Income (Expense).</font><font style="font-family:inherit;font-size:10pt;">&#32;Other expense for both the three months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes interest expense of approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for interest related to our debt. Also included in other expense for the three months ended June 30, 2017 was </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of advisory fees related to the Merger.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations for the Six Months Ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;31</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales. </font><font style="font-family:inherit;font-size:10pt;">Net sales were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Net Sales</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">508</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,042</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(534</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales decreased by $0.5 million, or 51%, for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to the same period in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">. The decrease is entirely due to the decrease in cases processed during the six months ended June 30, 2017 as compared to the same period in 2016.  We processed 429 cases during the six months ended June 30, 2017 as compared to 727 cases during the same period in 2016, or a 41% decrease in cases. The decrease in volume is the result of turnover of key sales personnel.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of Diagnostic Services.</font><font style="font-family:inherit;font-size:10pt;">&#32;Cost of diagnostic services includes material and supply costs for the patient tests performed and other direct costs (primarily personnel costs and rent) associated with the operations of our laboratory. Cost of diagnostic services remained flat for the six months ended June 30, 2017 as compared to the same period in 2016. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Gross Profit.</font><font style="font-family:inherit;font-size:10pt;">&#32;Gross profit and gross margins were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Margin %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross (Loss) Profit</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross profit was 8% of total net sales, for the six months ended June 30, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, compared to 54% of total net sales, for the same period of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">. The gross profit decreased by $0.5 million during the six months ended June 30, 2017 as compared to the same period in 2016 and was due to the decreased revenues discussed above.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;Operating expenses primarily consist of personnel costs, professional fees, travel costs, facility costs and depreciation. Our operating expenses increased by $0.3 million to $1.4 million for the six months ended June&#160;30, 2017 as compared to the same period in 2016. The increase in operating expenses reflects the increase fees attributed to legal and professional expenses related to the Merger. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Income (Expense).</font><font style="font-family:inherit;font-size:10pt;">&#32;Other expense for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes interest expense of approximately $0.3 million and $0.2 million, respectively, for interest related to our debt. The increase in the current year is due to increased interest bearing instruments outstanding during the six months ended June 30, 2017 as compared to the same period in 2016. Also included in other expense for the six months ended June 30, 2017 was $2.6 million of advisory fees related to the Merger.</font></div><div><a name="s3D9A0DC7375455DEBEECE77B6CC3E27D"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. As of June 30, 2017, the Company had a net loss of $4.4 million and negative working capital of $14.5 million. The Company&#8217;s ability to continue as a going concern is dependent upon a combination of achieving its business plan, including generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio is currently in discussions with certain investors to raise additional capital.  There can be no assurance such capital is available at terms favorable or agreeable to management, if at all, or that the Company will successfully complete the proposed capital raise. Since the outcome of these matters cannot be predicted with any certainty at this time, there is substantial doubt that the Company will be able to continue as a going concern.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company&#8217;s ability to continue as a going concern.  There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern. The accompanying financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of the outcome of this uncertainty.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our working capital positions at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were as follows:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets (including cash and cash equivalents of $967 and $51, respectively)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">552</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,246</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,314</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,012</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,302</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,516</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,460</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,056</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We completed the Merger on June 29, 2017 and in connection with the Merger we raised approximately $1.2 million in gross proceeds. At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash on hand of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. To execute our strategic plan, management is currently planning to raise additional investment capital. On August 1, 2017, we announced that we were planning a public offering of common stock and warrants in an underwritten public offering. There can be no assurances as to whether the offering will be completed, or as to the size or terms of the offering. Even if the offering is completed, we will need to raise additional funding. We cannot be certain that additional financing will be available on acceptable terms, or at all, and our failure to raise capital could limit our ability to continue our operations. The accompanying financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might result should we be unable to continue as a going concern as a result of the outcome of this uncertainty. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8C27830844175EDF9A938851520A02BD"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Analysis of Cash Flows - </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Six Months Ended</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">2016</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Change in Cash and Cash Equivalents.</font><font style="font-family:inherit;font-size:10pt;">&#32;Cash and cash equivalents increased by $0.9 million during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to a decrease of less than $0.1 million during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows Used in Operating Activities.</font><font style="font-family:inherit;font-size:10pt;">&#32;The cash flows used in operating activities of </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;included a net loss of </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and an increase in accounts receivable of $0.1 million. These were partially offset by an increase in accounts payable, accrued expenses and other liabilities of $0.8 million and non-cash adjustments of $3.0 million. The cash flows used in operating activities in the first </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;months of </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;included the net loss of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and an increase in accounts receivable of $0.3 million. These were partially offset by an increase in accounts payable, accrued expenses and other liabilities of $0.3 million and non-cash adjustments of $0.4 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows Provided by Investing Activities.</font><font style="font-family:inherit;font-size:10pt;">&#32;Cash flows provided by investing activities were $0.1 million and zero for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2016, respectively. The $0.1 million for the six months ended June 30, 2017 was cash acquired as part of the merger transaction.  </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows Provided by Financing Activities.</font><font style="font-family:inherit;font-size:10pt;">&#32;Cash flows provided by financing activities totaled $1.7 million for the six months ended June 30, 2017, which included proceeds of $0.3 million from the issuance of senior notes, $1.4 million from the issuance of convertible notes, and $0.4 million from the issuance of preferred stock. These proceeds were partially offset by payments on our debt, capital lease obligations and for deferred financing costs of $0.4 million. Cash flows provided by financing activities during the six months ended June 30, 2016 included proceeds of $0.5 million from the issuance of convertible notes partially offset by $0.1 million of payments on our debt, capital lease obligations and for deferred financing costs.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sD3F60BFE839153929209D3635452D41F"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At each of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into certain operating leases and purchase commitments as part of our normal course of business. See the accompanying unaudited condensed consolidated financial statements and Note 7 - &#8220;Contingencies&#8221; in the Notes to unaudited condensed consolidated financial statements for additional information regarding our contractual obligations and commitments</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s46E0A04F232D5ADD9B8EA7E366273193"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounting policies used in the preparation of our financial statements may involve the use of management judgments and estimates. Certain of our accounting policies are considered critical as they are both important to the portrayal of our financial statements and require significant or complex judgments on the part of management. Our judgments and estimates are based on experience and assumptions that we believe are reasonable under the circumstances. Further, we evaluate our judgments and estimates from time to time as circumstances change. Actual financial results based on judgments or estimates may vary under different assumptions or circumstances. For additional information regarding our critical accounting policies and estimates, see the accompanying unaudited condensed consolidated financial statements and Note 2 - &#8220;Summary of Significant Accounting Policies&#8221; in the Notes to unaudited condensed consolidated Financial Statements and Note 1 of the audited financial statements and notes thereto of Precipio Diagnostics for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;contained in our current report on Form 8-K/A, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 31, 2017. </font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFFE49E2A3F6F5229A77A002E633C1A95"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See the accompanying unaudited condensed consolidated financial statements and Note 2 - &#8220;Summary of Significant Accounting Policies&#8221; in the Notes to unaudited condensed financial statements for additional information regarding recently issued accounting pronouncements.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF9E88913752955A58F3522DABA6D59FF"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact of Inflation</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not believe that price inflation or deflation had a material adverse effect on our financial condition or results of operations during the periods presented.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6A3C871B25CC53CD8F0C1F38D3CE8EE7"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s957689494F765D44BBBE817074D0DD7B"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;font-size:10pt;text-indent:-48px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Controls and Procedures.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">management</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;text-decoration:underline;">has concluded that</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">our disclosure controls and procedures</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;text-decoration:underline;">n</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">or our internal controls over financial reporting will prevent all</font><font style="font-family:inherit;font-size:10pt;">&#32;fraud and material error. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving our objectives and our President and Chief Financial Officer concluded that our disclosure controls and procedures are</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;text-decoration:underline;">not</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">effective at</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;text-decoration:underline;">a</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">&#32;</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">reasonable assurance level</font><font style="font-family:inherit;font-size:10pt;">. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A&#160;material&#160;weakness&#160;is a significant deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a remote likelihood that a&#160;material&#160;misstatement of the annual or interim financial statements will not be prevented or detected.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that, as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the following deficiencies are believed to be material weaknesses:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s inability to account for the complex technical accounting treatment of complex debt and equity instruments.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s controls as related to revenue recognition resulting from the fact the Company does not have contracts with certain payors and does not have proper controls over the estimates for doubtful accounts  and contractual allowances.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Accounting for technical accounting and valuation of complex debt and equity instruments</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A&#160;material&#160;weakness&#160;exists pertaining to a lack of expertise in the technical accounting and valuation of complex debt and equity instruments that are required to be reported in accordance with accounting principles generally accepted in the United States of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">America and the valuation of fair values.&#160; To address the&#160;material&#160;weaknesses the Company continues to seek assistance with various third parties with expertise in such instruments and matters of fair value, in order to ensure that the Company's financial statements were prepared in accordance with U.S. GAAP on a timely basis.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Controls related to revenue recognition</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A material weakness exists due to the fact the Company does not have contracts with certain payors and does not have proper controls over the estimates for doubtful accounts and contractual allowances.  The Company&#8217;s net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered.  Revenue estimates are also subject to retroactive adjustments under reimbursement agreements.  Healthcare reimbursement laws and regulations governing Medicare and Medicaid programs that represent a portion of the Company&#8217;s net patient service revenues are extremely complex and subject to interpretation.  As a result, there is at least a reasonable possibility that recorded estimates could change by a material amount in the near future.  To address the material weakness the Company has added an additional review and reconciliation step to the revenue recognition process to ensure that all reported revenue recognizes appropriate third party contractual allowances and allowance for doubtful accounts. In addition, the additional review process will include current collection trends of payments and their impact on realizable revenues. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2017, the reverse merger of Precipio Diagnostics, Inc. and Transgenomic Inc. was completed.  The reporting period for the six months ended June 30, 2017, reflects the financial statements and operating activity of Precipio Diagnostic, the controlling entity of the merger transaction.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the merger, Precipio Diagnostics was a privately operated company.   Effective with the merger, Transgenomic changed its name to Precipio, Inc. and Mr. Ilan Danieli, Chief Executive Officer of Precipio Diagnostics and Carl Iberger, Chief Financial Officer of Precipio Diagnostics were appointed CEO and CFO respectively of Precipio, Inc., replacing Mr. Paul Kinnon, CEO and acting CFO of Transgenomic Inc.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have evaluated the changes in our internal control over the financial reporting that occurred during the six months ended June 30, 2017.  Management has identified a lack of sufficient personnel in the accounting function due to our limited resources with appropriate skills, training and experience to perform the review processes to ensure the complete and proper application of generally accepted accounting principles.  Management is addressing this material weakness with the addition of accounting and financial resource with proper skills, training and experience. As of the merger date, June 29, 2017, Management has added experienced accounting staff consisting of a Director of Accounting, Director of Financial Reporting and a staff accountant and additional administrative staff. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;35</font></div></div><hr style="page-break-after:always"><div><a name="s5FD994F1FD275EA6898AD5671EE3E65D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="s076A0F8DD2095797AABF3AE847836BE9"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings </font></div></td></tr></table><div style="line-height:120%;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See the accompanying unaudited condensed consolidated financial statements and Note 7 - &#8220;Contingencies&#8221; in the Notes to unaudited condensed consolidated financial statements for additional information regarding legal proceedings.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE6F43987BB6853A28AEB15D5BF659761"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a number of risks and uncertainties that may have a material effect on the operating results of our business and our financial condition. The following information updates, and should be read in conjunction with, the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2016, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K, as updated in our Quarterly Report for the quarter ended March 31, 2017 and this Quarterly Report, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to our Business and Strategy</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred losses since our inception and expect to incur losses for the foreseeable future. We cannot be certain that we will achieve or sustain profitability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred losses since our inception and expect to incur losses in the future.&#160;As of June 30, 2017 and December&#160;31, 2016, we have an accumulated total deficit of approximately $12.7&#160;million and $10.8&#160;million, respectively.&#160;For the six months ended June 30, 2017 and the fiscal year ended December&#160;31, 2016, we had a net loss and comprehensive loss attributable to common stockholders of approximately $1.8&#160;million and $4.1&#160;million, respectively.&#160;To date, we have experienced negative cash flow from development of our diagnostic technology, as well as from the costs associated with establishing a laboratory and building a sales force to market our products and services.&#160;We expect to incur substantial net losses for the foreseeable future to further develop and commercialize our diagnostic technology.&#160;We also expect that our selling, general and administrative expenses will continue to increase due to the additional costs associated with market development activities and expanding our staff to sell and support our products. Our ability to achieve or, if achieved, sustain profitability is based on numerous factors, many of which are beyond our control, including the market acceptance of our products, competitive product development and our market penetration and margins. We may never be able to generate sufficient revenue to achieve or, if achieved, sustain profitability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with further development and commercialization of our diagnostic technology and any future tests, we are unable to predict the extent of any future losses or when we will become profitable, if ever.&#160;We may never become profitable and you may never receive a return on an investment in our common stock.&#160;An investor in our common stock must carefully consider the substantial challenges, risks and uncertainties inherent in the development and commercialization of tests in the medical diagnostic industry.&#160;We may never successfully commercialize our diagnostic technology or any future tests, and our business may fail.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need to raise substantial additional capital to commercialize our diagnostic technology, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 30, 2017, our cash balance was $1.0&#160;million and our working capital was approximately negative $16.3&#160;million.&#160;Due to our recurring losses from operations and the expectation that we will continue to incur losses in the future, we will be required to raise additional capital to complete the development and commercialization of our current product candidates.&#160;To date, to fund our operations and develop and commercialize our products, we have relied primarily on equity and debt financings. When we seek additional capital, we may seek to sell additional equity and/or debt securities or to obtain a credit facility, which we may not be able to do on favorable terms, or at all.&#160;Our ability to obtain additional financing will be subject to a number of factors, including market conditions, our operating performance and investor sentiment.&#160;If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of our product candidates, restrict our operations or obtain funds by entering into agreements on unattractive terms.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The commercial success of our product candidates will depend upon the degree of market acceptance of these products among physicians, patients, health care payors and the medical community and on our ability to successfully market our product candidates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products may never gain significant acceptance in the marketplace and, therefore, may never generate substantial revenue or profits for us. Our ability to achieve commercial market acceptance for our existing and future products will depend on several factors, including:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to convince the medical community of the clinical utility of our products and their potential advantages over existing diagnostics technology;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the willingness of physicians and patients to utilize our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the agreement by commercial third-party payors and government payors to reimburse our products, the scope and amount of which will affect patients&#8217; willingness or ability to pay for our products and will likely heavily influence physicians&#8217; decisions to recommend our products.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;In addition, physicians may rely on guidelines issued by industry groups, such as the National Comprehensive Cancer Network, medical societies, such as the College of American Pathologists, or CAP, or other key oncology-related organizations before utilizing any diagnostic test. Although we have a study underway to demonstrate the clinical utility of our existing products, none of our products are, and may never be, listed in any such guidelines.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that publications of scientific and medical results in peer-reviewed journals and presentations at leading conferences are critical to the broad adoption of our products. Publication in leading medical journals is subject to a peer-review process, and peer reviewers may not consider the results of studies involving our products sufficiently novel or worthy of publication. The failure to be listed in physician guidelines or to be published in peer-reviewed journals could limit the adoption of our products. Failure to achieve widespread market acceptance of our products would materially harm our business, financial condition, and results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we cannot compete successfully with our competitors, including new entrants in the market, we may be unable to increase or sustain our revenue or achieve and sustain profitability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The medical diagnostic industry is intensely competitive and characterized by rapid technological progress.&#160;In each of our potential product areas, we face significant competition from large biotechnology, medical diagnostic and other companies. Our closest competitors fall largely into two groups, consisting of companies that specialize in oncology and offer directly competing services to our diagnostic services, offering their services to oncologists and pathology departments within hospitals, as well as large commercial companies that offer a wide variety of laboratory tests that range from simple chemistry tests to complex genetic testing.&#160;The technologies associated with the molecular diagnostics industry are evolving rapidly and there is intense competition within such industry.&#160;Certain molecular diagnostics companies have established technologies that may be competitive to our product candidates and any future tests that we develop.&#160;Some of these tests may use different approaches or means to obtain diagnostic results, which could be more effective or less expensive than our tests for similar indications.&#160;Moreover, these and other future competitors have or may have considerably greater resources than we do in terms of technology, sales, marketing, commercialization and capital resources.&#160;These competitors may have substantial advantages over us in terms of research and development expertise, experience in clinical studies, experience in regulatory issues, brand name exposure and expertise in sales and marketing as well as in operating central laboratory services.&#160;Many of these organizations have financial, marketing and human</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">resources greater than ours; therefore, there can be no assurance that we can successfully compete with present or potential competitors or that such competition will not have a materially adverse effect on our business, financial position or results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our diagnostic technology is under development, we cannot predict the relative competitive position of any product based upon our diagnostic technology.&#160;However, we expect that the following factors will determine our ability to compete effectively: safety and efficacy; product price; turnaround time; ease of administration; performance; reimbursement; and marketing and sales capability.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, we commenced a study to demonstrate the impact of academic pathology expertise on diagnostic accuracy. There is no assurance that this study, or other studies or trials we may conduct, will demonstrate favorable results. If the results of this study, or other studies or trials we may conduct, demonstrate unfavorable or inconclusive results, customers may choose our competitors&#8217; products over our products and our commercial opportunities may be reduced or eliminated.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that many of our competitors spend significantly more on research and development-related activities than we do.&#160;Our competitors may discover new diagnostic tools or develop existing technologies to compete with our diagnostic technology.&#160;Our commercial opportunities will be reduced or eliminated if these competing products are more effective, are more convenient or are less expensive than our product candidates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to develop new products or enhance the capabilities of our systems to keep pace with rapidly changing technology and customer requirements, which could have a material adverse effect on our business and operating results.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success depends on our ability to develop new products and applications for our diagnostic technology in existing and new markets, while improving the performance and cost-effectiveness of our systems. New technologies, techniques or products could emerge that might offer better combinations of price and performance than our current or future products and systems. Existing or future markets for our products, as well as potential markets for our diagnostic product candidates, are characterized by rapid technological change and innovation. It is critical to our success that we anticipate changes in technology and customer requirements and successfully introduce new, enhanced and competitive technologies to meet our customers&#8217; and prospective customers&#8217; needs on a timely and cost-effective basis. At the same time, however, we must carefully manage the introduction of new products. If customers believe that such products will offer enhanced features or be sold for a more attractive price, they may delay purchases until such products are available. We may also have excess or obsolete inventory of older products as we transition to new products and our experience in managing product transitions is very limited. If we do not successfully innovate and introduce new technology into our product lines or effectively manage the transitions to new product offerings, our revenues and results of operations will be adversely impacted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competitors may respond more quickly and effectively than we do to new or changing opportunities, technologies, standards or customer requirements. We anticipate that we will face increased competition in the future as existing companies and competitors develop new or improved products and as new companies enter the market with new technologies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently depend on the services of pathologists at a single academic partner and the loss of the services of these pathologists would adversely impact our ability to develop, commercialize and deliver our products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently depend on the services of pathologists at a single academic partner to review and render their diagnostic interpretation of our test results and to prepare the final diagnostic results that we integrate into our final report for our customers. Although we are in the process of adding new academic partners, it would be difficult to replace the services provided by the pathologists at our current partner if their services became unavailable to us for any reason prior to adding other academic partners. If this academic partner does not successfully carry out its contractual duties or obligations and meet expected deadlines; if this partner needs to be replaced, or if the quality or accuracy of the services provided by the pathologists at this partner were compromised for any reason, we would likely not be able to provide our services in a manner expected by our customers, and our financial results and the commercial prospects for our products could be harmed. The loss of the services of these pathologists would severely harm our ability to develop, commercialize and deliver our products, and our business, financial condition and operating results would be materially adversely affected.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend upon our officers, and if we are not able to retain them or recruit additional qualified personnel, the commercialization of our product candidates and any future tests that we develop could be delayed or negatively impacted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success is largely dependent upon the continued contributions of our officers.&#160;Our success also depends in part on our ability to attract and retain highly qualified scientific, commercial and administrative personnel.&#160;In order to pursue our test development and commercialization strategies, we will need to attract and hire additional personnel with specialized experience in a number of disciplines, including assay development, laboratory and clinical operations, sales and marketing, billing and reimbursement.&#160;There is intense competition for personnel in the fields in which we operate.&#160;If we are unable to attract new employees and retain existing employees, the development and commercialization of our product candidates and any future tests could be delayed or negatively impacted.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a small company with 30 full-time employees as of July&#160;31, 2017.&#160;Future growth will impose significant added responsibilities on members of management, including the need to identify, attract, retain, motivate and integrate highly skilled personnel.&#160;We may increase the number of employees in the future depending on the progress of our development of diagnostic technology.&#160;Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively.&#160;To that end, we must be able to:.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manage our clinical studies effectively;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">integrate additional management, administrative, manufacturing and regulatory personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">maintain sufficient administrative, accounting and management information systems and controls; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">hire and train additional qualified personnel.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;We may not be able to accomplish these tasks, and our failure to accomplish any of them could harm our financial results.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently have limited experience in marketing products.&#160;If we are unable to establish marketing and sales capabilities and retain the proper talent to execute on our sales and marketing strategy, we may not be able to generate product revenue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have developed limited experience in marketing our products and services.&#160;We intend to continue to develop our in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other diagnostic companies to recruit, hire, train and retain marketing and sales personnel.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to further grow our internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our product candidates or future products, however, we may not be able to establish or maintain such collaborative arrangements, or if we are able to do so, they may not have effective sales forces.&#160;Any revenue we receive will depend upon the efforts of such third parties, which may not be successful.&#160;We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves.&#160;We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not realize the anticipated benefits of our merger with Precipio Diagnostics.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, we completed our merger with Precipio Diagnostics, LLC, or Precipio Diagnostics. Integrating the operations of the businesses of Precipio Diagnostics successfully or otherwise realizing any of the anticipated benefits of the merger with Precipio, including anticipated cost savings and additional revenue opportunities, involves a number of potential challenges. The failure to meet these integration challenges could seriously harm our results of operations and the market price of our common stock may decline as a result.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Realizing the benefits of the merger will depend in part on the integration of information technology, operations and personnel. These integration activities are complex and time-consuming and we may encounter unexpected difficulties or incur unexpected costs, including:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our inability to achieve the cost savings and operating synergies anticipated in the merger, including synergies relating to increased purchasing efficiencies and a reduction in costs associated with the merger;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">diversion of management attention from ongoing business concerns to integration matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulties in consolidating and rationalizing information technology platforms and administrative infrastructures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">complexities associated with managing the geographic separation of the combined businesses and consolidating multiple physical locations where management may determine consolidation is desirable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulties in integrating personnel from different corporate cultures while maintaining focus on providing consistent, high quality customer service;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">challenges in demonstrating to our customers that the merger will not result in adverse changes in customer service standards or business focus; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">possible cash flow interruption or loss of revenue as a result of change of ownership transitional matters.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;We may not successfully integrate the operations of the businesses in a timely manner and may not realize the anticipated net reductions in costs and expenses and other benefits and synergies of the merger with Precipio Diagnostics to the extent, or in the timeframe, anticipated. In addition to the integration risks discussed above, our ability to realize these net reductions in costs and expenses and other benefits and synergies could be adversely impacted by practical or legal constraints on our ability to combine operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reimbursement and Regulatory Risks Relating to Our Business</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If commercial third-party payors or government payors fail to provide coverage or adequate reimbursement, or if there is a decrease in the amount of reimbursement for our existing products or any future products we develop, our ability to successfully commercialize our technology, and our revenue and prospects for profitability, would be harmed.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of our existing and any future products we develop will depend, in large part, upon the availability of reimbursement from third-party payors. These third-party payors include government healthcare programs such as Medicare and Medicaid, managed care providers, accountable care organizations, private health insurers, and other organizations. In particular, we believe that obtaining a positive local coverage determination or national coverage determination, and a favorable reimbursement rate from the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, or the applicable Medicare Administrative Contractor, or MAC, for each of our existing products, and any future products we develop, across substantially all medically indicated cancers will be a necessary element in achieving material commercial success. Physicians and patients may not order our products unless commercial third-party payors and government payors authorize such ordering and pay for all, or a substantial portion, of the list price, and certain </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">commercial third-party payors may not agree to reimburse our existing products or future products if CMS or the MACs assigned to the jurisdictions in which our operational laboratory facilities are located do not issue positive coverage decisions for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial third-party payors and government payors are increasingly attempting to contain healthcare costs by demanding price discounts, by limiting coverage on which diagnostic products they will pay for and the amounts that they will pay for new molecular diagnostic products, and by creating conditions to reimbursement, such as coverage eligibility requirements based upon clinical evidence development involving research studies and the collection of physician decision impact and patient outcomes data. Because of these cost-containment trends, commercial third-party payors and government payors that currently provide or in the future may provide reimbursement for one or more of our products may reduce, suspend, revoke, or discontinue payments or coverage at any time, including those payors that designate one or more of our existing products and/or clinically indicated tumor types as experimental and investigational. Payors may also create conditions to coverage or contract with third-party vendors to manage laboratory benefit coverage, in both cases creating burdens for ordering physicians and patients that may make our products more difficult to sell. The percentage of submitted claims that are ultimately paid, the length of time to receive payment on claims, and the average reimbursement of those paid claims, is likely to vary from period to period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result, there is significant uncertainty surrounding whether the use of products that incorporate new technology, such as our products, will be eligible for coverage by commercial third-party payors and government payors or, if eligible for coverage, what the reimbursement rates will be for these products. The fact that a diagnostic product has been approved for reimbursement in the past, or has received U.S. Food and Drug Administration, or FDA, approval, for any particular indication or in any particular jurisdiction, does not guarantee that such diagnostic product will remain approved for reimbursement or that similar or additional diagnostic products and/or clinically indicated tumor types will be approved in the future. Reimbursement of our existing and future products by commercial third-party payors and government payors may depend on a number of factors, including a payor&#8217;s determination that our existing and future products are:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not experimental or investigational;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">medically reasonable and necessary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">appropriate for the specific patient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cost effective;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">supported by peer-reviewed publications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">included in clinical practice guidelines and pathways; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">supported by clinical utility and health economic studies demonstrating improved outcomes and cost effectiveness.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market acceptance, sales of products based upon our diagnostic technology, and our profitability may depend on reimbursement policies and health care reform measures.&#160;Several entities conduct technology assessments of medical tests and devices and provide the results of their assessments for informational purposes to other parties.&#160;These assessments may be used by third-party payors and health care providers as grounds to deny coverage for a test or procedure.&#160;The levels at which government authorities and third-party payors, such as private health insurers and health maintenance organizations, may reimburse the price patients pay for such products could affect whether we are able to commercialize our products.&#160;Our product candidates may receive negative assessments that may impact our ability to receive reimbursement of the test.&#160;Since each payor makes its own decision as to whether to establish a policy to reimburse our test, seeking these approvals may be a time-consuming and costly process.&#160;We cannot be sure that reimbursement in the United States or elsewhere will be available for any of our products in the future.&#160;If reimbursement is not available or is limited, we may not be able to commercialize our products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United States and foreign governments continue to propose and pass legislation designed to reduce the cost of healthcare. We expect that there will continue to be federal and state proposals to implement governmental controls or impose healthcare requirements. In addition, the Medicare program and increasing emphasis on managed or accountable care in the United States will continue to put pressure on product utilization and pricing. Utilization and cost control initiatives could decrease the volume of orders and payment that we would receive for any products in the future, which would limit our revenue and profitability. If we are unable to obtain reimbursement approval from commercial third-party payors and Medicare and Medicaid programs for our product candidates, or if the amount reimbursed is inadequate, our ability to generate revenues could be limited.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in the way that the FDA regulates laboratory tests developed, manufactured, validated, and performed by laboratories like ours could result in additional expense in offering our current and any future products or even possibly delay or suspend development, manufacture, or commercialization of such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA does not currently regulate most laboratory developed tests, or LDTs. The FDA historically took the position that, although such LDTs are medical devices, it would exercise enforcement discretion by not requiring compliance with the Federal Food, Drug, and Cosmetic Act, or the FDCA, or its regulations. However, in June 2010, the FDA announced that it intended to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">no longer exercise enforcement discretion for LDTs and in October 2014, the FDA published two draft guidance documents that, if finalized, would implement a regulatory approach for most LDTs. In the draft guidance documents, the FDA stated that it had serious concerns regarding the lack of independent review of the evidence of clinical validity of LDTs and asserted that the requirements under Clinical Laboratory Improvement Amendments, or CLIA, do not address the clinical validity of any LDT. The draft guidance documents proposed to impose a risk-based, phased-in approach for LDTs similar to the existing framework for</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">diagnostic devices. In November 2016, the FDA announced that it would not finalize the draft guidance documents for LDTs prior to the end of the Obama administration.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FDA released a discussion paper synthesizing public comments on the 2014 draft guidance documents and outlining a possible approach to regulation of LDTs. The discussion paper has no legal status and does not represent a final version of the LDT draft guidance documents. In the discussion paper, the FDA states that there is &#8220;a growing consensus that additional oversight of LDTs is necessary.&#8221; Similar to the FDA&#8217;s 2014 draft guidance, the FDA&#8217;s discussion paper proposes a risk-based framework that would require most LDTs to comply with most of the FDA&#8217;s regulatory requirements for medical devices. Unlike the draft guidance, however, the discussion paper proposes to exempt currently marketed LDTs from premarket review, requiring only new or modified tests to be approved or cleared by the agency. In addition, the FDA proposed requiring LDTs to comply with only a subset of the medical device quality system regulations, or QSRs, and proposed other changes from the 2014 draft guidance. We cannot predict whether the FDA will take action to regulate LDTs under the new administration or what approach the FDA will seek to take.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legislative proposals have been introduced in Congress or publicly circulated, each of which would implement differing approaches to the regulation of LDTs. We cannot predict whether any of these legislative proposals will be enacted into law or the impact such new legal requirements would have on our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, in November 2013, the FDA finalized guidance regarding the sale and use of products labeled for research or investigational use only. Among other things, the guidance states that the FDA continues to be concerned about distribution of research- or investigational-use only products intended for clinical diagnostic use. The guidance states that the FDA will assess whether a manufacturer of such research- or investigational-use only products intends its products be used for clinical diagnostic purposes by examining the totality of circumstances, including advertising, instructions for clinical interpretation, presentations that describe clinical use, and specialized technical support such as assistance performing clinical validation, surrounding the distribution of the product in question. The FDA has advised that if evidence demonstrates that a product is inappropriately labeled for research-&#160;or investigational-use only, the device could be deemed misbranded and adulterated within the meaning of the FDCA. If the FDA were to undertake enforcement actions, some of our suppliers may cease selling research-use only products to us, and any failure to obtain an acceptable substitute could significantly and adversely affect our business, financial condition and results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">For tests that are subject to FDA regulation, we may not be able to obtain timely approvals for our tests or otherwise comply with FDA regulatory requirements, which could delay or prevent us from commercializing our tests or subject us to enforcement action and harm our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the FDA takes action to finalize and implement a regulatory system for LDTs, or if legislation is enacted that subjects LDTs to FDA regulation, we would need to comply with FDA regulatory requirements for our LDTs or any future LDTs intended for clinical use. For products that are subject to FDA requirements, including requirements for premarket clearance or approval, we may not be able to obtain such clearance or approvals on a timely basis, or at all. Our business could be negatively impacted if we are required to stop selling molecular information products pending their clearance or approval, or the launch of any new products that we develop could be delayed. The cost of conducting clinical trials and otherwise developing data and information to support premarket applications may be significant. In order to conduct a clinical investigation involving human subjects for the purpose of demonstrating the safety and effectiveness of a device, a sponsor of an investigation must, among other things, apply for and obtain institutional review board, or IRB, approval of the proposed investigation. In addition, if the clinical study involves a &#8220;significant risk&#8221; (as defined by the FDA) to human health, the sponsor of the investigation must also submit and obtain FDA approval of an investigational device exemption, or IDE, application. We or the applicable study sponsor, as applicable, may not be able to obtain FDA and/or IRB approval to undertake clinical trials in the United States for any new devices we intend to market in the United States.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a product is classified as a Class III medical device, that product would likely be required to be approved by the FDA under a premarket approval, or PMA, which must be supported by valid scientific evidence to demonstrate a reasonable assurance of safety and effectiveness of the subject product, typically including the results of human clinical trials that demonstrate the clinical utility of that product. During the review of our PMAs, the FDA may indicate areas in which the FDA believes additional data or information is necessary to reach a decision on the application. We may need to expend significant time and resources in responding to such FDA requests, which could include performing additional testing or developing new data to support the PMA. Depending </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on the nature of the requests, we may not be able to provide the data or information that the FDA believes necessary to resolve the deficiencies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For devices not subject to a PMA, we may be required to submit either a de novo reclassification request or, if classified as a Class II medical device, a premarket notification or 510(k). Under the 510(k) process, we must demonstrate that our products are substantially equivalent in technological characteristics and intended use to legally-marketed predicate devices. If we are unable to identify an appropriate predicate that is substantially equivalent to our device, we would be required to submit a PMA or a de novo reclassification request. The FDA&#8217;s 510(k) clearance process usually takes from four to twelve months, but it can take longer. Under the de novo process, we may request that the FDA classify a low or moderate risk device that lacks an appropriate predicate as a Class I or Class II device. The de novo process typically requires the development of clinical data and usually takes between six to twelve months from the time of submission of the de novo application, but can take longer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, as part of its review of a PMA, the FDA may conduct preapproval inspections pursuant to the FDA&#8217;s Bioresearch Monitoring (BIMO) program. During such inspections, FDA investigators may review the data and information supporting our PMA applications or may review the procedures and systems used to design or manufacture the device that is under review.&#160;The FDA may indicate areas where additional data or information is necessary, or areas where corrective or preventive actions should be implemented. We may need to expend significant time and resources in responding to such FDA requests, and depending on the nature of the requests, we may not be able to provide the data or information or implement the actions that the FDA believes are necessary.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After approval, products subject to FDA regulation are required to comply with post-market requirements. Among the requirements, we and our suppliers must comply with the FDA&#8217;s QSR, which sets forth requirements for manufacturers of devices, including the methods and documentation for the design, control testing, quality assurance, labeling, packaging, storage, and shipping of our devices. Further, if there are any modifications made to our PMA-approved marketed products, a PMA supplement may be required to be submitted to, and approved by, the FDA before the modified device may be marketed. Other post-market requirements include facility registration, product listing, adverse event reporting, recalls, corrections and removals, and restrictions on advertising and promotion. These requirements could subject our business to further regulatory risks and costs. The FDA enforces the requirements of the FDCA through announced and unannounced inspections. Failure to comply with the FDA&#8217;s view of our satisfaction of applicable regulatory requirements could require us to expend time and resources to respond to the FDA&#8217;s observations and to implement corrective and preventive actions, as appropriate. If we cannot resolve such issues to the satisfaction of the FDA, we may be subject to enforcement actions, including untitled or warning letters, fines, injunctions, or civil or criminal penalties. In addition, we could be subject to a recall or seizure of current or future products, operating restrictions, a partial suspension, or a total shutdown of production. Any such enforcement action would have a material adverse effect on our business, financial condition, and operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to the data privacy, security and breach notification requirements of HIPAA, HITECH and other data privacy and security laws, and the failure to comply with these rules, or allegations that we have failed to do so, could result in civil or criminal sanctions.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerous federal and state laws and regulations, including the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and the Health Information Technology for Economic and Clinical Health Act, as amended, or HITECH, govern the collection, dissemination, security, use and confidentiality of patient-identifiable health information. As required by HIPAA, the United States Department of Health and Human Services, or HHS, has adopted standards to protect the privacy and security of this health-related information. The HIPAA privacy regulations contain detailed requirements concerning the use and disclosure of individually identifiable health information and the grant of certain rights to patients with respect to such information by &#8220;covered entities.&#8221; Because of our CLIA laboratory we are a covered entity under HIPAA. We have taken actions to comply with the HIPAA privacy regulations including the creation and implementation of policies and procedures, staff training, execution of HIPAA-compliant contractual arrangements with certain service providers and various other measures. Although we believe we are in substantial compliance, ongoing implementation and oversight of these measures involves significant time, effort and expense.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the privacy requirements, HIPAA covered entities must implement certain administrative, physical, and technical security standards to protect the integrity, confidentiality and availability of certain electronic health-related information received, maintained, or transmitted by covered entities or their business associates. Although we have taken actions in an effort to be in compliance with these security regulations, a security incident that bypasses our information security systems causing an information security breach, loss of protected health information, or PHI, or other data subject to privacy laws or a material disruption of our operational systems could have a material adverse effect on our business, along with fines. Furthermore, ongoing implementation and oversight of these security measures involves significant time, effort and expense.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, HITECH, as implemented in part by an omnibus final rule&#160;published in the Federal Register on January&#160;25, 2013, further requires that patients be notified of any impermissible acquisition, access, use, or disclosure of their unsecured PHI that compromises the privacy or security of such information. HHS has established the presumption that all impermissible uses or disclosures of unsecured PHI constitute breaches unless the covered entity or business associate establishes affirmatively through a risk analysis that there is a low probability the information has been compromised. HITECH and implementing regulations specify that such notifications must be made without unreasonable delay and in no case later than 60 calendar days after discovery of the breach. Breaches affecting 500 patients or more must be reported immediately to HHS, which will post the name of the breaching entity on its public website. Furthermore, breaches affecting 500 patients or more in the same state or jurisdiction must also be reported to the local media. If a breach involves fewer than 500 people, the covered entity must record it in a log and notify HHS of such breaches at least annually. These breach notification requirements apply not only to impermissible disclosures of unsecured PHI to outside third parties but also to impermissible internal access to or use of such PHI. All breaches also require written notice to be sent to affected individuals.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The scope of the privacy and security requirements under HIPAA was substantially expanded by HITECH, which also increased penalties for violations. Currently, violations of the HIPAA privacy, security and breach notification standards may result in civil penalties ranging from $100 to $50,000 per violation, subject to a cap of $1,500,000 in the aggregate for violations of the same standard in a single calendar year. The amount of penalty that may be assessed depends, in part, upon the culpability of the applicable covered entity or business associate in committing the violation. HITECH also authorized state attorneys general to file suit on behalf of residents of their states. Applicable courts may be able to award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. HITECH also mandates that the Secretary of HHS conduct periodic compliance audits of a cross-section of HIPAA covered entities and business associates. Every covered entity and business associate is subject to being audited, regardless of the entity&#8217;s compliance record.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State laws may impose more protective privacy restrictions related to health information and may afford individuals a private right of action with respect to the violation of such laws. Both state and federal laws are subject to modification or enhancement of privacy protection at any time. We are subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These statutes vary and could impose additional requirements on us and more severe penalties for disclosures of health information. If we fail to comply with HIPAA, similar state laws or any new laws, including laws addressing data confidentiality, security or breach notification, we could incur substantial monetary penalties and substantial damage to our reputation.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">States may also impose restrictions related to the confidentiality of personal information that is not considered PHI under HIPAA, including certain identifying information and financial information of our patients. These state laws may impose additional notification requirements in the event of a breach of such personal information. Failure to comply with such data confidentiality, security and breach notification laws may result in substantial monetary penalties.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HIPAA and HITECH also include standards for common healthcare electronic transactions and code sets, such as claims information, plan eligibility and payment information. Covered entities such as us (with our CLIA laboratory) are required to conform to such transaction set standards.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may become subject to the Anti-Kickback Statute, Stark Law, False Claims Act, Civil Monetary Penalties Law and may be subject to analogous provisions of applicable state laws and could face substantial penalties if we fail to comply with such laws.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are several federal laws addressing fraud and abuse that apply to businesses that receive reimbursement from a federal health care program. There are also a number of similar state laws covering fraud and abuse with respect to, for example, private payors, self-pay and insurance. Currently, we receive a substantial percentage of our revenue from private payors and from Medicare. Accordingly, our business is subject to federal fraud and abuse laws, such as the Anti-Kickback Statute, the Stark Law, the False Claims Act, the Civil Monetary Penalties Law and other similar laws. Moreover, we are already subject to similar state laws. We have operated, and intend to continue to operate, our business in compliance with these laws. However, these laws are subject to</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">modification and changes in interpretation, and are enforced by authorities vested with broad discretion. Federal and state enforcement entities have significantly increased their scrutiny of healthcare companies and providers which has led to investigations, prosecutions, convictions and large settlements. We continually monitor developments in this area. If these laws are interpreted in a manner contrary to our interpretation or are reinterpreted or amended, or if new legislation is enacted with respect to healthcare fraud and abuse, illegal remuneration, or similar issues, we may be required to restructure our affected operations to maintain compliance with applicable law. There can be no assurances that any such restructuring will be possible or, if possible, would not have a material adverse effect on our results of operations, financial position, or cash flows.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Anti-Kickback Statute</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A federal law commonly referred to as the &#8220;Anti-Kickback Statute&#8221; prohibits the knowing and willful offer, payment, solicitation or receipt of remuneration, directly or indirectly, in return for the referral of patients or arranging for the referral of patients, or in return for the recommendation, arrangement, purchase, lease or order of items or services that are covered, in whole or in part, by a federal healthcare program such as Medicare or Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value such as gifts, discounts, rebates, waiver of payments or providing anything at less than its fair market value. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, amended the intent requirement of the Anti-Kickback Statute such that a person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate the statute. Further, the PPACA now provides that claims submitted in violation of the Anti-Kickback Statute constitute false or fraudulent claims for purposes of the federal False Claims Act, or FCA, including the failure to timely return an overpayment. Many states have adopted similar prohibitions against kickbacks and other practices that are intended to influence the purchase, lease or ordering of healthcare items and services reimbursed by a governmental health program or state Medicaid program. Some of these state prohibitions apply to remuneration for referrals of healthcare items or services reimbursed by any third-party payor, including commercial payors and self-pay patients.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stark Law</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Section&#160;1877 of the Social Security Act, or the Stark Law, prohibits a physician from referring a patient to an entity for certain &#8220;designated health services&#8221; reimbursable by Medicare if the physician (or close family members) has a financial relationship with that entity, including an ownership or investment interest, a loan or debt relationship or a compensation relationship, unless an exception to the Stark Law is fully satisfied. The designated health services covered by the law include, among others, laboratory and imaging services. Some states have self-referral laws similar to the Stark Law for Medicaid claims and commercial claims.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Violation of the Stark Law may result in prohibition of payment for services rendered, a refund of any Medicare payments for services that resulted from an unlawful referral, $15,000 civil monetary penalties for specified infractions, criminal penalties, and potential exclusion from participation in government healthcare programs, and potential false claims liability. The repayment provisions in the Stark Law are not dependent on the parties having an improper intent; rather, the Stark Law is a strict liability statute and any violation is subject to repayment of all amounts arising out of tainted referrals. If physician self-referral laws are interpreted differently or if other legislative restrictions are issued, we could incur significant sanctions and loss of revenues, or we could have to change our arrangements and operations in a way that could have a material adverse effect on our business, prospects, damage to our reputation, results of operations and financial condition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">False Claims Act</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FCA prohibits providers from, among other things, (1)&#160;knowingly presenting or causing to be presented, claims for payments from the Medicare, Medicaid or other federal healthcare programs that are false or fraudulent; (2)&#160;knowingly making, using or causing to be made or used, a false record or statement to get a false or fraudulent claim paid or approved by the federal government; or (3)&#160;knowingly making, using or causing to be made or used, a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. The &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; provisions of the FCA allow private individuals to bring actions under the FCA on behalf of the government. These private parties are entitled to share in any amounts recovered by the government, and, as a result, the number of &#8220;whistleblower&#8221; lawsuits that have been filed against providers has increased significantly in recent years. Defendants found to be liable under the FCA may be required to pay three times the actual damages sustained by the government, plus civil penalties ranging between $5,500 and $11,000 for each separate false claim.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are many potential bases for liability under the FCA. The government has used the FCA to prosecute Medicare and other government healthcare program fraud such as coding errors, billing for services not provided, and providing care that is not medically necessary or that is substandard in quality. The PPACA also provides that claims submitted in connection with patient referrals that result from violations of the Anti-Kickback Statute constitute false claims for the purpose of the FCA, and some courts have held that a violation of the Stark law can result in FCA liability, as well. In addition, a number of states have adopted their own false claims and whistleblower provisions whereby a private party may file a civil lawsuit in state court. We are required to provide information to our employees and certain contractors about state and federal false claims laws and whistleblower provisions and protections.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Civil Monetary Penalties Law</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Civil Monetary Penalties Law prohibits, among other things, the offering or giving of remuneration to a Medicare or Medicaid beneficiary that the person or entity knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider or supplier of items or services reimbursable by a federal or state healthcare program. This broad provision applies to many kinds of inducements or benefits provided to patients, including complimentary items, services or transportation that are of more than a nominal value. This law could affect how we have to structure our operations and activities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare policy changes, including legislation reforming the U.S. healthcare system, may have a material adverse effect on our financial condition, results of operations, and cash flows.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2010, legislation collectively referred to as the Affordable Care Act, or ACA, was enacted in the United States. The ACA, as subsequently amended, made a number of substantial changes in the way healthcare is financed by both governmental and private insurers. Among other things, the ACA:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requires each medical device manufacturer and importer to pay an excise tax equal to 2.3% of the sale price for its taxable medical devices. In 2015, Congress imposed a 2-year moratorium on this medical device tax, so that medical device sales during the period between January&#160;1, 2016 and December&#160;31, 2017 are exempt from the tax. Absent further legislative action, the tax will be automatically reinstated for medical device sales starting on January&#160;1, 2018. If the tax is reinstated and if our products become regulated as medical devices, we could be required to begin paying this tax on the sales of our products for which we submit a marketing application, such as a 510(k) or PMA, to the FDA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">mandates a reduction in payments for clinical laboratory services paid under the Medicare Clinical Laboratory Fee Schedule, or CLFS, of 1.75% for the years 2011 through 2015. In addition, a productivity adjustment is made to the fee schedule payment amount.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;On April&#160;1, 2013, cuts to the federal budget were implemented, known as sequestration, resulting in a 2% annual cut in Medicare payments for all services, including clinical laboratory testing. Congress has since extended this 2% Medicare sequester through fiscal year 2025. At this time, it remains uncertain how long the cuts will be continued.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many CPT procedure codes for molecular pathology tests that we use to bill our products were revised by the American Medical Association, or AMA, effective January&#160;1, 2013. These new CPT codes were developed and implemented for individual genes, or the components of a multi-gene panel. In a final rule for calendar year 2013, CMS announced that it decided to keep the new molecular codes on the CLFS rather than move them to the Physician Fee Schedule. CMS then announced that for 2013, it would price the new codes using a &#8220;gap filling&#8221; process. Under this approach, CMS referred the CPT codes to the MACs to allow them to determine an appropriate price. CMS then calculated the median of the pricing provided by the MACs to establish and publish a National Limitation Amount, or NLA, by CPT code for 2014.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, the AMA approved and implemented new CPT codes for genomic sequencing-based panel tests in cancer, effective January&#160;1, 2015. In 2015, CMS used a &#8220;gap filling&#8221; process to price some of these new codes, which involved referring the new codes to the MACs to allow them to determine and submit to CMS an appropriate price if they deemed a code to be a covered service. CMS then established and published for 2016 an NLA for some of these codes, including the code associated with testing for 5-50 genes as calculated by determining the median price as provided by the MACs for the applicable code. If CMS reduces reimbursement for the new CPT codes for individual genes or fails to price new multi-gene panel codes which cover our products, or if commercial payors who often base pricing on Medicare fee schedules reduce non-contracted payment rates below the new NLA amount for CPT codes corresponding to individual genes, mandate use of the new sequencing-based panel CPT codes, or decide to stop payment on specific CPT codes altogether, our revenue could be adversely affected.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, in April 2014 the Protecting Access to Medicare Act of 2014, or PAMA, was enacted into law. Section&#160;216 of PAMA reforms the Medicare payment system for clinical laboratory tests paid through the CLFS. PAMA establishes a market-based payment system for Medicare payment for clinical diagnostic laboratory tests. Under this new methodology, CMS will establish Medicare payment for each test based on the weighted median of the payment rates for private payors for the test. PAMA also creates a new class of test called the Advanced Diagnostic Laboratory Test, or ADLT, defined as a test offered and furnished by a single laboratory that is not sold for use by a laboratory other than the original developing laboratory and is either a (1)&#160;multi-biomarker test of DNA, RNA or proteins with a unique algorithm yielding a single, patient-specific result, (2)&#160;test that is cleared or approved by the FDA, or (3)&#160;test meeting other similar criteria established by the Secretary of Health and Human Services.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PAMA requires certain clinical laboratories meeting a threshold of Medicare revenues to report private payor payment rates and corresponding test volumes. PAMA also directed CMS to establish parameters to implement PAMA by June&#160;30, 2015 and requires the market-based payment system to start on January&#160;1, 2017. In June 2016, CMS issued the Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule, or the Final Rule, to implement the laboratory test payment provisions of PAMA. Because the issuance of the Final Rule was delayed, CMS delayed the market-based payment rates until January&#160;1, 2018. The agency has issued sub-regulatory guidance on data collection and reporting and on additional topics, including a list of specific billing codes for which laboratories must report data. CMS is expected to publish additional sub-regulatory guidance describing how PAMA will be implemented, including an application process for ADLTs. At this time, the full impact of the implementation of PAMA on new and existing tests is uncertain. Our average commercial payor reimbursement starting in 2018 could be adversely affected depending upon if and how commercial payors adopt this new Medicare pricing methodology and the payment rates.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Center for Medicare and Medicaid Innovation announced in June 2016 the launch of the Oncology Care Model, or OCM, beginning on July&#160;1, 2016. The OCM is a five-year voluntary program that includes 190 physician practices in 31 states, as well as 16 private payors. Under the OCM, participating practices receive performance based payments on the basis of how their prices for 6-month &#8220;episodes&#8221; of cancer care triggered by receipt of chemotherapy compare to &#8220;benchmark&#8221; prices for similar episodes. These benchmarks are based on the historical data for the period of January 2012 through June 2015. The model may impact the utilization of our tests among those practices participating in OCM.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finally, the recent presidential and congressional elections in the U.S. could result in significant changes in, and uncertainty with respect to, legislation, regulation and government policy that could significantly impact our business and the healthcare industry. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election that could have a material impact on us include, but are not limited to, the repeal of the ACA, modifications and elimination of programs and reductions in staffing at the FDA and CMS, and initiatives to contain or reduce governmental spending in the healthcare area, including Medicare and Medicaid reimbursement. We cannot predict what future healthcare initiatives will be introduced or implemented at the federal or state level, or how any future legislation or regulation may affect us. Any taxes imposed by federal legislation and the expansion of the government&#8217;s role in the U.S. healthcare industry generally, as well as changes to the reimbursement amounts paid by payors for our existing and future products, may reduce our profits and have a material adverse effect on our business, financial condition, results of operations, and cash flows.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with the complex federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention, or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration, participation in proficiency testing, patient test management, quality control, quality assurance, and inspections. Our laboratory facilities located in the United States each have a current certificate of accreditation under CLIA to conduct our analyses through our accreditation by CAP. To renew these certificates, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make unannounced inspections of our clinical reference laboratories at any time.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business. Most CLIA deficiencies are not classified as &#8220;condition-level&#8221; deficiencies, and there are no adverse effects upon the laboratory operations as long as the deficiencies are corrected. Remediation of these deficiencies are routine matters, with corrections occurring within several hours or weeks. More serious CLIA deficiencies could rise to the level of &#8220;condition-level&#8221; deficiencies, and CMS has the authority to impose a wide range of sanctions, including revocation of the CLIA certification along with a bar on the ownership or operation of a CLIA certified laboratory by any owners or operators of the deficient laboratory. There is an administrative hearing procedure that can be pursued by the laboratory in the event of imposition of such sanctions, during which the sanctions are stayed, but the process can take a number of years to complete. If we were to lose our CLIA certification or CAP accreditation, we would not be able to operate our clinical laboratories and perform our molecular tests, which would result in material harm to our business and results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to CLIA and HIPAA, our operations are subject to other extensive federal, state, local, and foreign laws and regulations, all of which are subject to change. These laws and regulations currently include, among others:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HIPAA, under which the Department of Health and Human Services established comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions; certain of our services, are subject to these standards and requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">amendments to HIPAA under the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act, and related regulatory amendments, which strengthen and expand HIPAA privacy and security standards, increase penalties for violators, extend enforcement authority to state attorneys general, and impose requirements for breach notification;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal healthcare program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Stark physician self-referral law, which prohibits a physician from making a referral for certain designated health services covered by a federal healthcare program, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services, unless the financial relationship falls within an applicable exception to the prohibition;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal False Claims Act, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or other federal or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or other federal or state healthcare program, unless an exception applies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, prohibitions on the provision of products at no or discounted cost to induce physician or patient adoption, and false claims acts, which may extend to services reimbursable by any third-party payor, including private insurers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the prohibition on reassignment of Medicare clinical laboratory claims, which, subject to certain exceptions, precludes the reassignment of such Medicare claims to any other party;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rules regarding billing for diagnostic tests reimbursable by the Medicare program, which in certain circumstances prohibit laboratories from charging the Medicare program directly for services provided to hospital inpatients and outpatients, and also prohibit a physician or other supplier from marking up the price of the technical component or professional component of certain diagnostic tests ordered by the physician or other supplier and supervised or performed by a physician who does not &#8220;share a practice&#8221; with the billing physician or supplier;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state laws that prohibit other specified practices, such as billing physicians for testing that they order; waiving coinsurance, copayments, deductibles, and other amounts owed by patients; billing a state Medicaid program at a price that is higher than what is charged to one or more other payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal and state laws regulating lobbying activities, including the disclosure of payments made in connection with such activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">similar foreign laws and regulations that apply to us in the countries in which we operate.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Our failure to comply could lead to civil or criminal penalties, exclusion from participation in government healthcare programs, or prohibitions or restrictions on our ability to conduct commercial activities. We believe that we are in material compliance with all statutory and regulatory requirements, but there is a risk that one or more government agencies could take a contrary position. These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. If one or more such agencies allege that we may be in violation of any of these requirements, regardless of the outcome, it could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations and other commercial third-party payors.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property Risks Related to Our Business</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on patent protection as well as a combination of trademark, copyright and trade secret protection, and other contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage.&#160;If we fail to protect our intellectual property, we will be unable to prevent third parties from using our technologies and they will be able to compete more effectively against us.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future patent applications may not result in issued patents and any patents issued to us may be challenged, invalidated or held unenforceable.&#160;We may not be successful in defending challenges made in connection with our patents and patent applications.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our patents, we rely on contractual restrictions to protect our proprietary technology.&#160;We require our employees and third parties to sign confidentiality agreements and employees to also sign agreements assigning to us all intellectual property arising from their work for us.&#160;Nevertheless, these measures may not be effective in protecting our intellectual property rights.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend on certain technologies that are licensed to us. We do not control these technologies and any loss of our rights to them could prevent us from selling some of our products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into several license agreements with third parties for certain licensed technologies that are, or may become, relevant to the products we market, or plan to market, including our license agreement with Dana-Farber Cancer Institute, Inc., pursuant to which we license our ICE-COLD-PCR technology. In addition, we may in the future elect to license third party intellectual property to further our business objectives and/or as needed for freedom to operate for our products. We do not and will not own the patents, patent applications or other intellectual property rights that are a subject of these licenses. Our rights to use these technologies and employ the inventions claimed in the licensed patents, patent applications and other intellectual property rights are or will be subject to the continuation of and compliance with the terms of those licenses.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We might not be able to obtain licenses to technology or other intellectual property rights that we require. Even if such licenses are obtainable, they may not be available at a reasonable cost or multiple licenses may be needed for the same product (e.g., stacked royalties). We could therefore incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins. Further, we could encounter delays in product introductions, or interruptions in product sales, as we develop alternative methods or products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In some cases, we do not or may not control the prosecution, maintenance, or filing of the patents or patent applications to which we hold licenses, or the enforcement of these patents against third parties. As a result, we cannot be certain that drafting or prosecution of the licensed patents and patent applications by the licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The patents issued to us may not be broad enough to provide any meaningful protection one or more of our competitors may develop more effective technologies, designs or methods without infringing our intellectual property rights and one or more of our competitors may design around our proprietary technologies.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are not able to protect our proprietary technology, trade secrets and know-how, our competitors may use our inventions to develop competing products.&#160;We own certain patents relating to our diagnostic technology.&#160;However, these patents may not protect us against our competitors, and patent litigation is very expensive.&#160;We may not have sufficient cash available to pursue any patent litigation to its conclusion because other than revenue from licensing, milestone and royalty income we currently generate only minimal revenue from our diagnostic services.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot rely solely on our current patents to be successful.&#160;The standards that the U.S.&#160;Patent and Trademark Office and foreign patent office&#8217;s use to grant patents, and the standards that U.S. and foreign courts use to interpret patents, are not the same and are not always applied predictably or uniformly and can change, particularly as new technologies develop.&#160;As such, the degree of patent protection obtained in the U.S. may differ substantially from that obtained in various foreign countries.&#160;In some instances, patents have been issued in the U.S. while substantially less or no protection has been obtained in Europe or other countries.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot be certain of the level of protection, if any, which will be provided by our patents if we attempt to enforce them and they are challenged in court where our competitors may raise defenses such as invalidity, unenforceability or possession of a valid license.&#160;In addition, the type and extent of any patent claims that may be issued to us in the future are uncertain.&#160;Any patents which are issued may not contain claims that will permit us to stop competitors from using similar technology.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use, our diagnostic technology.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third parties may challenge the validity of our patents and other intellectual property rights, resulting in costly litigation or other time-consuming and expensive proceedings, which could deprive us of valuable rights.&#160;If we become involved in any intellectual property litigation, interference or other judicial or administrative proceedings, we will incur substantial expenses and the diversion of financial resources and technical and management personnel.&#160;An adverse determination may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all.&#160;Further, if such claims are proven valid, through litigation or otherwise, we may be required to pay substantial financial damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly delay development, marketing, selling and licensing of the affected products and intellectual property rights.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours.&#160;Any such patent application may have priority over our patent applications and could further require us to obtain rights to issued patents covering such technologies.&#160;There may be third-party patents, patent applications and other intellectual property relevant to our potential products that may block or compete with our products or processes.&#160;If another party has filed a United States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the United States Patent and Trademark Office to determine priority of invention in the United States.&#160;The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our United States patent position with respect to such inventions.&#160;In addition, we may not prevail in any of these suits or that the damages or other remedies if any, awarded against us could be substantial.&#160;Claims of intellectual property infringement may require us to enter into royalty or license agreements with third parties that may not be available on acceptable terms, if at all.&#160;We may also become subject to injunctions against the further development and use of our technology, which would have a material adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.&#160;In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third parties may assert ownership or commercial rights to inventions we develop.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third parties may in the future make claims challenging the inventorship or ownership of our intellectual property. For example, third parties that have been introduced to or have benefited from our inventions may attempt to replicate or reverse engineer our products and circumvent ownership of our inventions. We have written agreements with collaborators that provide for the ownership of intellectual property arising from our collaborations. In some instances, there may not be adequate written provisions to address clearly the resolution of intellectual property rights that may arise from a collaboration. If we cannot successfully negotiate sufficient ownership and commercial rights to the inventions that result from our use of a third-party collaborator&#8217;s materials where required, or if disputes otherwise arise with respect to the intellectual property developed with the use of a collaborator&#8217;s samples, we may be limited in our ability to capitalize on the market potential of these inventions. In addition, we may face claims that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such inventions. Litigation may be necessary to resolve an ownership dispute, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome could have an adverse impact on our business.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We employ individuals who were previously employed at other diagnostic or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The testing, manufacturing and marketing of medical diagnostic devices entails an inherent risk of product liability and personal injury claims.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have experienced no product liability or personal injury claims, but any such claims arising in the future could have a material adverse effect on our business, financial condition and results of operations.&#160;Potential product liability or personal injury claims may exceed the amount of our insurance coverage or may be excluded from coverage under the terms of our policy or limited by other claims under our umbrella insurance policy.&#160;Additionally, our existing insurance may not be renewed by us at a cost and level of coverage comparable to that presently in effect, if at all.&#160;In the event that we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, such claim could have a material adverse effect on our cash flow and thus potentially a materially adverse effect on our business, financial condition and results of operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">All of our diagnostic technology development and our clinical services are performed at two laboratories, and in the event either or both of these facilities were to be affected by a termination of the lease or a man-made or natural disaster, our operations could be severely impaired.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are performing all of our diagnostic services in our CLIA laboratory located in New Haven, Connecticut and our research and development operations are based in our facility in Omaha, Nebraska.&#160;Despite precautions taken by us, any future natural or man-made disaster at these laboratories, such as a fire, earthquake or terrorist activity, could cause substantial delays in our operations, damage or destroy our equipment and testing samples or cause us to incur additional expenses.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we are leasing the facilities where our laboratories operate.&#160;We are currently in compliance with all and any lease obligations, but should the leases terminate for any reason, or if at any time either of the laboratories is moved due to conditions outside our control, it could cause substantial delay in our diagnostics operations, damage or destroy our equipment and biological samples or cause us to incur additional expenses.&#160;In the event of an extended shutdown of either laboratory, we may be unable to perform our services in a timely manner or at all and therefore would be unable to operate in a commercially competitive manner.&#160;This could harm our operating results and financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, if we have to use a substitute laboratory while our facilities were shut down, we could only use another facility with established state licensure and accreditation under CLIA.&#160;We may not be able to find another CLIA-certified facility and comply with applicable procedures, or find any such laboratory that would be willing to perform the tests for us on commercially reasonable terms.&#160;Additionally, any new laboratory opened by us would be subject to certification under CLIA and licensure by various states, which would take a significant amount of time and result in delays in our ability to continue our operations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;50</font></div></div><hr style="page-break-after:always"><div><a name="sD33F4997F32155398AE50323C4305DFC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.            &#160;&#160;&#160;&#160;Unregistered  Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None other than the sales previously disclosed in our Current reports on Form 8-K filed on April 17,2017, June 27, 2017 and June 20, 2017.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4FA28EE63B8F5CF9B9C1906D06A902EC"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6.</font></div></td><td style="vertical-align:top;padding-left:90px;"><div style="line-height:120%;text-align:right;font-size:10pt;text-indent:-90px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Amendment to the Merger Agreement (incorporated by reference to Exhibit 2.1 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certificate of Elimination (incorporated by reference to Exhibit 3.3 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities Purchase Agreement, dated as of April 13, 2017, between the Company and the investors parties thereto (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed on April 17, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Bridge Notes (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 8-K filed on April 17, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Bridge Warrant (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Form 8-K filed on April 17, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio Note (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Form 8-K filed on April 17, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subordination Agreement (incorporated by reference to Exhibit 10.5 of the Company&#8217;s Form 8-K filed on April 17, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Side Letter to extend Maturity Date of Unsecured Convertible Promissory Note by and between the Company and MAZ Partners LP, dated as of June 21, 2017 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed on June 27, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed on June 28, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Non-Qualified Stock Option Agreement for Non-Employee Directors (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 8-K filed on June 28, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Non-Qualified Stock Option Agreement for Company Employees (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Form 8-K filed on June 28, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Form 8-K filed on June 28, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities Purchase Agreement with the Private Placement Purchasers (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investors&#8217; Rights Agreement (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exchange Agreement (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">New Bridge Securities Purchase Agreement (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of New Bridge Promissory Note (incorporated by reference to Exhibit 10.5 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of New Bridge Warrant (incorporated by reference to Exhibit 10.6 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Form of Side Warrant (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Form 8-K filed on June 30, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Pathology Services Agreement, dated March&#160;21, 2017, by and between the Company and Yale University (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Form 8-K/A filed on July 31, 2017)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease, dated July&#160;11, 2017, by and between the Company and Science Park Development Corporation (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 8-K/A filed on July 31, 2017)</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Ilan Danieli, Chief Executive Officer, pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002, as amended.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Carl Iberger, Chief Financial Officer, pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002, as amended.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Ilan Danieli, Chief Executive Officer, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, as amended.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification of Carl Iberger, Chief Financial Officer, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, as amended.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;52</font></div></div><hr style="page-break-after:always"><div><a name="sB790CFCABC7D58CF9FFAB0C86DFF0213"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;" href="#s0B41536D70595A8FACE3BDDB381D9B60"><font style="font-family:inherit;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:6%;"></td><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PRECIPIO,&#160;INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:40px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;21, 2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ ILAN DANIELI</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ilan Danieli</font></div><div style="padding-bottom:1px;text-align:center;text-indent:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Executive Officer (Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August&#160;21, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/</font><font style="font-family:inherit;font-size:8pt;">S</font><font style="font-family:inherit;font-size:10pt;">/ CARL IBERGER</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carl Iberger</font></div><div style="padding-bottom:1px;text-align:center;text-indent:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer (Principal Financial Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;53</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>prpo-ex311_20170630x10q.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s19B8A4F53CED54EAB259160A6F5149DB"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Ilan Danieli, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Precipio, Inc. (the Registrant);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and I have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to me by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.40625%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ ILAN DANIELI</font></div><div style="padding-bottom:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ilan Danieli</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Executive Officer (Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">August&#160;21, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>prpo-ex312_20170630x10q.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFFB07F039D7C58CBAE8E1AE2939B0797"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Carl Iberger, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Precipio, Inc. (the Registrant);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and we have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.40625%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ CARL IBERGER</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carl Iberger</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer (Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">August&#160;21, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>prpo-ex321_20170630x10q.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4DA21D84B84D520DBA95FFC606ACD3BF"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the accompanying Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, I, Ilan Danieli, Chief Executive Officer of Precipio, Inc., hereby certify pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in such Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, fairly presents, in all material respects, the financial condition and results of operations of Precipio, Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.40625%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ ILAN DANIELI</font></div><div style="padding-bottom:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ilan Danieli</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Executive Officer (Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">August&#160;21, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of the certification required by Section&#160;906 has been provided to Precipio, Inc. and will be retained by Precipio, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>prpo-ex322_20170630x10q.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s0DCC389EE0A35D0394EEBE1DD4A1F72A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the accompanying Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, I, Carl Iberger, Chief Financial Officer of Precipio, Inc., hereby certify pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in such Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, fairly presents, in all material respects, the financial condition and results of operations of Precipio, Inc.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:41.40625%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ CARL IBERGER</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Carl Iberger</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chief Financial Officer (Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">August&#160;21, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of the certification required by Section&#160;906 has been provided to Precipio, Inc. and will be retained by Precipio, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>prpo-20170630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:74f300e7d6e84f5ab5f8f1a885bfa1df,x:8e7c3632802d435ebdb68ffc6c36926f-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:prpo="http://www.precipiodx.com/20170630" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="prpo-20170630.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Aug.16">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-16</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prpo:PreferredStockSeriesASeniorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prpo:PreferredStockSeriesASeniorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prpo:PreferredStockSeriesASeniorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prpo:PreferredStockSeriesASeniorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorandJuniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorandJuniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:A2017BridgeNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorandJuniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:A2017BridgeNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorandJuniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:A2017BridgeNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorandJuniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_PrecipioDiagnosticMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:PrecipioDiagnosticMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2YTD_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_prpo_BacklogMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">prpo:BacklogMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Dec.1_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:WebsterBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-01</xbrli:startDate>
			<xbrli:endDate>2014-12-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q4APr.1_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2012-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q2May.1_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-05-01</xbrli:startDate>
			<xbrli:endDate>2013-05-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorandJuniorNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.17_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2May.1_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-05-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q4APr.1_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2012-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q4Apr.1_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-04-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:WebsterBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorandJuniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q4Dec.1_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:WebsterBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q4APr.1_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2012-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:WebsterBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jan.17_us-gaap_DebtInstrumentAxis_prpo_AdditionalNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:AdditionalNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-17</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Dec.1_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:WebsterBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-01</xbrli:startDate>
			<xbrli:endDate>2014-12-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:A2017NewBridgeNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_NewBridgeNotesIMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:NewBridgeNotesIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_AegisWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:AegisWarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SideWarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:ConvertibleBridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:ConvertibleBridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.28_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:A2017BridgeNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:A2017NewBridgeNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SideWarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:ConvertibleBridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_NewBridgeNotesIMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:NewBridgeNotesIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:ConvertibleBridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SideWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:ConvertibleBridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:ConvertibleBridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:A2017NewBridgeNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_AwardTypeAxis_prpo_UponExecutionMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prpo:UponExecutionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SideWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SideWarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.28_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:A2017BridgeNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-28</xbrli:startDate>
			<xbrli:endDate>2017-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SideWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_AwardTypeAxis_prpo_UponExecutionMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prpo:UponExecutionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SideWarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:ConvertibleBridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SideWarrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_UnsecuredConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:UnsecuredConvertibleBridgeLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Sep.13_us-gaap_LitigationCaseAxis_prpo_EdgeBioSystemsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:EdgeBioSystemsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-13</xbrli:startDate>
			<xbrli:endDate>2016-09-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Apr.7_us-gaap_LitigationCaseAxis_prpo_SmithMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:SmithMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-07</xbrli:startDate>
			<xbrli:endDate>2017-04-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CPAGlobalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Nov.30_us-gaap_LitigationCaseAxis_prpo_ScienceParkDevelopmentCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:ScienceParkDevelopmentCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-11-30</xbrli:startDate>
			<xbrli:endDate>2016-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_LitigationCaseAxis_prpo_IDTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:IDTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Dec.19_us-gaap_LitigationCaseAxis_prpo_SmithMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:SmithMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-19</xbrli:startDate>
			<xbrli:endDate>2016-12-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul.13_us-gaap_LitigationCaseAxis_prpo_FoxChaseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:FoxChaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-13</xbrli:startDate>
			<xbrli:endDate>2017-07-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_SmithMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:SmithMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Mar.6_us-gaap_LitigationCaseAxis_prpo_ScienceParkDevelopmentCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:ScienceParkDevelopmentCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-06</xbrli:startDate>
			<xbrli:endDate>2017-03-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q2June23_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:MountSinaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-23</xbrli:startDate>
			<xbrli:endDate>2016-06-23</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LitigationCaseAxis_prpo_UNMCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:UNMCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul.13_us-gaap_LitigationCaseAxis_prpo_IDTMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:IDTMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:MountSinaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:XIFINInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb.6_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CPAGlobalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-06</xbrli:startDate>
			<xbrli:endDate>2017-02-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Feb25_us-gaap_LitigationCaseAxis_prpo_UNMCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:UNMCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-02-25</xbrli:startDate>
			<xbrli:endDate>2016-02-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct.27_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:MountSinaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-27</xbrli:startDate>
			<xbrli:endDate>2016-10-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_UNMCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:UNMCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_LitigationCaseAxis_prpo_FoxChaseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:FoxChaseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_EdgeBioSystemsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:EdgeBioSystemsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb.21_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:XIFINInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-21</xbrli:startDate>
			<xbrli:endDate>2017-02-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LitigationCaseAxis_prpo_UNMCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:UNMCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:MountSinaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.28_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prpo:PreferredStockSeriesASeniorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Mar1-31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-03-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prpo:PreferredStockSeriesASeniorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.28_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-28</xbrli:startDate>
			<xbrli:endDate>2017-06-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.29_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-29</xbrli:startDate>
			<xbrli:endDate>2017-06-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:WebsterBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Jun.13_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:WebsterBankMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SideWarrantMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJune2022BMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:VariousInstitutionalHoldersJune2022BMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJanuary2021TwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:VariousInstitutionalHoldersJanuary2021TwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJune2022Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:VariousInstitutionalHoldersJune2022Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJanuary2018Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:VariousInstitutionalHoldersJanuary2018Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersDecember2020OneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:VariousInstitutionalHoldersDecember2020OneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJanuary2021OneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:VariousInstitutionalHoldersJanuary2021OneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersApril2020Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:VariousInstitutionalHoldersApril2020Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersFebruary2020Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:VariousInstitutionalHoldersFebruary2020Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Jun.13_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-13</xbrli:startDate>
			<xbrli:endDate>2017-06-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">prpo:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">prpo:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">prpo:A2016WarrantLiabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prpo:EquityIncentivePlan2006Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prpo:EquityIncentivePlan2006Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001043961</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prpo:EquityIncentivePlan2006Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q2YTD" id="Fact-5DBA2CDB579257998236B3B0BDCE4D8F">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q2YTD" id="Fact-9333E5042B8E50C19BB28B645D608C4E">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q2YTD" id="Fact-74D27FB311C6556E8E8E92E2F3C6A509">Q2</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q2YTD" id="Fact-F52061EF3DD65E3BB6561DAFF5F86F5F">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q2YTD" id="Fact-693FB7F83FA358EC8362601C8BAB7522">2017-06-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q2YTD" id="Fact-890381EE664B5CDF9EBBBB31B8FDB63C">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q2YTD" id="Fact-82E756A0ED4C550AB921BE827D223E36">0001043961</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q3Aug.16" decimals="INF" id="Fact-DD856B13271B50058BE54D6A389FB732" unitRef="shares">6407860</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2017Q2YTD" id="Fact-C994FA002E8B599D87F892ABDCB594FD">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q2YTD" id="Fact-04261F5851B25C69B32E0F8A2D24004D">PRECIPIO, INC.</dei:EntityRegistrantName>
	<prpo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-4E3758511F7AC4DEC8FEF5CCFA0AF889" unitRef="shares">64593</prpo:AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares>
	<prpo:AgentFees contextRef="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-A7849DFF59EC306B896DF5B64AEF4067" unitRef="usd">84000</prpo:AgentFees>
	<prpo:BeneficialConversionFeatureonIssuanceofDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-85F94760659B4C84260B027A8A985ECD" unitRef="usd">0</prpo:BeneficialConversionFeatureonIssuanceofDebt>
	<prpo:BeneficialConversionFeatureonIssuanceofDebt contextRef="FD2017Q2YTD" decimals="-3" id="Fact-EAA4EFEABC7801D7D2E9FF815F596B8D" unitRef="usd">1856000</prpo:BeneficialConversionFeatureonIssuanceofDebt>
	<prpo:BeneficialConversionFeatureonIssuanceofDebt contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D8ACB711747315B0AF66FF815F73181C" unitRef="usd">1856000</prpo:BeneficialConversionFeatureonIssuanceofDebt>
	<prpo:BusinessCombinationAcquiredEntitiesCommonStock contextRef="D2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-EDD1A003587A0933BF6EE28250E236AA" unitRef="usd">6088000</prpo:BusinessCombinationAcquiredEntitiesCommonStock>
	<prpo:BusinessCombinationFairValueofDebtConverted contextRef="D2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-85A56C09CB4E27BEEB70E2819BDE2ECE" unitRef="usd">1996000</prpo:BusinessCombinationFairValueofDebtConverted>
	<prpo:BusinessCombinationFairValueofDebtConvertedtoCommonStock contextRef="D2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-5765C648A2C09D712F9C0643354EF760" unitRef="usd">2398000</prpo:BusinessCombinationFairValueofDebtConvertedtoCommonStock>
	<prpo:BusinessCombinationFairValueofDebtConvertedtoPreferredStock contextRef="D2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-6C4FDE9A78AB7027FAB306456DCA0348" unitRef="usd">9796000</prpo:BusinessCombinationFairValueofDebtConvertedtoPreferredStock>
	<prpo:ChangeinStockAppreciationRightsLiability contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="-3" id="Fact-F03BAAA176E47B126C1305AB57859F50" unitRef="usd">-5000</prpo:ChangeinStockAppreciationRightsLiability>
	<prpo:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="FD2017Q2YTD_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember" decimals="INF" id="Fact-6934A1534C905B8BAEB4AF5176D93814" unitRef="shares">2777</prpo:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
	<prpo:ClassofWarrantorRightTerm contextRef="D2016Q1Mar1-31" id="Fact-B6E91FFF69BC5CAB362B06744C6CCEF3">P10Y</prpo:ClassofWarrantorRightTerm>
	<prpo:ClassofWarrantorRightTerm contextRef="FD2017Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" id="Fact-405AA918DEB9E81D067CEC9EE9B79B77">P5Y</prpo:ClassofWarrantorRightTerm>
	<prpo:ClassofWarrantorRightTerm contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" id="Fact-FE1316D1CBA9F1615A7E04E5F9BCF43E">P7Y</prpo:ClassofWarrantorRightTerm>
	<prpo:ConversionofStockDiscountRate contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-82A422F6D0033AF72A15ECD86C7C227A" unitRef="number">0.3</prpo:ConversionofStockDiscountRate>
	<prpo:ConversionofStockDiscountRate contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-858E7DDAFD6482F14B46ECD5D03E0824" unitRef="number">0.3</prpo:ConversionofStockDiscountRate>
	<prpo:ConversionofStockDiscountRate contextRef="FI2017Q2_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="INF" id="Fact-6F5473D3C97277E58198EC589A7ACFA5" unitRef="number">0.15</prpo:ConversionofStockDiscountRate>
	<prpo:ConversionofStockPerShareConversionPrice contextRef="FI2017Q2_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="INF" id="Fact-CF3CC7CAF80BADC84F09EC55A541D1F9" unitRef="usdPerShare">3.736329</prpo:ConversionofStockPerShareConversionPrice>
	<prpo:ConversionofStockPerShareConversionPrice contextRef="I2017Q2Jun.13_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9A476E9D81A451E85371FFC42A4FA46B" unitRef="usdPerShare">10.2502</prpo:ConversionofStockPerShareConversionPrice>
	<prpo:ConversionofStockPerShareConversionPrice contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-BA2B8097BD9AEC344ED6ECA75F37DC11" unitRef="usdPerShare">3.736329</prpo:ConversionofStockPerShareConversionPrice>
	<prpo:ConversionofStockPerShareConversionPrice contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_NewBridgeNotesIMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-8C3EEBFFA2399EC9DE0704BBC2839A06" unitRef="usdPerShare">3.736329</prpo:ConversionofStockPerShareConversionPrice>
	<prpo:DebtInstrumentDebtConvertedRate contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-FBA21D0D56808AEB20B8F60619E7A26F" unitRef="number">0.7</prpo:DebtInstrumentDebtConvertedRate>
	<prpo:DeemedDividend contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="-5" id="Fact-453DE70987F4F8CC6D9C04F9E995476C" unitRef="usd">5200000</prpo:DeemedDividend>
	<prpo:EquitySecuritiesTransferedtoDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-246DB2AA3666507FF4B1027985CCCC1D" unitRef="usd">1715000</prpo:EquitySecuritiesTransferedtoDebt>
	<prpo:EquitySecuritiesTransferedtoDebt contextRef="FD2017Q2YTD" decimals="-3" id="Fact-38376D8D4DAA0EDAA1BD027985BABE2D" unitRef="usd">0</prpo:EquitySecuritiesTransferedtoDebt>
	<prpo:GainLossOnStockWarrantsRevaluation contextRef="FD2016Q2QTD" decimals="-3" id="Fact-3EF5EE13772255FEBF0119B26A4FD712" unitRef="usd">1000</prpo:GainLossOnStockWarrantsRevaluation>
	<prpo:GainLossOnStockWarrantsRevaluation contextRef="FD2016Q2YTD" decimals="-3" id="Fact-E6AD2AB211875DB4AB2C976962CBD421" unitRef="usd">0</prpo:GainLossOnStockWarrantsRevaluation>
	<prpo:GainLossOnStockWarrantsRevaluation contextRef="FD2017Q2QTD" decimals="-3" id="Fact-2C656D6BD1655E87A8C00B21616751B6" unitRef="usd">-3000</prpo:GainLossOnStockWarrantsRevaluation>
	<prpo:GainLossOnStockWarrantsRevaluation contextRef="FD2017Q2YTD" decimals="-3" id="Fact-42EE0342EEFA51D182BDE7BBDB5DE1BB" unitRef="usd">-3000</prpo:GainLossOnStockWarrantsRevaluation>
	<prpo:InterestIncomeAndExpenseNet contextRef="FD2016Q2QTD" decimals="-3" id="Fact-80440197D6435C188B82D7D0A215CA94" unitRef="usd">-160000</prpo:InterestIncomeAndExpenseNet>
	<prpo:InterestIncomeAndExpenseNet contextRef="FD2016Q2YTD" decimals="-3" id="Fact-5C9872D30E2451409CDCB995FD0B3279" unitRef="usd">-242000</prpo:InterestIncomeAndExpenseNet>
	<prpo:InterestIncomeAndExpenseNet contextRef="FD2017Q2QTD" decimals="-3" id="Fact-E9D85B1E8FE15B7E8FC0D35524E73CE3" unitRef="usd">-220000</prpo:InterestIncomeAndExpenseNet>
	<prpo:InterestIncomeAndExpenseNet contextRef="FD2017Q2YTD" decimals="-3" id="Fact-A96B9FE2A1B25A0CBFE33C9975CB947A" unitRef="usd">-382000</prpo:InterestIncomeAndExpenseNet>
	<prpo:LitigationSettlementInstallmentPaymentAmount contextRef="FI2017Q2_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_LitigationCaseAxis_prpo_IDTMember" decimals="-3" id="Fact-4E094EF063BE89855ABAE7621E5DFE37" unitRef="usd">175000</prpo:LitigationSettlementInstallmentPaymentAmount>
	<prpo:LitigationSettlementInstallmentPaymentAmount contextRef="I2017Q3Jul.13_us-gaap_LitigationCaseAxis_prpo_IDTMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-2" id="Fact-369A16FC97AA309A9AD4E792D617CAD0" unitRef="usd">27800</prpo:LitigationSettlementInstallmentPaymentAmount>
	<prpo:LitigationSettlementPayments contextRef="FD2017Q2YTD_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_LitigationCaseAxis_prpo_FoxChaseMember" decimals="INF" id="Fact-88F7F6A3C249CF8CBAAEE76340A8F27E" unitRef="number">3</prpo:LitigationSettlementPayments>
	<prpo:NoncashAccruedMergerCost contextRef="FD2016Q2YTD" decimals="-3" id="Fact-690C7710A3BA33B2974BFF6E8B180A1F" unitRef="usd">0</prpo:NoncashAccruedMergerCost>
	<prpo:NoncashAccruedMergerCost contextRef="FD2017Q2YTD" decimals="-3" id="Fact-B19FDF20826372E96288FF6E8B0E5A7F" unitRef="usd">10000</prpo:NoncashAccruedMergerCost>
	<prpo:OtherIncomeExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-7746363EEA2858CA85AF41D4A9BE2081" unitRef="usd">-159000</prpo:OtherIncomeExpense>
	<prpo:OtherIncomeExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-53C23D81087154EDAD55E620C342F0C7" unitRef="usd">-239000</prpo:OtherIncomeExpense>
	<prpo:OtherIncomeExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-39313CD92A945FB1819BBD94B2886FF6" unitRef="usd">-2879000</prpo:OtherIncomeExpense>
	<prpo:OtherIncomeExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-0C5648340F3A5FA6AA9D3A630C3940B6" unitRef="usd">-3041000</prpo:OtherIncomeExpense>
	<prpo:PercentageofPerShareOfferingPrice contextRef="I2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9BE2E19E886551469659FFB60E2D679A" unitRef="number">1.1</prpo:PercentageofPerShareOfferingPrice>
	<prpo:PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent contextRef="I2017Q2Jan.17_us-gaap_DebtInstrumentAxis_prpo_AdditionalNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="4" id="Fact-166F6E7D9D9B5F3382EC88ECE81A8227" unitRef="number">0.3333</prpo:PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent>
	<prpo:PremiumRateonDebtSettlement contextRef="I2017Q2Jun.28_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-78865D69E8BAC858D993EC7FFCD87CEE" unitRef="number">0.2</prpo:PremiumRateonDebtSettlement>
	<prpo:PremiumRateonDebtSettlement contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-94AEC2E6266FC0D08D4EECA8E25E3185" unitRef="number">0.2</prpo:PremiumRateonDebtSettlement>
	<prpo:PremiumRateonDebtSettlement contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_NewBridgeNotesIMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-6FBB00BB9AE33B3378C604B707DBDAD1" unitRef="number">0.2</prpo:PremiumRateonDebtSettlement>
	<prpo:PremiumRateonDebtSettlementAmount contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="0" id="Fact-11BECAB2EF8DCB1AB66E04996BE3251E" unitRef="usd">160000</prpo:PremiumRateonDebtSettlementAmount>
	<prpo:PremiumRateonDebtSettlementAmount contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_NewBridgeNotesIMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-3" id="Fact-39D6B17ED6DF9469B7B60490594DC827" unitRef="usd">240000</prpo:PremiumRateonDebtSettlementAmount>
	<prpo:ProceedsFromtheSalesofDebtInstrument contextRef="D2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-3" id="Fact-FDA13880553625DDAB6DECAFF304CE81" unitRef="usd">721000</prpo:ProceedsFromtheSalesofDebtInstrument>
	<prpo:RequiredCumulativePaymentonPrincipalPerAmendmentPercent contextRef="I2017Q2Jan.17_us-gaap_DebtInstrumentAxis_prpo_AdditionalNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="4" id="Fact-059E985FFEBE5E9B8E86334024ED9939" unitRef="number">0.6667</prpo:RequiredCumulativePaymentonPrincipalPerAmendmentPercent>
	<prpo:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="INF" id="Fact-C891DB0A7CB75BEA9DA7C985E03D9C51" unitRef="shares">2777</prpo:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
	<prpo:ShortTermDebtConvertedtoLongTermDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-F1DE4467452D9827629702731EB2354C" unitRef="usd">1120000</prpo:ShortTermDebtConvertedtoLongTermDebt>
	<prpo:ShortTermDebtConvertedtoLongTermDebt contextRef="FD2017Q2YTD" decimals="-3" id="Fact-0D66699BD4A31A48FEBB02731EAF18F4" unitRef="usd">0</prpo:ShortTermDebtConvertedtoLongTermDebt>
	<prpo:StockWarrantPotentialEntityOwnershipPercentageifExercised contextRef="FI2016Q1" decimals="2" id="Fact-293C036E9F21E13E5C81067254DC2BCF" unitRef="number">0.60</prpo:StockWarrantPotentialEntityOwnershipPercentageifExercised>
	<prpo:StockholdersEquityNoteReverseStockSplitConversionRatio contextRef="I2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="1" id="Fact-4D3159522F794E00A75BE1A08B6F725A" unitRef="number">0.1</prpo:StockholdersEquityNoteReverseStockSplitConversionRatio>
	<prpo:StockholdersEquityNoteReverseStockSplitConversionRatio contextRef="I2016Q4Oct12_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="4" id="Fact-4544704DA81AC5189B08E1A05E0F1E8E" unitRef="number">0.0333</prpo:StockholdersEquityNoteReverseStockSplitConversionRatio>
	<prpo:WorkingCapitalDeficiency contextRef="FI2017Q2" decimals="-5" id="Fact-95AD3025F66C0A3CFD85E1966BCAFF10" unitRef="usd">-14500000</prpo:WorkingCapitalDeficiency>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-FC2518BDF3215788A9119AFDD82CE5AA" unitRef="usd">1084000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-6556D670783D5DE9B771507292873121" unitRef="usd">10328000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-3500093C7ADF56E998BC816F98C3CA45" unitRef="usd">388000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-AB7A747A91C55858A5023F854D15602F" unitRef="usd">569000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-486C210B87C95CECB45B1DC38F1C9879" unitRef="usd">700000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-4DBFEE60798055A3A43D9B2FBDA68511" unitRef="usd">3521000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-3" id="Fact-6054953F6B5D55779475F7143EE4A6E5" unitRef="usd">4376000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q2" decimals="-3" id="Fact-98292890F25A579B9BFE44D10F160791" unitRef="usd">34975000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember" decimals="-3" id="Fact-BE55E6B6448A6544BF5CF5D8BA658D8E" unitRef="usd">887000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-18074C8C272F097247E0F5D8BA61664F" unitRef="usd">885000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-48C7301CCD50B26717D7F5D8BA5E0515" unitRef="usd">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember" decimals="-3" id="Fact-2C452EF4A1063E127314F5DD1D1999E1" unitRef="usd">4771000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-EED6EA0F9428B71856C6F5DD1623760B" unitRef="usd">4749000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-017201022C7F11B65510F5DD12E0992B" unitRef="usd">14000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-EBAD9914078807055CAFF5DD5D387D4B" unitRef="usd">8000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q2YTD" decimals="-3" id="Fact-EF45286E323B76F84C42F5C8C91EE9E6" unitRef="usd">28000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-068DC524A3A7503190EB69125F98ECC3" unitRef="usd">27000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C66FAC79F6A474264D8CF5C8C963AB2B" unitRef="usd">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q2YTD" decimals="-5" id="Fact-0A1C2E85D6EC125C7F36F5A8A28C3B23" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q2YTD" decimals="-5" id="Fact-D46060B0927F52CB94C1F5A7DEE9474A" unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2016Q2YTD" decimals="-3" id="Fact-46ECC9D85A72AB82689CE179922E29B1" unitRef="usd">18000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2017Q2YTD" decimals="-3" id="Fact-4BD0D45F0E1614AD9BC9E179922C031C" unitRef="usd">57000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q2YTD" decimals="INF" id="Fact-84D72837CBC35885BD37646800DB54CA" unitRef="shares">2771149</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q2YTD" decimals="INF" id="Fact-5D05E0B1E5FE532EA82FCBE59B41CE08" unitRef="shares">2545463</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-F296322F19B35225B65CA92803C62299" unitRef="usd">842000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q2" decimals="-3" id="Fact-BAC8A6B6A5FF5CF1BD0A8F02ECEAEBA1" unitRef="usd">37010000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-7D2611FFFED65F9B8E083DF638E4E692" unitRef="usd">552000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-A35D6F0F23705C6B911D1C22C6EA4B99" unitRef="usd">1798000</us-gaap:AssetsCurrent>
	<us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="FD2016Q2YTD_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="2" id="Fact-09E286A2EE41396947FFE26F7C84B11A" unitRef="usdPerShare">-2.07</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
	<us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="FD2017Q2YTD_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="2" id="Fact-0AA229F83F8BFE445DA8E26F7C8422DD" unitRef="usdPerShare">-2.16</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
	<us-gaap:BusinessAcquisitionSharePrice contextRef="I2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember" decimals="2" id="Fact-EA2A4C1F9547D0AC756BE28D87F2DA38" unitRef="usdPerShare">6.80</us-gaap:BusinessAcquisitionSharePrice>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2016Q2YTD_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-5ED7861B4B58FF7EC2D8E26EA5134BA0" unitRef="usd">-13266000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="FD2017Q2YTD_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-0357F0CB9D4549E2AFF8E26EA517162D" unitRef="usd">-13864000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
	<us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="FD2016Q2YTD_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-F2B6E641DB4D3FA6B1F8E26E04D36632" unitRef="usd">1783000</us-gaap:BusinessAcquisitionsProFormaRevenue>
	<us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="FD2017Q2YTD_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-E49DC0E9D76570F378C1E26E04D6AEA7" unitRef="usd">1472000</us-gaap:BusinessAcquisitionsProFormaRevenue>
	<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="D2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-D91D14E98BF5F43FCE6FE27A85F34D44" unitRef="usd">21602000</us-gaap:BusinessCombinationConsiderationTransferred1>
	<us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="D2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-0E3122BCD94793585EBDE27C77B8F2EE" unitRef="usd">49000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
	<us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="D2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-CF47374848C604067A46064636F0590E" unitRef="usd">1275000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-01F75BDE259B408E9103E2598FEFC494" unitRef="usd">35380000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-3D0B5BA8A040D3520A00E257037D1ED3" unitRef="usd">419000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-F0EB72E10F796AD3E9D5E25AEA6BB6A2" unitRef="usd">13604000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-32F5EE8BE7144F294E77E25ED7474B4B" unitRef="usd">21100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_prpo_BacklogMember" decimals="-3" id="Fact-229C20719D224B1071BAE260ADA7F795" unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_CustomerRelationshipsMember" decimals="-3" id="Fact-016D531483E64A9B40F0E260A82B7C28" unitRef="usd">250000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-3" id="Fact-DC348BB2866A979B2888E260A63B4478" unitRef="usd">18990000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-3" id="Fact-B726283E9538CC2B7399E260AF55E291" unitRef="usd">1590000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_NoncompeteAgreementsMember" decimals="-3" id="Fact-44B3E5FC589B55A7D359E260A9E4B424" unitRef="usd">30000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-3" id="Fact-6090A2D7B8A7DB17ABBDE260ABE5EBD6" unitRef="usd">40000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-0B83F009B96C43196D48E25BAA63B39D" unitRef="usd">13778000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-4DDAAA371AF3B324521EE25B56474E23" unitRef="usd">174000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-469C854E3D045ACBB6A1E257A0978340" unitRef="usd">29000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-E5DF6E35C66C12CA3A7BE25C425256A8" unitRef="usd">21602000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
	<us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="FD2016Q2QTD" decimals="-3" id="Fact-C2C751FCDD54408FCAB4FC2907C8C5DA" unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
	<us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="FD2016Q2YTD" decimals="-3" id="Fact-B51C535C563D887F41F6FC2907DA6CFA" unitRef="usd">0</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
	<us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="FD2017Q2QTD" decimals="-3" id="Fact-216C034BAB6314AB3A1BFC2907B963F6" unitRef="usd">2603000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
	<us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="FD2017Q2QTD_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember" decimals="-3" id="Fact-21E3791D019A058321D2049FA112673E" unitRef="usd">414000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
	<us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="FD2017Q2QTD_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E39949F6144FDD51602104F02958400A" unitRef="usd">414000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
	<us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="FD2017Q2YTD" decimals="-3" id="Fact-4F4443F41C27D71DB7EDFC2907B90F08" unitRef="usd">2603000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
	<us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="FD2017Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember" decimals="0" id="Fact-BFA618C6E3D898983F6C04A1936C9ED9" unitRef="usd">414000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
	<us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed contextRef="FD2017Q2YTD_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-08E5DECDB7091D9AFEF704F1A9641518" unitRef="usd">414000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
	<us-gaap:CapitalLeaseObligationsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-E914C897881751ED95B855B9BBCC6125" unitRef="usd">46000</us-gaap:CapitalLeaseObligationsCurrent>
	<us-gaap:CapitalLeaseObligationsCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-4D6581E235A355E19E0BF938352D627A" unitRef="usd">48000</us-gaap:CapitalLeaseObligationsCurrent>
	<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-5DACD9C23262539E911D739A914D3BD7" unitRef="usd">163000</us-gaap:CapitalLeaseObligationsNoncurrent>
	<us-gaap:CapitalLeaseObligationsNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-CC2A12111FFD5ED085D032FED3F38150" unitRef="usd">138000</us-gaap:CapitalLeaseObligationsNoncurrent>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2016Q2YTD" decimals="-3" id="Fact-CEA3AF9424CE27325AA4E185EBB38360" unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2017Q2YTD" decimals="-3" id="Fact-E4E131CB40F3F2748760E185EBA7A269" unitRef="usd">101000</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-375A2C136CB154C1AEA0C0F1EF1EB452" unitRef="usd">235000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q2" decimals="-3" id="Fact-2191E9187CDA5A0481146F3117F4DC7D" unitRef="usd">197000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-875A7A5817D2522CBA2D959C98978617" unitRef="usd">51000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q2" decimals="-3" id="Fact-B06F85904A4358D2B2E8AC5273BCFFDD" unitRef="usd">967000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q2YTD" decimals="-3" id="Fact-4619082DAB905652AABFA3D53A001521" unitRef="usd">-38000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q2YTD" decimals="-3" id="Fact-2FC625ADA2585E4183F03831012A83C9" unitRef="usd">916000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A3EFEB93D652216B8FA6EC8C094C8643" unitRef="usdPerShare">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersApril2020Member" decimals="2" id="Fact-51B1A2F12C1F5925883AB00CAEEF2FE6" unitRef="usdPerShare">120.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersDecember2020OneMember" decimals="2" id="Fact-A9C48F0B294B583CBEEE7592BC693C00" unitRef="usdPerShare">49.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersFebruary2020Member" decimals="2" id="Fact-8800B3855E9157D0BF0257195E8E9AEF" unitRef="usdPerShare">67.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJanuary2018Member" decimals="2" id="Fact-E044AC03D1B05FD885D09B1E1DACB417" unitRef="usdPerShare">270.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJanuary2021OneMember" decimals="2" id="Fact-B147046138B95829B6A335983EA06BAE" unitRef="usdPerShare">36.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJanuary2021TwoMember" decimals="2" id="Fact-169C7A783EC257AAA2020FEBFFD8549B" unitRef="usdPerShare">36.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJune2022BMember" decimals="2" id="Fact-D02B4570A0F60686F155EBBDD5DD05BE" unitRef="usdPerShare">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJune2022Member" decimals="2" id="Fact-2EDCA447A8E0C8975A3DEBBDCF107094" unitRef="usdPerShare">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q2Jun.28_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-6D99FFD7C09FD93D5D7B04DA506699A4" unitRef="usdPerShare">2.93</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_AegisWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-6743AACD3A713A5C0FAFEC83493F17B7" unitRef="usdPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-066BCA4AE6BC6619A9CAEB9C4FD3CF59" unitRef="usdPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q2Jun.29_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="2" id="Fact-61F8607CBB13043FEBAEFFB6AE189515" unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="2" id="Fact-29E011BBAFABEB8519C8FFB57CDB4212" unitRef="usdPerShare">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2016Q1" decimals="INF" id="Fact-869F0A65A44C586D1F89067332235A74" unitRef="shares">1958204</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2" decimals="INF" id="Fact-29369844DE2853EE9BF6073316A87182" unitRef="shares">268379</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_AwardTypeAxis_prpo_UponExecutionMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-45BE383DBD7DDD110059EC97025E8B86" unitRef="shares">22857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5CB1B899FC3C4841B1A5EC9727CFCAD3" unitRef="shares">68572</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-025040099A9F4E42ADE6EC8C7FE7039C" unitRef="shares">91429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersApril2020Member" decimals="INF" id="Fact-AEBF5574E3CE5E0383444F5926D4E4BE" unitRef="shares">12487</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersDecember2020OneMember" decimals="INF" id="Fact-A707367200D9536BB637BB5279B45B05" unitRef="shares">4081</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersFebruary2020Member" decimals="INF" id="Fact-660B144BC1B15180A1D544B122F42FE9" unitRef="shares">23826</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJanuary2018Member" decimals="INF" id="Fact-ED514BDF21D059F89F7E4AF9318A9270" unitRef="shares">23055</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJanuary2021OneMember" decimals="INF" id="Fact-A4BD6236B45B5D09952F4C338993D28D" unitRef="shares">38733</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJanuary2021TwoMember" decimals="INF" id="Fact-AFB0BFC2B1605376B0C005E221EC1402" unitRef="shares">29168</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJune2022BMember" decimals="INF" id="Fact-C2D00B43D59C017931C0EBBDD29ACF9F" unitRef="shares">91429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_VariousInstitutionalHoldersJune2022Member" decimals="INF" id="Fact-6FD3B462C7C92F7D56DBEBBDCAEAF2F6" unitRef="shares">45600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-B3AF3684AB7BDF5990ED04E5DE20A8C5" unitRef="shares">20000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q2Jun.28_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-C40207C397214A49E97A04D8AEB5D375" unitRef="shares">8542</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_AegisWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-78F3B88C38C31EC66819EBA5C0D028CC" unitRef="shares">5600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-87601C2068F48858ACBAEB99678A0F8E" unitRef="shares">40000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-91DAC16660028A65E7EAFFB521269055" unitRef="shares">45600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q2_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" decimals="INF" id="Fact-EDD2C62BCEC654B08C7849FB944CAD78" unitRef="shares">25584</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-52EECBB10DF058599E6C7817BA5634C1" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q2" decimals="INF" id="Fact-6E02018A35675FFF9B9C217FEA85D22D" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-C651A4F64CF45113B007DFF5FB0255A9" unitRef="shares">1806850</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q2" decimals="INF" id="Fact-F62B2CB6F9A5574F888796A8343FBC6A" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-B44ED6BAD6235F548482F82CC2A32663" unitRef="shares">449175</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q2" decimals="INF" id="Fact-A0071D528DC850AE87DEF2F8609EA892" unitRef="shares">6407860</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-D0F1926E3BC9586CAFF0289BED43A5D1" unitRef="shares">449175</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q2" decimals="INF" id="Fact-7238CE9122D550BFB188129B9D63DE66" unitRef="shares">6407860</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember" decimals="INF" id="Fact-A652B4E620A1399995F8E292BBA8448A" unitRef="shares">895334</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-D693909B0A8956C3B4EE14858BBDBFBC" unitRef="usd">4000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q2" decimals="-3" id="Fact-C3E2D93EF5AE563DB15E9E71B10247DF" unitRef="usd">64000</us-gaap:CommonStockValue>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="D2017Q2Jun.29" decimals="-6" id="Fact-69C81B6765EE17131205E1FEE66E27EE" unitRef="usd">3000000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2016Q2YTD" decimals="-3" id="Fact-12557A379D0C544B9EEB284185FC3953" unitRef="usd">433000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2017Q2YTD" decimals="-3" id="Fact-6E5B4F449E43589CB67D887A66B8461A" unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2889FD5E53B90A386E56F5E5472913F8" unitRef="usd">8000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockAmountConverted1 contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-701C89FD2CC62AF3B77FF5E54717B34D" unitRef="usd">-8000</us-gaap:ConversionOfStockAmountConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_PrecipioDiagnosticMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C376DECCD457D49D2D81E1F9DE681572" unitRef="shares">5352847</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-907AE246E9E3CE117363E20BE38D6C53" unitRef="shares">7155</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="D2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C0EDBCA30A4C4CB46037FFD93777229E" unitRef="shares">4317152</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-76D6470DA7DE63AC0216F5E38965C73C" unitRef="shares">788647</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConversionOfStockSharesConverted1 contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-06780EB0D89858F016EBF5E389675B9F" unitRef="shares">-788647</us-gaap:ConversionOfStockSharesConverted1>
	<us-gaap:ConvertibleDebt contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-4" id="Fact-758A2E47D217F920A9B6E63A8FF1F99F" unitRef="usd">1120000</us-gaap:ConvertibleDebt>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-AA5FF9A939E981882997E120AB08ABF4" unitRef="usd">695000</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:ConvertibleDebtCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-56DA19206EEFE612C865E120AAF5B280" unitRef="usd">166000</us-gaap:ConvertibleDebtCurrent>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2016Q2QTD" decimals="-3" id="Fact-CFB26E1D681B5300B5F243BC6D134BCE" unitRef="usd">241000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2016Q2YTD" decimals="-3" id="Fact-E9EC20C6DE7C5525A32DC5A18066077E" unitRef="usd">479000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q2QTD" decimals="-3" id="Fact-1C627551E8C05EDFBE0CE9CAC2ED22BC" unitRef="usd">284000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q2YTD" decimals="-3" id="Fact-1BEAA898824E5DE6841D928F8512BBBC" unitRef="usd">466000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4" decimals="-3" id="Fact-8F7CF3A25E5E4C532463E5F0055726B7" unitRef="usd">4522000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-3" id="Fact-79341EA277B3AF8999AEF601248F3B84" unitRef="usd">695000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="-3" id="Fact-8ADCFA1A7FC6D5A18CACE6FC05490E03" unitRef="usd">243000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="-3" id="Fact-42FDC7708D2CBFFA18F7E704E12B23D0" unitRef="usd">328000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember" decimals="0" id="Fact-E6E9AB78A36C32BF1B10E6A75BA026EA" unitRef="usd">583821</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember" decimals="-3" id="Fact-C792CAEF64D8327088ADE5F1F849CD2D" unitRef="usd">584000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="0" id="Fact-6DCEFBAD74A12BC862ADE6A6E49AB597" unitRef="usd">3269968</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-5B147434057E2E2FC61BE5F1F507989B" unitRef="usd">3270000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-3" id="Fact-D0EA1033D9CF870CE4B5E5F2040066F0" unitRef="usd">0</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="0" id="Fact-B58F58CA6B598C0CE36BE6F41A7D7934" unitRef="usd">162066</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2016Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="-3" id="Fact-2AC22C7416D4FF672C32E5F1F9EC39FF" unitRef="usd">162000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2" decimals="-3" id="Fact-FF532C13E578F1D6E2CCE5F0039E3B93" unitRef="usd">513000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-5" id="Fact-653DEEF5983AE1B37CC5ECFD362837D0" unitRef="usd">2000000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="-3" id="Fact-43832BA988CDEFF1F401E5F1FABFD978" unitRef="usd">226000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="0" id="Fact-6256A7E44A1166DF4FCDE6FBD3A28893" unitRef="usd">225714</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="-3" id="Fact-E0BB681975175060F46EE5F1FED7AEF1" unitRef="usd">0</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="INF" id="Fact-3A3588E9C6181B17D217E704E04C4505" unitRef="usd">0</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember" decimals="-3" id="Fact-13D80A53619D7BA8FA0BE5F1F751CAB3" unitRef="usd">0</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember" decimals="INF" id="Fact-C977AFB29FF501D6361CE6A5A558C13D" unitRef="usd">0</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-F49FF6C8F48894E47804E6A20D8468B4" unitRef="usd">0</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-38D243B1BC5903FF6B33E5F1F436B572" unitRef="usd">0</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="-3" id="Fact-C5DBFC257E05E7BA5815E5F202DC923A" unitRef="usd">125000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="0" id="Fact-39762E34ACCD5277CB45E6F37A18F86C" unitRef="usd">162066</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="FI2017Q2_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="-3" id="Fact-868B4E9634FF6832D8FDE5F1F8F07763" unitRef="usd">162000</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="I2017Q2Jun.17_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="0" id="Fact-F07AE71418423DCC03F5E72057EBAB11" unitRef="usd">143041</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="I2017Q2Jun.29_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember" decimals="0" id="Fact-30048BB0209AE1770611E69FC29B6D27" unitRef="usd">583821</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtAndCapitalLeaseObligations contextRef="I2017Q2Jun.29_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="0" id="Fact-F09F03225F288BAE197BE69FA4441861" unitRef="usd">3584968</us-gaap:DebtAndCapitalLeaseObligations>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember" decimals="INF" id="Fact-811131CA99C2C6DC84CFE2064B32F446" unitRef="usd">3000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="D2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B636066D99CE7C18CA2FECECD638C9BA" unitRef="usd">695000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2016Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember" decimals="-3" id="Fact-E806AA90D20399139309FC3108792481" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2016Q2YTD_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-3" id="Fact-FC6FD7D385BC5D068323FC31085A6B26" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember" decimals="-3" id="Fact-B3BF94709F3CE42424D0FC31085ACE94" unitRef="usd">4771000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="FD2017Q2YTD_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-3" id="Fact-A35C0CBFC1C5328EC607FC310869920D" unitRef="usd">877000</us-gaap:DebtConversionConvertedInstrumentAmount1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7EB8F4B3FB446E13AB0AE204FD1C7BA3" unitRef="shares">352630</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-D55E77BE2F295B9AA95AE20479BC38F4" unitRef="shares">802925</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-CCCC99C44FDF421323A0F609D805BA64" unitRef="shares">155639</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="D2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-AE2999A144B097B8B42DE1FBD79F21A3" unitRef="shares">802920</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="FD2017Q2YTD_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BED7ED8CB218D44CBA02F5DC5B213C70" unitRef="shares">155639</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-1A831BC2F41367C9852EFFA7778565C6" unitRef="shares">1414700</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FF7C97F45DC178161D6CF5DD1047C4FB" unitRef="shares">1414700</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-FA43E528636B4E64CB6BF5DD5BF410B0" unitRef="shares">802920</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2014Q4Dec.1_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" decimals="INF" id="Fact-95A9125D8C551F140BFBE703E4E830D7" unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember" decimals="INF" id="Fact-6EB47224428BDB8CF2F7E64289B976A0" unitRef="usd">583821</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-64AE84A5C051DB9AB2E3E64247DC92FF" unitRef="usd">2744968</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2017Q2_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-BF1759F207B3575EA1E67C4F2855DB94" unitRef="usd">125000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2013Q2May.1_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="INF" id="Fact-81CC51FC8660521E7D36E6F89E665452" unitRef="usd">300000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2014Q4Dec.1_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="INF" id="Fact-1D812F43992EEC2B778FE701A79D349A" unitRef="usd">500000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q2Jun.17_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-641FDE126FDC51398A6EE721BF9E4558" unitRef="usd">125000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_NewBridgeNotesIMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-5" id="Fact-B8EF8E6B5AD7C0A35D01FFAE9FF794BF" unitRef="usd">1200000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2017Q2Jun.29_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-4180409343BA7AB35BDAE24BF051E7F9" unitRef="usd">800000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-8D553857A0BA6C89E04EECCD87862A07" unitRef="number">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_UnsecuredConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-57E5B3B9EB5B0C459F7EECDFC9E757C1" unitRef="number">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember" decimals="INF" id="Fact-A412C6D5B36D00929411E645481877C5" unitRef="number">0.15</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-D732A18DFD269E0A7B81E616AC27FADB" unitRef="number">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="INF" id="Fact-112DF6C0B181DCB60512E64D39FE2EC6" unitRef="number">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2017Q2_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="INF" id="Fact-FBB482E2865D5EA5B4AB85E70D10E708" unitRef="number">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2012Q4Apr.1_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="INF" id="Fact-A1F3B7E0AB2B30314012E6E677828D30" unitRef="number">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2013Q2May.1_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="INF" id="Fact-FA1442E02A9CB5C74B69E6F9C340DEB1" unitRef="number">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2014Q4Dec.1_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="INF" id="Fact-AC8DC80AA49DEFD3803BE70272766D3A" unitRef="number">0.0116</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2017Q2Jun.28_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-23027A7CC30F1F40F3E3EC7C7548F1E1" unitRef="number">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-D5A56AF9B636D702F69EECA8415E1077" unitRef="number">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_NewBridgeNotesIMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="INF" id="Fact-4F1F79696BB487FB7F7804BA7F635B83" unitRef="number">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentMaturityDate contextRef="D2012Q4APr.1_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" id="Fact-F7AEC2583054BCD19F59E6E865E932F3">2018-09-01</us-gaap:DebtInstrumentMaturityDate>
	<us-gaap:DebtInstrumentMaturityDate contextRef="D2013Q2May.1_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" id="Fact-42E72BABEEFA0183A50CE6FACA6945A8">2023-04-23</us-gaap:DebtInstrumentMaturityDate>
	<us-gaap:DebtInstrumentMaturityDate contextRef="D2014Q4Dec.1_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" id="Fact-1A453EA62AA727284A80E709A741FD24">2018-05-31</us-gaap:DebtInstrumentMaturityDate>
	<us-gaap:DebtInstrumentMaturityDate contextRef="FD2017Q2YTD_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" id="Fact-1AA2AEDBFC4CF8BF6133E71E87FEC307">2017-06-17</us-gaap:DebtInstrumentMaturityDate>
	<us-gaap:DebtInstrumentPeriodicPayment contextRef="D2012Q4APr.1_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="0" id="Fact-45685A51CC0AC7C14240E6EAF30A0F7E" unitRef="usd">12206</us-gaap:DebtInstrumentPeriodicPayment>
	<us-gaap:DebtInstrumentPeriodicPayment contextRef="D2012Q4APr.1_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="0" id="Fact-E38880B673677D478AC4E6EAF2EB98DC" unitRef="usd">7436</us-gaap:DebtInstrumentPeriodicPayment>
	<us-gaap:DebtInstrumentPeriodicPaymentInterest contextRef="D2012Q4APr.1_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="0" id="Fact-8266E16F6CA4EDF9EA24E6EEB7E019FB" unitRef="usd">1041</us-gaap:DebtInstrumentPeriodicPaymentInterest>
	<us-gaap:DebtInstrumentTerm contextRef="D2013Q2May.1_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" id="Fact-AA09F4105DC88852D213E6F6DB1DB008">P10Y</us-gaap:DebtInstrumentTerm>
	<us-gaap:DebtInstrumentTerm contextRef="D2014Q4Dec.1_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" id="Fact-358FB05818F10A9CEAF1E7015B63B442">P3Y6M</us-gaap:DebtInstrumentTerm>
	<us-gaap:DebtInstrumentTerm contextRef="D2017Q2Jun.28_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" id="Fact-FE55521775A245980BC9EC7E5E13E574">P90D</us-gaap:DebtInstrumentTerm>
	<us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-3" id="Fact-7179F825390761667CC00498A49F79F1" unitRef="usd">656000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
	<us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-5" id="Fact-EF753227C1EFDD1E918704AA0AFFC663" unitRef="usd">1700000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
	<us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_NewBridgeNotesIMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-3" id="Fact-EA4D1E5AA13EF1E7DD3C0492BE1142A2" unitRef="usd">989000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2016Q2YTD" decimals="-3" id="Fact-BF7621BA2AB2A3074E70FF6451942147" unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2017Q2YTD" decimals="-3" id="Fact-7FF71D2EAAA213A06363FF6451A80BB8" unitRef="usd">64000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DeferredFinanceCostsCurrentNet contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-5" id="Fact-2BFCB6C7DCCFB6D5CFB304A74B9B7089" unitRef="usd">100000</us-gaap:DeferredFinanceCostsCurrentNet>
	<us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="-3" id="Fact-1CB5F14638FAA1DEB35DE5F1FDF2909F" unitRef="usd">30000</us-gaap:DeferredFinanceCostsNoncurrentNet>
	<us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="FI2016Q4_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="-3" id="Fact-E500D137ED59404468FAE5F2020F0307" unitRef="usd">26000</us-gaap:DeferredFinanceCostsNoncurrentNet>
	<us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-9199BF5B842CFEE630F8E5F1F6AD365D" unitRef="usd">9000</us-gaap:DeferredFinanceCostsNoncurrentNet>
	<us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="-3" id="Fact-E981A4D219C4ACDC22E6E5F1FC8D7D07" unitRef="usd">0</us-gaap:DeferredFinanceCostsNoncurrentNet>
	<us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_WebsterBankMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" decimals="-3" id="Fact-3D34404EFA0A099B18CFE5F200D52FC3" unitRef="usd">0</us-gaap:DeferredFinanceCostsNoncurrentNet>
	<us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="FI2017Q2_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-6E58BAB76BFD4511F513E5F1F5B6F5CF" unitRef="usd">0</us-gaap:DeferredFinanceCostsNoncurrentNet>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-5" id="Fact-2421393B5E95535686817506060F1E7E" unitRef="usd">100000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-DE7A68D3CCD459148E4E99ADC6FCDBDB" unitRef="usd">92000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-0E7173EE914455518B5C01C3B7A00489" unitRef="usd">210000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q2" decimals="-5" id="Fact-1F30BC3E8569523ABCB46347707FAF3F" unitRef="usd">200000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:Depreciation contextRef="FD2016Q2QTD" decimals="-5" id="Fact-8A6E6F8C82BD28B720E8E1C9516B8BE2" unitRef="usd">100000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2016Q2YTD" decimals="-5" id="Fact-9EBA0AD11E8C58FB1EABE1C9C768B53F" unitRef="usd">100000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q2QTD" decimals="-5" id="Fact-628324BAFD74592CAC1856CE341CDD8F" unitRef="usd">100000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q2YTD" decimals="-5" id="Fact-1BAF5B8F5AF65989B9F34F2D202EA999" unitRef="usd">100000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q2YTD" decimals="-3" id="Fact-FD9FE969D60154A0981A8C5862A46DF7" unitRef="usd">55000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q2YTD" decimals="-3" id="Fact-EE4447DA3584588BAAEBEAEB6E7B9AE7" unitRef="usd">48000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-BF9FDB06EBCD5CDFBB1B650A1B95026D" unitRef="usd">0</us-gaap:DerivativeLiabilities>
	<us-gaap:DerivativeLiabilities contextRef="FI2017Q2" decimals="-3" id="Fact-9B20DB015C3E54DEABE24F7A8178A837" unitRef="usd">618000</us-gaap:DerivativeLiabilities>
	<us-gaap:DividendsPreferredStockCash contextRef="D2016Q1Mar1-31" decimals="0" id="Fact-A419457BE0D863013EDD067003540988" unitRef="usd">432716</us-gaap:DividendsPreferredStockCash>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-EE101E6005E757F3A131203204836FED" unitRef="usdPerShare">-1.03</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q2YTD" decimals="2" id="Fact-365EBFB2BF6F5219AFC1892A909141FA" unitRef="usdPerShare">-6.10</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-1B7744881F375EC3A6DB6E26A5448078" unitRef="usdPerShare">-15.35</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q2YTD" decimals="2" id="Fact-E511369E0E3D51EDB09B3D2F19654826" unitRef="usdPerShare">-18.77</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-B241C0829E30E6338456E74F8C682569" unitRef="usd">155000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-8FA47570C051B7F66644E74F8C7D7276" unitRef="usd">791000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="FI2017Q2" decimals="-5" id="Fact-3FFBC8912F455582A4D67974F8DBCD82" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
	<us-gaap:EquityFairValueDisclosure contextRef="FI2017Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-A9174387101836384171E629DA33AFEC" unitRef="usd">2147716</us-gaap:EquityFairValueDisclosure>
	<us-gaap:ExtinguishmentOfDebtAmount contextRef="D2017Q2Jun.28_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_DebtInstrumentAxis_prpo_A2017BridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-5" id="Fact-3533E4D6FAAD66D47B05EB6B5898F8F5" unitRef="usd">1200000</us-gaap:ExtinguishmentOfDebtAmount>
	<us-gaap:ExtinguishmentOfDebtAmount contextRef="D2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_A2017NewBridgeNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-5" id="Fact-6E48BDDE41A5FF4F5265ECA3D8421435" unitRef="usd">800000</us-gaap:ExtinguishmentOfDebtAmount>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2016Q2YTD" decimals="-3" id="Fact-D1C9312730485AE498990CC3427F321B" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q2YTD" decimals="-3" id="Fact-47A17E9D06E35BC7B781558873D47E1D" unitRef="usd">3000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q2YTD_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" decimals="2" id="Fact-F675A7077ECF5056822C035B29A1437F" unitRef="number">1.21</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q2YTD_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" decimals="4" id="Fact-A3150533FF435183961310E87C65775D" unitRef="number">0.0164</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q2YTD_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" decimals="-3" id="Fact-454A8A92BC3A5E7AA7574294091E10EC" unitRef="usd">-3000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2017Q2YTD_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" decimals="-3" id="Fact-77506E3E8058566DB295DBF6F3963B40" unitRef="usd">615000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" decimals="-3" id="Fact-86D7EA78E7B25883AB28DD4AAE2E1ED9" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q2_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" decimals="-3" id="Fact-78AE2282F80C5A4483E3ED6B3344C985" unitRef="usd">618000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2016Q2QTD" decimals="-3" id="Fact-667F82A2E521E3AD5338EFA9AB1F3F80" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-64886C85803DF134ECA4EFA9AB0DF214" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q2QTD" decimals="-3" id="Fact-20CB650389746DD2AEF7EFA9AB174A9E" unitRef="usd">-53000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="FD2017Q2YTD" decimals="-3" id="Fact-7DD4DBB37AACF46F2F4DEFA9AB1A5F52" unitRef="usd">-53000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
	<us-gaap:Goodwill contextRef="FI2015Q4" decimals="-3" id="Fact-61BD21D756F752F299BBF8B380019C3E" unitRef="usd">0</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q2" decimals="-3" id="Fact-DB3B546B108C5A39A381F4F7B1F97906" unitRef="usd">13832000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2017Q2Jun.29_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" decimals="-3" id="Fact-E0BEFC7E0BBA9ABA81FFE257F3EC901C" unitRef="usd">13832000</us-gaap:Goodwill>
	<us-gaap:GrossProfit contextRef="FD2016Q2QTD" decimals="-3" id="Fact-08BD1369F4215A89A5AAE67B590A8886" unitRef="usd">263000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2016Q2YTD" decimals="-3" id="Fact-1AEB5C31F0EB5F7CBA897519F48AFF98" unitRef="usd">563000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q2QTD" decimals="-3" id="Fact-906C820A80755E9BB604EC1C79A7A82D" unitRef="usd">-24000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q2YTD" decimals="-3" id="Fact-7A368D085DD95FACB4854D38ABB056AE" unitRef="usd">42000</us-gaap:GrossProfit>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2017Q2YTD" decimals="INF" id="Fact-F1311B22D53173F8F116E1E19EFB5B6E" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="FD2016Q2YTD" decimals="-3" id="Fact-BD698CD523D5504F8FBDE12DFBB5D552" unitRef="usd">-752000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="FD2017Q2YTD" decimals="-3" id="Fact-668922BB671B52248B17190F3B47F821" unitRef="usd">-4439000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q2QTD" decimals="-3" id="Fact-3080DBE52DD55E03AC38A2CF197FF4AD" unitRef="usd">-444000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2016Q2YTD" decimals="-3" id="Fact-DEB6662922ED53C7B1229C41A9CF678B" unitRef="usd">-752000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q2QTD" decimals="-3" id="Fact-CC03E57FDAF05B8DA632EE6A27DAAD9E" unitRef="usd">-3680000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q2YTD" decimals="-3" id="Fact-4F85A71228A45F16821B9EA0EEB56B5C" unitRef="usd">-4439000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q2QTD" decimals="-3" id="Fact-F6A7C9507F905E32A1C14C471541A88C" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q2YTD" decimals="-3" id="Fact-69B797B36A795C0986DACB8EFCFD1A49" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q2QTD" decimals="-3" id="Fact-DDB64585488A5009B5D92922AE1AD062" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q2YTD" decimals="-3" id="Fact-059CCF9A461F5FF8B79A7C4D94F165C0" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q2YTD" decimals="-3" id="Fact-D2561C966A5657E2BB7122C817165EFA" unitRef="usd">91000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q2YTD" decimals="-3" id="Fact-EE4F8C3909DA545E92202EB509E14046" unitRef="usd">290000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q2YTD" decimals="-3" id="Fact-6C289EE71B315D18B2C37C679B2A8E44" unitRef="usd">340000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q2YTD" decimals="-3" id="Fact-DC0EBFDDEE425CF284AE1743C8840EF7" unitRef="usd">136000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q2YTD" decimals="-3" id="Fact-108B7B190B0D555CBE753B0D3192B47F" unitRef="usd">18000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q2YTD" decimals="-3" id="Fact-31528CB4E9DE57D88EEC4B31B56190FD" unitRef="usd">-7000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-C104C0C86B2F557EA8C899E8D1B90B0E" unitRef="usd">238000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-9ADDEA67DB5A5ACE8D6B1C71AD3A5FC7" unitRef="usd">484000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2016Q2YTD" decimals="-3" id="Fact-16433DFCE075526B99CDD0B4B83FB645" unitRef="usd">-1000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2017Q2YTD" decimals="-3" id="Fact-ECC76B1F0C6653B58971A85780C59988" unitRef="usd">1000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2016Q4" decimals="-3" id="Fact-40AB4B34BD025D3990C198D837183F68" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2017Q2" decimals="-3" id="Fact-2A36B91AF74E57A88FF6F3C7D0B617FA" unitRef="usd">21100000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestPaid contextRef="FD2016Q2YTD" decimals="-3" id="Fact-3D0F1F70507653DB97CB42AB01607B2A" unitRef="usd">18000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2017Q2YTD" decimals="-3" id="Fact-A99EA829263A5F829272D6CAC12E84B6" unitRef="usd">30000</us-gaap:InterestPaid>
	<us-gaap:InterestPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-F570652ADBB6DF3451E7E753014467C6" unitRef="usd">495000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-A7C37B047FB92E36C59DE7530144D23C" unitRef="usd">170000</us-gaap:InterestPayableCurrent>
	<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="FI2016Q4" decimals="0" id="Fact-6F6F721597C7375E7C11E640690B98AC" unitRef="usd">61073</us-gaap:InterestPayableCurrentAndNoncurrent>
	<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_JuniorNotesMember" decimals="0" id="Fact-4AC1269919D9489EBBC6E6A7FBA77848" unitRef="usd">71258</us-gaap:InterestPayableCurrentAndNoncurrent>
	<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="FI2016Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-1" id="Fact-670941655EA763B10E2CE6A7FB5259BF" unitRef="usd">279740</us-gaap:InterestPayableCurrentAndNoncurrent>
	<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="FI2017Q2_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" decimals="-4" id="Fact-A1BB6B4557553E21FE8A04AAC22E91A5" unitRef="usd">10000</us-gaap:InterestPayableCurrentAndNoncurrent>
	<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="I2017Q2Jun.17_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember" decimals="0" id="Fact-4E1DD9F76E001DA6C367E7226FBA55C9" unitRef="usd">18041</us-gaap:InterestPayableCurrentAndNoncurrent>
	<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="I2017Q2Jun.29_us-gaap_DebtInstrumentAxis_prpo_ConvertibleBridgeLoanMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-978922539AF030D32308F606DA3E3AB3" unitRef="usd">192000</us-gaap:InterestPayableCurrentAndNoncurrent>
	<us-gaap:InterestPayableCurrentAndNoncurrent contextRef="I2017Q2Jun.29_us-gaap_LongtermDebtTypeAxis_prpo_SeniorandJuniorNotesMember" decimals="0" id="Fact-8CD9CAC4C5DC3FD68679FF98C570FCA5" unitRef="usd">602373</us-gaap:InterestPayableCurrentAndNoncurrent>
	<us-gaap:InventoryNet contextRef="FI2016Q4" decimals="-3" id="Fact-EF91D02EB73A59A3BF7C0A68D5C3E394" unitRef="usd">100000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2017Q2" decimals="-3" id="Fact-A3070B70300B5BCEAE86C0E746D06104" unitRef="usd">108000</us-gaap:InventoryNet>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-B3C616F5711A5513B2FDDC44A5995655" unitRef="usd">7302000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q2" decimals="-3" id="Fact-BA19234B5A605893B3EBFE608DDB7264" unitRef="usd">17241000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-4AA9415DEBE859019E337097E710DC36" unitRef="usd">842000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q2" decimals="-3" id="Fact-2E4BD475B3E15304B33EFC4223AE0F8A" unitRef="usd">37010000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-A5C114339A9A559DA6DC6FC22036948F" unitRef="usd">3012000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-38C71B2F647D5F6AB4038093EC47EE59" unitRef="usd">16314000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2012Q4Apr.1_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember" decimals="INF" id="Fact-6E2F1828E367021945EEE6E4420547A5" unitRef="usd">500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LitigationSettlementAmount contextRef="D2017Q3Jul.13_us-gaap_LitigationCaseAxis_prpo_FoxChaseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-3" id="Fact-AD9E3A938D77E4D17B49E7948DE48AF4" unitRef="usd">139000</us-gaap:LitigationSettlementAmount>
	<us-gaap:LongTermDebtCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6BE0983A36D55D228442E18A683B675E" unitRef="usd">395000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-89CE20B23D7459C79D8027D2B0CE59D5" unitRef="usd">513000</us-gaap:LongTermDebtCurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-F4A96FEFA68E5507A518FD41634B3ABC" unitRef="usd">4127000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-FC976B4D829E5EC29B09ECCDC7E13C25" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2016Q4_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" decimals="-5" id="Fact-7BF4B80E278A11AA412704CA6DE1C1C9" unitRef="usd">700000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2016Q4_us-gaap_LitigationCaseAxis_prpo_UNMCMember" decimals="-5" id="Fact-08B0D6849BA3F3BBE7B604C43138C3B2" unitRef="usd">400000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q1_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" decimals="-5" id="Fact-A953C4E410A7AC3D9F7B04C91E69AA49" unitRef="usd">700000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q1_us-gaap_LitigationCaseAxis_prpo_UNMCMember" decimals="-5" id="Fact-6685ED9AC7D59214596704C2508C2739" unitRef="usd">400000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q2_dei_LegalEntityAxis_prpo_TransgenomicsMember_us-gaap_LitigationCaseAxis_prpo_IDTMember" decimals="-5" id="Fact-3FD48E00D8352CFA7F1A0649C323C469" unitRef="usd">300000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember" decimals="-5" id="Fact-851FD91C56F9484D1BCC04D14C39D36F" unitRef="usd">200000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_EdgeBioSystemsInc.Member" decimals="-5" id="Fact-CF8129C475BBD82B57F504D249F731F2" unitRef="usd">100000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_SmithMember" decimals="-5" id="Fact-E8CCC66E50BA1C18305804CD3571EBB1" unitRef="usd">600000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_UNMCMember" decimals="-5" id="Fact-85A9E82ECFFDC60FC4F9064965783165" unitRef="usd">400000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2017Q2_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member" decimals="-5" id="Fact-F8B9DB9BA6990265EE2A04CE636B8CAD" unitRef="usd">300000</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2016Q4Oct.27_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" decimals="-5" id="Fact-91C13C6D74B3D382315C04C8C761D5F0" unitRef="usd">700000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2017Q1Mar.6_us-gaap_LitigationCaseAxis_prpo_ScienceParkDevelopmentCorporationMember" decimals="-5" id="Fact-34A10D9DA3A0777A305504CF8640EF5C" unitRef="usd">400000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesAwardedValue contextRef="D2017Q2Apr.7_us-gaap_LitigationCaseAxis_prpo_SmithMember" decimals="-5" id="Fact-8437A2B9DA6EAE70E55B04CCBB3D60A8" unitRef="usd">600000</us-gaap:LossContingencyDamagesAwardedValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q1Feb25_us-gaap_LitigationCaseAxis_prpo_UNMCMember" decimals="-5" id="Fact-32C09EB722610B8F9F9504C1DB8834A1" unitRef="usd">700000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q2June23_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" decimals="-5" id="Fact-1EFB6EB51FBF04D38A1C04C7FA23938D" unitRef="usd">700000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q3Sep.13_us-gaap_LitigationCaseAxis_prpo_EdgeBioSystemsInc.Member" decimals="-5" id="Fact-072F71F5D12DDE152FCB04D1DF02F025" unitRef="usd">100000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q4Dec.19_us-gaap_LitigationCaseAxis_prpo_SmithMember" decimals="-5" id="Fact-10A419F32589C7D82C1B04CC356F54BF" unitRef="usd">2200000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2016Q4Nov.30_us-gaap_LitigationCaseAxis_prpo_ScienceParkDevelopmentCorporationMember" decimals="-5" id="Fact-6A288AC2122EEDDCDF6D04CF0E4EB15D" unitRef="usd">400000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2017Q1Feb.21_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member" decimals="-4" id="Fact-3D58E2046D23159E858C04CDE67BE0F6" unitRef="usd">270000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:LossContingencyDamagesSoughtValue contextRef="D2017Q1Feb.6_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember" decimals="-5" id="Fact-1CE4E63688B8BF674A4E04D0A00B8FCD" unitRef="usd">200000</us-gaap:LossContingencyDamagesSoughtValue>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-773924EC8D0A53D6BB021A8F82862D09" unitRef="usd">352000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-0DA9AE697E84528BB5C0B77D087A51D8" unitRef="usd">1712000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-62C52D2053225D77B848104559DE0779" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-18D11F0257455F4BAEA82B569030364C" unitRef="usd">101000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q2YTD" decimals="-3" id="Fact-9D62819FDED5539D96232D83E0319605" unitRef="usd">-390000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q2YTD" decimals="-3" id="Fact-00753BC104305AAEB7673F92FA84A9C5" unitRef="usd">-897000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-53F03B2EFF0257809E3018FE3709EE38" unitRef="usd">-444000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2YTD" decimals="-3" id="Fact-F9BF1F56025F587FBA0323D5800AD798" unitRef="usd">-752000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-582572140A5151EBB6A13274FFA32896" unitRef="usd">-3680000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2YTD" decimals="-3" id="Fact-96C7C979F67F5DC18D60699F0CAF80D5" unitRef="usd">-4439000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-774C3BD932CD5ECEBE5DC237CAD98153" unitRef="usd">-4439000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q2QTD" decimals="-3" id="Fact-47D6245F70E55A93827B89BB1B22832E" unitRef="usd">-444000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q2YTD" decimals="-3" id="Fact-F387D1FA44C751B5A5D55C8A95AD60BC" unitRef="usd">-2607000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q2QTD" decimals="-3" id="Fact-C5C4FB709E6D541CAFEB1A1DB51A5166" unitRef="usd">-8928000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q2YTD" decimals="-3" id="Fact-D75BCFA39A185EFC8B56C074EB1D932E" unitRef="usd">-9687000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="FD2016Q2YTD" decimals="-3" id="Fact-39B6538A0E005E4C9C2EDE0635058A06" unitRef="usd">49000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
	<us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 contextRef="FD2017Q2YTD" decimals="-3" id="Fact-A8D82491517E518183F0BA1F3585C652" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
	<us-gaap:OperatingExpenses contextRef="FD2016Q2QTD" decimals="-3" id="Fact-231A60A5BE6C5816A2083E123B5C4BA5" unitRef="usd">548000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q2YTD" decimals="-3" id="Fact-0FE95F4065AE565FBB3BD49FCB57D72E" unitRef="usd">1076000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q2QTD" decimals="-3" id="Fact-D3FF7F76F2E859A790253050DCAB8489" unitRef="usd">777000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q2YTD" decimals="-3" id="Fact-AEE8306FDF935706BE5203323814212E" unitRef="usd">1440000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-E70CE2A338C901812F8FE15B1D74AE31" unitRef="usd">-285000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q2YTD" decimals="-3" id="Fact-F1E7CA46269412A81713E15B1D7767DD" unitRef="usd">-513000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-80600E6655590F0BB71FE15B1D68224A" unitRef="usd">-801000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q2YTD" decimals="-3" id="Fact-9E6F4B854D60BCAD4E8BE15B1D69C45E" unitRef="usd">-1398000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6E212773357AF235C06DE757D61316C8" unitRef="usd">50000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-16688AAD7404CA542492E757D6207716" unitRef="usd">2560000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="-3" id="Fact-CF5502C32C2792079B3905AF3C55F1F1" unitRef="usd">7000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-959E657590D25164B363E6F677226B63" unitRef="usd">13000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q2" decimals="-5" id="Fact-A69191BB1B165044B445F668FECB6D93" unitRef="usd">200000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-D74B40D177955209A5409C1F20732FDF" unitRef="usd">154000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-0AA0EA59496850AEB88C926680E020C2" unitRef="usd">10000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-AEA82E4518DF5A7F800EE12008359066" unitRef="usd">18000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-F866B3BDAF765A3C823DCC86ED9DB74C" unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2017Q2" decimals="-3" id="Fact-4AF052F2DE5E587D989EAF9DD79795A8" unitRef="usd">1528000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-5B32A526AF1D522982637F7B1DB7F09C" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q2" decimals="-3" id="Fact-6B5D35BCDF285FB4BE0C5E2187FC229B" unitRef="usd">171000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q2QTD" decimals="-3" id="Fact-C2ADB3F91E085B2C80A58D53970D54A5" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q2YTD" decimals="-3" id="Fact-6EA0FEAF8B0E593588991D66B33A03EC" unitRef="usd">3000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q2QTD" decimals="-3" id="Fact-9B826F1DB0F7503CBC9C6FCF8D6E4FC5" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q2YTD" decimals="-3" id="Fact-7B4D561C6B16555E83DAF671A1B9D226" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherReceivablesNetCurrent contextRef="FI2017Q2" decimals="-5" id="Fact-E6B50A93CA20532496D860D48331B7A2" unitRef="usd">100000</us-gaap:OtherReceivablesNetCurrent>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2016Q2YTD" decimals="-3" id="Fact-73B79D55352B55C78E0B8C5555BABE37" unitRef="usd">10000</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2017Q2YTD" decimals="-3" id="Fact-68CD97730547566ABE9709A25A7F8762" unitRef="usd">25000</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PreferredStockDividendRatePercentage contextRef="D2016Q1Mar1-31" decimals="INF" id="Fact-6CA44F3D967E4540F449066C43F2C5B5" unitRef="number">0.08</us-gaap:PreferredStockDividendRatePercentage>
	<us-gaap:PreferredStockDividendRatePercentage contextRef="D2017Q2Jun.29_dei_LegalEntityAxis_prpo_TransgenomicsMember" decimals="INF" id="Fact-10AF821B4F3A4C6F44CBE29684B67543" unitRef="number">0.08</us-gaap:PreferredStockDividendRatePercentage>
	<us-gaap:PreferredStockDividendRatePercentage contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="INF" id="Fact-4ACDAF65156B3E8BC905EC5780C7F4DA" unitRef="number">0.08</us-gaap:PreferredStockDividendRatePercentage>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2016Q2QTD" decimals="-3" id="Fact-0E2F6113E634518AAF22917D7C18F3C5" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2016Q2QTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="-3" id="Fact-F907B2A7B1CDC4F3AC71E15B1D67664B" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2016Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-9E6B6FC0D799AB1D2257E15B1D4F8E35" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2016Q2YTD" decimals="-3" id="Fact-899EA898CFFB59308025ED1245B478FE" unitRef="usd">1855000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2016Q2YTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="-3" id="Fact-B5A2912C19668072BF15E15B1D76874C" unitRef="usd">1422000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2016Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-9C351221F1C8E6FA34E6E15B1D5FC486" unitRef="usd">433000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q2QTD" decimals="-3" id="Fact-4149F55A09905BA592E07F5B91E8AC4B" unitRef="usd">5248000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q2QTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="-3" id="Fact-432333A9CE9308F51FC5E15B1D65CAC3" unitRef="usd">5248000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-B5E82D0AF5573CFD7561E15B1D6CF0AC" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q2YTD" decimals="-3" id="Fact-A349D0F89C2F5C74B3490241DB6FF393" unitRef="usd">5248000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="-3" id="Fact-699EA85244CF77357316E15B1D6DACB0" unitRef="usd">5248000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-926A9C1E3A22E4946F64E15B1D70FDBF" unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-606F1D097AEA413486F2FC1F95332EF7" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q2" decimals="INF" id="Fact-8C05D404809AFC929E98EC4DB351852B" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="INF" id="Fact-5E80084A457D61B05B79EC524E7CF48A" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-6374FD94D574B2E34B90FC1F29043CD7" unitRef="shares">1294434</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q2" decimals="0" id="Fact-F489FB9C01092B203C25F611095CCAB4" unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q2" decimals="INF" id="Fact-0BB4699AB0C72FB86DE3E15838C6E2DB" unitRef="shares">15000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="INF" id="Fact-558A038F9CAA0720D072EC4C41C9002B" unitRef="shares">4100000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-69A3DAB20436E23515D9FC1F728DC6CB" unitRef="shares">780105</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q2" decimals="INF" id="Fact-D43A03C66B3D41FB1720E1583C365CA9" unitRef="shares">1712901</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-BD58F72476D21FFB4BC60666E81AAB0A" unitRef="shares">275237</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-F22B4FCF76B76EC0A67B0668051D5516" unitRef="shares">208087</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-AFD9F7ADA806DA201342FC1F8128A805" unitRef="shares">780105</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-FD19F559636F2E53EA62EC4231EDD7F3" unitRef="shares">367299</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="INF" id="Fact-A6D9C338406BB93951CEEC428E2200FA" unitRef="shares">412806</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q2" decimals="INF" id="Fact-8C859F833545B81445DAE1583F4C9724" unitRef="shares">1712901</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q2_us-gaap_StatementClassOfStockAxis_prpo_PreferredStockSeriesASeniorMember" decimals="INF" id="Fact-19845BA67CE50A7B2DDBEC5E0CC84CAC" unitRef="shares">1712901</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2016Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-FDE3B80CB4A4E0B1E035066A7C927C78" unitRef="usd">750000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q1_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" decimals="-3" id="Fact-4025BC161AB2A7CDD7A8066A7CF8E113" unitRef="usd">965000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-7DD3FAD8442039DED43AE12BECBDF736" unitRef="usd">8000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q2" decimals="-3" id="Fact-F98F2450896DAAE11D67E12BEAEF06BA" unitRef="usd">17000</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2017Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-9C7D9F760CC442FCA5BFE62D189A8DE1" unitRef="usd">1715000</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2017Q2" decimals="-5" id="Fact-7D915567917C5E22951FDB9DCE00182B" unitRef="usd">100000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2016Q2YTD" decimals="-3" id="Fact-4854430976C153388E1DC1D63D03663E" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2016Q4YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-F37934A675C4930F569DE64AD237F0E4" unitRef="usd">525000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2017Q2YTD" decimals="-3" id="Fact-54F4B95C9E17558D8E9DA4C6CEFF93D3" unitRef="usd">315000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2017Q2YTD_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" decimals="-3" id="Fact-1CE54809BB5833409300E64C98312501" unitRef="usd">315000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2016Q2YTD" decimals="-3" id="Fact-12411CC09A3A5C0B9458E9DC75CC256F" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="FD2017Q2YTD" decimals="-3" id="Fact-A855D697521C5877A0FC4AB0A8C64B69" unitRef="usd">400000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="FD2017Q3QTD_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-6" id="Fact-0641B58B9EF2296B3701ECC41FC64DB7" unitRef="usd">7000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2016Q2YTD" decimals="-3" id="Fact-C4CE4492057A40A4CAA6E18AC09B8427" unitRef="usd">455000</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromNotesPayable contextRef="FD2017Q2YTD" decimals="-3" id="Fact-73AC4107A91D434C604DE18AC09BA4F2" unitRef="usd">1365000</us-gaap:ProceedsFromNotesPayable>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2016Q2YTD" decimals="-3" id="Fact-A66898AE42CB5DA8AB3880CB3029BB81" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2017Q2YTD" decimals="-3" id="Fact-F3DC389A94D455E39829C8E1F0B9FB59" unitRef="usd">25000</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-9D574D13946C50829EC8294669FBB881" unitRef="usd">280000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q2" decimals="-3" id="Fact-37B4AD717FD650529B6AF44B72AE1390" unitRef="usd">262000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="FD2016Q2YTD" decimals="-3" id="Fact-9FF1C550C2235D36963ADD30E61B081D" unitRef="usd">229000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="FD2017Q2YTD" decimals="-3" id="Fact-3E4CC3FC1BA051CD97DA3B66899657C4" unitRef="usd">111000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="FD2016Q2YTD" decimals="-3" id="Fact-DC50433D95625238A1E17D3F10263071" unitRef="usd">19000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="FD2017Q2YTD" decimals="-3" id="Fact-217D5DA9E9BE52E0B3F4FA336FEB0387" unitRef="usd">23000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2016Q2YTD" decimals="-3" id="Fact-BE4D93394D0453E2BECEE67860B58F09" unitRef="usd">74000</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2017Q2YTD" decimals="-3" id="Fact-7CE8109A49F85CE796E0E07718DBBA8C" unitRef="usd">345000</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:RestrictedStockExpense contextRef="FD2017Q2YTD" decimals="0" id="Fact-6B6EAA88111DCED887DBFFD510194D7D" unitRef="usd">28000</us-gaap:RestrictedStockExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-8F097A37785753CE95A5C164253A905C" unitRef="usd">-10848000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q2" decimals="-3" id="Fact-610358A559BC5744925020CAC245A649" unitRef="usd">-15287000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2016Q2QTD" decimals="-3" id="Fact-2FEEC7661D8479EF373FE1654E4164B1" unitRef="usd">615000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q2YTD" decimals="-3" id="Fact-8FFB287F0913EFB3A1F4E1654E2E4F2C" unitRef="usd">1271000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD" decimals="-3" id="Fact-0C32CD6C882FC9257F8AE1654E4A8FAF" unitRef="usd">316000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2YTD" decimals="-3" id="Fact-4D10DABA8A6271F8A309E1654E3A8D8A" unitRef="usd">619000</us-gaap:Revenues>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q2Jun.29_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-3CE5F5CD3D2697E5E018E24A866EE4C9" unitRef="usd">400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SalesAllowancesServices contextRef="FD2016Q2QTD" decimals="-3" id="Fact-39B9C5E480C0ED9276AEE160A9CBD68C" unitRef="usd">111000</us-gaap:SalesAllowancesServices>
	<us-gaap:SalesAllowancesServices contextRef="FD2016Q2YTD" decimals="-3" id="Fact-AA4DAE15E0F33F7B6389E160A9D233CD" unitRef="usd">229000</us-gaap:SalesAllowancesServices>
	<us-gaap:SalesAllowancesServices contextRef="FD2017Q2QTD" decimals="-3" id="Fact-997420134C70824ED195E160A9D47660" unitRef="usd">56000</us-gaap:SalesAllowancesServices>
	<us-gaap:SalesAllowancesServices contextRef="FD2017Q2YTD" decimals="-3" id="Fact-D43E908B4D699777DBBCE160A9DD6D86" unitRef="usd">111000</us-gaap:SalesAllowancesServices>
	<us-gaap:SalesRevenueServicesNet contextRef="FD2016Q2QTD" decimals="-3" id="Fact-CA71FBDFDFA218434768E15B1D63F311" unitRef="usd">504000</us-gaap:SalesRevenueServicesNet>
	<us-gaap:SalesRevenueServicesNet contextRef="FD2016Q2YTD" decimals="-3" id="Fact-20B6F7C5E7AC996410EDE15B1D5DFB67" unitRef="usd">1042000</us-gaap:SalesRevenueServicesNet>
	<us-gaap:SalesRevenueServicesNet contextRef="FD2017Q2QTD" decimals="-3" id="Fact-7CC75DA3BB9E8E6F5560E15B1D62791E" unitRef="usd">260000</us-gaap:SalesRevenueServicesNet>
	<us-gaap:SalesRevenueServicesNet contextRef="FD2017Q2YTD" decimals="-3" id="Fact-2677B2FEBC470D6DE532E15B1D72D389" unitRef="usd">508000</us-gaap:SalesRevenueServicesNet>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q2YTD" decimals="-3" id="Fact-316E39F11D285A2F8691B57F211DD44B" unitRef="usd">7000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q2YTD" decimals="-3" id="Fact-3D8D10566729593887F69D4E11F4961A" unitRef="usd">23000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q2YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-F12C9F2FB4DF5E62A4AAB879B2A38A2C">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q2YTD_us-gaap_TitleOfIndividualAxis_us-gaap_ExecutiveOfficerMember" id="Fact-FA86DB2C038E54D5952923FCA7AA484A">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="2" id="Fact-4D42CD32F2255B0A929C9750BD1D2DC0" unitRef="usdPerShare">129.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="FD2017Q2YTD" id="Fact-8166A9A40EDD536E8EE8805842694508">P1Y0M0D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" id="Fact-EF3A1F267CCC5BE6A0B8ACAC28E66204">P6Y3M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="D2017Q2Jun.28_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-A44F5FBDC4B17257708804DD6B3E2D22" unitRef="number">0.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="D2017Q2Jun.28_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="INF" id="Fact-C82D0B6DA0CC38A976D704DF3B1FB2D0" unitRef="number">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="INF" id="Fact-B1DC81AAC1F45889BDDC1B9FE11FCB5F" unitRef="shares">19908</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="2" id="Fact-F2179D0860405FD5BD885D0E54AE62E7" unitRef="usdPerShare">119.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="INF" id="Fact-37A0E93C26FE5A1F9AD2E8755A90C7FA" unitRef="shares">2460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="INF" id="Fact-052FA2452B2F54BD97432C5362633EA4" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="INF" id="Fact-BEE9C01CADA8580BB3A656010976FFD4" unitRef="shares">24600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="INF" id="Fact-A1F8A00709EC5F36B9785D9820BFCE75" unitRef="shares">22140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="2" id="Fact-18A22CA69615592BB3A5B5462A686328" unitRef="usdPerShare">107.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="2" id="Fact-622D1B99DA645A0FAACDD57785FCE87C" unitRef="usdPerShare">111.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="INF" id="Fact-7A9C561321DB507C82F511EB1BB42A7F" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="INF" id="Fact-FBC165BB77CA5995933B2B67C7553A43" unitRef="shares">21713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="2" id="Fact-0FD1A31F8F0259DABF8462B34598EDEF" unitRef="usdPerShare">75.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" decimals="2" id="Fact-8BE94A187625516FB49A29DC43EF289F" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="FI2017Q2_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" decimals="INF" id="Fact-61117DA1D0765BBDAA71F5D56AAD6C24" unitRef="usdPerShare">9.00</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="2" id="Fact-29B88ABA344FF068DE6FFF8B818D4AD9" unitRef="usdPerShare">12.20</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_StockAppreciationRightsSARSMember" decimals="INF" id="Fact-7E61A450F5F6568089BE12B858876E9D" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2017Q2YTD" id="Fact-40426E41DE985EE091A21220B77A2800">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D2017Q2Jun.28_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" id="Fact-375023240CA60BD26E2104DE90EAA7F9">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2006Member" id="Fact-2E4CF7724B66512C8E2894B7841F6636">P6Y11M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A9EC7EDA268759708EF4D3B2E50D021C" unitRef="shares">449175</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-C4498F5221BB5EEB949723FC96132EDB" unitRef="shares">780105</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-403EFA067CED9DB46E9AF5C225EC732C" unitRef="shares">6407860</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-A594CF4B55D156AD8CB82F7DD6AD02EF" unitRef="shares">6407860</us-gaap:SharesOutstanding>
	<us-gaap:SharesOutstanding contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-5D989193595F366A2FCDF5C225F538E5" unitRef="shares">1712901</us-gaap:SharesOutstanding>
	<us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="FD2016Q2YTD" decimals="-3" id="Fact-D084AE54A935ADAECFE2027D1CB9838A" unitRef="usd">0</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
	<us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="FD2017Q2YTD" decimals="-3" id="Fact-E0223A696917A9854BA3FF7BE2D11106" unitRef="usd">414000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
	<us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1CF8A493C92DDAF654E0FF7BE2D67150" unitRef="usd">414000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="D2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-BDAC9C62753C176867280657BDE734F1" unitRef="shares">2200000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-3319A52735CCCF7D510AF5D1ACBAFE16" unitRef="shares">1255119</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-A207A49AE52EE68B6516F5D1ACA8DDF0" unitRef="shares">802925</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-93C9276A07693E42FF20F5C731290A9D" unitRef="shares">1958166</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-310ABDF27122A5E1201FF5C35EEF7673" unitRef="shares">8542</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="D2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-36B89CE77C6540190D8706569F3ABF10" unitRef="shares">321821</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-72134C2D95CD96C6A33CF5D677C0E73F" unitRef="shares">321821</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q2Jun.29_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C7EA496DE577A6B479AC0658ECC43720" unitRef="shares">135000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-835484D3864DD7BEB0620654339F38B8" unitRef="shares">200081</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q2Jun.29_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" decimals="INF" id="Fact-543F6D3C2BAF62EC87CBE24532278369" unitRef="shares">107056</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-240885A488B5F26C75AAF5CEFBA5921A" unitRef="shares">107056</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="FD2017Q2QTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AAB7A2B23FDF08E277C1FFCEE61E7D44" unitRef="shares">59563</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
	<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2308741B752E0CEE0EDBFFCF77A03132" unitRef="shares">59533</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q2YTD" decimals="-3" id="Fact-99210040E8957CDD5832F5D38EFF151C" unitRef="usd">20098000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9E873C756F3FC9F1B0F0F5D38F11C585" unitRef="usd">20078000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B7AD79EED34D46F68728F5D38F2050CB" unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-FEE89EFAFD4D97B1E42FF5D38F26C46F" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E7D154659B7F2CC5873DF5C75A9706D7" unitRef="usd">-20000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-D254362683F686E4D6D0F5C75A9993EF" unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-23DD5ED328870B98403CF5C56AA838E1" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2017Q2YTD_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2072EB169EDDDAECA0F7F5C56AB6E8CA" unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="FD2017Q2YTD" decimals="-3" id="Fact-DE638102668B6655795EF5D5CE3867B7" unitRef="usd">2189000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F0F144F8176FF11A0E50F5D5CE321D9C" unitRef="usd">2186000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-731F148F030C5F598921F5D5CE347442" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q2YTD" decimals="-3" id="Fact-AA78C37490FC973A0D1CF5CCB72F4117" unitRef="usd">400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5BB50B9E3A808B8D6292F5CCB73664F3" unitRef="usd">399000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-8430F8117E0A61E907A1F5CCB731B5D2" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="FD2016Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-3DA5C51015D5E54F7E1CE632A49EB63A" unitRef="usd">432716</us-gaap:StockIssuedDuringPeriodValueStockDividend>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-0E7BBE0003AD58E2AE242E3E9B1726CD" unitRef="usd">-6460000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-AC7A50A8A08F5FD383D71B0BD1E7BE1C" unitRef="usd">4376000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6C4987A9CF4B59CDA6122412E9AB2453" unitRef="usd">4000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-9CE47FC6D88F53DBB569CBD44D0E12D1" unitRef="usd">8000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E7749A1AD5705E1F82A12E0E9F496DC9" unitRef="usd">-10848000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q2" decimals="-3" id="Fact-506EF9EFCA7852FAB0036E23F354BBAD" unitRef="usd">19769000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5405EC0B748973313394F5C1DC67DD66" unitRef="usd">34975000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2E621432CC575A098436F5C1DC61062B" unitRef="usd">64000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-24BC19E2B87EE875B7F7F5C1DC6D21E3" unitRef="usd">17000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-98861AFFDAC473BE4AB7F5C1DC6AD638" unitRef="usd">-15287000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2017Q2Jun.13_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8F1E94BB5D3DA365C026EB4074F9D608" unitRef="number">0.03</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="FD2016Q2YTD" decimals="-3" id="Fact-2B3039D67FB15AD0A598B0758C735BE7" unitRef="usd">81000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
	<us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="FD2017Q2YTD" decimals="-3" id="Fact-4A56E12B5131563F954E9F3964B6F171" unitRef="usd">0</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
	<us-gaap:TreasuryStockCommonShares contextRef="I2017Q2Jun.29" decimals="0" id="Fact-DCF4E1DC40CE3F27C3A7FFD29112545C" unitRef="shares">64593</us-gaap:TreasuryStockCommonShares>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2016Q1" decimals="0" id="Fact-27139C9DB61C64CB961F067520FB8704" unitRef="usd">1421738</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2017Q2" decimals="-3" id="Fact-0BD1FCCBD478DFBA445A0497693CE6E5" unitRef="usd">211000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2017Q2_us-gaap_AwardTypeAxis_prpo_UponExecutionMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember" decimals="-3" id="Fact-32739354C4DFDAC001AD04A25FB6E731" unitRef="usd">73000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F689096FF758BAFFBEFE04F3A73D398D" unitRef="usd">73000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="FI2017Q2_us-gaap_ClassOfWarrantOrRightAxis_prpo_SideWarrantMember" decimals="-3" id="Fact-F25F6B0D5372B15B3EA1049CC33C5319" unitRef="usd">487000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="I2017Q2Jun.28_us-gaap_ShortTermDebtTypeAxis_us-gaap_LineOfCreditMember_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-3" id="Fact-4496638EE6C3F70840CE04DB9722A109" unitRef="usd">6000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="I2017Q2Jun.29" decimals="-3" id="Fact-780D13700C53EBA3DE130676192ACE1E" unitRef="usd">211000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q2QTD" decimals="0" id="Fact-4BC6AA48BFEF559AB3103BC810FC8885" unitRef="shares">429819</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q2YTD" decimals="0" id="Fact-52FDE6A9E7F055D999B9AA3329F1CDD5" unitRef="shares">427217</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q2QTD" decimals="0" id="Fact-AFCAFB7877CA5ED1BF6B03895EA755AA" unitRef="shares">581481</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q2YTD" decimals="0" id="Fact-FF98F47290F255B98AB33BD62007BBC5" unitRef="shares">515968</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<prpo:BeneficialConversionFeaturePolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-BDB5A869510B2192760204837917F0B7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Beneficial Conversion Features.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</prpo:BeneficialConversionFeaturePolicyTextBlock>
	<prpo:ConcentrationOfCashPolicyPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-AE2F7CDD130350B78B98218F0E5A43C7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentrations of Risk.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, we may maintain a cash position with financial institutions in amounts that exceed Federal Deposit Insurance Corporation insured limits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</prpo:ConcentrationOfCashPolicyPolicyTextBlock>
	<prpo:RisksAndUncertaintiesPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-FC93A771C17C5BFF9A2EA069D31668DB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Risks and Uncertainties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</prpo:RisksAndUncertaintiesPolicyTextBlock>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-3C14E874C3B1D973FD19E7373F362DBF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;ACCRUED EXPENSES.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.5859375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-5FCF777F1CB15ADBA1BED84CC2B4740E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to June 30, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than what is disclosed in Note 12 - Subsequent Events, there were no other subsequent events that required recognition or disclosure. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto of Precipio Diagnostics for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; contained in our current report on Form 8-K/A, filed with the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) on July 31, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="FD2017Q2YTD" id="Fact-2A60FFFF67426DC066D2E27195ACAAAD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dollars in thousands, except per share amounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Six months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,472&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss available to common stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,864&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-263C22B03083B43C8C64E1F3F6A28F77">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;REVERSE MERGER&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June&amp;#160;29, 2017 (the &amp;#8220;Closing Date&amp;#8221;), the Company completed the Merger with Precipio Diagnostics, in accordance with the terms of the Merger Agreement. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements. Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On the Closing Date, the outstanding common and preferred units of Precipio Diagnostics and certain debt of Precipio Diagnostics were converted into (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,352,847&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock, together with cash in lieu of fractional units, and (ii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;802,920&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio preferred stock with an aggregate face amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:11px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, on the Closing Date, Precipio also issued promissory notes and shares of Precipio preferred and common stock in a number of transactions, whereby:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:11px;text-align:left;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:32px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Holders of certain secured indebtedness of Transgenomic received in exchange for such indebtedness &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;802,925&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio preferred stock in an amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; stated value, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;352,630&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:61px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:32px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Holders of Transgenomic preferred stock converted it into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,155&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:61px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:61px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:32px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Precipio issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,056&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio preferred stock to certain investors in exchange for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in a private placement. Precipio also completed the sale of an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$800,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of promissory notes pursuant to a securities purchase agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:61px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Purchase Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preliminary estimated purchase consideration based on the value of the equity of Transgenomic, the accounting acquiree, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.2265625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Legacy Transgenomic common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of preferred stock converted to common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of debt converted to common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of debt converted to preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,796&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of existing bridge notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Purchase consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In estimating the preliminary purchase consideration above, Transgenomic used its closing stock price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.80&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of the Closing Date. Transgenomic had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;895,334&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares outstanding prior to the Merger. In connection with the Merger, Transgenomic preferred stock converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,155&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock and certain of Transgenomic debt and accrued interest converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;352,630&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;802,925&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio preferred stock, face value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with an &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; annual dividend. At the Closing Date, the preferred stock had a fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Allocation of Purchase Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth an allocation of the purchase consideration to the identifiable tangible and intangible assets of Transgenomic, the accounting acquiree, based on fair values as of the Closing Date with the excess recorded as goodwill:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current and other assets  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other intangible assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current liabilities  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other liabilities  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net assets acquired  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:37px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:13px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other intangible assets consist of:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acquired technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer relationships&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-compete agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trademark and trade name&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Backlog&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We determined the estimated fair value of the acquired technology but using the multi-period excess earnings method of the income approach.  The estimated fair value of the remaining identifiable intangible assets acquired were determined primarily by using the income approach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Unaudited pro forma information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The operating results of Transgenomic for the period after the Closing Date to June 30, 2017 have been included in the Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dollars in thousands, except per share amounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Six months ended June 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,472&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss available to common stockholders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,864&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss per common share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="FD2017Q2YTD" id="Fact-49B1BD22396956669980505A779FDC64">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;BUSINESS DESCRIPTION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Business Description&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Precipio, Inc., and Subsidiary, (&amp;#8220;we&amp;#8221;, &amp;#8220;us&amp;#8221;, &amp;#8220;our&amp;#8221;, the &amp;#8220;Company&amp;#8221; or &amp;#8220;Precipio&amp;#8221;) is a cancer diagnostics company providing diagnostic products and services to the oncology market. We have built and continue to develop a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory located in New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and technologies developed within academia so that we can provide a better standard of cancer diagnostics and solve the growing problem of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development of ICE-COLD-PCR (&amp;#8220;ICP&amp;#8221;), the patented technology which was exclusively licensed by us from Dana-Farber Cancer Institute, Inc. (&amp;#8220;Dana-Farber&amp;#8221;) at Harvard University (&amp;#8220;Harvard&amp;#8221;). The research and development center will focus on the development of this technology, which we believe will enable us to commercialize other technologies developed by our current and future academic partners. Our platform connects patients, physicians and diagnostic experts residing within academic institutions. Launched in 2017, the platform facilitates the following relationships:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Patients: patients may search for physicians in their area and consult directly with academic experts that are on the platform. Patients may also have access to new academic discoveries as they become commercially available.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Physicians: physicians can connect with academic experts to seek consultations on behalf of their patients and may also provide consultations for patients in their area seeking medical expertise in that physician&amp;#8217;s relevant specialty. Physicians will also have access to new diagnostic solutions to help improve diagnostic accuracy.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Academic Experts: academic experts on the platform can make themselves available for patients or physicians seeking access to their expertise. Additionally, these experts have a platform available to commercialize their research discoveries.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We intend to continue updating our platform to allow for patient-to-patient communications and allow individuals to share stories and provide support for one another, to allow physicians to consult with their peers to discuss and share challenges and solutions, and to allow academic experts to interact with others in academia on the platform to discuss their research and cross-collaborate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ICP was developed at Harvard and is licensed exclusively by us from Dana-Farber. The technology enables the detection of genetic mutations in liquid biopsies, such as blood samples. The field of liquid biopsies is a rapidly growing market, aimed at solving the challenge of obtaining genetic information on disease progression and changes from sources other than a tumor biopsy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gene sequencing is performed on tissue biopsies taken surgically from the tumor site in order to identify potential therapies that will be more effective in treating the patient. There are several limitations to this process. First, surgical procedures have several limitations, including:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cost: surgical procedures are usually performed in a costly hospital environment. For example, according to a recent study the mean cost of lung biopsies is greater than $14,000; surgery also involves hospitalization and recovery time.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Surgical access: various tumor sites are not always accessible (e.g. brain tumors), in which cases no biopsy is available for diagnosis.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk: patient health may not permit undergoing an invasive surgery; therefore a biopsy cannot be obtained at all.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Time: the process of scheduling and coordinating a surgical procedure often takes time, delaying the start of patient treatment.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Second, there are several tumor-related limitations that provide a challenge to obtaining such genetic information from a tumor:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Tumors are heterogeneous by nature: a tissue sample from one area of the tumor may not properly represent the tumor&amp;#8217;s entire genetic composition; thus, the diagnostic results from a tumor may be incomplete and non-representative.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Metastases: in order to accurately test a patient with metastatic disease, ideally an individual biopsy sample should be taken from each site (if those sites are even known). These biopsies are very difficult to obtain; therefore physicians often rely on biopsies taken from the primary tumor site.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The advent of technologies enabling liquid biopsies as an alternative to tumor biopsy and analysis is based on the fact that tumors (both primary and metastatic) shed cells and fragments of DNA into the blood stream. These blood samples are called &amp;#8220;liquid biopsies&amp;#8221; that contain circulating tumor DNA, or ctDNA, which hold the same genetic information found in the tumor(s). That tumor DNA is the target of genetic analysis. However, since the quantity of tumor DNA is very small in proportion to the &amp;#8220;normal&amp;#8221; (or &amp;#8220;healthy&amp;#8221;) DNA within the blood stream, there is a need to identify and separate the tumor DNA from the normal DNA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ICP is an enrichment technology that enables the laboratory to focus its analysis on the tumor DNA by enriching, and thereby &amp;#8220;multiplying&amp;#8221; the presence of, tumor DNA, while maintaining the normal DNA at its same level. Once the enrichment process has been completed, the laboratory genetic testing equipment is able to identify genetic abnormalities presented in the ctDNA, and an analysis can be conducted at a higher level of sensitivity, to enable the detection of such genetic abnormalities. The technology is encapsulated into a chemical that is provided in the form of a kit and sold to other laboratories who wish to conduct these tests in-house. The chemical within the kit is added to the specimen preparation process, enriching the sample for the tumor DNA so that the analysis will detect those genetic abnormalities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Merger Transaction&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June&amp;#160;29, 2017, the Company (then known as &amp;#8220;Transgenomic, Inc.&amp;#8221;, or &amp;#8220;Transgenomic&amp;#8221;), completed a reverse merger (the &amp;#8220;Merger&amp;#8221;) with Precipio Diagnostics, LLC, a privately held Delaware limited liability company (&amp;#8220;Precipio Diagnostics&amp;#8221;) in accordance with the terms of the Agreement and Plan of Merger (the &amp;#8220;Merger Agreement&amp;#8221;), dated October&amp;#160;12, 2016, as amended on February&amp;#160;2, 2017 and June&amp;#160;29, 2017, by and among Transgenomic, Precipio Diagnostics and New Haven Labs Inc. (&amp;#8220;Merger Sub&amp;#8221;) a wholly-owned subsidiary of Transgenomic. Pursuant to the Merger Agreement, Merger Sub merged with and into Precipio Diagnostics, with Precipio Diagnostics surviving the Merger as a wholly-owned subsidiary of the combined company (See Note 3 - Reverse Merger). In connection with the Merger, the Company changed its name from Transgenomic, Inc. to Precipio, Inc., relisted its common stock under Precipio, Inc. on the National Association of Securities Dealers Automated Quotations (&amp;#8220;NASDAQ&amp;#8221;), and effected a 1-for-30 reverse stock split of its common stock. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements. Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods. As a result of the Merger, historical preferred stock, common stock, restricted units, warrants and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the effect of the Merger exchange ratio. Pursuant to the Merger Agreement, each outstanding share of capital stock of Precipio Diagnostic was exchanged for 10.2502 pre-reverse stock split shares of Company Common Stock (the &amp;#8220;Exchange Ratio&amp;#8221;). See Note 3 - Reverse Merger for additional discussion of the Merger.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Going Concern&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. As of June 30, 2017, the Company had a net loss of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and negative working capital of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company&amp;#8217;s ability to continue as a going concern is dependent upon a combination of achieving its business plan, including generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Precipio is currently in discussions with certain investors to raise additional capital.  There can be no assurance such capital is or will be available at terms favorable or agreeable to management, if at all, or that the Company will successfully complete the proposed capital raise. Since the outcome of these matters cannot be predicted with any certainty at this time, there is substantial doubt that the Company will be able to continue as a going concern. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company&amp;#8217;s ability to continue as a going concern.  There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern. The accompanying financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of the outcome of this uncertainty.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-4CF5D8610AB552699D4AFE5C2CD9D8AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents and Other Current Assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-C73973A8EBA75E44ACBEB44CAF5FFFB3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;CONTINGENCIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is involved in legal proceedings related to matters, which are incidental to its business. The Company has also assumed a number of claims as a result of the Merger. See below for a discussion on these matters. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The healthcare industry is subject to numerous laws and regulations of federal, state and local governments.  These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed.  Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations.  While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The outcome of legal proceedings and claims brought against us are subject to significant uncertainty.  Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management&amp;#8217;s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Claims assumed in the Merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assumed a number of claims as a result of the Merger. In addition to the claims described below, we are delinquent on the payment of outstanding accounts payable certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 25, 2016, the Board of Regents of the University of Nebraska (&amp;#8220;UNMC&amp;#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; owed by us to UNMC.  A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay $0.4 million to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of the initial payment due to UNMC. A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at June 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On April 13, 2016, Fox Chase Cancer Center (&amp;#8220;Fox Chase&amp;#8221;) filed a lawsuit against Transgenomic in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &amp;#8220;Court of Common Pleas&amp;#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement Transgenomic entered into with Fox Chase in August 2000, as amended (the &amp;#8220;License Agreement&amp;#8221;), as well as the assignment of certain of Transgenomic's rights under the License Agreement to Integrated DNA Technologies, Inc. (&amp;#8220;IDT&amp;#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement Transgenomic entered into with IDT effective as of July 1, 2014 (the &amp;#8220;IDT Agreement&amp;#8221;). Pursuant to the terms of the IDT Agreement, Transgenomic agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained Transgenomic's preliminary objections to several of Fox Chase&amp;#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&amp;#8217;s fees.&amp;#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remained pending against Transgenomic. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During June 2017, prior to the Merger, Transgenomic entered into a settlement agreement with Fox Chase (the &amp;#8220;Agreement&amp;#8221;) which will resolve all outstanding claims in the litigation brought in April 2016 by Fox Chase against Transgenomic in the Court of Common Pleas of Philadelphia County (the &amp;#8220;Action&amp;#8221;). The case will remain pending with the Court until all settlement payments to Fox Chase have been made. Under the Agreement the Company will make three (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) payments to Fox Chase totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$175,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The last payment is to be made on or before September 30, 2017, and once received Fox Chase is obligated to cause the Action to be formally dismissed with prejudice. Also, on July 13, 2017 the Company entered into an agreement with its co-Defendant, IDT, regarding the Company&amp;#8217;s indemnity obligations to IDT for legal fees and expenses incurred in the Action pursuant to the terms of the IDT Agreement. The IDT Agreement provides for monthly payments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$27,800&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the Company to IDT, in the total amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$139,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, commencing on August 15, 2017 and concluding on December 15, 2017. A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at June 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&amp;#8220;Mount Sinai&amp;#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Mount Sinai in installments over a period of time. A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at June 30, 2017.  Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 19, 2016, Todd Smith (&amp;#8220;Smith&amp;#8221;) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties.  On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to Smith in installments over a period of time. A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at June 30, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 21, 2017, XIFIN, Inc. (&amp;#8220;XIFIN&amp;#8221;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.27 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; liability has been recorded and is reflected in accrued expenses at June 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We and Science Park Development Corporation (&amp;#8220;SPDC&amp;#8221;) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the &amp;#8220; SPDC Lease&amp;#8221;).   In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease.  Specifically, SPDC alleges that we failed to pay approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease.  We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at June 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;CPA Global provides us with certain patent management services.  On February 6, 2017, CPA Global claimed that we owe approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for certain patent maintenance services rendered.  CPA Global has not filed claims against us in connection with this allegation.  A liability of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been recorded and is reflected in accrued expenses at June 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 9, 2016, counsel for Edge BioSystems, Inc. (&amp;#8220;EdgeBio&amp;#8221;) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the &amp;#8220;EdgeBio Agreement&amp;#8221;). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement.  On September 13, 2016, we received a demand for payment letter from EdgeBio&amp;#8217;s counsel alleging that the balance due to EdgeBio is approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  A liability of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; has been recorded and is reflected in accrued expenses at June 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 17, 2017, Jesse Campbell (&amp;#8220;Campbell&amp;#8221;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&amp;#8217;s deal protection provisions deter superior offers.&amp;#160; As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&amp;#160; Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case.  Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-011AABADC3AA58C1A5FD68DBEA67FCC7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated financial statements include the accounts of Precipio, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-1AC1D574D4BB5B0EB1FD04E8A944EEE0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;DEBT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Dollars&amp;#160;in&amp;#160;Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Senior Note debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Junior Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Connecticut Innovations - line of credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Department of Economic and Community Development (DECD)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;DECD debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Webster Bank&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Webster Bank debt discounts and issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible promissory notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, net of current maturities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Senior and Junior Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During 2016, the Company raised &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$525,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from members through the issuance of senior notes which accrue interest at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and are payable at the sooner of the closing of a qualified public offering, as outlined in the note agreement, or five years from date of issuance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Also during 2016, the Company restructured equity through a redemption and exchange agreement by exchanging Member Equity comprised of Series A and Series B Convertible Preferred Units in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,147,716&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (members&amp;#8217; initial investment of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,715,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, plus declared dividends on these preferred units of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$432,716&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;), and Convertible Bridge Notes of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,120,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, plus accrued interest of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$61,073&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for new senior notes of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2,744,968&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;Senior Notes&amp;#8221;) and new junior notes of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$583,821&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;Junior Notes&amp;#8221;). The Senior and Junior Notes accrue interest at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and have maturity dates ranging from March 2021 to September 2021, or earlier based on certain qualifying events as outlined in the note agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the six months ended June 30, 2017, the Company raised &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$315,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from members through the issuance of Senior Notes at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; interest that are payable at the sooner of the closing of a qualified public offering, as outlined in the note agreement, or five years from date of issuance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On the Closing Date of the Merger, the outstanding balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,584,968&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in Senior Notes and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$583,821&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in Junior Notes, plus accrued interest of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$602,373&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, were converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;802,920&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio preferred stock and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,414,700&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Senior or Junior Notes outstanding as June 30, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2016, the outstanding balance of Senior and Junior Notes was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3,269,968&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$583,821&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, with accrued interest included within the accrued expenses on the accompanying condensed consolidated balance sheet of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$279,740&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$71,258&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Connecticut Innovations, Incorporated&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company entered into a line of credit on April 1, 2012 with Connecticut Innovations, Incorporated (Connecticut Innovations), an entity affiliated with a director of the Company, for up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with interest paid monthly at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, due on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;1, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Principal and interest payments began February 1, 2013 and ranged from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,436&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12,206&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; until September 2016, when the Company entered into a forbearance agreement to 1) defer monthly principal payments until October 2017 and 2) make interest-only payments totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,041&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per month through October 2017. Pursuant to the forbearance agreement, the Company was also restricted from any additional borrowings under the line of credit. The line was secured by substantially all of the Company&amp;#8217;s assets.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, the Company was to pay in full its loan obligations with Connecticut Innovations. The outstanding balance was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$162,066&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at both June 30, 2017 and December 31, 2016.  The outstanding principal and accrued interest balance was paid in full in July 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Department of Economic and Community Development.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company entered into a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year term loan with the Department of Economic and Community Development (&amp;#8220;DECD&amp;#8221;) on May 1, 2013 for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$300,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, with interest paid monthly at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, due on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;April&amp;#160;23, 2023&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The loan was secured by substantially all of the Company&amp;#8217;s assets but was subordinate to the term loan with Webster Bank and the Connecticut Innovations line of credit.  In connection with the Merger, the Company was to pay in full its loan obligations with DECD. The outstanding balance was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$225,714&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$243,287&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of June 30, 2017 and December 31, 2016, respectively.  The outstanding principal and accrued interest balance was paid in full in July 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Webster Bank.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company entered into a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year term loan with Webster Bank on December 1, 2014 for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$500,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, with interest paid monthly at the one month LIBOR rate (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.16%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at June 30, 2017) plus 500 basis points, due on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The line was secured by substantially all of the Company&amp;#8217;s assets and had first priority over all other outstanding debt. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The term loan with Webster Bank was subject to financial covenants relating to maintaining adequate cash runway, as defined in the term loan agreement. As of December 31, 2016 the Company was not in compliance with these covenants and, as such, the Webster Bank debt has all been presented as current in the accompanying condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On June 29, 2017, the closing date of the Merger, the Company paid in full its loan obligations (including principal and interest) with Webster Bank. The outstanding balance was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$328,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of June 30, 2017 and December 31, 2016, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three and six months ended June 30, 2017, the Company incurred a loss on extinguishment of debt in the approximate amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$53,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, related to the extinguishment of the Connecticut Innovations, DECD and Webster Bank loans.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Promissory Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company, as part of the merger, assumed an Unsecured Convertible Promissory Note (the &amp;#8220;Note&amp;#8221;) with an accredited investor (the &amp;#8220;Investor&amp;#8221;) in the aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$125,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and interest accrues at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year. The Note provided that two-thirds of the outstanding principal amount of the Note was due upon the earlier to occur of the close of the Merger or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;17, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (such applicable date, the &amp;#8220;Maturity Date&amp;#8221;).&amp;#160; The remaining one-third of the principal amount outstanding on the Note was to be paid on the six month anniversary of the Maturity Date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On the Maturity Date, the then outstanding aggregate amount owed on the Note of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;143,041&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$125,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in principal amount and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18,041&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of accrued interest which is included within accrued expenses on the accompanying consolidated condensed balance sheet) became due. Pursuant to the terms of the Note, the Company&amp;#8217;s failure to pay any principal or interest within 10 days of the date such payment is due will constitute an event of default (the &amp;#8220;Prospective Event of Default&amp;#8221;). On June 21, 2017, the Investor agreed to waive the Prospective Event of Default and agreed to further extend the Maturity Date of the Note pursuant to a side letter to the Note (the &amp;#8220;Side Letter&amp;#8221;). The Side Letter provides that two-thirds of the outstanding principal amount of the Note must be paid upon the earlier to occur of (1) the closing of a public offering by the Company of either common stock, convertible preferred stock or convertible preferred notes or (2) August 16, 2017 (such applicable date, the &amp;#8220;Deferred Maturity Date&amp;#8221;). As of August 21, 2017, the Company has not made any payment related to amounts that were due on August 16, 2017. Pursuant to the terms of the Notes, the Company&amp;#8217;s failure to pay any principal or interest within 10 days of the date such payment is due will constitute an event of default. The Company is attempting to negotiate a resolution with the Investor so that the Company will not default on such payment; however, there is no guarantee that the Company will be able to work out a satisfactory resolution. The remaining one-third of the principal amount outstanding on the Note must be paid on the six month anniversary of the Deferred Maturity Date (the &amp;#8220;Extended Maturity Date&amp;#8221;). All accrued and unpaid interest on the outstanding principal amount of the Note will be due and immediately payable on the Extended Maturity Date, unless the Note is converted in which case such interest will be payable in shares of the Company&amp;#8217;s common stock as part of the conversion.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q2YTD" id="Fact-F91814126CE65020AC34D95E7B196AD7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;STOCK OPTIONS &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's 2006 Equity Incentive Plan (the "2006 Plan") was terminated as to future awards on July 12, 2016. The Company's 2017 Stock Option and Incentive Plan (the "2017 Plan") was adopted by the Company's stockholders on June 5, 2017 and will expire on June 5, 2027. The following table summarizes stock option activity under our plans during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,460&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,713&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options that were vested or expected to vest with an aggregate intrinsic value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with a remaining weighted average contractual life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Appreciation Rights (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;SARs&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8221;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,777&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; outstanding and exercisable SARs shares were vested or expected to vest. All outstanding SARs were issued solely to a former chief executive officer. The weighted-average exercise price of these SARs was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$129.60&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share and the aggregate intrinsic value was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with a remaining weighted average contractual life of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. During the six months ended June 30, 2017, the SARs liability decreased approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and at June 30, 2017, a liability of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was recorded in accrued expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="FD2017Q2YTD" id="Fact-0FE24E49E87A55139AAA9FC8CAA1E179">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option activity under our plans during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at January&amp;#160;1, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,460&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;111.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable at June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;119.13&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-4FABA3F2562D5B86B1F8FB28DD17C5C4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Loss Per Share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q2YTD" id="Fact-B69B673E53F357DA9DA1406192ADB6EE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended June 30, 2017, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:72.4609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Dollars in Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance at April 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions - liability assumed in the Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total (gains) or losses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Recognized in earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at June 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-4D9DC17CCE44522C87BBFC6BDC164AC5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-5CFA5B76426457DEA1E14B29AA8DD4FF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;FAIR VALUE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;1&amp;#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;2&amp;#8212;Observable inputs other than those included in Level&amp;#160;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level&amp;#160;3&amp;#8212;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock Warrant Liabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2016 Warrant Liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assumed the 2016 Warrant Liability in the merger and it represents the fair value of Transgenomic warrants issued in January 2016, of which, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,584&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants remain outstanding as of June 30, 2017. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2016 Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model.  This method is well suited to valuing options with non-standard features.  Assumptions and inputs used in the valuation of the common stock warrants include: our equity value, which was estimated using our stock price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of June 30, 2017; volatility of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;121%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;; and a risk-free interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.64%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the three months ended June 30, 2017, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:72.4609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Dollars in Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance at April 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Additions - liability assumed in the Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;615&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total (gains) or losses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Recognized in earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at June 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;618&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-0F04778DAAE3078E3F30E1C265936A4B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As a result of the Merger, the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration. See Note 3 - Reverse Merger for the amounts recorded.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may impact goodwill. Impairment occurs when the carrying value is determined to be not recoverable, thereby causing the carrying value of the goodwill to exceed its fair value. If impaired, the asset&amp;#8217;s carrying value is reduced to its fair value. No events have transpired in the six months ended June 30, 2017 that would require an impairment analysis prior to our scheduled review.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Intangibles&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group). There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairment charges during the six months ended June 30, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) represents the fair value assigned to research and development assets that were not fully developed at the date of the Merger. Until the IPR&amp;amp;D projects are completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. For the six months ended June 30, 2017, there was no impairment of IPR&amp;amp;D. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-5C1ED81CBBA45D219AC1056ECB7F449D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;INCOME TAXES &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We file a US federal consolidated income tax return and state income tax returns in various jurisdictions. We have statutes of limitation open for federal &amp;amp; state income tax returns related to tax years 2014 through 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense for both the three months and six months ended June&amp;#160;30, 2017 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as a result of recording a full valuation allowance against the deferred tax asset generated predominantly by net operating losses. For the three and six months ended June 30, 2016, the Company was organized as a limited liability company and operated under the default classification as a partnership until July 31, 2016. Consequently, prior to August 1, 2016, income tax expense or benefits were calculated at the members&amp;#8217; level.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We had no material interest or penalties during fiscal 2017 or fiscal 2016, and we do not anticipate any such items during the next twelve months.  Our policy is to record interest and penalties directly related to uncertain tax positions as income tax expense in the condensed consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As a result of the merger, there was a change in ownership as defined in IRS &amp;#167; 382. Because of this change, use of a portion of the accumulated net operating losses and tax credit carryforwards will be limited in future periods. Further, a portion of the carryforwards will expire before being applied to reduce future income tax liabilities. Since the net deferred tax assets have a full valuation allowance recorded, any limitation generated from this calculation would not effect the current financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-01F42C2ECD64109D9189E1C7A3A02E00">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ncome Taxes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent that it is more likely than not that they will not be realized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-486A56674348500389AE55D5855ABF95">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&amp;#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&amp;#8217;s financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August&amp;#160;2016, FASB issued ASU No.&amp;#160;2016-15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Classification of Certain Cash Receipts and Cash Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASU No.&amp;#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&amp;#160;2016-15 is effective for fiscal years beginning after December&amp;#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&amp;#160;2016-15 will have a material effect on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, FASB issued ASU No.&amp;#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01 adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January&amp;#160;2017, FASB issued ASU No. 2017-04, Intangibles &amp;#8212; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which removes Step 2 from the goodwill impairment test.&amp;#160;It is effective for annual and interim periods beginning after December&amp;#160;15, 2019.&amp;#160;Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after January&amp;#160;1, 2017. The Company has adopted this standard and there was no impact on its consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2017, FASB issued ASU No. 2017-11, Earning Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815), which was issued in two parts, Part I, Accounting for Certain Financial Instruments with Down Round Features and Part II, Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of ASC No. 2017-11 addresses the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&amp;#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in Part II of ASU 2017-11 recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the codification, to a scope exception. Part II amendments do not have an accounting effect. The ASU 2017-11 is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company has early adopted this standard as of January 1, 2017 with the only impact being that the warrants with down round provisions entered into in June 2017 were treated as equity classification. (See Note 5 - Convertible Bridge Notes).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q2YTD" id="Fact-761BC8C39F3E5870B195711363E5F1CB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Sales Recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue is realized and earned when all of the following criteria are met:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Persuasive evidence of an arrangement exists;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Delivery has occurred or services have been rendered;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The seller&amp;#8217;s price to the buyer is fixed or determinable; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In our New Haven, Connecticut laboratory, we primarily recognize revenue for services rendered upon completion of the testing process.  Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payors.  Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2017Q2YTD" id="Fact-5F49378B0F0D612DC63EE73B05D9BB78">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.5859375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,560&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;791&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;170&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="FD2017Q2YTD" id="Fact-998143D21E892D8DF340E28AEC7573E6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preliminary estimated purchase consideration based on the value of the equity of Transgenomic, the accounting acquiree, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.2265625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:3%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Legacy Transgenomic common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,088&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of preferred stock converted to common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of debt converted to common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of debt converted to preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,796&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of existing bridge notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,996&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Purchase consideration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table sets forth an allocation of the purchase consideration to the identifiable tangible and intangible assets of Transgenomic, the accounting acquiree, based on fair values as of the Closing Date with the excess recorded as goodwill:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current and other assets  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;419&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,832&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:0px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other intangible assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current liabilities  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,604&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other liabilities  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net assets acquired  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,602&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:37px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:13px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other intangible assets consist of:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acquired technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Customer relationships&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-compete agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="padding-bottom:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trademark and trade name&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Backlog&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2017Q2YTD" id="Fact-E463CE0DBE91CA0D67A6E5EA74B25F97">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Dollars&amp;#160;in&amp;#160;Thousands&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;June 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Senior Note debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Junior Notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;584&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Connecticut Innovations - line of credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Department of Economic and Community Development (DECD)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;243&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;DECD debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Webster Bank&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;328&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Webster Bank debt discounts and issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible promissory notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term debt, net of current maturities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2017Q2YTD" id="Fact-4665048B434959A5B39B90F9F6816F8D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.9375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:5%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Issue&amp;#160;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Underlying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Warrants Assumed in Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$270.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;April 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$120.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$67.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$49.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(7)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(8)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;268,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in January 2013. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with a private placement which was completed in October 2014.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in February 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in July 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were originally issued in connection with an offering in July 2015, and were amended in connection with an offering which was completed in January 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in January 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These are the 2017 New Bridge Warrants which were issued in connection with the Merger. See discussion above for additional information.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These are the Side Warrants which were issued in connection with the Merger. See discussion above for additional information&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2017Q2YTD" id="Fact-9BDA2C7CEDBD5692BBE27F61D4B7D0D5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year contractual terms. Unvested awards as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; had vesting periods of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years from the date of grant. None of the awards outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are subject to performance or market-based vesting conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:ShortTermDebtTextBlock contextRef="FD2017Q2YTD" id="Fact-31D93F292FF1E943377EEC8687F81FC4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;&amp;#160;CONVERTIBLE BRIDGE NOTES.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Bridge Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the year ended December 31, 2016, the Company had outstanding &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$695,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of unsecured convertible bridge notes.  The notes accrued interest at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and were payable on the extended maturity date of December 31, 2016. During January 2017, the holders of the convertible bridge notes agreed to waive the maturity date of December 31, 2016 and change it to payable on demand and accrue interest until paid.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The convertible bridge notes had conversion terms of (i) convertible into Series C Preferred Units of the Company (at a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; discount) upon a Qualified Series C Financing (as defined in the note agreement), (ii) at the option of the holders of a majority of the then-outstanding principal amount of the notes, convertible into Series C Preferred Units of the Company (at a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; discount) upon any other Series C Financing, or (iii) if no such Qualified Series C Financing occurs, or no such optional conversion takes place by the maturity date (as hereinafter defined), the convertible notes will be fully repaid by Company or the notes and accrued and unpaid interest shall convert into Preferred Series B Units (at a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; discount) of the Preferred Series B conversion Price as defined in the operating agreement provided that notice is given to the Company at least one day prior to maturity.&amp;#160; In the event a Deemed Liquidity Event (merger, sale, IPO, or transaction with exchange of 50% or more of voting power) the holders of the notes at their sole discretion can (a) require the Company to pay an amount equal to two times the principal and accrued and unpaid interest or (b) convert all unpaid principal and interest at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the applicable security.&amp;#160; These notes were subordinated to Connecticut Innovations, DECD and Webster Bank.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, on the Closing Date, convertible bridge notes of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$695,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, plus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$192,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of accrued interest, were converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155,639&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2017 New Bridge Notes I.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to the Merger, the Company (then Transgenomic) completed the sale of an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of non-convertible promissory notes (the &amp;#8220;2017 Bridge Notes&amp;#8221;) in a bridge financing pursuant to a securities purchase agreement (the &amp;#8220;Purchase Agreement&amp;#8221;), for which $561,500 was then given to Precipio Diagnostics through the issuance of a promissory note and is eliminated in consolidation. The financing was intended to help facilitate the completion of the Merger. The 2017 Bridge Notes had an annual interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-day maturity. The 2017 Bridge Notes may be repaid by the Company at any time in cash upon payment of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; premium. In connection with the issuance of the 2017 Bridge Notes, the Company issued warrants (the &amp;#8220;2017 Bridge Warrants&amp;#8221;) to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, subject to anti-dilution protection. The Purchase Agreement provides certain piggyback registration rights for the holders of the 2017 Bridge Warrants for a period of six months after the closing of the bridge financing. Aegis Capital Corp. acted as placement agent for the bridge financing and received a placement agent fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$84,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and warrants (the &amp;#8220;Aegis Warrants&amp;#8221;) to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,600&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The Aegis Warrants are identical to the 2017 Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the time of the Merger, the 2017 Bridge Notes were extinguished and replaced with convertible promissory notes (the &amp;#8220;2017 New Bridge Notes I&amp;#8221;) with an original principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the aggregate pursuant to an Exchange Agreement (the &amp;#8220;Exchange Agreement&amp;#8221;) entered into on the Closing Date. The 2017 New Bridge Notes I have an annual interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and are due and payable upon the earlier to occur of (i) October 1, 2017 or (ii) the closing of a Qualified Offering (as defined in the 2017 New Bridge Notes I). The 2017 New Bridge Notes I are convertible into shares of our common stock at an initial conversion price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.736329&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, subject to adjustment, and may be convertible into shares of our preferred stock at the holder&amp;#8217;s option if the Company does not complete a Qualified Offering (as defined in the 2017 New Bridge Notes I) by October 1, 2017. The Company may redeem the 2017 New Bridge Notes I at any time in cash upon payment of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; premium, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$240,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As the convertible promissory notes were convertible into the Company's common stock at a conversion rate lower than the fair market value of the common stock at the time of issuance, the Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$989,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as a beneficial conversion feature, which was recorded as a debt discount in the balance sheet. The discount will be amortized using the effective interest method through the first conversion date of the 2017 New Bridge Notes I.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the Exchange Agreement, the 2017 Bridge Warrants were canceled and replaced with new warrants to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,600&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock (the &amp;#8220;2017 New Bridge Warrants&amp;#8221;). The initial exercise price of the 2017 New Bridge Warrants is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (subject to adjustments). If the Company completes a Qualified Offering (as defined in the 2017 New Bridge warrants), the exercise price of the 2017 New Bridge Warrants will become the lower of (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or (ii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;110%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the per share offering price in the Qualified Offering, but in no event lower than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, which has been considered a down round provision. At issuance, the 2017 New Bridge Warrants had a fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$211,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and were recorded as a debt discount to the related 2017 New Bridge Notes I, with the corresponding entry to additional paid in capital as the warrants were considered classified as equity in accordance with GAAP. As discussed in Note 2 of the accompanying unaudited condensed consolidated financial statements, the Company early adopted ASU 2017-11, which allowed the Company to treat the warrants as equity classified, despite the down round provision.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;2017 New Bridge Note II.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, on the Closing Date and pursuant to a Securities Purchase Agreement (the &amp;#8220;Bridge Purchase Agreement&amp;#8221;), the Company completed the sale of an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$800,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of a convertible promissory note (the &amp;#8220;2017 New Bridge Note II&amp;#8221;). The Company received net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$721,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the sale of the 2017 New Bridge Note II, which will be used for working capital purposes. The 2017 New Bridge Note II has an annual interest rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and are due and payable upon the earlier to occur of (i) October 1, 2017 or (ii) the closing of a Qualified Offering (as defined in the 2017 New Bridge Note II). The 2017 New Bridge Note II is convertible into shares of our common stock at an initial conversion price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.736329&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, subject to adjustment, and may be convertible into shares of our preferred stock at the holder&amp;#8217;s option if the Company does not complete a Qualified Offering (as defined in the 2017 New Bridge Note II) by October 1, 2017. The Company may redeem the 2017 New Bridge Note II at any time in cash upon payment of a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; premium, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$160,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As the 2017 New Bridge Note II was convertible into the Company's common stock at a conversion rate lower than the fair market value of the common stock at the time of issuance, the Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$656,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as a beneficial conversion feature, which was recorded as a debt discount in the balance sheet. The discount will be amortized using the effective interest method through the first conversion date of the 2017 New Bridge Note II.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the bridge financing and the assumption of certain obligations by an entity controlled by Mark Rimer (a director of the Company), the Company issued to that entity warrants (the &amp;#8220;Side Warrants&amp;#8221;) to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,429&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share (subject to adjustment), with a fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$487,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at the date of issuance. The Side Warrants have a term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and are exercisable as to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,857&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock upon grant and as to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68,572&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock upon the entity&amp;#8217;s performance of the assumed obligations. The Company has recorded merger advisory expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$414,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the Side Warrants during the three and six months ended June 30, 2017. The remaining fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$73,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will be recorded as expense at the time the performance obligations are met.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition, upon the Company consummating one or more rounds of equity financing following July 1, 2017, with aggregate gross proceeds of at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company will use a portion of the proceeds from such financing to repay the principal amount of the 2017 New Bridge Notes, together with any premium and interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of June 30, 2017, the outstanding convertible notes balance was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, net of debt discounts of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and debt issuance cost of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  Accrued interest of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is included within accrued expenses on the accompanying condensed consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShortTermDebtTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q2YTD" id="Fact-01C2523F381A5CD2A3214574DCAE2F4A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to June 30, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than what is disclosed in Note 12 - Subsequent Events, there were no other subsequent events that required recognition or disclosure. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;three and six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto of Precipio Diagnostics for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; contained in our current report on Form 8-K/A, filed with the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) on July 31, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed consolidated financial statements include the accounts of Precipio, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Risks and Uncertainties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in the healthcare industry which is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse.  Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.  Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.  See Note 10 - Fair Value for additional information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents and Other Current Assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of June 30, 2017 of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes prepaid assets of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and other receivables of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and consisted of primarily prepaid assets as of December 31, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentrations of Risk.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, we may maintain a cash position with financial institutions in amounts that exceed Federal Deposit Insurance Corporation insured limits.  We have not experienced any losses on such accounts as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Service companies in the health care industry typically grant credit without collateral to patients.  The majority of these patients are insured under third-party insurance agreements. The services provided by the Company are routinely billed utilizing the Current Procedural Terminology (CPT) code set designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial, and analytical purposes. CPT codes are currently identified by the Centers for Medicare and Medicaid Services and third-party payors. The Company utilizes CPT codes for Pathology and Laboratory Services contained within codes 80000-89398.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property and Equipment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense related to property and equipment was less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the six months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Goodwill and Intangible Assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As a result of the Merger, the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration. See Note 3 - Reverse Merger for the amounts recorded.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may impact goodwill. Impairment occurs when the carrying value is determined to be not recoverable, thereby causing the carrying value of the goodwill to exceed its fair value. If impaired, the asset&amp;#8217;s carrying value is reduced to its fair value. No events have transpired in the six months ended June 30, 2017 that would require an impairment analysis prior to our scheduled review.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Intangibles&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group). There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairment charges during the six months ended June 30, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In-process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) represents the fair value assigned to research and development assets that were not fully developed at the date of the Merger. Until the IPR&amp;amp;D projects are completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. For the six months ended June 30, 2017, there was no impairment of IPR&amp;amp;D. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year contractual terms. Unvested awards as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; had vesting periods of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years from the date of grant. None of the awards outstanding at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are subject to performance or market-based vesting conditions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended both &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2016, we recorded compensation expense for all stock awards of less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; within operating expense.  As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the unrecognized compensation expense related to unvested stock awards was less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Included in our stock awards outstanding as of June 30, 2017 were fully vested stock appreciation rights (&amp;#8220;SARs&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,777&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock. The SARs were issued solely to a former executive officer and vested over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years from the date of grant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Sales Recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue is realized and earned when all of the following criteria are met:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Persuasive evidence of an arrangement exists;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Delivery has occurred or services have been rendered;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The seller&amp;#8217;s price to the buyer is fixed or determinable; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:66px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In our New Haven, Connecticut laboratory, we primarily recognize revenue for services rendered upon completion of the testing process.  Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payors.  Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At each of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, deferred net sales included in the balance sheet in deferred revenue were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Presentation of Insurance Claims and Related Insurance Recoveries.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for its insurance claims and related insurance recoveries at their gross values as standards for health care entities do not allow the Company to net insurance recoveries against the related claim liabilities.  There were no insurance claims or insurance recoveries recorded during the three and six months ended June 30, 2017 and 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent that it is more likely than not that they will not be realized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Beneficial Conversion Features.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The intrinsic value of a beneficial conversion feature (&amp;#8220;BCF&amp;#8221;) inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the first conversion date using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the BCF is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;         Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares. When the preferred shares are non-redeemable the BCF is fully amortized into additional paid-in capital and preferred discount. If the preferred shares are redeemable, the discount is amortized from the commitment date to the first conversion date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Loss Per Share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,545,463&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,771,149&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock have been excluded from the computation of diluted loss per share at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, because the effect is anti-dilutive due to the net loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&amp;#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&amp;#8217;s financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August&amp;#160;2016, FASB issued ASU No.&amp;#160;2016-15&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Classification of Certain Cash Receipts and Cash Payments.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASU No.&amp;#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&amp;#160;2016-15 is effective for fiscal years beginning after December&amp;#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&amp;#160;2016-15 will have a material effect on our financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2017, FASB issued ASU No.&amp;#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01 adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&amp;#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January&amp;#160;2017, FASB issued ASU No. 2017-04, Intangibles &amp;#8212; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which removes Step 2 from the goodwill impairment test.&amp;#160;It is effective for annual and interim periods beginning after December&amp;#160;15, 2019.&amp;#160;Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after January&amp;#160;1, 2017. The Company has adopted this standard and there was no impact on its consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2017, FASB issued ASU No. 2017-11, Earning Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815), which was issued in two parts, Part I, Accounting for Certain Financial Instruments with Down Round Features and Part II, Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of ASC No. 2017-11 addresses the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&amp;#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in Part II of ASU 2017-11 recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the codification, to a scope exception. Part II amendments do not have an accounting effect. The ASU 2017-11 is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company has early adopted this standard as of January 1, 2017 with the only impact being that the warrants with down round provisions entered into in June 2017 were treated as equity classification. (See Note 5 - Convertible Bridge Notes).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q2YTD" id="Fact-EC45CA1CDCDD529A845B15E32BBFBF30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;STOCKHOLDERS&amp;#8217; EQUITY (DEFICIT)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;150,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;shares of common stock authorized for issuance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, the Company effected a 1-for-30 reverse stock split of its common stock. This reverse stock split became effective on June 13, 2017 and, unless otherwise indicated, all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying unaudited condensed consolidated financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split. Additionally, as a result of the Merger, the Company has recapitalized its stock. All historical preferred stock, common stock, restricted units, warrants and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the effect of the Merger exchange ratio. Pursuant to the Merger Agreement, each outstanding share of capital stock of Precipio Diagnostics was exchanged for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.2502&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; pre-reverse stock split shares of the Company's common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2016, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;449,175&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; share of common stock outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During 2017, restricted stock of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;59,563&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were granted during the three and six months ended June 30, 2017, none of which vested prior to the merger, upon closing of the merger, all shares fully vested. During 2017, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64,593&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares were released to common stock. We recorded stock compensation expense of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$28,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to restricted stock that vested during the six months ended June 30, 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On the Closing Date, Precipio Diagnostics received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,317,152&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock from the conversion of preferred stock, senior and junior debt, bridge notes and warrants. Also, certain advisors of Precipio Diagnostics received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;321,821&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock related to services performed in connection with the Merger. The fair value of these advisory shares was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at the date of the Merger and is included as a merger advisory fee expense in the accompanying financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the Merger, Precipio Diagnostics also received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,081&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock that have not been issued yet. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;135,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of these shares are being held for future issuance to advisors pending completion of certain performance obligations. If these performance obligations are not met, the shares will remain with Precipio Diagnostics as part of the unissued pool. For any shares that remain unissued, it is the intent of the Company to allocate these to Precipio Diagnostics shareholders on a pro rata basis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Also, upon completion of the Merger, Transgenomic legacy stockholders had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,255,119&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:11px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of June 30, 2017, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,407,860&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock Warrants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior to the merger, in connection with the line of credit with Connecticut Innovations, the Company issued warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,542&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series A Preferred shares of the Company, which were classified as an equity warrant, at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.93&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per unit, subject to adjustments as defined in the warrant agreement. The warrants were valued at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at the date of the grant utilizing the Black-Sholes model (volatility &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, expected life &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and risk free rate &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.36%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;). The value of the warrants were treated as a debt discount. At the Merger date, the warrants were exercised and then converted into shares of Precipio common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Webster Bank agreement, the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Series B Preferred shares of the Company. At the Merger date, Webster Bank declined to exercise their warrants and, per the terms of the warrant agreement, the warrants were retired.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the Company entered into a redemption and exchange agreement with certain member's relating to their &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;275,237&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Preferred A Units and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;208,087&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Preferred B Units. Under the terms of the agreement, the unit holders would exchange their units in the Company for the issuance of debt. The aggregate purchase price per the agreement was the member's initial investment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$750,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for Preferred A Units and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$965,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for Preferred B Units, along with a preferred return of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, recorded as a dividend in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$432,716&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition to the debt issued as consideration for the member's preferred units, the Company also issued common warrant units, which allows the holders to collectively purchase common units of the Company, representing approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company at the time of exercise. At the time of issuance, this represented approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,958,204&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common units. The common warrant units had a $0.00 exercise price with a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year expiration date. The common warrant units were classified as equity awards and the fair value upon issuance was calculated utilizing a discounted cash flow analysis to value the Company's equity and an option pricing method to allocate the value of the equity. The fair value of the warrants was determined directly utilizing the option pricing method as the exercise price was $0.00. The aggregate value of the common warrant units was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,421,738&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was considered a deemed dividend. At the time of the Merger, these warrants were converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,958,204&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Precipio common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Warrants Assumed in Merger&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the time of the Merger, Transgenomic had a number of outstanding warrants related to various financing transactions that occurred between 2013-2016. Details related to year issued, expiration date, amount of underlying common shares and exercise price are included in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;2017 New Bridge Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the six months ended June 30, 2017, prior to the Merger, Transgenomic completed the sale of the 2017 Bridge Notes in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the issuance of the 2017 Bridge Warrants to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, subject to anti-dilution protection. Aegis Capital Corp. acted as placement agent for the bridge financing and received Aegis Warrants to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,600&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Transgenomic common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The Aegis Warrants are identical to the 2017 Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection. (See Note 5 - Convertible Bridge Notes).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, the holders of the 2017 Bridge Notes, the 2017 Bridge Warrants and the Aegis Warrants agreed to exchange the 2017 Bridge Notes, the 2017 Bridge Warrants and the Aegis Warrants for 2017 New Bridge Notes and the 2017 New Bridge Warrants to acquire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,600&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of our common stock. (See Note 5 - Convertible Bridge Notes). The initial exercise price of the 2017 New Bridge Warrants is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (subject to adjustments). If the Company completes a Qualified Offering (as defined in the 2017 New Bridge Warrants), the exercise price of the 2017 New Bridge Warrants will become the lower of (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or (ii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;110%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the per share offering price in the Qualified Offering, but in no event lower than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At issuance, the 2017 New Bridge Warrants had a fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$211,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and were recorded as a debt discount to the related 2017 New Bridge Notes I, with the corresponding entry to additional paid in capital as the warrants were considered classified as equity in accordance with GAAP.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Side Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the bridge financing and the assumption of certain obligations by an entity controlled by Mark Rimer (a director of the Company), the Company issued to that entity Side Warrants to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,429&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock at an exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share (subject to adjustment), with a fair value of $487,000 at the date of issuance. The Side Warrants have a term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and are exercisable as to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,857&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock upon grant and as to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68,572&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock upon the entity&amp;#8217;s performance of the assumed obligations. The Company has recorded merger advisory expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$414,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the Side Warrants during the three and six months ended June 30, 2017. The remaining fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$73,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will be recorded as expense at the time the performance obligations are met. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following represents a summary of the warrants outstanding as of June 30, 2017:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.9375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:5%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:29%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Issue&amp;#160;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Underlying&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Warrants Assumed in Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2013&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$270.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;April 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,487&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$120.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$67.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$49.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January 2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(7)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(8)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;91,429&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;268,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in January 2013. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with a private placement which was completed in October 2014.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in February 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in July 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were originally issued in connection with an offering in July 2015, and were amended in connection with an offering which was completed in January 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These warrants were issued in connection with an offering which was completed in January 2016.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These are the 2017 New Bridge Warrants which were issued in connection with the Merger. See discussion above for additional information.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These are the Side Warrants which were issued in connection with the Merger. See discussion above for additional information&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Series A and Series B Preferred Stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company had outstanding preferred units of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;367,299&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for Series A and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;412,806&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for Series B as of December 31, 2016.  These shares have been recapitalized and are included in preferred stock. On the Closing Date, the outstanding preferred units for Series A and Series B, along with the related accumulated dividends, were converted into common shares of the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred Stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s Board of Directors is authorized to issue up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i)&amp;#160;the number of shares; (ii)&amp;#160;the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii)&amp;#160;whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv)&amp;#160;whether shares shall be convertible and, if so, the terms and provisions thereof; (v)&amp;#160;what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi)&amp;#160;whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends.  We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Series A Senior Preferred Stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware on June 29, 2017, designating &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s Preferred Stock, par value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, as Series A Senior Convertible Preferred Stock ("Series A Senior") and establishing the rights, preferences and privileges of the new preferred stock. Generally, the holders of the Series A Senior stock are entitled to vote as a single voting group with the holders of the Company's common stock, and the holders of the Series A Senior stock are generally entitled to that number of votes as is equal to the number of whole shares of the Company's common stock into which the Series A Senior stock may be converted as of the record date of such vote or consent.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;So long as the shares of Series A Senior stock are outstanding certain actions will require the separate approval of at least two-thirds of the Series A Senior stock, including: changes to the terms (requires three-fourths approval) of the Series A Senior stock, changes to the number of authorized shares of Series A Senior stock, issuing a series of preferred stock that is senior to the Series A Senior stock, changing the size of the board of directors, certain changes to the capital stock of the Company, bankruptcy proceedings and granting security interests in the Company&amp;#8217;s assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Series A Senior stock will be convertible into the Company's common stock at any time at the then applicable conversion price. The initial conversion price for the Series A Senior stock issued in connection with the Merger and the other transactions described herein is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.736329&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, but will be subject to anti-dilution protections including adjustments for stock splits, stock dividends, other distributions, recapitalizations and the like. Additionally, each holder of the Series A Senior stock will have a right to convert such holder's Series A Senior stock into securities issued in any future private offering of the Company's securities at a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; discount to the proposed price in such private offering.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Series A Senior stock will be entitled to an annual &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; cumulative payment in lieu of interest or dividends, payable in-kind for the first two years and in cash or in-kind thereafter, at the option of the Company. The Series A Senior stock also will be entitled to share in any dividends paid on the Company's common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As discussed in Note 3 - Reverse Merger, in connection with the Merger, the Company issued 1) to holders of certain Transgenomic secured indebtedness, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;802,925&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Senior stock in an amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, 2) to holders of certain Precipio Diagnostic indebtedness, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;802,920&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Senior stock in an amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 3) to certain investors, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107,056&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Series A Senior stock in exchange for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in a private placement. The Company had outstanding Series A Senior shares of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,712,901&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of June 30, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We determined that there was a beneficial conversion feature in connection with the issuances of the Series A Senior stock since the conversion price of  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.736329&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was at a discount to the fair market value of the Company's common stock at issuance date. The Series A Senior stock is non-redeemable and as a result, the Company recognized the full beneficial conversion feature in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as a deemed dividend at the time of issuance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q2YTD" id="Fact-B396E091ADB253BAA76680BFEFA11834">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUBSEQUENT EVENTS &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On August 1, 2017, the Company announced that it was planning a public offering of common stock and warrants in an underwritten public offering. There can be no assurances as to whether the offering will be completed, or as to the size or terms of the offering. Even if the offering is completed, the Company will need to raise additional funding.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q2YTD" id="Fact-C4417ACA36BD884E8B4CF5F030E96630">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>prpo-20170630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.precipiodx.com/20170630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:prpo="http://www.precipiodx.com/20170630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prpo-20170630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prpo-20170630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prpo-20170630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prpo-20170630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpenses" roleURI="http://www.precipiodx.com/role/AccruedExpenses">
        <link:definition>2110100 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.precipiodx.com/role/AccruedExpensesDetails">
        <link:definition>2410402 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.precipiodx.com/role/AccruedExpensesTables">
        <link:definition>2310301 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDescription" roleURI="http://www.precipiodx.com/role/BusinessDescription">
        <link:definition>2101100 - Disclosure - BUSINESS DESCRIPTION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDescriptionDetails" roleURI="http://www.precipiodx.com/role/BusinessDescriptionDetails">
        <link:definition>2401401 - Disclosure - BUSINESS DESCRIPTION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.precipiodx.com/role/Contingencies">
        <link:definition>2111100 - Disclosure - CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.precipiodx.com/role/ContingenciesDetails">
        <link:definition>2411401 - Disclosure - CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleBridgeLoan" roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan">
        <link:definition>2109100 - Disclosure - CONVERTIBLE BRIDGE LOAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleBridgeLoan2017NewBridgeNotesIDetails" roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIDetails">
        <link:definition>2409402 - Disclosure - CONVERTIBLE BRIDGE LOAN (2017 New  Bridge Notes I) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIiDetails">
        <link:definition>2409403 - Disclosure - CONVERTIBLE BRIDGE LOAN (2017 New Bridge Notes II) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleBridgeLoanConvertibleBridgeNotesDetails" roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoanConvertibleBridgeNotesDetails">
        <link:definition>2409401 - Disclosure - CONVERTIBLE BRIDGE LOAN (Convertible Bridge Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.precipiodx.com/role/Debt">
        <link:definition>2108100 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConnecticutInnovationsIncorporatedDetails" roleURI="http://www.precipiodx.com/role/DebtConnecticutInnovationsIncorporatedDetails">
        <link:definition>2408404 - Disclosure - DEBT (Connecticut Innovations, Incorporated) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtConvertiblePromissoryNotesDetails" roleURI="http://www.precipiodx.com/role/DebtConvertiblePromissoryNotesDetails">
        <link:definition>2408407 - Disclosure - DEBT (Convertible Promissory Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" roleURI="http://www.precipiodx.com/role/DebtDepartmentOfEconomicAndCommunityDevelopmentDetails">
        <link:definition>2408405 - Disclosure - DEBT (Department of Economic and Community Development) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleOfDebtDetails" roleURI="http://www.precipiodx.com/role/DebtScheduleOfDebtDetails">
        <link:definition>2408402 - Disclosure - DEBT (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSeniorAndJuniorNotesDetails" roleURI="http://www.precipiodx.com/role/DebtSeniorAndJuniorNotesDetails">
        <link:definition>2408403 - Disclosure - DEBT (Senior and Junior Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.precipiodx.com/role/DebtTables">
        <link:definition>2308301 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtWebsterBankDetails" roleURI="http://www.precipiodx.com/role/DebtWebsterBankDetails">
        <link:definition>2408406 - Disclosure - DEBT (Webster Bank) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.precipiodx.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://www.precipiodx.com/role/FairValue">
        <link:definition>2114100 - Disclosure - FAIR VALUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueDetails" roleURI="http://www.precipiodx.com/role/FairValueDetails">
        <link:definition>2414403 - Disclosure - FAIR VALUE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueNarrativesDetails" roleURI="http://www.precipiodx.com/role/FairValueNarrativesDetails">
        <link:definition>2414402 - Disclosure - FAIR VALUE (Narratives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://www.precipiodx.com/role/FairValueTables">
        <link:definition>2314301 - Disclosure - FAIR VALUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.precipiodx.com/role/IncomeTaxes">
        <link:definition>2112100 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.precipiodx.com/role/IncomeTaxesDetails">
        <link:definition>2412401 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMerger" roleURI="http://www.precipiodx.com/role/ReverseMerger">
        <link:definition>2107100 - Disclosure - REVERSE MERGER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMergerConsiderationDetails" roleURI="http://www.precipiodx.com/role/ReverseMergerConsiderationDetails">
        <link:definition>2407403 - Disclosure - REVERSE MERGER (Consideration) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMergerIntangibleAssetsAcquiredDetails" roleURI="http://www.precipiodx.com/role/ReverseMergerIntangibleAssetsAcquiredDetails">
        <link:definition>2407405 - Disclosure - REVERSE MERGER (Intangible Assets Acquired) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMergerNarrativesDetails" roleURI="http://www.precipiodx.com/role/ReverseMergerNarrativesDetails">
        <link:definition>2407402 - Disclosure - REVERSE MERGER (Narratives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMergerNetAssetsAcquiredDetails" roleURI="http://www.precipiodx.com/role/ReverseMergerNetAssetsAcquiredDetails">
        <link:definition>2407404 - Disclosure - REVERSE MERGER (Net Assets Acquired) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMergerProFormaDisclosuresDetails" roleURI="http://www.precipiodx.com/role/ReverseMergerProFormaDisclosuresDetails">
        <link:definition>2407406 - Disclosure - REVERSE MERGER (Pro-forma Disclosures) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMergerTables" roleURI="http://www.precipiodx.com/role/ReverseMergerTables">
        <link:definition>2307301 - Disclosure - REVERSE MERGER (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptions" roleURI="http://www.precipiodx.com/role/StockOptions">
        <link:definition>2115100 - Disclosure - STOCK OPTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsStockAppreciationRightsDetails" roleURI="http://www.precipiodx.com/role/StockOptionsStockAppreciationRightsDetails">
        <link:definition>2415403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsStockOptionsDetails" roleURI="http://www.precipiodx.com/role/StockOptionsStockOptionsDetails">
        <link:definition>2415402 - Disclosure - STOCK OPTIONS (Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsTables" roleURI="http://www.precipiodx.com/role/StockOptionsTables">
        <link:definition>2315301 - Disclosure - STOCK OPTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficit" roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficit">
        <link:definition>2113100 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitCommonStockDetails" roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockDetails">
        <link:definition>2413402 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Common Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitCommonStockWarrantsDetails" roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockWarrantsDetails">
        <link:definition>2413403 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Common Stock Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitPreferredStockDetails" roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitPreferredStockDetails">
        <link:definition>2413406 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails">
        <link:definition>2413405 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Series A and Series B Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesSeniorPreferredStockDetails">
        <link:definition>2413407 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Series A Senior Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitSideWarrantsDetails" roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSideWarrantsDetails">
        <link:definition>2413404 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Side Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitTables" roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitTables">
        <link:definition>2313301 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.precipiodx.com/role/SubsequentEvents">
        <link:definition>2117100 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails">
        <link:definition>2402402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cash and Cash Equivalents and Other Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesLossPerShareDetails" roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesLossPerShareDetails">
        <link:definition>2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Loss Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails">
        <link:definition>2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Net Sales Recognition) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails">
        <link:definition>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails">
        <link:definition>2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Stock-based Compensation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="prpo_A2016WarrantLiabilityMember" name="A2016WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_A2017BridgeNotesMember" name="A2017BridgeNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_A2017NewBridgeNotesMember" name="A2017NewBridgeNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_AdditionalNotesMember" name="AdditionalNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" name="AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_AegisWarrantMember" name="AegisWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_AgentFees" name="AgentFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_BacklogMember" name="BacklogMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_BeneficialConversionFeaturePolicyTextBlock" name="BeneficialConversionFeaturePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_BeneficialConversionFeatureonIssuanceofDebt" name="BeneficialConversionFeatureonIssuanceofDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="prpo_BusinessCombinationAcquiredEntitiesCommonStock" name="BusinessCombinationAcquiredEntitiesCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="prpo_BusinessCombinationFairValueofDebtConverted" name="BusinessCombinationFairValueofDebtConverted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock" name="BusinessCombinationFairValueofDebtConvertedtoCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock" name="BusinessCombinationFairValueofDebtConvertedtoPreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_CPAGlobalMember" name="CPAGlobalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_ChangeinStockAppreciationRightsLiability" name="ChangeinStockAppreciationRightsLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_ClassofWarrantorRightTerm" name="ClassofWarrantorRightTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_ConcentrationOfCashPolicyPolicyTextBlock" name="ConcentrationOfCashPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_ConversionofStockDiscountRate" name="ConversionofStockDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="prpo_ConversionofStockPerShareConversionPrice" name="ConversionofStockPerShareConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="prpo_ConvertibleBridgeLoanMember" name="ConvertibleBridgeLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_DebtInstrumentDebtConvertedRate" name="DebtInstrumentDebtConvertedRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="prpo_DeemedDividend" name="DeemedDividend" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_DepartmentofEconomicandCommunityDevelopmentMember" name="DepartmentofEconomicandCommunityDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_EdgeBioSystemsInc.Member" name="EdgeBioSystemsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_EquityIncentivePlan2006Member" name="EquityIncentivePlan2006Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_EquitySecuritiesTransferedtoDebt" name="EquitySecuritiesTransferedtoDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_FoxChaseMember" name="FoxChaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_GainLossOnStockWarrantsRevaluation" name="GainLossOnStockWarrantsRevaluation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_IDTMember" name="IDTMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_InterestIncomeAndExpenseNet" name="InterestIncomeAndExpenseNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="prpo_LitigationSettlementInstallmentPaymentAmount" name="LitigationSettlementInstallmentPaymentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="prpo_LitigationSettlementPayments" name="LitigationSettlementPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_MountSinaiMember" name="MountSinaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_NewBridgeNotesIMember" name="NewBridgeNotesIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_NoncashAccruedMergerCost" name="NoncashAccruedMergerCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="prpo_OtherIncomeExpense" name="OtherIncomeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="prpo_PercentageofPerShareOfferingPrice" name="PercentageofPerShareOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" name="PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="prpo_PrecipioDiagnosticMember" name="PrecipioDiagnosticMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_PreferredStockSeriesASeniorMember" name="PreferredStockSeriesASeniorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_PremiumRateonDebtSettlement" name="PremiumRateonDebtSettlement" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="prpo_PremiumRateonDebtSettlementAmount" name="PremiumRateonDebtSettlementAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="prpo_ProceedsFromtheSalesofDebtInstrument" name="ProceedsFromtheSalesofDebtInstrument" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent" name="RequiredCumulativePaymentonPrincipalPerAmendmentPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="prpo_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_ScienceParkDevelopmentCorporationMember" name="ScienceParkDevelopmentCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_SeniorandJuniorNotesMember" name="SeniorandJuniorNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="prpo_ShortTermDebtConvertedtoLongTermDebt" name="ShortTermDebtConvertedtoLongTermDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_SideWarrantMember" name="SideWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_SmithMember" name="SmithMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised" name="StockWarrantPotentialEntityOwnershipPercentageifExercised" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="prpo_StockholdersEquityNoteReverseStockSplitConversionRatio" name="StockholdersEquityNoteReverseStockSplitConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="prpo_TermLoanMember" name="TermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_TotalGainsOrLossesAbstract" name="TotalGainsOrLossesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_TransgenomicsMember" name="TransgenomicsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_UNMCMember" name="UNMCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_UnsecuredConvertibleBridgeLoanMember" name="UnsecuredConvertibleBridgeLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_UponExecutionMember" name="UponExecutionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_VariousInstitutionalHoldersApril2020Member" name="VariousInstitutionalHoldersApril2020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_VariousInstitutionalHoldersDecember2020OneMember" name="VariousInstitutionalHoldersDecember2020OneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_VariousInstitutionalHoldersFebruary2020Member" name="VariousInstitutionalHoldersFebruary2020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_VariousInstitutionalHoldersJanuary2018Member" name="VariousInstitutionalHoldersJanuary2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_VariousInstitutionalHoldersJanuary2021OneMember" name="VariousInstitutionalHoldersJanuary2021OneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_VariousInstitutionalHoldersJanuary2021TwoMember" name="VariousInstitutionalHoldersJanuary2021TwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_VariousInstitutionalHoldersJune2022BMember" name="VariousInstitutionalHoldersJune2022BMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_VariousInstitutionalHoldersJune2022Member" name="VariousInstitutionalHoldersJune2022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_WebsterBankMember" name="WebsterBankMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_WorkingCapitalDeficiency" name="WorkingCapitalDeficiency" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="prpo_XIFINInc.Member" name="XIFINInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>prpo-20170630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.precipiodx.com/role/AccruedExpenses" xlink:href="prpo-20170630.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/AccruedExpensesDetails" xlink:href="prpo-20170630.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/AccruedExpensesTables" xlink:href="prpo-20170630.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/BusinessDescription" xlink:href="prpo-20170630.xsd#BusinessDescription" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/BusinessDescriptionDetails" xlink:href="prpo-20170630.xsd#BusinessDescriptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheets" xlink:href="prpo-20170630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:href="prpo-20170630.xsd#CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/Contingencies" xlink:href="prpo-20170630.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ContingenciesDetails" xlink:href="prpo-20170630.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIDetails" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoan2017NewBridgeNotesIDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoanConvertibleBridgeNotesDetails" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoanConvertibleBridgeNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/Debt" xlink:href="prpo-20170630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtConnecticutInnovationsIncorporatedDetails" xlink:href="prpo-20170630.xsd#DebtConnecticutInnovationsIncorporatedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtConvertiblePromissoryNotesDetails" xlink:href="prpo-20170630.xsd#DebtConvertiblePromissoryNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:href="prpo-20170630.xsd#DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtScheduleOfDebtDetails" xlink:href="prpo-20170630.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtSeniorAndJuniorNotesDetails" xlink:href="prpo-20170630.xsd#DebtSeniorAndJuniorNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtTables" xlink:href="prpo-20170630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtWebsterBankDetails" xlink:href="prpo-20170630.xsd#DebtWebsterBankDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DocumentAndEntityInformation" xlink:href="prpo-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValue" xlink:href="prpo-20170630.xsd#FairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValueDetails" xlink:href="prpo-20170630.xsd#FairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValueNarrativesDetails" xlink:href="prpo-20170630.xsd#FairValueNarrativesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValueTables" xlink:href="prpo-20170630.xsd#FairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/IncomeTaxes" xlink:href="prpo-20170630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/IncomeTaxesDetails" xlink:href="prpo-20170630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMerger" xlink:href="prpo-20170630.xsd#ReverseMerger" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerConsiderationDetails" xlink:href="prpo-20170630.xsd#ReverseMergerConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerIntangibleAssetsAcquiredDetails" xlink:href="prpo-20170630.xsd#ReverseMergerIntangibleAssetsAcquiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerNarrativesDetails" xlink:href="prpo-20170630.xsd#ReverseMergerNarrativesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerNetAssetsAcquiredDetails" xlink:href="prpo-20170630.xsd#ReverseMergerNetAssetsAcquiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerProFormaDisclosuresDetails" xlink:href="prpo-20170630.xsd#ReverseMergerProFormaDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerTables" xlink:href="prpo-20170630.xsd#ReverseMergerTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptions" xlink:href="prpo-20170630.xsd#StockOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptionsStockAppreciationRightsDetails" xlink:href="prpo-20170630.xsd#StockOptionsStockAppreciationRightsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptionsStockOptionsDetails" xlink:href="prpo-20170630.xsd#StockOptionsStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptionsTables" xlink:href="prpo-20170630.xsd#StockOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficit" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockWarrantsDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitCommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitPreferredStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSideWarrantsDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitSideWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitTables" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SubsequentEvents" xlink:href="prpo-20170630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesLossPerShareDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="prpo-20170630.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="prpo-20170630.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="prpo-20170630.xsd#UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e20e4396-1ab7-d9ec-b779-e1a72ae620da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:to="loc_us-gaap_InterestPayableCurrent_d9abcce1-c2aa-ae62-a692-f2fc9e1deb74" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/BusinessDescription" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/BusinessDescriptionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_979060bb-bdba-fd3f-8dd5-05b622a57ee4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_979060bb-bdba-fd3f-8dd5-05b622a57ee4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b65887e3-1865-ef3e-c8ae-81780cbff9ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_2481d529-2911-4e71-2975-f0b62d3c248e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_2481d529-2911-4e71-2975-f0b62d3c248e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_6743ba80-ee40-7fb3-fa59-4c41257a91a1" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_6743ba80-ee40-7fb3-fa59-4c41257a91a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_4ae0c14d-f040-07bc-a290-e35634191a44" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DerivativeLiabilities_4ae0c14d-f040-07bc-a290-e35634191a44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_27b15389-386a-f983-c189-731d6d3c3fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d28874fa-4543-5746-c91a-559d7ab47f77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/Contingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoanConvertibleBridgeNotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/Debt" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/DebtConnecticutInnovationsIncorporatedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/DebtConvertiblePromissoryNotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_3d1ff4d2-78b4-0876-a2bf-23c555b4696e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_3d1ff4d2-78b4-0876-a2bf-23c555b4696e" xlink:to="loc_us-gaap_LongTermDebtCurrent_c3b0ebc6-4623-301c-8c00-aa6b946b1d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_3d1ff4d2-78b4-0876-a2bf-23c555b4696e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_898d9dde-51c0-10b5-4600-dc6b12c399c4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/DebtSeniorAndJuniorNotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/DebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/DebtWebsterBankDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/FairValue" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/FairValueDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/FairValueNarrativesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/FairValueTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ReverseMerger" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1cfa18f1-6d01-6fcf-27ff-e3121c7b3afe" xlink:type="locator" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationAcquiredEntitiesCommonStock" xlink:label="loc_prpo_BusinessCombinationAcquiredEntitiesCommonStock_E9586AB99E04C0A387860644AA987FC8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1cfa18f1-6d01-6fcf-27ff-e3121c7b3afe" xlink:to="loc_prpo_BusinessCombinationAcquiredEntitiesCommonStock_E9586AB99E04C0A387860644AA987FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d970c17f-fbf9-ddd0-e4ce-8c67bde1a146" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1cfa18f1-6d01-6fcf-27ff-e3121c7b3afe" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d970c17f-fbf9-ddd0-e4ce-8c67bde1a146" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_9691A04D06A25CFED0C60643294E0B49" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1cfa18f1-6d01-6fcf-27ff-e3121c7b3afe" xlink:to="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_9691A04D06A25CFED0C60643294E0B49" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_0CA4057D5507FB5216D806455F6030BF" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1cfa18f1-6d01-6fcf-27ff-e3121c7b3afe" xlink:to="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_0CA4057D5507FB5216D806455F6030BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a4858e31-a3fb-07a7-a1c3-55068c62bf54" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1cfa18f1-6d01-6fcf-27ff-e3121c7b3afe" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_a4858e31-a3fb-07a7-a1c3-55068c62bf54" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConverted" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConverted_FC3B2650D6119D4CA288E2817F266D61" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1cfa18f1-6d01-6fcf-27ff-e3121c7b3afe" xlink:to="loc_prpo_BusinessCombinationFairValueofDebtConverted_FC3B2650D6119D4CA288E2817F266D61" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerIntangibleAssetsAcquiredDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerNarrativesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerNetAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_acc18a8d-a5d6-4fd2-9e96-73ebc959b850" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_acc18a8d-a5d6-4fd2-9e96-73ebc959b850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_5f2c9250-df4b-601d-4991-7138b987be1c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_acc18a8d-a5d6-4fd2-9e96-73ebc959b850" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_5f2c9250-df4b-601d-4991-7138b987be1c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_be07dd0f-4dac-2e35-9d0a-97c001db45cf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_acc18a8d-a5d6-4fd2-9e96-73ebc959b850" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_be07dd0f-4dac-2e35-9d0a-97c001db45cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_acc18a8d-a5d6-4fd2-9e96-73ebc959b850" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_00bc711a-f441-7a2b-f270-5792bfbbf725" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_acc18a8d-a5d6-4fd2-9e96-73ebc959b850" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_00bc711a-f441-7a2b-f270-5792bfbbf725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f76ca64-b2a1-a8a3-2018-3afb3e9049c6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2369a635-b49d-b747-8525-86de401fdea0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f76ca64-b2a1-a8a3-2018-3afb3e9049c6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_53657408-edcf-158c-b0b9-b9177e38b601" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f76ca64-b2a1-a8a3-2018-3afb3e9049c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_53657408-edcf-158c-b0b9-b9177e38b601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_a21c9ec2-c9ab-787b-c48d-8d70161c242f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_0f76ca64-b2a1-a8a3-2018-3afb3e9049c6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_a21c9ec2-c9ab-787b-c48d-8d70161c242f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerProFormaDisclosuresDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockOptions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockOptionsStockAppreciationRightsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockOptionsStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockOptionsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitPreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitSideWarrantsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_24485696-f982-096a-ee6a-f5e510cdb21c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_24485696-f982-096a-ee6a-f5e510cdb21c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_24372e3a-d7cf-aeb5-3e3e-92a986bb9251" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_24372e3a-d7cf-aeb5-3e3e-92a986bb9251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_b5694f1e-dcf2-1bc6-f680-0b7c6bcecb68" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_b5694f1e-dcf2-1bc6-f680-0b7c6bcecb68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7125e76f-5cae-cb43-9a8d-1e5d11b5b5f7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7125e76f-5cae-cb43-9a8d-1e5d11b5b5f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_866e0d33-eabf-2b46-aabe-ae0e1d229b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_44a700f6-fd76-d81b-18cc-566e56087517" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_44a700f6-fd76-d81b-18cc-566e56087517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9ae738f0-5b10-fcbb-98fe-43bb46377ad9" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08614f0c-c3a2-4c92-7c1d-aed5de18fe70" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9ae738f0-5b10-fcbb-98fe-43bb46377ad9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_11be17d8-cdf3-5dff-9c97-3bc59877acaf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95f67350-d3ec-5d41-e3b2-a4fe7a19e15b" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_11be17d8-cdf3-5dff-9c97-3bc59877acaf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_2245080c-ee8d-00a0-e6cc-a345f6455504" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_2245080c-ee8d-00a0-e6cc-a345f6455504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_ad8bf556-b7c8-7821-188c-b2f20d2a1601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3358d115-01c9-6550-edda-293e7863fabe" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3358d115-01c9-6550-edda-293e7863fabe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_51b81a6f-f6af-160e-e526-5abd0f450976" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_51b81a6f-f6af-160e-e526-5abd0f450976" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_9be7b5fd-c415-be42-12be-69610ea5f445" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_9be7b5fd-c415-be42-12be-69610ea5f445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5d4a5cdc-af3d-5a6b-4771-61ef2a3cbcb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ffe19198-61f8-be6a-6111-42f645804604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d8c0a214-0b0d-1fc8-686b-ed5eca49895f" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d8c0a214-0b0d-1fc8-686b-ed5eca49895f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_6497c9ca-b570-d510-eb1e-c94e7a7aedb4" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_975a3fab-7f49-5162-2cb5-31bb1479931f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_6497c9ca-b570-d510-eb1e-c94e7a7aedb4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_a3cfa2ef-65ce-536b-4778-0ecfaa8afbb9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_SalesRevenueServicesNet_a3cfa2ef-65ce-536b-4778-0ecfaa8afbb9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueServicesNet_a3cfa2ef-65ce-536b-4778-0ecfaa8afbb9" xlink:to="loc_us-gaap_Revenues_4ce4747e-ba05-83d9-3458-6f9d1635c2ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="loc_us-gaap_SalesAllowancesServices_6f02608b-ed02-bbc9-7651-fade92e5e532" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueServicesNet_a3cfa2ef-65ce-536b-4778-0ecfaa8afbb9" xlink:to="loc_us-gaap_SalesAllowancesServices_6f02608b-ed02-bbc9-7651-fade92e5e532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_368e9778-4d12-f736-79b9-637804de9992" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_368e9778-4d12-f736-79b9-637804de9992" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_OtherIncomeExpense" xlink:label="loc_prpo_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:type="locator" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_InterestIncomeAndExpenseNet" xlink:label="loc_prpo_InterestIncomeAndExpenseNet_e4a1216b-a474-58e8-0f45-94cabe150921" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prpo_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:to="loc_prpo_InterestIncomeAndExpenseNet_e4a1216b-a474-58e8-0f45-94cabe150921" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_GainLossOnStockWarrantsRevaluation" xlink:label="loc_prpo_GainLossOnStockWarrantsRevaluation_7d1e7a9a-aabd-3d19-b2db-94cabdc11cdf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prpo_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:to="loc_prpo_GainLossOnStockWarrantsRevaluation_7d1e7a9a-aabd-3d19-b2db-94cabdc11cdf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prpo_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_bc155cc8-6ee1-5ea7-d824-9c91dc052636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_2245080c-ee8d-00a0-e6cc-a345f6455504" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prpo_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_2245080c-ee8d-00a0-e6cc-a345f6455504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prpo_OtherIncomeExpense_4ad7300b-237c-82a9-1da0-94cabdd01228" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_887cbdfa-41ea-fa5b-a522-ded45c1dacc2" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_11a7c554-b3e3-7a3c-a81e-5c5ff89c25e9" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_887cbdfa-41ea-fa5b-a522-ded45c1dacc2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>prpo-20170630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.precipiodx.com/role/AccruedExpenses" xlink:href="prpo-20170630.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/AccruedExpensesDetails" xlink:href="prpo-20170630.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/AccruedExpensesTables" xlink:href="prpo-20170630.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/BusinessDescription" xlink:href="prpo-20170630.xsd#BusinessDescription" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/BusinessDescriptionDetails" xlink:href="prpo-20170630.xsd#BusinessDescriptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheets" xlink:href="prpo-20170630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:href="prpo-20170630.xsd#CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/Contingencies" xlink:href="prpo-20170630.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ContingenciesDetails" xlink:href="prpo-20170630.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIDetails" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoan2017NewBridgeNotesIDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoanConvertibleBridgeNotesDetails" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoanConvertibleBridgeNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/Debt" xlink:href="prpo-20170630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtConnecticutInnovationsIncorporatedDetails" xlink:href="prpo-20170630.xsd#DebtConnecticutInnovationsIncorporatedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtConvertiblePromissoryNotesDetails" xlink:href="prpo-20170630.xsd#DebtConvertiblePromissoryNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:href="prpo-20170630.xsd#DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtScheduleOfDebtDetails" xlink:href="prpo-20170630.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtSeniorAndJuniorNotesDetails" xlink:href="prpo-20170630.xsd#DebtSeniorAndJuniorNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtTables" xlink:href="prpo-20170630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtWebsterBankDetails" xlink:href="prpo-20170630.xsd#DebtWebsterBankDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DocumentAndEntityInformation" xlink:href="prpo-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValue" xlink:href="prpo-20170630.xsd#FairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValueDetails" xlink:href="prpo-20170630.xsd#FairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValueNarrativesDetails" xlink:href="prpo-20170630.xsd#FairValueNarrativesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValueTables" xlink:href="prpo-20170630.xsd#FairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/IncomeTaxes" xlink:href="prpo-20170630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/IncomeTaxesDetails" xlink:href="prpo-20170630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMerger" xlink:href="prpo-20170630.xsd#ReverseMerger" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerConsiderationDetails" xlink:href="prpo-20170630.xsd#ReverseMergerConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerIntangibleAssetsAcquiredDetails" xlink:href="prpo-20170630.xsd#ReverseMergerIntangibleAssetsAcquiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerNarrativesDetails" xlink:href="prpo-20170630.xsd#ReverseMergerNarrativesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerNetAssetsAcquiredDetails" xlink:href="prpo-20170630.xsd#ReverseMergerNetAssetsAcquiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerProFormaDisclosuresDetails" xlink:href="prpo-20170630.xsd#ReverseMergerProFormaDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerTables" xlink:href="prpo-20170630.xsd#ReverseMergerTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptions" xlink:href="prpo-20170630.xsd#StockOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptionsStockAppreciationRightsDetails" xlink:href="prpo-20170630.xsd#StockOptionsStockAppreciationRightsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptionsStockOptionsDetails" xlink:href="prpo-20170630.xsd#StockOptionsStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptionsTables" xlink:href="prpo-20170630.xsd#StockOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficit" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockWarrantsDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitCommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitPreferredStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSideWarrantsDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitSideWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitTables" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SubsequentEvents" xlink:href="prpo-20170630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesLossPerShareDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="prpo-20170630.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="prpo-20170630.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="prpo-20170630.xsd#UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/AccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/BusinessDescription" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/BusinessDescriptionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E65508C4E45E96C6140604805C36FD5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:to="loc_us-gaap_RangeAxis_E65508C4E45E96C6140604805C36FD5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_E65508C4E45E96C6140604805C36FD5C" xlink:to="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_E65508C4E45E96C6140604805C36FD5C" xlink:to="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_33E1D5E0D54DF54CC5F004805C360D5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC" xlink:to="loc_us-gaap_MaximumMember_33E1D5E0D54DF54CC5F004805C360D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC" xlink:to="loc_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A91CD0779EB2C4F8414E04805C3734F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A91CD0779EB2C4F8414E04805C3734F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_73DACA12CFB77D314F0904805C37F11D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A91CD0779EB2C4F8414E04805C3734F8" xlink:to="loc_us-gaap_ClassOfStockDomain_73DACA12CFB77D314F0904805C37F11D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_73DACA12CFB77D314F0904805C37F11D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A91CD0779EB2C4F8414E04805C3734F8" xlink:to="loc_us-gaap_ClassOfStockDomain_73DACA12CFB77D314F0904805C37F11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A36A3EC6D96638181C4604805C37AF90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_73DACA12CFB77D314F0904805C37F11D" xlink:to="loc_us-gaap_CommonStockMember_A36A3EC6D96638181C4604805C37AF90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_642A6662749D16E97CEF048071354777" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_642A6662749D16E97CEF048071354777" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WorkingCapitalDeficiency" xlink:label="loc_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:to="loc_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_StockholdersEquityNoteReverseStockSplitConversionRatio" xlink:label="loc_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:to="loc_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/Contingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_571ECD3909D6C7410FC5063C461915A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:to="loc_dei_LegalEntityAxis_571ECD3909D6C7410FC5063C461915A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3276B64F62504A35A58A063C46199B9F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_571ECD3909D6C7410FC5063C461915A9" xlink:to="loc_dei_EntityDomain_3276B64F62504A35A58A063C46199B9F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3276B64F62504A35A58A063C46199B9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_571ECD3909D6C7410FC5063C461915A9" xlink:to="loc_dei_EntityDomain_3276B64F62504A35A58A063C46199B9F" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_7739098496F4369AF43B063C46194AB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3276B64F62504A35A58A063C46199B9F" xlink:to="loc_prpo_TransgenomicsMember_7739098496F4369AF43B063C46194AB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:to="loc_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UNMCMember" xlink:label="loc_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_FoxChaseMember" xlink:label="loc_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_IDTMember" xlink:label="loc_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_MountSinaiMember" xlink:label="loc_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SmithMember" xlink:label="loc_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_XIFINInc.Member" xlink:label="loc_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ScienceParkDevelopmentCorporationMember" xlink:label="loc_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_CPAGlobalMember" xlink:label="loc_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_EdgeBioSystemsInc.Member" xlink:label="loc_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_48C22E65B1C30FD109E2063C461993F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_48C22E65B1C30FD109E2063C461993F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_DCBAAB7FFB9CCD27F100063C46191787_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_48C22E65B1C30FD109E2063C461993F4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_DCBAAB7FFB9CCD27F100063C46191787_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_DCBAAB7FFB9CCD27F100063C46191787" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_48C22E65B1C30FD109E2063C461993F4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_DCBAAB7FFB9CCD27F100063C46191787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_54B764C0A2271C4E431C063C461AC084" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_DCBAAB7FFB9CCD27F100063C46191787" xlink:to="loc_us-gaap_SubsequentEventMember_54B764C0A2271C4E431C063C461AC084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_LitigationSettlementPayments" xlink:label="loc_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_LitigationSettlementInstallmentPaymentAmount" xlink:label="loc_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3CF09EEAFF4B23EC5558048089853189" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3CF09EEAFF4B23EC5558048089853189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_20A23A5079E90EDB079304808985B846_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3CF09EEAFF4B23EC5558048089853189" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_20A23A5079E90EDB079304808985B846_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_20A23A5079E90EDB079304808985B846" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3CF09EEAFF4B23EC5558048089853189" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_20A23A5079E90EDB079304808985B846" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AegisWarrantMember" xlink:label="loc_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_20A23A5079E90EDB079304808985B846" xlink:to="loc_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50DC6B5BBB5388D966BF04808985FD26" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50DC6B5BBB5388D966BF04808985FD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_EC7C9617186EA3C9B7DF048089857241_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50DC6B5BBB5388D966BF04808985FD26" xlink:to="loc_us-gaap_ClassOfStockDomain_EC7C9617186EA3C9B7DF048089857241_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_EC7C9617186EA3C9B7DF048089857241" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50DC6B5BBB5388D966BF04808985FD26" xlink:to="loc_us-gaap_ClassOfStockDomain_EC7C9617186EA3C9B7DF048089857241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8B06DDE305EA2566B410048089855F26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_EC7C9617186EA3C9B7DF048089857241" xlink:to="loc_us-gaap_CommonStockMember_8B06DDE305EA2566B410048089855F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_6E91FF93C2E0B4F5BF8A048089857AEB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_dei_LegalEntityAxis_6E91FF93C2E0B4F5BF8A048089857AEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_B7DF555CC23F6355061004808986685F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6E91FF93C2E0B4F5BF8A048089857AEB" xlink:to="loc_dei_EntityDomain_B7DF555CC23F6355061004808986685F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_B7DF555CC23F6355061004808986685F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6E91FF93C2E0B4F5BF8A048089857AEB" xlink:to="loc_dei_EntityDomain_B7DF555CC23F6355061004808986685F" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_B73FE8306D6028B138E3048089868D3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_B7DF555CC23F6355061004808986685F" xlink:to="loc_prpo_TransgenomicsMember_B73FE8306D6028B138E3048089868D3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_C9B437F9621CC8296BE5048089864CA6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_C9B437F9621CC8296BE5048089864CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8D4EE147DB8F5132079F04808986DA32_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_C9B437F9621CC8296BE5048089864CA6" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8D4EE147DB8F5132079F04808986DA32_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8D4EE147DB8F5132079F04808986DA32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_C9B437F9621CC8296BE5048089864CA6" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8D4EE147DB8F5132079F04808986DA32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_0492876F711B8C9D84390480898603CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8D4EE147DB8F5132079F04808986DA32" xlink:to="loc_us-gaap_BridgeLoanMember_0492876F711B8C9D84390480898603CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_FB7E07FF366366A2C7CA0480898625B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_DebtInstrumentAxis_FB7E07FF366366A2C7CA0480898625B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_FB7E07FF366366A2C7CA0480898625B1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_FB7E07FF366366A2C7CA0480898625B1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017BridgeNotesMember" xlink:label="loc_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9" xlink:to="loc_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_NewBridgeNotesIMember" xlink:label="loc_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9" xlink:to="loc_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6F0A208903B8143A0BFC0480898618C5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_RangeAxis_6F0A208903B8143A0BFC0480898618C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_EF9B658EBB89D02BAE51048089864520_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6F0A208903B8143A0BFC0480898618C5" xlink:to="loc_us-gaap_RangeMember_EF9B658EBB89D02BAE51048089864520_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_EF9B658EBB89D02BAE51048089864520" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6F0A208903B8143A0BFC0480898618C5" xlink:to="loc_us-gaap_RangeMember_EF9B658EBB89D02BAE51048089864520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_DB2D22D2091E1B6A635C048089866E8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_EF9B658EBB89D02BAE51048089864520" xlink:to="loc_us-gaap_MinimumMember_DB2D22D2091E1B6A635C048089866E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D182107B8D67A97D1B9704808986EBD4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D182107B8D67A97D1B9704808986EBD4" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="loc_prpo_ConversionofStockPerShareConversionPrice_93E8A4E076756751A33504BCE04A485A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_ConversionofStockPerShareConversionPrice_93E8A4E076756751A33504BCE04A485A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_193EAB8D243F2CDD34B10480898600E2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_DebtInstrumentTerm_193EAB8D243F2CDD34B10480898600E2" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlement" xlink:label="loc_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlementAmount" xlink:label="loc_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2B0622CF511255AADB3004808987A38B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2B0622CF511255AADB3004808987A38B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D437D4FAAF02663699B0048089874373" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D437D4FAAF02663699B0048089874373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1FB0B4BAA73202292ADF049768920148" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1FB0B4BAA73202292ADF049768920148" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PercentageofPerShareOfferingPrice" xlink:label="loc_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_122CFA787884E5635D1F04808987C077" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_122CFA787884E5635D1F04808987C077" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AgentFees" xlink:label="loc_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_68FE91D421DB2C40C744069A1522D805" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_68FE91D421DB2C40C744069A1522D805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_CA277B9DA94B65714542069A1522468E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_68FE91D421DB2C40C744069A1522D805" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_CA277B9DA94B65714542069A1522468E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_CA277B9DA94B65714542069A1522468E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_68FE91D421DB2C40C744069A1522D805" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_CA277B9DA94B65714542069A1522468E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_519300BB3DFBF780698B069A152267B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_CA277B9DA94B65714542069A1522468E" xlink:to="loc_us-gaap_BridgeLoanMember_519300BB3DFBF780698B069A152267B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8BF43F9B683DB30C5843069A1522546A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_DebtInstrumentAxis_8BF43F9B683DB30C5843069A1522546A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8BF43F9B683DB30C5843069A1522546A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8BF43F9B683DB30C5843069A1522546A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017NewBridgeNotesMember" xlink:label="loc_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D" xlink:to="loc_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConvertibleBridgeLoanMember" xlink:label="loc_prpo_ConvertibleBridgeLoanMember_484F48E8F081153B8600069A1523A657" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D" xlink:to="loc_prpo_ConvertibleBridgeLoanMember_484F48E8F081153B8600069A1523A657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_540219E2B87F51B19CE4069A15236318" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_540219E2B87F51B19CE4069A15236318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_7890896F0C62B029B200069A1523FC25_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_540219E2B87F51B19CE4069A15236318" xlink:to="loc_us-gaap_ClassOfStockDomain_7890896F0C62B029B200069A1523FC25_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_7890896F0C62B029B200069A1523FC25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_540219E2B87F51B19CE4069A15236318" xlink:to="loc_us-gaap_ClassOfStockDomain_7890896F0C62B029B200069A1523FC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3D679CB68BEB1A845DA7069A1523F17F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7890896F0C62B029B200069A1523FC25" xlink:to="loc_us-gaap_CommonStockMember_3D679CB68BEB1A845DA7069A1523F17F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_69B4EC098F32AAA4A0DB069A15238657" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_69B4EC098F32AAA4A0DB069A15238657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6827027171DD5B58D728069A1523F3BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69B4EC098F32AAA4A0DB069A15238657" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6827027171DD5B58D728069A1523F3BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6827027171DD5B58D728069A1523F3BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69B4EC098F32AAA4A0DB069A15238657" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6827027171DD5B58D728069A1523F3BF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SideWarrantMember" xlink:label="loc_prpo_SideWarrantMember_4FFCB11DE1E4FAF06963069A152360DA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6827027171DD5B58D728069A1523F3BF" xlink:to="loc_prpo_SideWarrantMember_4FFCB11DE1E4FAF06963069A152360DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A6EF7003E0509DFB9B9A069A1523E7E8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_AwardTypeAxis_A6EF7003E0509DFB9B9A069A1523E7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A6EF7003E0509DFB9B9A069A1523E7E8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A6EF7003E0509DFB9B9A069A1523E7E8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UponExecutionMember" xlink:label="loc_prpo_UponExecutionMember_B2F83C544D5753DF27FA069A15238673" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68" xlink:to="loc_prpo_UponExecutionMember_B2F83C544D5753DF27FA069A15238673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BCD1D252351D8665212E069A1523E33B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68" xlink:to="loc_us-gaap_PerformanceSharesMember_BCD1D252351D8665212E069A1523E33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:to="loc_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_58D110A1A11B8E095863069A1524A3AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_58D110A1A11B8E095863069A1524A3AB" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ProceedsFromtheSalesofDebtInstrument" xlink:label="loc_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_56518594C7D304367B58069A1529BCDA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_56518594C7D304367B58069A1529BCDA" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="loc_prpo_ConversionofStockPerShareConversionPrice_65D9C62F5262C4BA875E069A15299C24" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_ConversionofStockPerShareConversionPrice_65D9C62F5262C4BA875E069A15299C24" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlement" xlink:label="loc_prpo_PremiumRateonDebtSettlement_F7A4E8968518221A9567069A1529DEEA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_PremiumRateonDebtSettlement_F7A4E8968518221A9567069A1529DEEA" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlementAmount" xlink:label="loc_prpo_PremiumRateonDebtSettlementAmount_D1B16C1CADC35261F372069A152AFBF1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_PremiumRateonDebtSettlementAmount_D1B16C1CADC35261F372069A152AFBF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_ED15132D161F84AB9DCE069A152AA92C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_ED15132D161F84AB9DCE069A152AA92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3BC232CDB268AD3BBDD8069A152A983D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3BC232CDB268AD3BBDD8069A152A983D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_44BAE5BA0823A33DE1D3069A152A96B6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_44BAE5BA0823A33DE1D3069A152A96B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_FBCA14B216189F92E9B9069A152A0C80" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_FBCA14B216189F92E9B9069A152A0C80" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassofWarrantorRightTerm" xlink:label="loc_prpo_ClassofWarrantorRightTerm_4B62A759990396FEC778069A152A055C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_ClassofWarrantorRightTerm_4B62A759990396FEC778069A152A055C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_633DC465337BE2B0865A069A152AFA90" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_633DC465337BE2B0865A069A152AFA90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_679C9AEEA5B4BEDDFFD8069A152AAF10" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_679C9AEEA5B4BEDDFFD8069A152AAF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_963366FF2953728B6239069A152A3C91" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_963366FF2953728B6239069A152A3C91" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoanConvertibleBridgeNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_8D00CEA3784FED94BB08F5BF0162736C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_8D00CEA3784FED94BB08F5BF0162736C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4890D087732E43F5E5D0F5BF01625E9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8D00CEA3784FED94BB08F5BF0162736C" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4890D087732E43F5E5D0F5BF01625E9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4890D087732E43F5E5D0F5BF01625E9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8D00CEA3784FED94BB08F5BF0162736C" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4890D087732E43F5E5D0F5BF01625E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_140A7CAFF607A2890EC5F5BF0163E77F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4890D087732E43F5E5D0F5BF01625E9C" xlink:to="loc_us-gaap_BridgeLoanMember_140A7CAFF607A2890EC5F5BF0163E77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_29003CA271993C509FF5F5BF0163FA62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:to="loc_us-gaap_DebtInstrumentAxis_29003CA271993C509FF5F5BF0163FA62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_29003CA271993C509FF5F5BF0163FA62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_29003CA271993C509FF5F5BF0163FA62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConvertibleBridgeLoanMember" xlink:label="loc_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B" xlink:to="loc_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UnsecuredConvertibleBridgeLoanMember" xlink:label="loc_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B" xlink:to="loc_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EFF95FF84E0B6BCCFB85F5BF01635673" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:to="loc_us-gaap_StatementClassOfStockAxis_EFF95FF84E0B6BCCFB85F5BF01635673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EFF95FF84E0B6BCCFB85F5BF01635673" xlink:to="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EFF95FF84E0B6BCCFB85F5BF01635673" xlink:to="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_918D4222D55F7903B18AF5BF01642BDD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:to="loc_us-gaap_CommonStockMember_918D4222D55F7903B18AF5BF01642BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_95AAA294C8B7D41EAD38F601A4149B31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_95AAA294C8B7D41EAD38F601A4149B31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52FB3CE3D28749CE6D14F5BF01649837" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52FB3CE3D28749CE6D14F5BF01649837" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockDiscountRate" xlink:label="loc_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DebtInstrumentDebtConvertedRate" xlink:label="loc_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7F350E0467C8717FEAC9F5BF0165FDE1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7F350E0467C8717FEAC9F5BF0165FDE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4E0AA7E3B814709F25DAF60C2FD0890F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4E0AA7E3B814709F25DAF60C2FD0890F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/Debt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DebtConnecticutInnovationsIncorporatedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_EE83D97E3C7ADB87F45BF5BF0187AC72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtInstrumentTable_EE83D97E3C7ADB87F45BF5BF0187AC72" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_765BF370137350922BCCF5BF0187B5D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EE83D97E3C7ADB87F45BF5BF0187AC72" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_765BF370137350922BCCF5BF0187B5D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_0B72EC3C240A4012F432F5BF01874BFD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_765BF370137350922BCCF5BF0187B5D1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_0B72EC3C240A4012F432F5BF01874BFD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_0B72EC3C240A4012F432F5BF01874BFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_765BF370137350922BCCF5BF0187B5D1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_0B72EC3C240A4012F432F5BF01874BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_7B7F2061EA6F866038F6F5BF0187F361" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_0B72EC3C240A4012F432F5BF01874BFD" xlink:to="loc_us-gaap_LineOfCreditMember_7B7F2061EA6F866038F6F5BF0187F361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B6E72B73F5F47D318665F5BF018743B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_EE83D97E3C7ADB87F45BF5BF0187AC72" xlink:to="loc_us-gaap_RangeAxis_B6E72B73F5F47D318665F5BF018743B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_B6E72B73F5F47D318665F5BF018743B6" xlink:to="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_B6E72B73F5F47D318665F5BF018743B6" xlink:to="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_047DE1F2593F10E0BD4CF5BF0187D336" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E" xlink:to="loc_us-gaap_MinimumMember_047DE1F2593F10E0BD4CF5BF0187D336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D9BA7B80C9BCE5AE4DCBF5BF01878164" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E" xlink:to="loc_us-gaap_MaximumMember_D9BA7B80C9BCE5AE4DCBF5BF01878164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD019C65BC8EC468E7D0F5BF01888A7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD019C65BC8EC468E7D0F5BF01888A7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_F5C5D6743CD8A4E7F171F5BF01883FB8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_F5C5D6743CD8A4E7F171F5BF01883FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_94FBD998D22D97AFF6E9F5BF0188FA74" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_94FBD998D22D97AFF6E9F5BF0188FA74" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DebtConvertiblePromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_07CE7C8C230E2BC3B357EC9413B1BE80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_07CE7C8C230E2BC3B357EC9413B1BE80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_ABD534F4A8683D41023FEC9413B191A5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_07CE7C8C230E2BC3B357EC9413B1BE80" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_ABD534F4A8683D41023FEC9413B191A5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_ABD534F4A8683D41023FEC9413B191A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_07CE7C8C230E2BC3B357EC9413B1BE80" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_ABD534F4A8683D41023FEC9413B191A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_CEF8C9D6A9A6F543161BEC9413B13567" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_ABD534F4A8683D41023FEC9413B191A5" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_CEF8C9D6A9A6F543161BEC9413B13567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_ADB47F666D7DF7FC58FAEC9413B15DEA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:to="loc_us-gaap_DebtInstrumentAxis_ADB47F666D7DF7FC58FAEC9413B15DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60575600E99D1185877DEC9413B157BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ADB47F666D7DF7FC58FAEC9413B15DEA" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60575600E99D1185877DEC9413B157BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60575600E99D1185877DEC9413B157BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ADB47F666D7DF7FC58FAEC9413B15DEA" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60575600E99D1185877DEC9413B157BF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AdditionalNotesMember" xlink:label="loc_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60575600E99D1185877DEC9413B157BF" xlink:to="loc_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_B4D2F099C916445273D5EC9413B1AC67" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_B4D2F099C916445273D5EC9413B1AC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_880E227DC8B5FB679346EC9413B21F68_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_B4D2F099C916445273D5EC9413B1AC67" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_880E227DC8B5FB679346EC9413B21F68_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_880E227DC8B5FB679346EC9413B21F68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_B4D2F099C916445273D5EC9413B1AC67" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_880E227DC8B5FB679346EC9413B21F68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_7EC2D848D4B61089CDA7EC9413B2BA65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_880E227DC8B5FB679346EC9413B21F68" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_7EC2D848D4B61089CDA7EC9413B2BA65" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" xlink:label="loc_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent" xlink:label="loc_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_48401F79AB01FC12145EEC9413B26123" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_48401F79AB01FC12145EEC9413B26123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9EB557F00D03221833BAEC9413B26D47" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9EB557F00D03221833BAEC9413B26D47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_613AD1002A2B06FADC54EC9413B226AD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_613AD1002A2B06FADC54EC9413B226AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_EB918F2379674DE49DEBEC9413B21593" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_EB918F2379674DE49DEBEC9413B21593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_D723FBAB806FB5801941EC9413B27D15" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_D723FBAB806FB5801941EC9413B27D15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E151005CB31DDD4C987BEC9413B27377" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E151005CB31DDD4C987BEC9413B27377" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1F1002DC1175BE439E3FE6F697DA919C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtInstrumentTable_1F1002DC1175BE439E3FE6F697DA919C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_F874295D93BCD9957A42E6F697DA2319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1F1002DC1175BE439E3FE6F697DA919C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_F874295D93BCD9957A42E6F697DA2319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0E0EC0B7250618F21E06E6F697DA988A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F874295D93BCD9957A42E6F697DA2319" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0E0EC0B7250618F21E06E6F697DA988A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0E0EC0B7250618F21E06E6F697DA988A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F874295D93BCD9957A42E6F697DA2319" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0E0EC0B7250618F21E06E6F697DA988A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TermLoanMember" xlink:label="loc_prpo_TermLoanMember_D8960907B2C5934726EEE6F7294AA871" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0E0EC0B7250618F21E06E6F697DA988A" xlink:to="loc_prpo_TermLoanMember_D8960907B2C5934726EEE6F7294AA871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_36585DDDDE22C1DF2305E6F697DA9C33" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1F1002DC1175BE439E3FE6F697DA919C" xlink:to="loc_us-gaap_DebtInstrumentAxis_36585DDDDE22C1DF2305E6F697DA9C33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4D20F68EC2EBA27DC237E6F697DA2657_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_36585DDDDE22C1DF2305E6F697DA9C33" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4D20F68EC2EBA27DC237E6F697DA2657_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4D20F68EC2EBA27DC237E6F697DA2657" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_36585DDDDE22C1DF2305E6F697DA9C33" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4D20F68EC2EBA27DC237E6F697DA2657" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_45274D27B202FE3F1CA3E6F727F6F395" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4D20F68EC2EBA27DC237E6F697DA2657" xlink:to="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_45274D27B202FE3F1CA3E6F727F6F395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_5BB3A5229C8977A3CF46E6F6DA50EC1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtInstrumentTerm_5BB3A5229C8977A3CF46E6F6DA50EC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9C5DCB5800D43D310420E6FCA13DB6E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9C5DCB5800D43D310420E6FCA13DB6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16C5C890DEB6CF2D99C2E6FCA14BA078" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16C5C890DEB6CF2D99C2E6FCA14BA078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_F0CE403E58AE548D5A9AE6FCA157BB9F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_F0CE403E58AE548D5A9AE6FCA157BB9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_1EF258E7F1502E1AFDF5E6FCA1649A90" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_1EF258E7F1502E1AFDF5E6FCA1649A90" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:to="loc_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_JuniorNotesMember" xlink:label="loc_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:to="loc_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TermLoanMember" xlink:label="loc_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:to="loc_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:to="loc_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1B1E5B88069FF98F1158F5BF019816B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1B1E5B88069FF98F1158F5BF019816B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:to="loc_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:to="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WebsterBankMember" xlink:label="loc_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:to="loc_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="loc_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DebtSeniorAndJuniorNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15041FF23EDED5462730FF96A93AF199" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15041FF23EDED5462730FF96A93AF199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15041FF23EDED5462730FF96A93AF199" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15041FF23EDED5462730FF96A93AF199" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_340B0030271951180D6AFF96A93A5720" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:to="loc_us-gaap_SeniorNotesMember_340B0030271951180D6AFF96A93A5720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_JuniorNotesMember" xlink:label="loc_us-gaap_JuniorNotesMember_970899DE34EDD2C2B4D5FF96A93D8663" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:to="loc_us-gaap_JuniorNotesMember_970899DE34EDD2C2B4D5FF96A93D8663" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SeniorandJuniorNotesMember" xlink:label="loc_prpo_SeniorandJuniorNotesMember_1C925BC4E5F8982E882BFFA10DE4BAB6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:to="loc_prpo_SeniorandJuniorNotesMember_1C925BC4E5F8982E882BFFA10DE4BAB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_B3F0C925F2E1CA6C6C4EFF96A93D61CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_B3F0C925F2E1CA6C6C4EFF96A93D61CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2D5DC3AA79FF9F9FAEFAFF96A93DF99B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_B3F0C925F2E1CA6C6C4EFF96A93D61CA" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2D5DC3AA79FF9F9FAEFAFF96A93DF99B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2D5DC3AA79FF9F9FAEFAFF96A93DF99B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_B3F0C925F2E1CA6C6C4EFF96A93D61CA" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2D5DC3AA79FF9F9FAEFAFF96A93DF99B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_72C6D46BCB5B21731E32FF96A93D223F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2D5DC3AA79FF9F9FAEFAFF96A93DF99B" xlink:to="loc_us-gaap_BridgeLoanMember_72C6D46BCB5B21731E32FF96A93D223F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8662E8CC15EBFC709E3CFF96A93DFBF8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8662E8CC15EBFC709E3CFF96A93DFBF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8662E8CC15EBFC709E3CFF96A93DFBF8" xlink:to="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8662E8CC15EBFC709E3CFF96A93DFBF8" xlink:to="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_6393F5BF470B84C4C101FFAA4A7E1AF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:to="loc_us-gaap_PreferredStockMember_6393F5BF470B84C4C101FFAA4A7E1AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A2869161FC7A743C524EFFA9586680B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:to="loc_us-gaap_CommonStockMember_A2869161FC7A743C524EFFA9586680B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_412CEEE5CAAE32F9D54DFF96A93D3D52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_412CEEE5CAAE32F9D54DFF96A93D3D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_398D9570CB97CCCCE23BFF96A93D620F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_398D9570CB97CCCCE23BFF96A93D620F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_606DC94E70D3F4B48A6FFF96A93D8BC7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_PreferredStockValue_606DC94E70D3F4B48A6FFF96A93D8BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_46A30FFB3B9E126EC800FF96A93D566D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_46A30FFB3B9E126EC800FF96A93D566D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_DC015E4899D6AF54AB0DFF96A93DA0A1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_DC015E4899D6AF54AB0DFF96A93DA0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_266E557633192A6C3D48FF96A93D6415" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_266E557633192A6C3D48FF96A93D6415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_54DFDD167E4EAF18CE24FFA2F02B05A5" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_54DFDD167E4EAF18CE24FFA2F02B05A5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DebtWebsterBankDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AF03D50B795EE5950DF40480899D7EB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_AF03D50B795EE5950DF40480899D7EB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_506E2A43A81EE5238CFB0480899DF9F8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AF03D50B795EE5950DF40480899D7EB1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_506E2A43A81EE5238CFB0480899DF9F8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_506E2A43A81EE5238CFB0480899DF9F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AF03D50B795EE5950DF40480899D7EB1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_506E2A43A81EE5238CFB0480899DF9F8" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TermLoanMember" xlink:label="loc_prpo_TermLoanMember_50D55973A4FF5EEF67F10480899DC530" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_506E2A43A81EE5238CFB0480899DF9F8" xlink:to="loc_prpo_TermLoanMember_50D55973A4FF5EEF67F10480899DC530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_19F959BA6BC7CC14A3B60480899E1FBE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:to="loc_us-gaap_DebtInstrumentAxis_19F959BA6BC7CC14A3B60480899E1FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_945AAADF063E7E54E5020480899ED4BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_19F959BA6BC7CC14A3B60480899E1FBE" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_945AAADF063E7E54E5020480899ED4BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_945AAADF063E7E54E5020480899ED4BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_19F959BA6BC7CC14A3B60480899E1FBE" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_945AAADF063E7E54E5020480899ED4BF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WebsterBankMember" xlink:label="loc_prpo_WebsterBankMember_6AE9FC411DB3B8D103750480899E6410" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_945AAADF063E7E54E5020480899ED4BF" xlink:to="loc_prpo_WebsterBankMember_6AE9FC411DB3B8D103750480899E6410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:to="loc_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:to="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:to="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7E56BD0658969C7BDB720480899E2A87" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7E56BD0658969C7BDB720480899E2A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_52170F87AFA6E7BF3E6E0480899E9418" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_52170F87AFA6E7BF3E6E0480899E9418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/FairValue" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/FairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_657233ACB3CAD3EF2A02E79B54D9E719" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_657233ACB3CAD3EF2A02E79B54D9E719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CE4A99326A6F3C721586E79B54D92255_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_657233ACB3CAD3EF2A02E79B54D9E719" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CE4A99326A6F3C721586E79B54D92255_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CE4A99326A6F3C721586E79B54D92255" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_657233ACB3CAD3EF2A02E79B54D9E719" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CE4A99326A6F3C721586E79B54D92255" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="loc_prpo_A2016WarrantLiabilityMember_BE8138DA57D309D414DFE79B54D90D1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CE4A99326A6F3C721586E79B54D92255" xlink:to="loc_prpo_A2016WarrantLiabilityMember_BE8138DA57D309D414DFE79B54D90D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TotalGainsOrLossesAbstract" xlink:label="loc_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:to="loc_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/FairValueNarrativesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="loc_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:to="loc_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_452E0DF6396EC5E87C93F5BF00C0DA0B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="loc_us-gaap_SharePrice_452E0DF6396EC5E87C93F5BF00C0DA0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/FairValueTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ReverseMerger" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ReverseMergerConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_751BE69082ED8B8EF8C2069A16206FB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_751BE69082ED8B8EF8C2069A16206FB3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_751BE69082ED8B8EF8C2069A16206FB3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_8F8E77EE100DBEF07FE5069A16209A78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:to="loc_prpo_TransgenomicsMember_8F8E77EE100DBEF07FE5069A16209A78" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationAcquiredEntitiesCommonStock" xlink:label="loc_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConverted" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ReverseMergerIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_17603C8DC3C9F0940BCAEC78C33FCA7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17603C8DC3C9F0940BCAEC78C33FCA7C" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_45FC32A378EA9515D2C5EC78C33ED9C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_45FC32A378EA9515D2C5EC78C33ED9C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F3A66F26F00678A941ACEC78C33E1E2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_45FC32A378EA9515D2C5EC78C33ED9C9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F3A66F26F00678A941ACEC78C33E1E2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F3A66F26F00678A941ACEC78C33E1E2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_45FC32A378EA9515D2C5EC78C33ED9C9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F3A66F26F00678A941ACEC78C33E1E2A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_8F0875B6FAB8B7E69AE2EC78C33E0648" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F3A66F26F00678A941ACEC78C33E1E2A" xlink:to="loc_prpo_TransgenomicsMember_8F0875B6FAB8B7E69AE2EC78C33E0648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BacklogMember" xlink:label="loc_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17603C8DC3C9F0940BCAEC78C33FCA7C" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ReverseMergerNarrativesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_67A6693C04D97F84F1680268AE20C3BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="loc_us-gaap_StatementClassOfStockAxis_67A6693C04D97F84F1680268AE20C3BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_67A6693C04D97F84F1680268AE20C3BE" xlink:to="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_67A6693C04D97F84F1680268AE20C3BE" xlink:to="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_85BD3A014825E8CBAA310268AE21BCED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15" xlink:to="loc_us-gaap_CommonStockMember_85BD3A014825E8CBAA310268AE21BCED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_E8A9B48C64BB009414790268AE21B12C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15" xlink:to="loc_us-gaap_PreferredStockMember_E8A9B48C64BB009414790268AE21B12C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="loc_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:to="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:to="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PrecipioDiagnosticMember" xlink:label="loc_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:to="loc_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:to="loc_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:to="loc_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_FFC9FED3FFB0581626CC0268AE22F6EE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_FFC9FED3FFB0581626CC0268AE22F6EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6DBB2BE0E8F8E2A2C33B0268AE227558_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_FFC9FED3FFB0581626CC0268AE22F6EE" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6DBB2BE0E8F8E2A2C33B0268AE227558_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6DBB2BE0E8F8E2A2C33B0268AE227558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_FFC9FED3FFB0581626CC0268AE22F6EE" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6DBB2BE0E8F8E2A2C33B0268AE227558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6DBB2BE0E8F8E2A2C33B0268AE227558" xlink:to="loc_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ReverseMergerNetAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635670A14D167F32A7CBFF7C6E2DD977" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635670A14D167F32A7CBFF7C6E2DD977" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3F6DA8D4331E5F897C09FF7C6E2DAD57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635670A14D167F32A7CBFF7C6E2DD977" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3F6DA8D4331E5F897C09FF7C6E2DAD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_245CEE9F4E1A56A7DA8BFF7C6E2DE491_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3F6DA8D4331E5F897C09FF7C6E2DAD57" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_245CEE9F4E1A56A7DA8BFF7C6E2DE491_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_245CEE9F4E1A56A7DA8BFF7C6E2DE491" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3F6DA8D4331E5F897C09FF7C6E2DAD57" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_245CEE9F4E1A56A7DA8BFF7C6E2DE491" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_3B6AA8D81E648A7C1D9CFF7C6E308A04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_245CEE9F4E1A56A7DA8BFF7C6E2DE491" xlink:to="loc_prpo_TransgenomicsMember_3B6AA8D81E648A7C1D9CFF7C6E308A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8026077D3CE84A4061DFFF7C6E30A30B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_Goodwill_8026077D3CE84A4061DFFF7C6E30A30B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_57B81A48280740010921FF7C6E306ED2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_57B81A48280740010921FF7C6E306ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ReverseMergerProFormaDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C4128BA9B94A48BE24063C46A63459" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C4128BA9B94A48BE24063C46A63459" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A60233223DD6F94CBC0F063C46A733C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C4128BA9B94A48BE24063C46A63459" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A60233223DD6F94CBC0F063C46A733C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64980A0BE70AB99E369F063C46A7587D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A60233223DD6F94CBC0F063C46A733C4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64980A0BE70AB99E369F063C46A7587D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64980A0BE70AB99E369F063C46A7587D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A60233223DD6F94CBC0F063C46A733C4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64980A0BE70AB99E369F063C46A7587D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_319D86BCE4AAF0DF107D063C46A760D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64980A0BE70AB99E369F063C46A7587D" xlink:to="loc_prpo_TransgenomicsMember_319D86BCE4AAF0DF107D063C46A760D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/ReverseMergerTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockOptions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockOptionsStockAppreciationRightsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3706FD1ED9BF02FD85FC05B0CA22D5B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3706FD1ED9BF02FD85FC05B0CA22D5B1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_64238DE8F5411BE9EA6F05B0CA223B8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3706FD1ED9BF02FD85FC05B0CA22D5B1" xlink:to="loc_us-gaap_AwardTypeAxis_64238DE8F5411BE9EA6F05B0CA223B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDDACE316AC95966898505B0CA22F264_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_64238DE8F5411BE9EA6F05B0CA223B8D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDDACE316AC95966898505B0CA22F264_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDDACE316AC95966898505B0CA22F264" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_64238DE8F5411BE9EA6F05B0CA223B8D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDDACE316AC95966898505B0CA22F264" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDDACE316AC95966898505B0CA22F264" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:to="loc_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7AD5CF02B91767CF1C4E05B0CA23BC96" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7AD5CF02B91767CF1C4E05B0CA23BC96" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ChangeinStockAppreciationRightsLiability" xlink:label="loc_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3145D04DC7ADE379148A05B0CA23FBCB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3145D04DC7ADE379148A05B0CA23FBCB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockOptionsStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B8D8185619178778CE9C05B0CA29BB8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:to="loc_us-gaap_AwardTypeAxis_B8D8185619178778CE9C05B0CA29BB8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CCC55095E63A8A313AF805B0CA2914E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B8D8185619178778CE9C05B0CA29BB8B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CCC55095E63A8A313AF805B0CA2914E9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CCC55095E63A8A313AF805B0CA2914E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B8D8185619178778CE9C05B0CA29BB8B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CCC55095E63A8A313AF805B0CA2914E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CCC55095E63A8A313AF805B0CA2914E9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:to="loc_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:to="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:to="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_EquityIncentivePlan2006Member" xlink:label="loc_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:to="loc_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockOptionsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficit" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9C97674701C15EF4E0F90666A5AF2ABC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9C97674701C15EF4E0F90666A5AF2ABC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EC6A08413C698B8AFDB00666A5AF3E68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9C97674701C15EF4E0F90666A5AF2ABC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_EC6A08413C698B8AFDB00666A5AF3E68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EC6A08413C698B8AFDB00666A5AF3E68" xlink:to="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EC6A08413C698B8AFDB00666A5AF3E68" xlink:to="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_075477B840E845267F3E0666A5AFFE60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76" xlink:to="loc_us-gaap_CommonStockMember_075477B840E845267F3E0666A5AFFE60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_57A194FB782CADCB19C40666A5AF5F27" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76" xlink:to="loc_us-gaap_PreferredStockMember_57A194FB782CADCB19C40666A5AF5F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_475183C31F217FF1BB930666A5B0074F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9C97674701C15EF4E0F90666A5AF2ABC" xlink:to="loc_us-gaap_AwardTypeAxis_475183C31F217FF1BB930666A5B0074F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3D9ADC7D1FC8CB6FA080666A5B08D29_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_475183C31F217FF1BB930666A5B0074F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3D9ADC7D1FC8CB6FA080666A5B08D29_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3D9ADC7D1FC8CB6FA080666A5B08D29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_475183C31F217FF1BB930666A5B0074F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3D9ADC7D1FC8CB6FA080666A5B08D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_08161DF256E5238879EA0666A5B00CA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3D9ADC7D1FC8CB6FA080666A5B08D29" xlink:to="loc_us-gaap_PerformanceSharesMember_08161DF256E5238879EA0666A5B00CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0A179094F83779BEBB930666A5B06739" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0A179094F83779BEBB930666A5B06739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="loc_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F46DDBD08CA5948CD1BA0666A5B080D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_F46DDBD08CA5948CD1BA0666A5B080D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_2831BAA1A844A56167720666A5B0FB8F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_2831BAA1A844A56167720666A5B0FB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D2FB8C2D3D258194F6140666A5B0FE31" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D2FB8C2D3D258194F6140666A5B0FE31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_3460ADD7A273AE70C32E0664AD7FBE6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_3460ADD7A273AE70C32E0664AD7FBE6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3460ADD7A273AE70C32E0664AD7FBE6D" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3460ADD7A273AE70C32E0664AD7FBE6D" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_17DCA36E995323171D7D0664AD7FFF89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8" xlink:to="loc_us-gaap_LineOfCreditMember_17DCA36E995323171D7D0664AD7FFF89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_13A1A4E95A2B283C8E070664AD7F3D32" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8" xlink:to="loc_us-gaap_BridgeLoanMember_13A1A4E95A2B283C8E070664AD7F3D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6F4CCEBADFDE3E0E45CB0664AD7FB94F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6F4CCEBADFDE3E0E45CB0664AD7FB94F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6BFC15D9FE0E2BA5EB2B0664AD80E4C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6F4CCEBADFDE3E0E45CB0664AD7FB94F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6BFC15D9FE0E2BA5EB2B0664AD80E4C5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6BFC15D9FE0E2BA5EB2B0664AD80E4C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6F4CCEBADFDE3E0E45CB0664AD7FB94F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6BFC15D9FE0E2BA5EB2B0664AD80E4C5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TermLoanMember" xlink:label="loc_prpo_TermLoanMember_56D1F3D8487DEE26930D0664AD80F237" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6BFC15D9FE0E2BA5EB2B0664AD80E4C5" xlink:to="loc_prpo_TermLoanMember_56D1F3D8487DEE26930D0664AD80F237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7C900DB30991F3EFD7150664AD80E229" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_DebtInstrumentAxis_7C900DB30991F3EFD7150664AD80E229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7C900DB30991F3EFD7150664AD80E229" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7C900DB30991F3EFD7150664AD80E229" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WebsterBankMember" xlink:label="loc_prpo_WebsterBankMember_BA3C2551CFAAE1EE08640664AD80A886" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3" xlink:to="loc_prpo_WebsterBankMember_BA3C2551CFAAE1EE08640664AD80A886" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017BridgeNotesMember" xlink:label="loc_prpo_A2017BridgeNotesMember_E4643FFD68712C7E659A0664AD801EA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3" xlink:to="loc_prpo_A2017BridgeNotesMember_E4643FFD68712C7E659A0664AD801EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3E69E335BEF6551FA05D0664AD806B91" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3E69E335BEF6551FA05D0664AD806B91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3E69E335BEF6551FA05D0664AD806B91" xlink:to="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3E69E335BEF6551FA05D0664AD806B91" xlink:to="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3686C7F4A8BBCD9B66880664AD80D92B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:to="loc_us-gaap_CommonStockMember_3686C7F4A8BBCD9B66880664AD80D92B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_E137EC93234C0127C3890664AD8024AB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_E137EC93234C0127C3890664AD8024AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12FA90F745F0FD15BB670664AD80E106" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_dei_LegalEntityAxis_12FA90F745F0FD15BB670664AD80E106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_59035BA3BDE4CB8DDA870664AD80DDB8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_12FA90F745F0FD15BB670664AD80E106" xlink:to="loc_dei_EntityDomain_59035BA3BDE4CB8DDA870664AD80DDB8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_59035BA3BDE4CB8DDA870664AD80DDB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_12FA90F745F0FD15BB670664AD80E106" xlink:to="loc_dei_EntityDomain_59035BA3BDE4CB8DDA870664AD80DDB8" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_93836301921BAFB80B140664AD8033D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_59035BA3BDE4CB8DDA870664AD80DDB8" xlink:to="loc_prpo_TransgenomicsMember_93836301921BAFB80B140664AD8033D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7B81A434E31A36C923FB0664AD80D04D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7B81A434E31A36C923FB0664AD80D04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5BE2901E77C3ECAC67300664AD80CF82_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7B81A434E31A36C923FB0664AD80D04D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5BE2901E77C3ECAC67300664AD80CF82_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5BE2901E77C3ECAC67300664AD80CF82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7B81A434E31A36C923FB0664AD80D04D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5BE2901E77C3ECAC67300664AD80CF82" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AegisWarrantMember" xlink:label="loc_prpo_AegisWarrantMember_FA1E626E1136A6C2D3BA0664AD81DB26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5BE2901E77C3ECAC67300664AD80CF82" xlink:to="loc_prpo_AegisWarrantMember_FA1E626E1136A6C2D3BA0664AD81DB26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_DCC1D4CB634F6CF17C3D0664AD81BF02" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_RangeAxis_DCC1D4CB634F6CF17C3D0664AD81BF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F5B8C60D77AD5D1125620664AD814288_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_DCC1D4CB634F6CF17C3D0664AD81BF02" xlink:to="loc_us-gaap_RangeMember_F5B8C60D77AD5D1125620664AD814288_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F5B8C60D77AD5D1125620664AD814288" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_DCC1D4CB634F6CF17C3D0664AD81BF02" xlink:to="loc_us-gaap_RangeMember_F5B8C60D77AD5D1125620664AD814288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8D712D39D161F0AB64750664AD81C4B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_F5B8C60D77AD5D1125620664AD814288" xlink:to="loc_us-gaap_MinimumMember_8D712D39D161F0AB64750664AD81C4B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8C8A948225A2DC1D5E040664AD810664" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8C8A948225A2DC1D5E040664AD810664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_32D9E52519EBA01843E50664AD813313" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_32D9E52519EBA01843E50664AD813313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ECF381BA761DB00E0BF80664AD81B96D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ECF381BA761DB00E0BF80664AD81B96D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassofWarrantorRightTerm" xlink:label="loc_prpo_ClassofWarrantorRightTerm_73F8ACA7BBD8D4A75A0E0664AD81B217" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_prpo_ClassofWarrantorRightTerm_73F8ACA7BBD8D4A75A0E0664AD81B217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_CD565C5817DA1AF8027406668D9AE653" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_CD565C5817DA1AF8027406668D9AE653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_9CDB58B370EB2F93D948066C7F893A1C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_9CDB58B370EB2F93D948066C7F893A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised" xlink:label="loc_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_107F2F32E5C6A9E82C050664AD813E49" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_107F2F32E5C6A9E82C050664AD813E49" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PercentageofPerShareOfferingPrice" xlink:label="loc_prpo_PercentageofPerShareOfferingPrice_6892ADDAABA753EE0DF80664AD810AE4" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_prpo_PercentageofPerShareOfferingPrice_6892ADDAABA753EE0DF80664AD810AE4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_128F20EAF23A4E43FC99F5BF00FD6AC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_128F20EAF23A4E43FC99F5BF00FD6AC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B6A6368FA60AD3CAD0BBF5BF00FDF531_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_128F20EAF23A4E43FC99F5BF00FD6AC9" xlink:to="loc_us-gaap_ClassOfStockDomain_B6A6368FA60AD3CAD0BBF5BF00FDF531_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B6A6368FA60AD3CAD0BBF5BF00FDF531" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_128F20EAF23A4E43FC99F5BF00FD6AC9" xlink:to="loc_us-gaap_ClassOfStockDomain_B6A6368FA60AD3CAD0BBF5BF00FDF531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B6A6368FA60AD3CAD0BBF5BF00FDF531" xlink:to="loc_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_5222D1AC493432CFBEC8EC438A5A8EA9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_DAA5EDEF9EC5631DC1B9EC438A5AB121" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5222D1AC493432CFBEC8EC438A5A8EA9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_DAA5EDEF9EC5631DC1B9EC438A5AB121" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2B8367016725FE24AE71EC438A5A9010" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_DAA5EDEF9EC5631DC1B9EC438A5AB121" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2B8367016725FE24AE71EC438A5A9010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2B8367016725FE24AE71EC438A5A9010" xlink:to="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2B8367016725FE24AE71EC438A5A9010" xlink:to="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_AC74218D5706957BD402EC438A69D83F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_AC74218D5706957BD402EC438A69D83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_01B2CAC552CAE945ACD4EC438A79C7FC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_01B2CAC552CAE945ACD4EC438A79C7FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9FB7ED58692C4454610CEC438A5A1E1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5222D1AC493432CFBEC8EC438A5A8EA9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9FB7ED58692C4454610CEC438A5A1E1A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_662E1B3493C4874C23AE048088AA846E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_662E1B3493C4874C23AE048088AA846E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_662E1B3493C4874C23AE048088AA846E" xlink:to="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_662E1B3493C4874C23AE048088AA846E" xlink:to="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PreferredStockSeriesASeniorMember" xlink:label="loc_prpo_PreferredStockSeriesASeniorMember_A7494ED8C9C2D897116C048088ABA2B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF" xlink:to="loc_prpo_PreferredStockSeriesASeniorMember_A7494ED8C9C2D897116C048088ABA2B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_892F66CEC7EB1FA5C5A5048088ABC9E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF" xlink:to="loc_us-gaap_PreferredStockMember_892F66CEC7EB1FA5C5A5048088ABC9E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5A8833A9F236E0202F3C048088ABC4C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:to="loc_dei_LegalEntityAxis_5A8833A9F236E0202F3C048088ABC4C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DE88A2D186A6C8390AF8048088AB9418_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5A8833A9F236E0202F3C048088ABC4C9" xlink:to="loc_dei_EntityDomain_DE88A2D186A6C8390AF8048088AB9418_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DE88A2D186A6C8390AF8048088AB9418" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5A8833A9F236E0202F3C048088ABC4C9" xlink:to="loc_dei_EntityDomain_DE88A2D186A6C8390AF8048088AB9418" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_48078963FC911F3CBBA8048088AB6319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_DE88A2D186A6C8390AF8048088AB9418" xlink:to="loc_prpo_TransgenomicsMember_48078963FC911F3CBBA8048088AB6319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_B6D76E7AF6292110BFCD048088AB52F9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_B6D76E7AF6292110BFCD048088AB52F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38C98358D94099B4A629048088AB6FFA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B6D76E7AF6292110BFCD048088AB52F9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38C98358D94099B4A629048088AB6FFA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38C98358D94099B4A629048088AB6FFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B6D76E7AF6292110BFCD048088AB52F9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38C98358D94099B4A629048088AB6FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_02524F2EE12212889191048088AB267A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38C98358D94099B4A629048088AB6FFA" xlink:to="loc_us-gaap_PrivatePlacementMember_02524F2EE12212889191048088AB267A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_46C72747180B668771C1048088ABBEC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_46C72747180B668771C1048088ABBEC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_312F7AF8A9EE593762C8048088ABDD2E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_312F7AF8A9EE593762C8048088ABDD2E" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="loc_prpo_ConversionofStockPerShareConversionPrice_7C5873851B30477BB105048088ABC7F2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_prpo_ConversionofStockPerShareConversionPrice_7C5873851B30477BB105048088ABC7F2" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockDiscountRate" xlink:label="loc_prpo_ConversionofStockDiscountRate_2A1D7EDE2477FBAC75FF048088ACEABD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_prpo_ConversionofStockDiscountRate_2A1D7EDE2477FBAC75FF048088ACEABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_0C0D8AF8D14E00A0FF87048088AC5415" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_0C0D8AF8D14E00A0FF87048088AC5415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_D313FAF92788BD218B06048088ACB478" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_D313FAF92788BD218B06048088ACB478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6FA8FD4247A5873D0FB9048088ACF413" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6FA8FD4247A5873D0FB9048088ACF413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_2636F956824FBF581648048088AC334D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_2636F956824FBF581648048088AC334D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_088F415DF3D3A3C417DD048088AC30C4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_088F415DF3D3A3C417DD048088AC30C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_04C0EEDEA861AABA82C9048088ACEBCB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_04C0EEDEA861AABA82C9048088ACEBCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_668B96FFDA75571ACA96048088AC4206" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_668B96FFDA75571ACA96048088AC4206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_AC11BB0216FA7358E8A8048088AC83C5" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_AC11BB0216FA7358E8A8048088AC83C5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DeemedDividend" xlink:label="loc_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitSideWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SideWarrantMember" xlink:label="loc_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJanuary2018Member" xlink:label="loc_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersApril2020Member" xlink:label="loc_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersFebruary2020Member" xlink:label="loc_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersDecember2020OneMember" xlink:label="loc_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJanuary2021OneMember" xlink:label="loc_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJanuary2021TwoMember" xlink:label="loc_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJune2022Member" xlink:label="loc_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJune2022BMember" xlink:label="loc_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:to="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:to="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:to="loc_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:to="loc_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UponExecutionMember" xlink:label="loc_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:to="loc_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:to="loc_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassofWarrantorRightTerm" xlink:label="loc_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesLossPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E7A05C451C2F21EE62A005ABC0969866" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E7A05C451C2F21EE62A005ABC0969866" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E7A05C451C2F21EE62A005ABC0969866" xlink:to="loc_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:to="loc_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E7A05C451C2F21EE62A005ABC0969866" xlink:to="loc_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:to="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:to="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:to="loc_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_35D9D243B232BF4C601D027706693EC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_35D9D243B232BF4C601D027706693EC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_50145C2DB3B1526F98E602770669513B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_35D9D243B232BF4C601D027706693EC1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_50145C2DB3B1526F98E602770669513B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_50145C2DB3B1526F98E602770669513B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_35D9D243B232BF4C601D027706693EC1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_50145C2DB3B1526F98E602770669513B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_50145C2DB3B1526F98E602770669513B" xlink:to="loc_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_97CEE60B224F53E5D4A0027706697998" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_97CEE60B224F53E5D4A0027706697998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_361AE87FE3C84E2DC52F027706696C89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_97CEE60B224F53E5D4A0027706697998" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_361AE87FE3C84E2DC52F027706696C89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_361AE87FE3C84E2DC52F027706696C89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_97CEE60B224F53E5D4A0027706697998" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_361AE87FE3C84E2DC52F027706696C89" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SeniorandJuniorNotesMember" xlink:label="loc_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_361AE87FE3C84E2DC52F027706696C89" xlink:to="loc_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_AEBD17905F110BA22A200277066FF706" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_AEBD17905F110BA22A200277066FF706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_F40D90A8E4F23AE301700277066FF54A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_F40D90A8E4F23AE301700277066FF54A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:to="loc_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_819E6A99DB79FB69D55E027706722A94" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_819E6A99DB79FB69D55E027706722A94" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ShortTermDebtConvertedtoLongTermDebt" xlink:label="loc_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_EquitySecuritiesTransferedtoDebt" xlink:label="loc_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_062A869CA03F98B40A43027706721D41" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_062A869CA03F98B40A43027706721D41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BeneficialConversionFeatureonIssuanceofDebt" xlink:label="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_NoncashAccruedMergerCost" xlink:label="loc_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D5E73C11F6F835CE3AE8FF640D93C0FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_StatementTable_D5E73C11F6F835CE3AE8FF640D93C0FC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_D0AC128347F0375E2FB8FF640D93A8E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D5E73C11F6F835CE3AE8FF640D93C0FC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_D0AC128347F0375E2FB8FF640D93A8E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D0AC128347F0375E2FB8FF640D93A8E5" xlink:to="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D0AC128347F0375E2FB8FF640D93A8E5" xlink:to="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PreferredStockSeriesASeniorMember" xlink:label="loc_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA" xlink:to="loc_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_A8095C6F597A422AFE8AFF640D93325E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA" xlink:to="loc_us-gaap_PreferredStockMember_A8095C6F597A422AFE8AFF640D93325E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="loc_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_InterestIncomeAndExpenseNet" xlink:label="loc_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_GainLossOnStockWarrantsRevaluation" xlink:label="loc_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F78051A9CDAFD28EBA81FF640D93637A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F78051A9CDAFD28EBA81FF640D93637A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1AAC0A96EE717FF49B4BFF640D93043B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1AAC0A96EE717FF49B4BFF640D93043B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_OtherIncomeExpense" xlink:label="loc_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D0EAA53BB018C222338D063C471EE8FB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_D0EAA53BB018C222338D063C471EE8FB" xlink:to="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:to="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:to="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_D86EA77130D3FD2F6AEC063C471D4067" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:to="loc_us-gaap_PreferredStockMember_D86EA77130D3FD2F6AEC063C471D4067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AA20D02A4E39C1FA65C4063C471DEAD8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:to="loc_us-gaap_CommonStockMember_AA20D02A4E39C1FA65C4063C471DEAD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:to="loc_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_02D0EAA1CB60FE342F57063C471D5DAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_02D0EAA1CB60FE342F57063C471D5DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_209EB2CA80B200F42EF3063C471D1BED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02D0EAA1CB60FE342F57063C471D5DAC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_209EB2CA80B200F42EF3063C471D1BED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_209EB2CA80B200F42EF3063C471D1BED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02D0EAA1CB60FE342F57063C471D5DAC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_209EB2CA80B200F42EF3063C471D1BED" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SeniorandJuniorNotesMember" xlink:label="loc_prpo_SeniorandJuniorNotesMember_A7046B15EC183495349B063C471D565A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_209EB2CA80B200F42EF3063C471D1BED" xlink:to="loc_prpo_SeniorandJuniorNotesMember_A7046B15EC183495349B063C471D565A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_817D4076D42EC55CD894063C471D173E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:to="loc_us-gaap_DebtInstrumentAxis_817D4076D42EC55CD894063C471D173E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E63D21C3D7B79C8BBB22063C471D858B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_817D4076D42EC55CD894063C471D173E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E63D21C3D7B79C8BBB22063C471D858B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E63D21C3D7B79C8BBB22063C471D858B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_817D4076D42EC55CD894063C471D173E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E63D21C3D7B79C8BBB22063C471D858B" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017BridgeNotesMember" xlink:label="loc_prpo_A2017BridgeNotesMember_2BB15C819DAFCB133DB1063C471D377A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E63D21C3D7B79C8BBB22063C471D858B" xlink:to="loc_prpo_A2017BridgeNotesMember_2BB15C819DAFCB133DB1063C471D377A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2C5BE80C6DDCE112D1CE063C471D5186" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2C5BE80C6DDCE112D1CE063C471D5186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2C5BE80C6DDCE112D1CE063C471D5186" xlink:to="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2C5BE80C6DDCE112D1CE063C471D5186" xlink:to="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1D7DD7E963B4A106E133063C471ECCB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06" xlink:to="loc_us-gaap_CommonStockMember_1D7DD7E963B4A106E133063C471ECCB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_4005037E116120B100F8063C471E9EC4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06" xlink:to="loc_us-gaap_PreferredStockMember_4005037E116120B100F8063C471E9EC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D0EAA53BB018C222338D063C471EE8FB" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_0F89CFFBD9FD1AD3C067063C471E86FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_SharesOutstanding_0F89CFFBD9FD1AD3C067063C471E86FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B0E52458BAB399FE3941063C471EE29F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_NetIncomeLoss_B0E52458BAB399FE3941063C471EE29F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_B5D83C2A072B0F95564C063C471E6865" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_B5D83C2A072B0F95564C063C471E6865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_2C9893F978A55922FBEE063C471E82B8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_2C9893F978A55922FBEE063C471E82B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_E2504DB862AE6BB1EB9A063C471E000D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_E2504DB862AE6BB1EB9A063C471E000D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_05C9F300265D54349445063C471E0003" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_05C9F300265D54349445063C471E0003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8ED54A73E497799FC5EC063C471E2FAD" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8ED54A73E497799FC5EC063C471E2FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_608D581B288CA9368420063C471F534F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_608D581B288CA9368420063C471F534F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0F1F526AF4A0602D6ADA063C471F9F1F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0F1F526AF4A0602D6ADA063C471F9F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0D62D3E66414471C8C52063C471F0339" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0D62D3E66414471C8C52063C471F0339" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BeneficialConversionFeatureonIssuanceofDebt" xlink:label="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_3913C74DDE5870613D88063C471F612C" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_3913C74DDE5870613D88063C471F612C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="loc_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>prpo-20170630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_66F1D71B06AE746B7E2FF5BF0197DC54_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_66F1D71B06AE746B7E2FF5BF0197DC54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_66F1D71B06AE746B7E2FF5BF0197DC54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66F1D71B06AE746B7E2FF5BF0197DC54" xlink:to="lab_us-gaap_DebtDisclosureAbstract_66F1D71B06AE746B7E2FF5BF0197DC54" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:to="lab_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362" xlink:to="lab_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362" xlink:type="arc" />
    <link:label id="lab_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2_terseLabel_en-US" xlink:label="lab_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Junior Notes</link:label>
    <link:label id="lab_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2_label_en-US" xlink:label="lab_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Junior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_JuniorNotesMember" xlink:label="loc_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2" xlink:to="lab_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2" xlink:type="arc" />
    <link:label id="lab_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5_terseLabel_en-US" xlink:label="lab_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5_label_en-US" xlink:label="lab_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5_documentation_en-US" xlink:label="lab_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TermLoanMember" xlink:label="loc_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:to="lab_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible promissory notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51" xlink:to="lab_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_1B1E5B88069FF98F1158F5BF019816B8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_1B1E5B88069FF98F1158F5BF019816B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible promissory notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1B1E5B88069FF98F1158F5BF019816B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_1B1E5B88069FF98F1158F5BF019816B8" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_1B1E5B88069FF98F1158F5BF019816B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:to="lab_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:type="arc" />
    <link:label id="lab_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3_terseLabel_en-US" xlink:label="lab_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Department of Economic and Community Development (DECD)</link:label>
    <link:label id="lab_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3_label_en-US" xlink:label="lab_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Department of Economic and Community Development [Member]</link:label>
    <link:label id="lab_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3_documentation_en-US" xlink:label="lab_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Department of Economic and Community Development [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:to="lab_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:type="arc" />
    <link:label id="lab_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796_terseLabel_en-US" xlink:label="lab_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Webster Bank</link:label>
    <link:label id="lab_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796_label_en-US" xlink:label="lab_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Webster Bank [Member]</link:label>
    <link:label id="lab_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796_documentation_en-US" xlink:label="lab_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Webster Bank [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WebsterBankMember" xlink:label="loc_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:to="lab_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="lab_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD_totalLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt and Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498" xlink:to="lab_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_3C268E9C018DAFB74A7B048088E9D2AC_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_3C268E9C018DAFB74A7B048088E9D2AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3C268E9C018DAFB74A7B048088E9D2AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_3C268E9C018DAFB74A7B048088E9D2AC" xlink:to="lab_us-gaap_EquityAbstract_3C268E9C018DAFB74A7B048088E9D2AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:type="arc" />
    <link:label id="lab_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C_terseLabel_en-US" xlink:label="lab_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Side Warrants</link:label>
    <link:label id="lab_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C_label_en-US" xlink:label="lab_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Side Warrant [Member]</link:label>
    <link:label id="lab_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C_documentation_en-US" xlink:label="lab_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Side Warrant [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SideWarrantMember" xlink:label="loc_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:to="lab_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:type="arc" />
    <link:label id="lab_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064_terseLabel_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2018</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064_label_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2018 [Member]</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064_documentation_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2018 [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJanuary2018Member" xlink:label="loc_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:to="lab_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:type="arc" />
    <link:label id="lab_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514_terseLabel_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; April 2020</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514_label_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; April 2020 [Member]</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514_documentation_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; April 2020 [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersApril2020Member" xlink:label="loc_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:to="lab_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:type="arc" />
    <link:label id="lab_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4_terseLabel_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; February 2020</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4_label_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; February 2020 [Member]</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4_documentation_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; February 2020 [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersFebruary2020Member" xlink:label="loc_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:to="lab_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:type="arc" />
    <link:label id="lab_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27_terseLabel_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; December 2020</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27_label_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; December 2020 One [Member]</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27_documentation_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; December 2020 One [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersDecember2020OneMember" xlink:label="loc_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:to="lab_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:type="arc" />
    <link:label id="lab_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D_terseLabel_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D_label_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021 One [Member]</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D_documentation_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021 One [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJanuary2021OneMember" xlink:label="loc_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:to="lab_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:type="arc" />
    <link:label id="lab_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5_terseLabel_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5_label_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021 Two [Member]</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5_documentation_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; January 2021 Two [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJanuary2021TwoMember" xlink:label="loc_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:to="lab_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:type="arc" />
    <link:label id="lab_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3_terseLabel_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; June 2022</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3_label_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; June 2022 [Member]</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3_documentation_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; June 2022 [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJune2022Member" xlink:label="loc_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:to="lab_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:type="arc" />
    <link:label id="lab_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA_terseLabel_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; June 2022</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA_label_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; June 2022B [Member]</link:label>
    <link:label id="lab_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA_documentation_en-US" xlink:label="lab_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Various Institutional Holders; June 2022B [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJune2022BMember" xlink:label="loc_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:to="lab_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:to="lab_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:to="lab_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B" xlink:to="lab_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:to="lab_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:type="arc" />
    <link:label id="lab_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD_terseLabel_en-US" xlink:label="lab_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upon Execution</link:label>
    <link:label id="lab_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD_label_en-US" xlink:label="lab_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upon Execution [Member]</link:label>
    <link:label id="lab_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD_documentation_en-US" xlink:label="lab_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upon Execution [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UponExecutionMember" xlink:label="loc_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:to="lab_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Based</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31" xlink:to="lab_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying shares (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06" xlink:type="arc" />
    <link:label id="lab_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD_terseLabel_en-US" xlink:label="lab_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, term</link:label>
    <link:label id="lab_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD_label_en-US" xlink:label="lab_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label id="lab_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD_documentation_en-US" xlink:label="lab_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassofWarrantorRightTerm" xlink:label="loc_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:to="lab_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Merger advisory fees</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, fair value</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_5E10168AB7CB2730657AE5D971D10BDC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_5E10168AB7CB2730657AE5D971D10BDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_5E10168AB7CB2730657AE5D971D10BDC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_5E10168AB7CB2730657AE5D971D10BDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_5E10168AB7CB2730657AE5D971D10BDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_5E10168AB7CB2730657AE5D971D10BDC" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_5E10168AB7CB2730657AE5D971D10BDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_39D67B29DB02A2C97E76E158D48ACE63_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_39D67B29DB02A2C97E76E158D48ACE63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39D67B29DB02A2C97E76E158D48ACE63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39D67B29DB02A2C97E76E158D48ACE63" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_39D67B29DB02A2C97E76E158D48ACE63" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_B70437748421A65FA875E158D48A6629_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_B70437748421A65FA875E158D48A6629" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_B70437748421A65FA875E158D48A6629_label_en-US" xlink:label="lab_us-gaap_Depreciation_B70437748421A65FA875E158D48A6629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_B70437748421A65FA875E158D48A6629" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_B70437748421A65FA875E158D48A6629" xlink:to="lab_us-gaap_Depreciation_B70437748421A65FA875E158D48A6629" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_DB264E11571A34AB979DE7372C86C0D3_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_DB264E11571A34AB979DE7372C86C0D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_DB264E11571A34AB979DE7372C86C0D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_DB264E11571A34AB979DE7372C86C0D3" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_DB264E11571A34AB979DE7372C86C0D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4FABB41DFCC27048CA25E73AC4D62960_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4FABB41DFCC27048CA25E73AC4D62960" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4FABB41DFCC27048CA25E73AC4D62960_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4FABB41DFCC27048CA25E73AC4D62960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4FABB41DFCC27048CA25E73AC4D62960" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4FABB41DFCC27048CA25E73AC4D62960" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4FABB41DFCC27048CA25E73AC4D62960" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DBD93CB6EE93660957A05B0CA28752E_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DBD93CB6EE93660957A05B0CA28752E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DBD93CB6EE93660957A05B0CA28752E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DBD93CB6EE93660957A05B0CA28752E" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DBD93CB6EE93660957A05B0CA28752E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963" xlink:to="lab_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:to="lab_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:to="lab_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:type="arc" />
    <link:label id="lab_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583_terseLabel_en-US" xlink:label="lab_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2006</link:label>
    <link:label id="lab_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583_label_en-US" xlink:label="lab_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2006 [Member]</link:label>
    <link:label id="lab_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583_documentation_en-US" xlink:label="lab_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2006 [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_EquityIncentivePlan2006Member" xlink:label="loc_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:to="lab_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_552E4DB972A8218D6EDA05B0CA292D93_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_552E4DB972A8218D6EDA05B0CA292D93" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_552E4DB972A8218D6EDA05B0CA292D93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_552E4DB972A8218D6EDA05B0CA292D93" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_552E4DB972A8218D6EDA05B0CA292D93" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5F0FA9FA941D9211DAF305B0CA2AD94E_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5F0FA9FA941D9211DAF305B0CA2AD94E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5F0FA9FA941D9211DAF305B0CA2AD94E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5F0FA9FA941D9211DAF305B0CA2AD94E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5F0FA9FA941D9211DAF305B0CA2AD94E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expected to vest, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expected to vest, outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, expected to vest remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_079336573A5EE066E9CFF5BF00FD8AF9_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_079336573A5EE066E9CFF5BF00FD8AF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_079336573A5EE066E9CFF5BF00FD8AF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_079336573A5EE066E9CFF5BF00FD8AF9" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_079336573A5EE066E9CFF5BF00FD8AF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA" xlink:to="lab_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:to="lab_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_640A59ECBD6C4A2328D404808A06C427_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_640A59ECBD6C4A2328D404808A06C427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_640A59ECBD6C4A2328D404808A06C427_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_640A59ECBD6C4A2328D404808A06C427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_640A59ECBD6C4A2328D404808A06C427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_640A59ECBD6C4A2328D404808A06C427" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_640A59ECBD6C4A2328D404808A06C427" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_96927A07B2337BB29E5204808A06E7BF_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_96927A07B2337BB29E5204808A06E7BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_96927A07B2337BB29E5204808A06E7BF_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_96927A07B2337BB29E5204808A06E7BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_96927A07B2337BB29E5204808A06E7BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_96927A07B2337BB29E5204808A06E7BF" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_96927A07B2337BB29E5204808A06E7BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_F6D6BC6A9109D08FEA2804808A0632F9_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_F6D6BC6A9109D08FEA2804808A0632F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_F6D6BC6A9109D08FEA2804808A0632F9_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_F6D6BC6A9109D08FEA2804808A0632F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_F6D6BC6A9109D08FEA2804808A0632F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_F6D6BC6A9109D08FEA2804808A0632F9" xlink:to="lab_us-gaap_UseOfEstimates_F6D6BC6A9109D08FEA2804808A0632F9" xlink:type="arc" />
    <link:label id="lab_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9_terseLabel_en-US" xlink:label="lab_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9_label_en-US" xlink:label="lab_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9_documentation_en-US" xlink:label="lab_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9" xlink:to="lab_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_53D56113312890A3087304808A065837_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_53D56113312890A3087304808A065837" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_53D56113312890A3087304808A065837_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_53D56113312890A3087304808A065837" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_53D56113312890A3087304808A065837" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_53D56113312890A3087304808A065837" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_53D56113312890A3087304808A065837" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1A8A0C102FA8D831744304808A06F3B2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1A8A0C102FA8D831744304808A06F3B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Other Current Asssets</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1A8A0C102FA8D831744304808A06F3B2_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1A8A0C102FA8D831744304808A06F3B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1A8A0C102FA8D831744304808A06F3B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1A8A0C102FA8D831744304808A06F3B2" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1A8A0C102FA8D831744304808A06F3B2" xlink:type="arc" />
    <link:label id="lab_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45_terseLabel_en-US" xlink:label="lab_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Cash</link:label>
    <link:label id="lab_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45_label_en-US" xlink:label="lab_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Cash Policy [Policy Text Block]</link:label>
    <link:label id="lab_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45_documentation_en-US" xlink:label="lab_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration of Cash Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConcentrationOfCashPolicyPolicyTextBlock" xlink:label="loc_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45" xlink:to="lab_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_89C8CE050922DA0B90F604808A0631DE_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_89C8CE050922DA0B90F604808A0631DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_89C8CE050922DA0B90F604808A0631DE_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_89C8CE050922DA0B90F604808A0631DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_89C8CE050922DA0B90F604808A0631DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_89C8CE050922DA0B90F604808A0631DE" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_89C8CE050922DA0B90F604808A0631DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_237410658643A65D5E8D04808A067191_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_237410658643A65D5E8D04808A067191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_237410658643A65D5E8D04808A067191_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_237410658643A65D5E8D04808A067191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_237410658643A65D5E8D04808A067191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_237410658643A65D5E8D04808A067191" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_237410658643A65D5E8D04808A067191" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F8EB23C54815A4526F4304808A066650_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F8EB23C54815A4526F4304808A066650" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Sales Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F8EB23C54815A4526F4304808A066650_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F8EB23C54815A4526F4304808A066650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_F8EB23C54815A4526F4304808A066650" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_F8EB23C54815A4526F4304808A066650" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_F8EB23C54815A4526F4304808A066650" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1893C0C4D87276C529AA04808A0629DF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_1893C0C4D87276C529AA04808A0629DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1893C0C4D87276C529AA04808A0629DF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_1893C0C4D87276C529AA04808A0629DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1893C0C4D87276C529AA04808A0629DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_1893C0C4D87276C529AA04808A0629DF" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_1893C0C4D87276C529AA04808A0629DF" xlink:type="arc" />
    <link:label id="lab_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091_terseLabel_en-US" xlink:label="lab_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Feature</link:label>
    <link:label id="lab_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091_label_en-US" xlink:label="lab_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Feature [Policy Text Block]</link:label>
    <link:label id="lab_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091_documentation_en-US" xlink:label="lab_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Feature [Policy Text Block]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BeneficialConversionFeaturePolicyTextBlock" xlink:label="loc_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091" xlink:to="lab_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_C12B5FBA3D98FCD8116604808A06E50D_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_C12B5FBA3D98FCD8116604808A06E50D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_C12B5FBA3D98FCD8116604808A06E50D_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_C12B5FBA3D98FCD8116604808A06E50D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_C12B5FBA3D98FCD8116604808A06E50D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_C12B5FBA3D98FCD8116604808A06E50D" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_C12B5FBA3D98FCD8116604808A06E50D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_03EB306186CA4F324F9E04808A06FD12_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_03EB306186CA4F324F9E04808A06FD12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_03EB306186CA4F324F9E04808A06FD12_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_03EB306186CA4F324F9E04808A06FD12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_03EB306186CA4F324F9E04808A06FD12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_03EB306186CA4F324F9E04808A06FD12" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_03EB306186CA4F324F9E04808A06FD12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTextBlock_0E6DA61C4454718D9968EFA9C8C51678_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTextBlock_0E6DA61C4454718D9968EFA9C8C51678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONVERTIBLE BRIDGE LOAN</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTextBlock_0E6DA61C4454718D9968EFA9C8C51678_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTextBlock_0E6DA61C4454718D9968EFA9C8C51678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaap_ShortTermDebtTextBlock_0E6DA61C4454718D9968EFA9C8C51678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTextBlock_0E6DA61C4454718D9968EFA9C8C51678" xlink:to="lab_us-gaap_ShortTermDebtTextBlock_0E6DA61C4454718D9968EFA9C8C51678" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_92E17FF1A4C6564033370268AE201889_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_92E17FF1A4C6564033370268AE201889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_92E17FF1A4C6564033370268AE201889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_92E17FF1A4C6564033370268AE201889" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_92E17FF1A4C6564033370268AE201889" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Segment Allocation [Table]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Segment Allocation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD_label_en-US" xlink:label="lab_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:to="lab_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF_label_en-US" xlink:label="lab_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:to="lab_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:type="arc" />
    <link:label id="lab_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9_terseLabel_en-US" xlink:label="lab_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Precipio Diagnostic</link:label>
    <link:label id="lab_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9_label_en-US" xlink:label="lab_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Precipio Diagnostic [Member]</link:label>
    <link:label id="lab_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9_documentation_en-US" xlink:label="lab_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Precipio Diagnostic [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PrecipioDiagnosticMember" xlink:label="loc_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:to="lab_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:type="arc" />
    <link:label id="lab_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1_terseLabel_en-US" xlink:label="lab_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transgenomics</link:label>
    <link:label id="lab_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1_label_en-US" xlink:label="lab_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transgenomics [Member]</link:label>
    <link:label id="lab_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1_documentation_en-US" xlink:label="lab_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transgenomics [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:to="lab_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE" xlink:to="lab_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6" xlink:to="lab_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination Segment Allocation [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Segment Allocation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="lab_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF_verboseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares converted, shares</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44_verboseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares converted, value</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares converted from debt instrument (shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible promissory notes to equity</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, dividend rate (percentage)</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1_label_en-US" xlink:label="lab_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1" xlink:to="lab_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3F5228D45FF19C3C5D140264D47ABA21_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3F5228D45FF19C3C5D140264D47ABA21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3F5228D45FF19C3C5D140264D47ABA21_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3F5228D45FF19C3C5D140264D47ABA21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3F5228D45FF19C3C5D140264D47ABA21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3F5228D45FF19C3C5D140264D47ABA21" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3F5228D45FF19C3C5D140264D47ABA21" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3DEEB6675AA42D7ED7C40264D47A45B6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_3DEEB6675AA42D7ED7C40264D47A45B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3DEEB6675AA42D7ED7C40264D47A45B6_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_3DEEB6675AA42D7ED7C40264D47A45B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3DEEB6675AA42D7ED7C40264D47A45B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_3DEEB6675AA42D7ED7C40264D47A45B6" xlink:to="lab_us-gaap_PreferredStockSharesIssued_3DEEB6675AA42D7ED7C40264D47A45B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_873217D481CEB06A211B0264D47A47A5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_873217D481CEB06A211B0264D47A47A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_873217D481CEB06A211B0264D47A47A5_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_873217D481CEB06A211B0264D47A47A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_873217D481CEB06A211B0264D47A47A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_873217D481CEB06A211B0264D47A47A5" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_873217D481CEB06A211B0264D47A47A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3F8ED586EB6F9284865B0264D47A1BFF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_3F8ED586EB6F9284865B0264D47A1BFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3F8ED586EB6F9284865B0264D47A1BFF_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_3F8ED586EB6F9284865B0264D47A1BFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3F8ED586EB6F9284865B0264D47A1BFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_3F8ED586EB6F9284865B0264D47A1BFF" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_3F8ED586EB6F9284865B0264D47A1BFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B07125D6F26E2DEFCF930264D47A30CE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B07125D6F26E2DEFCF930264D47A30CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B07125D6F26E2DEFCF930264D47A30CE_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B07125D6F26E2DEFCF930264D47A30CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B07125D6F26E2DEFCF930264D47A30CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_B07125D6F26E2DEFCF930264D47A30CE" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_B07125D6F26E2DEFCF930264D47A30CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_FB324CC0497D55710DE60264D47A96C2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_FB324CC0497D55710DE60264D47A96C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_FB324CC0497D55710DE60264D47A96C2_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_FB324CC0497D55710DE60264D47A96C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_FB324CC0497D55710DE60264D47A96C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_FB324CC0497D55710DE60264D47A96C2" xlink:to="lab_us-gaap_CommonStockSharesIssued_FB324CC0497D55710DE60264D47A96C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EDC52CA746BC82DAAD4894CAF2768BC3_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89D99D9E919E5662A29A4B722105C0C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89D99D9E919E5662A29A4B722105C0C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89D99D9E919E5662A29A4B722105C0C5" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89D99D9E919E5662A29A4B722105C0C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_3889EDD8FC3174CBA64694CAF276448E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_FA25116630AF559DBCED6C6F0EFD1147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BUSINESS DESCRIPTION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_3889EDD8FC3174CBA64694CAF276448E_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_FA25116630AF559DBCED6C6F0EFD1147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_FA25116630AF559DBCED6C6F0EFD1147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_FA25116630AF559DBCED6C6F0EFD1147" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_FA25116630AF559DBCED6C6F0EFD1147" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4" xlink:type="arc" />
    <link:label id="lab_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2_terseLabel_en-US" xlink:label="lab_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (usd per share)</link:label>
    <link:label id="lab_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2_label_en-US" xlink:label="lab_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Per Share Conversion Price</link:label>
    <link:label id="lab_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2_documentation_en-US" xlink:label="lab_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Per Share Conversion Price</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="loc_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:to="lab_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted shares, (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790" xlink:to="lab_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock expense</link:label>
    <link:label id="lab_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D_label_en-US" xlink:label="lab_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D" xlink:to="lab_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock for consulting services in connection with the merger (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in connection with business combination (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9" xlink:to="lab_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_F3EC345614FBD0A37FF6EC78C234A4E9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_F3EC345614FBD0A37FF6EC78C234A4E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_F3EC345614FBD0A37FF6EC78C234A4E9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_F3EC345614FBD0A37FF6EC78C234A4E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_F3EC345614FBD0A37FF6EC78C234A4E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_F3EC345614FBD0A37FF6EC78C234A4E9" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_F3EC345614FBD0A37FF6EC78C234A4E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_BEBFA508647B7BFCFD00EC78C2346326_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_BEBFA508647B7BFCFD00EC78C2346326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_BEBFA508647B7BFCFD00EC78C2346326_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_BEBFA508647B7BFCFD00EC78C2346326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_BEBFA508647B7BFCFD00EC78C2346326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_BEBFA508647B7BFCFD00EC78C2346326" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_BEBFA508647B7BFCFD00EC78C2346326" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:to="lab_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C_terseLabel_en-US" xlink:label="lab_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Officers</link:label>
    <link:label id="lab_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C_label_en-US" xlink:label="lab_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C" xlink:to="lab_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864_label_en-US" xlink:label="lab_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:to="lab_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E_label_en-US" xlink:label="lab_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:to="lab_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69_label_en-US" xlink:label="lab_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69" xlink:to="lab_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, unvested options, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense related to unvested stock awards, not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested stock options, unrecognized compensation expense weighted average recognition period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC" xlink:type="arc" />
    <link:label id="lab_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06_verboseLabel_en-US" xlink:label="lab_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock rights issued (in shares)</link:label>
    <link:label id="lab_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06_label_en-US" xlink:label="lab_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Issued Warrants or Rights</link:label>
    <link:label id="lab_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06_documentation_en-US" xlink:label="lab_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Issued Warrants or Rights</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:to="lab_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3E215995EDAF1D32F776EB342151BA39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3E215995EDAF1D32F776EB342151BA39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stockholders' equity, including warrants and rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3E215995EDAF1D32F776EB342151BA39_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3E215995EDAF1D32F776EB342151BA39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3E215995EDAF1D32F776EB342151BA39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3E215995EDAF1D32F776EB342151BA39" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3E215995EDAF1D32F776EB342151BA39" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:to="lab_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:to="lab_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130" xlink:to="lab_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable rate on interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_52170F87AFA6E7BF3E6E0480899E9418_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations_52170F87AFA6E7BF3E6E0480899E9418" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_52170F87AFA6E7BF3E6E0480899E9418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_52170F87AFA6E7BF3E6E0480899E9418" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations_52170F87AFA6E7BF3E6E0480899E9418" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_28B60D7EEA65D62EB0EA02770668021A_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_28B60D7EEA65D62EB0EA02770668021A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_28B60D7EEA65D62EB0EA02770668021A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28B60D7EEA65D62EB0EA02770668021A" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_28B60D7EEA65D62EB0EA02770668021A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE_label_en-US" xlink:label="lab_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:to="lab_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C" xlink:to="lab_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C" xlink:type="arc" />
    <link:label id="lab_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3_terseLabel_en-US" xlink:label="lab_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior and Junior Notes</link:label>
    <link:label id="lab_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3_label_en-US" xlink:label="lab_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior and Junior Notes [Member]</link:label>
    <link:label id="lab_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3_documentation_en-US" xlink:label="lab_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior and Junior Notes [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SeniorandJuniorNotesMember" xlink:label="loc_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:to="lab_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="lab_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS USED IN OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred financing costs and debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation and change in liability of stock appreciation rights</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504" xlink:to="lab_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provision for losses on doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for Doubtful Accounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized PIK interest on convertible bridge notes</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant revaluation</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS PROVIDED BY INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash acquired in business combination</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET CHANGE IN CASH AND CASH EQUIVALENTS</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3D511417FDAB28CB2AAB02770671AA23_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3D511417FDAB28CB2AAB02770671AA23" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3D511417FDAB28CB2AAB02770671AA23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3D511417FDAB28CB2AAB02770671AA23" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3D511417FDAB28CB2AAB02770671AA23" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC_label_en-US" xlink:label="lab_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC" xlink:to="lab_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of equipment financed through capital lease</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_819E6A99DB79FB69D55E027706722A94_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_819E6A99DB79FB69D55E027706722A94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred unit dividend financed through exchange agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_819E6A99DB79FB69D55E027706722A94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_819E6A99DB79FB69D55E027706722A94" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_819E6A99DB79FB69D55E027706722A94" xlink:type="arc" />
    <link:label id="lab_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461_terseLabel_en-US" xlink:label="lab_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible bridge notes exchanged for long-term debt</link:label>
    <link:label id="lab_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461_label_en-US" xlink:label="lab_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Debt Converted to Long Term Debt</link:label>
    <link:label id="lab_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461_documentation_en-US" xlink:label="lab_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Debt Converted to Long Term Debt</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ShortTermDebtConvertedtoLongTermDebt" xlink:label="loc_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:to="lab_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:type="arc" />
    <link:label id="lab_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C_terseLabel_en-US" xlink:label="lab_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A and B preferred exchanged for long-term debt</link:label>
    <link:label id="lab_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C_label_en-US" xlink:label="lab_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities Transfered to Debt</link:label>
    <link:label id="lab_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C_documentation_en-US" xlink:label="lab_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities Transfered to Debt</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_EquitySecuritiesTransferedtoDebt" xlink:label="loc_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:to="lab_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D" xlink:type="arc" />
    <link:label id="lab_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2_terseLabel_en-US" xlink:label="lab_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recorded beneficial conversion feature on debt</link:label>
    <link:label id="lab_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2_label_en-US" xlink:label="lab_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Feature on Issuance of Debt</link:label>
    <link:label id="lab_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2_documentation_en-US" xlink:label="lab_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Beneficial Conversion Feature on Issuance of Debt</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BeneficialConversionFeatureonIssuanceofDebt" xlink:label="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:to="lab_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:type="arc" />
    <link:label id="lab_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93_terseLabel_en-US" xlink:label="lab_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued merger cost</link:label>
    <link:label id="lab_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93_label_en-US" xlink:label="lab_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Accrued Merger Cost</link:label>
    <link:label id="lab_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93_documentation_en-US" xlink:label="lab_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash Accrued Merger Cost</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_NoncashAccruedMergerCost" xlink:label="loc_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:to="lab_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for merger advisory fees</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F_terseLabel_en-US" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants in conjunction with issuance of side agreement</link:label>
    <link:label id="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F_label_en-US" xlink:label="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F" xlink:to="lab_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:type="arc" />
    <link:label id="lab_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3_terseLabel_en-US" xlink:label="lab_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Bridge Loan</link:label>
    <link:label id="lab_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3_label_en-US" xlink:label="lab_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Bridge Loan [Member]</link:label>
    <link:label id="lab_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3_documentation_en-US" xlink:label="lab_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Bridge Loan [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConvertibleBridgeLoanMember" xlink:label="loc_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:to="lab_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:type="arc" />
    <link:label id="lab_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3_terseLabel_en-US" xlink:label="lab_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Convertible Bridge Loan</link:label>
    <link:label id="lab_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3_label_en-US" xlink:label="lab_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Convertible Bridge Loan [Member]</link:label>
    <link:label id="lab_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3_documentation_en-US" xlink:label="lab_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unsecured Convertible Bridge Loan [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UnsecuredConvertibleBridgeLoanMember" xlink:label="loc_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:to="lab_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="lab_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:type="arc" />
    <link:label id="lab_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E_terseLabel_en-US" xlink:label="lab_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock, discount rate</link:label>
    <link:label id="lab_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E_label_en-US" xlink:label="lab_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Discount Rate</link:label>
    <link:label id="lab_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E_documentation_en-US" xlink:label="lab_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Discount Rate</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockDiscountRate" xlink:label="loc_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:to="lab_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:type="arc" />
    <link:label id="lab_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919_terseLabel_en-US" xlink:label="lab_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, debt converted into new debt</link:label>
    <link:label id="lab_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919_label_en-US" xlink:label="lab_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Converted Rate</link:label>
    <link:label id="lab_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919_documentation_en-US" xlink:label="lab_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Debt Converted Rate</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DebtInstrumentDebtConvertedRate" xlink:label="loc_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:to="lab_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4E0AA7E3B814709F25DAF60C2FD0890F_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4E0AA7E3B814709F25DAF60C2FD0890F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion of bridge notes into common stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4E0AA7E3B814709F25DAF60C2FD0890F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4E0AA7E3B814709F25DAF60C2FD0890F" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4E0AA7E3B814709F25DAF60C2FD0890F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_810D38D3395BE18496B2E7373F2B9830_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_810D38D3395BE18496B2E7373F2B9830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_810D38D3395BE18496B2E7373F2B9830_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_810D38D3395BE18496B2E7373F2B9830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_810D38D3395BE18496B2E7373F2B9830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_810D38D3395BE18496B2E7373F2B9830" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_810D38D3395BE18496B2E7373F2B9830" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7ABE076676F3B4C43630F5AFB44AA565_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7ABE076676F3B4C43630F5AFB44AA565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7ABE076676F3B4C43630F5AFB44AA565_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7ABE076676F3B4C43630F5AFB44AA565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7ABE076676F3B4C43630F5AFB44AA565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7ABE076676F3B4C43630F5AFB44AA565" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7ABE076676F3B4C43630F5AFB44AA565" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_162FBCA0EEF8FE910323F5B291F7F49D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_162FBCA0EEF8FE910323F5B291F7F49D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_162FBCA0EEF8FE910323F5B291F7F49D_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_162FBCA0EEF8FE910323F5B291F7F49D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_162FBCA0EEF8FE910323F5B291F7F49D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_162FBCA0EEF8FE910323F5B291F7F49D" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_162FBCA0EEF8FE910323F5B291F7F49D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPayableCurrent_6316ACEDD1C802DE2A03F5992067E1A2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_6316ACEDD1C802DE2A03F5992067E1A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_6316ACEDD1C802DE2A03F5992067E1A2_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent_6316ACEDD1C802DE2A03F5992067E1A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_6316ACEDD1C802DE2A03F5992067E1A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent_6316ACEDD1C802DE2A03F5992067E1A2" xlink:to="lab_us-gaap_InterestPayableCurrent_6316ACEDD1C802DE2A03F5992067E1A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_A3D0DCF44B14A394E616F5992068B3F0_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_A3D0DCF44B14A394E616F5992068B3F0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_A3D0DCF44B14A394E616F5992068B3F0_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_A3D0DCF44B14A394E616F5992068B3F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_A3D0DCF44B14A394E616F5992068B3F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_A3D0DCF44B14A394E616F5992068B3F0" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_A3D0DCF44B14A394E616F5992068B3F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9_label_en-US" xlink:label="lab_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9" xlink:to="lab_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_642A6662749D16E97CEF048071354777_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_642A6662749D16E97CEF048071354777" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_642A6662749D16E97CEF048071354777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_642A6662749D16E97CEF048071354777" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_642A6662749D16E97CEF048071354777" xlink:type="arc" />
    <link:label id="lab_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F_negatedLabel_en-US" xlink:label="lab_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Working deficiency</link:label>
    <link:label id="lab_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F_label_en-US" xlink:label="lab_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital (Deficiency)</link:label>
    <link:label id="lab_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F_documentation_en-US" xlink:label="lab_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working Capital (Deficiency)</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WorkingCapitalDeficiency" xlink:label="loc_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:to="lab_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:type="arc" />
    <link:label id="lab_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527_terseLabel_en-US" xlink:label="lab_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527_label_en-US" xlink:label="lab_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio</link:label>
    <link:label id="lab_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527_documentation_en-US" xlink:label="lab_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_StockholdersEquityNoteReverseStockSplitConversionRatio" xlink:label="loc_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:to="lab_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:type="arc" />
    <link:label id="lab_prpo_DocumentAndEntityInformationAbstract_8AC37BF644537DDB4F7C94CD8E555F24_label_en-US" xlink:label="lab_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_prpo_DocumentAndEntityInformationAbstract_8AC37BF644537DDB4F7C94CD8E555F24_documentation_en-US" xlink:label="lab_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DocumentAndEntityInformationAbstract" xlink:label="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="lab_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_6248E55EDAF42F6A0E9094CD8E55DE32_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_30B8BDAA15EA55C5812CAC37E29930EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_6248E55EDAF42F6A0E9094CD8E55DE32_label_en-US" xlink:label="lab_dei_EntityRegistrantName_30B8BDAA15EA55C5812CAC37E29930EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_30B8BDAA15EA55C5812CAC37E29930EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_30B8BDAA15EA55C5812CAC37E29930EB" xlink:to="lab_dei_EntityRegistrantName_30B8BDAA15EA55C5812CAC37E29930EB" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_11B279BBFD6E5DB3E79394CD8E55A35C_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_1764033C55315753A7E5FF086D95C4DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_11B279BBFD6E5DB3E79394CD8E55A35C_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_1764033C55315753A7E5FF086D95C4DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1764033C55315753A7E5FF086D95C4DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_1764033C55315753A7E5FF086D95C4DD" xlink:to="lab_dei_EntityCentralIndexKey_1764033C55315753A7E5FF086D95C4DD" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_D0557FB64A4953F3EAD694CD8E55F028_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_10042B2587C25DA48E7C7E4838F051DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_D0557FB64A4953F3EAD694CD8E55F028_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_10042B2587C25DA48E7C7E4838F051DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_10042B2587C25DA48E7C7E4838F051DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_10042B2587C25DA48E7C7E4838F051DB" xlink:to="lab_dei_CurrentFiscalYearEndDate_10042B2587C25DA48E7C7E4838F051DB" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_4B4718116B096CDB5FFE94CD8E55117C_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_19A05152F83B587DB487503A88FD92D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_4B4718116B096CDB5FFE94CD8E55117C_label_en-US" xlink:label="lab_dei_EntityFilerCategory_19A05152F83B587DB487503A88FD92D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_19A05152F83B587DB487503A88FD92D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_19A05152F83B587DB487503A88FD92D5" xlink:to="lab_dei_EntityFilerCategory_19A05152F83B587DB487503A88FD92D5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C33B73A52ED807F05CCB94CD8E5516BB_terseLabel_en-US" xlink:label="lab_dei_DocumentType_5A1DBCEA2F22584D85B693C82D4F382D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C33B73A52ED807F05CCB94CD8E5516BB_label_en-US" xlink:label="lab_dei_DocumentType_5A1DBCEA2F22584D85B693C82D4F382D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5A1DBCEA2F22584D85B693C82D4F382D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_5A1DBCEA2F22584D85B693C82D4F382D" xlink:to="lab_dei_DocumentType_5A1DBCEA2F22584D85B693C82D4F382D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_F2599E4BC610EF81508D94CD8E556D99_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_EE0BA25D60E25AB89755289BA18384E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_F2599E4BC610EF81508D94CD8E556D99_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_EE0BA25D60E25AB89755289BA18384E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_EE0BA25D60E25AB89755289BA18384E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_EE0BA25D60E25AB89755289BA18384E5" xlink:to="lab_dei_DocumentPeriodEndDate_EE0BA25D60E25AB89755289BA18384E5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_8DA073D5BA739FDB42FA94CD8E559CD9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_78856E616CD15EBB93C4A9C2C3C57041" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8DA073D5BA739FDB42FA94CD8E559CD9_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_78856E616CD15EBB93C4A9C2C3C57041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_78856E616CD15EBB93C4A9C2C3C57041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_78856E616CD15EBB93C4A9C2C3C57041" xlink:to="lab_dei_DocumentFiscalYearFocus_78856E616CD15EBB93C4A9C2C3C57041" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A91FCCEEF26E5EEE403294CD8E56CAC4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_95333E7419BD5B9FB881699052E65B75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A91FCCEEF26E5EEE403294CD8E56CAC4_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_95333E7419BD5B9FB881699052E65B75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_95333E7419BD5B9FB881699052E65B75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_95333E7419BD5B9FB881699052E65B75" xlink:to="lab_dei_DocumentFiscalPeriodFocus_95333E7419BD5B9FB881699052E65B75" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_A4D4531118F1D3F686DD94CD8E563483_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_522BCA79216F50EBB02E4BF9DCE7263F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_A4D4531118F1D3F686DD94CD8E563483_label_en-US" xlink:label="lab_dei_AmendmentFlag_522BCA79216F50EBB02E4BF9DCE7263F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_522BCA79216F50EBB02E4BF9DCE7263F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_522BCA79216F50EBB02E4BF9DCE7263F" xlink:to="lab_dei_AmendmentFlag_522BCA79216F50EBB02E4BF9DCE7263F" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8AD7125A9BC1AA93A9C394CD8E563A91_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_031712F0EE0A5AE3BD3F73298CE7544E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8AD7125A9BC1AA93A9C394CD8E563A91_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_031712F0EE0A5AE3BD3F73298CE7544E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_031712F0EE0A5AE3BD3F73298CE7544E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_031712F0EE0A5AE3BD3F73298CE7544E" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_031712F0EE0A5AE3BD3F73298CE7544E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_89E2BFB4B02BA6FC36BCF5BF00C07994_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_89E2BFB4B02BA6FC36BCF5BF00C07994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89E2BFB4B02BA6FC36BCF5BF00C07994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89E2BFB4B02BA6FC36BCF5BF00C07994" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_89E2BFB4B02BA6FC36BCF5BF00C07994" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:type="arc" />
    <link:label id="lab_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA_terseLabel_en-US" xlink:label="lab_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Warrant Liability</link:label>
    <link:label id="lab_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA_label_en-US" xlink:label="lab_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Warrant Liability [Member]</link:label>
    <link:label id="lab_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA_documentation_en-US" xlink:label="lab_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Warrant Liability [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="loc_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:to="lab_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C" xlink:to="lab_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, scheduled periodic payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, scheduled payment, interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95D2B6EE35519FFD3279EB341EFF3CD8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95D2B6EE35519FFD3279EB341EFF3CD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95D2B6EE35519FFD3279EB341EFF3CD8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95D2B6EE35519FFD3279EB341EFF3CD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95D2B6EE35519FFD3279EB341EFF3CD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95D2B6EE35519FFD3279EB341EFF3CD8" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95D2B6EE35519FFD3279EB341EFF3CD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:type="arc" />
    <link:label id="lab_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E_terseLabel_en-US" xlink:label="lab_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legacy Transgenomic common stock</link:label>
    <link:label id="lab_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E_label_en-US" xlink:label="lab_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquired Entities Common Stock</link:label>
    <link:label id="lab_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E_documentation_en-US" xlink:label="lab_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Acquired Entities Common Stock</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationAcquiredEntitiesCommonStock" xlink:label="loc_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:to="lab_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of preferred stock converted to common stock</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621" xlink:type="arc" />
    <link:label id="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6_terseLabel_en-US" xlink:label="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of debt converted to common stock</link:label>
    <link:label id="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6_label_en-US" xlink:label="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Fair Value of Debt Converted to Common Stock</link:label>
    <link:label id="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6_documentation_en-US" xlink:label="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Fair Value of Debt Converted to Common Stock</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:to="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:type="arc" />
    <link:label id="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD_terseLabel_en-US" xlink:label="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of debt converted to preferred stock</link:label>
    <link:label id="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD_label_en-US" xlink:label="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Fair Value of Debt Converted to Preferred Stock</link:label>
    <link:label id="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD_documentation_en-US" xlink:label="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Fair Value of Debt Converted to Preferred Stock</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:to="lab_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of existing bridge notes</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D" xlink:type="arc" />
    <link:label id="lab_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8_terseLabel_en-US" xlink:label="lab_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8_label_en-US" xlink:label="lab_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Fair Value of Debt Converted</link:label>
    <link:label id="lab_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8_documentation_en-US" xlink:label="lab_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Fair Value of Debt Converted</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConverted" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:to="lab_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SARs</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of SARs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:type="arc" />
    <link:label id="lab_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2_terseLabel_en-US" xlink:label="lab_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2_label_en-US" xlink:label="lab_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number</link:label>
    <link:label id="lab_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2_documentation_en-US" xlink:label="lab_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:to="lab_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock appreciation rights, aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D" xlink:type="arc" />
    <link:label id="lab_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44_negatedLabel_en-US" xlink:label="lab_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in SAR liability</link:label>
    <link:label id="lab_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44_label_en-US" xlink:label="lab_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Stock Appreciation Rights Liability</link:label>
    <link:label id="lab_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44_documentation_en-US" xlink:label="lab_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Stock Appreciation Rights Liability</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ChangeinStockAppreciationRightsLiability" xlink:label="loc_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:to="lab_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_EB478E47FC6EA898FC73E158D4A0C667_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_EB478E47FC6EA898FC73E158D4A0C667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_EB478E47FC6EA898FC73E158D4A0C667_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_EB478E47FC6EA898FC73E158D4A0C667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_EB478E47FC6EA898FC73E158D4A0C667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_EB478E47FC6EA898FC73E158D4A0C667" xlink:to="lab_us-gaap_OtherAssetsCurrent_EB478E47FC6EA898FC73E158D4A0C667" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_2A6783523A1DDBBAC47AE158D4A0BE79_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_2A6783523A1DDBBAC47AE158D4A0BE79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current prepaid expense</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_2A6783523A1DDBBAC47AE158D4A0BE79_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_2A6783523A1DDBBAC47AE158D4A0BE79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2A6783523A1DDBBAC47AE158D4A0BE79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_2A6783523A1DDBBAC47AE158D4A0BE79" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_2A6783523A1DDBBAC47AE158D4A0BE79" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_48DF9AF03D0F5D7DFDCAE158D4A53E8D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_48DF9AF03D0F5D7DFDCAE158D4A53E8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_48DF9AF03D0F5D7DFDCAE158D4A53E8D_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_48DF9AF03D0F5D7DFDCAE158D4A53E8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_48DF9AF03D0F5D7DFDCAE158D4A53E8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_48DF9AF03D0F5D7DFDCAE158D4A53E8D" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_48DF9AF03D0F5D7DFDCAE158D4A53E8D" xlink:type="arc" />
    <link:label id="lab_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150_terseLabel_en-US" xlink:label="lab_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aegis Warrants</link:label>
    <link:label id="lab_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150_label_en-US" xlink:label="lab_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aegis Warrant [Member]</link:label>
    <link:label id="lab_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150_documentation_en-US" xlink:label="lab_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aegis Warrant [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AegisWarrantMember" xlink:label="loc_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:to="lab_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:type="arc" />
    <link:label id="lab_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247_terseLabel_en-US" xlink:label="lab_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Bridge Notes</link:label>
    <link:label id="lab_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247_label_en-US" xlink:label="lab_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Bridge Notes [Member]</link:label>
    <link:label id="lab_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247_documentation_en-US" xlink:label="lab_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Bridge Notes [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017BridgeNotesMember" xlink:label="loc_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:to="lab_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:type="arc" />
    <link:label id="lab_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D_terseLabel_en-US" xlink:label="lab_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Bridge Notes I</link:label>
    <link:label id="lab_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D_label_en-US" xlink:label="lab_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Bridge Notes I [Member]</link:label>
    <link:label id="lab_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D_documentation_en-US" xlink:label="lab_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Bridge Notes I [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_NewBridgeNotesIMember" xlink:label="loc_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:to="lab_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of debt</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82" xlink:type="arc" />
    <link:label id="lab_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7_terseLabel_en-US" xlink:label="lab_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium rate changed upon settlement of debt</link:label>
    <link:label id="lab_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7_label_en-US" xlink:label="lab_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium Rate on Debt Settlement</link:label>
    <link:label id="lab_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7_documentation_en-US" xlink:label="lab_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium Rate on Debt Settlement</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlement" xlink:label="loc_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:to="lab_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:type="arc" />
    <link:label id="lab_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736_terseLabel_en-US" xlink:label="lab_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium on debt settlement</link:label>
    <link:label id="lab_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736_label_en-US" xlink:label="lab_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium Rate on Debt Settlement, Amount</link:label>
    <link:label id="lab_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736_documentation_en-US" xlink:label="lab_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium on Debt Settlement, Amount</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlementAmount" xlink:label="loc_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:to="lab_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD" xlink:type="arc" />
    <link:label id="lab_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2_terseLabel_en-US" xlink:label="lab_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of per share offering price</link:label>
    <link:label id="lab_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2_label_en-US" xlink:label="lab_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of Per Share Offering Price</link:label>
    <link:label id="lab_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2_documentation_en-US" xlink:label="lab_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of Per Share Offering Price</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PercentageofPerShareOfferingPrice" xlink:label="loc_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:to="lab_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:type="arc" />
    <link:label id="lab_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D_terseLabel_en-US" xlink:label="lab_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agent Fees</link:label>
    <link:label id="lab_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D_label_en-US" xlink:label="lab_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agent Fees</link:label>
    <link:label id="lab_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D_documentation_en-US" xlink:label="lab_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agent Fees</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AgentFees" xlink:label="loc_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:to="lab_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss available to common stockholders</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per common share (usd per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock issued, value</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F" xlink:to="lab_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends, preferred stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Preferred Stock, Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726" xlink:to="lab_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726" xlink:type="arc" />
    <link:label id="lab_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335_terseLabel_en-US" xlink:label="lab_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock warrant potential Entity ownership percentage</link:label>
    <link:label id="lab_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335_label_en-US" xlink:label="lab_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Warrant Potential Entity Ownership Percentage if Exercised</link:label>
    <link:label id="lab_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335_documentation_en-US" xlink:label="lab_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Warrant Potential Entity Ownership Percentage if Exercised</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised" xlink:label="loc_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:to="lab_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F" xlink:to="lab_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-compete agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77" xlink:to="lab_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77" xlink:type="arc" />
    <link:label id="lab_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A_terseLabel_en-US" xlink:label="lab_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Backlog</link:label>
    <link:label id="lab_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A_label_en-US" xlink:label="lab_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Backlog [Member]</link:label>
    <link:label id="lab_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A_documentation_en-US" xlink:label="lab_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Backlog [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BacklogMember" xlink:label="loc_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:to="lab_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trademark and trade name</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_83E96B4C625FCEFF8586E1D620E677A2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_83E96B4C625FCEFF8586E1D620E677A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_83E96B4C625FCEFF8586E1D620E677A2_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_83E96B4C625FCEFF8586E1D620E677A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_83E96B4C625FCEFF8586E1D620E677A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_83E96B4C625FCEFF8586E1D620E677A2" xlink:to="lab_us-gaap_DeferredRevenueCurrent_83E96B4C625FCEFF8586E1D620E677A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5EBC434A36CC4134302CFF640D931982_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_5EBC434A36CC4134302CFF640D931982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_5EBC434A36CC4134302CFF640D931982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_5EBC434A36CC4134302CFF640D931982" xlink:to="lab_us-gaap_IncomeStatementAbstract_5EBC434A36CC4134302CFF640D931982" xlink:type="arc" />
    <link:label id="lab_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0_terseLabel_en-US" xlink:label="lab_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock - series A senior</link:label>
    <link:label id="lab_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0_label_en-US" xlink:label="lab_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Series A Senior [Member]</link:label>
    <link:label id="lab_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0_documentation_en-US" xlink:label="lab_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Series A Senior [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PreferredStockSeriesASeniorMember" xlink:label="loc_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:to="lab_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_A8095C6F597A422AFE8AFF640D93325E_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_A8095C6F597A422AFE8AFF640D93325E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_A8095C6F597A422AFE8AFF640D93325E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_A8095C6F597A422AFE8AFF640D93325E" xlink:to="lab_us-gaap_PreferredStockMember_A8095C6F597A422AFE8AFF640D93325E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patient service revenue, net</link:label>
    <link:label id="lab_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433_label_en-US" xlink:label="lab_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433" xlink:to="lab_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">less provision for bad debts</link:label>
    <link:label id="lab_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895_label_en-US" xlink:label="lab_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Allowances, Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="loc_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895" xlink:to="lab_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96_totalLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96_label_en-US" xlink:label="lab_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Services, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96" xlink:to="lab_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COST OF DIAGNOSTIC SERVICES</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit (loss)</link:label>
    <link:label id="lab_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB_label_en-US" xlink:label="lab_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB" xlink:to="lab_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OPERATING EXPENSES</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB" xlink:to="lab_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">OPERATING LOSS</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6" xlink:to="lab_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER INCOME (EXPENSE):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:type="arc" />
    <link:label id="lab_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8_terseLabel_en-US" xlink:label="lab_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8_label_en-US" xlink:label="lab_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income and (expense), net</link:label>
    <link:label id="lab_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8_documentation_en-US" xlink:label="lab_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest income and (expense), net</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_InterestIncomeAndExpenseNet" xlink:label="loc_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:to="lab_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:type="arc" />
    <link:label id="lab_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007_terseLabel_en-US" xlink:label="lab_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant revaluation</link:label>
    <link:label id="lab_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007_label_en-US" xlink:label="lab_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Stock Warrants Revaluation</link:label>
    <link:label id="lab_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007_documentation_en-US" xlink:label="lab_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_GainLossOnStockWarrantsRevaluation" xlink:label="loc_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:to="lab_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F78051A9CDAFD28EBA81FF640D93637A_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F78051A9CDAFD28EBA81FF640D93637A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F78051A9CDAFD28EBA81FF640D93637A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F78051A9CDAFD28EBA81FF640D93637A" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_F78051A9CDAFD28EBA81FF640D93637A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1AAC0A96EE717FF49B4BFF640D93043B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1AAC0A96EE717FF49B4BFF640D93043B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Merger advisory fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1AAC0A96EE717FF49B4BFF640D93043B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1AAC0A96EE717FF49B4BFF640D93043B" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1AAC0A96EE717FF49B4BFF640D93043B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771" xlink:type="arc" />
    <link:label id="lab_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882_totalLabel_en-US" xlink:label="lab_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882_label_en-US" xlink:label="lab_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:label id="lab_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882_documentation_en-US" xlink:label="lab_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Income (Expense)</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_OtherIncomeExpense" xlink:label="loc_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:to="lab_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LOSS BEFORE INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAX EXPENSE</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET LOSS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811" xlink:to="lab_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">TOTAL DIVIDENDS</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_D927D851B9AB66767F34E1E14B1A7362_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_D927D851B9AB66767F34E1E14B1A7362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_D927D851B9AB66767F34E1E14B1A7362_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_D927D851B9AB66767F34E1E14B1A7362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_D927D851B9AB66767F34E1E14B1A7362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_D927D851B9AB66767F34E1E14B1A7362" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_D927D851B9AB66767F34E1E14B1A7362" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A" xlink:type="arc" />
    <link:label id="lab_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B_terseLabel_en-US" xlink:label="lab_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total (gains) or losses:</link:label>
    <link:label id="lab_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B_label_en-US" xlink:label="lab_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total gains or losses [Abstract]</link:label>
    <link:label id="lab_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B_documentation_en-US" xlink:label="lab_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total gains or losses [Abstract]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TotalGainsOrLossesAbstract" xlink:label="loc_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:to="lab_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Recognized in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7DF55E30EA9C7D1B59A1E79B54DA0C47_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7DF55E30EA9C7D1B59A1E79B54DA0C47" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7DF55E30EA9C7D1B59A1E79B54DA0C47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7DF55E30EA9C7D1B59A1E79B54DA0C47" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7DF55E30EA9C7D1B59A1E79B54DA0C47" xlink:type="arc" />
    <link:label id="lab_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1_terseLabel_en-US" xlink:label="lab_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 New Bridge Notes II</link:label>
    <link:label id="lab_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1_label_en-US" xlink:label="lab_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 New Bridge Notes [Member]</link:label>
    <link:label id="lab_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1_documentation_en-US" xlink:label="lab_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 New Bridge Notes</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017NewBridgeNotesMember" xlink:label="loc_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:to="lab_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969" xlink:to="lab_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969" xlink:type="arc" />
    <link:label id="lab_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918_terseLabel_en-US" xlink:label="lab_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of debt instrument</link:label>
    <link:label id="lab_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918_label_en-US" xlink:label="lab_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From the Sales of Debt Instrument</link:label>
    <link:label id="lab_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918_documentation_en-US" xlink:label="lab_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From the Sales of Debt Instrument</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ProceedsFromtheSalesofDebtInstrument" xlink:label="loc_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:to="lab_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from equity financing</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB" xlink:type="arc" />
    <link:label id="lab_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF_terseLabel_en-US" xlink:label="lab_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Notes</link:label>
    <link:label id="lab_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF_label_en-US" xlink:label="lab_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Notes [Member]</link:label>
    <link:label id="lab_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF_documentation_en-US" xlink:label="lab_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Notes [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AdditionalNotesMember" xlink:label="loc_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:to="lab_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:type="arc" />
    <link:label id="lab_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF_terseLabel_en-US" xlink:label="lab_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent</link:label>
    <link:label id="lab_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF_label_en-US" xlink:label="lab_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent</link:label>
    <link:label id="lab_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF_documentation_en-US" xlink:label="lab_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" xlink:label="loc_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:to="lab_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:type="arc" />
    <link:label id="lab_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1_terseLabel_en-US" xlink:label="lab_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required Cumulative Payment on Principal Per Amendment, Percent</link:label>
    <link:label id="lab_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1_label_en-US" xlink:label="lab_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Required Cumulative Payment on Principal Per Amendment, Percent</link:label>
    <link:label id="lab_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1_documentation_en-US" xlink:label="lab_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Required Cumulative Payment on Principal Per Amendment, Percent</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent" xlink:label="loc_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:to="lab_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:type="arc" />
    <link:label id="lab_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC_terseLabel_en-US" xlink:label="lab_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend</link:label>
    <link:label id="lab_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC_label_en-US" xlink:label="lab_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deemed Dividend</link:label>
    <link:label id="lab_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC_documentation_en-US" xlink:label="lab_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deemed Dividend</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DeemedDividend" xlink:label="loc_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:to="lab_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_398D9570CB97CCCCE23BFF96A93D620F_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_398D9570CB97CCCCE23BFF96A93D620F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Annual interest rate (as a percent)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_398D9570CB97CCCCE23BFF96A93D620F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_398D9570CB97CCCCE23BFF96A93D620F" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_398D9570CB97CCCCE23BFF96A93D620F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity instrument fair value</link:label>
    <link:label id="lab_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A_label_en-US" xlink:label="lab_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A" xlink:to="lab_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock dividend, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C" xlink:to="lab_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_06AB1C1727BFC6F0854C94CAF1DE21B8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_18EBA6BCDA7753CE9F8B98F2246A64C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK OPTIONS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_06AB1C1727BFC6F0854C94CAF1DE21B8_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_18EBA6BCDA7753CE9F8B98F2246A64C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_18EBA6BCDA7753CE9F8B98F2246A64C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_18EBA6BCDA7753CE9F8B98F2246A64C8" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_18EBA6BCDA7753CE9F8B98F2246A64C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6FA723D2B2A52EF6AB7B94CAF11BAFEA_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_87AE62A93B4C53D590749C60CB15C1A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6FA723D2B2A52EF6AB7B94CAF11BAFEA_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_87AE62A93B4C53D590749C60CB15C1A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_87AE62A93B4C53D590749C60CB15C1A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_87AE62A93B4C53D590749C60CB15C1A1" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_87AE62A93B4C53D590749C60CB15C1A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41DC293A8D3E0CE1427EE1D87270031C_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41DC293A8D3E0CE1427EE1D87270031C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, warrants and conversion rights, common stock callable and antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41DC293A8D3E0CE1427EE1D87270031C_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41DC293A8D3E0CE1427EE1D87270031C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41DC293A8D3E0CE1427EE1D87270031C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41DC293A8D3E0CE1427EE1D87270031C" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41DC293A8D3E0CE1427EE1D87270031C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4C8B51BEACA7113C8D44063C471D0679_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_4C8B51BEACA7113C8D44063C471D0679" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4C8B51BEACA7113C8D44063C471D0679" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4C8B51BEACA7113C8D44063C471D0679" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_4C8B51BEACA7113C8D44063C471D0679" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:to="lab_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26" xlink:to="lab_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47" xlink:to="lab_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_0F89CFFBD9FD1AD3C067063C471E86FE_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_0F89CFFBD9FD1AD3C067063C471E86FE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_0F89CFFBD9FD1AD3C067063C471E86FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_0F89CFFBD9FD1AD3C067063C471E86FE" xlink:to="lab_us-gaap_SharesOutstanding_0F89CFFBD9FD1AD3C067063C471E86FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_B0E52458BAB399FE3941063C471EE29F_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_B0E52458BAB399FE3941063C471EE29F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B0E52458BAB399FE3941063C471EE29F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_B0E52458BAB399FE3941063C471EE29F" xlink:to="lab_us-gaap_NetIncomeLoss_B0E52458BAB399FE3941063C471EE29F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock and preferred stock dividends</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_B5D83C2A072B0F95564C063C471E6865_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1_B5D83C2A072B0F95564C063C471E6865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock into common stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_B5D83C2A072B0F95564C063C471E6865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1_B5D83C2A072B0F95564C063C471E6865" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1_B5D83C2A072B0F95564C063C471E6865" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock and preferred stock dividends (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of bridge notes into common stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_05C9F300265D54349445063C471E0003_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_05C9F300265D54349445063C471E0003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for consulting services in connection with the merger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_05C9F300265D54349445063C471E0003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_05C9F300265D54349445063C471E0003" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_05C9F300265D54349445063C471E0003" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in connection with business combination</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0F1F526AF4A0602D6ADA063C471F9F1F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0F1F526AF4A0602D6ADA063C471F9F1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0F1F526AF4A0602D6ADA063C471F9F1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0F1F526AF4A0602D6ADA063C471F9F1F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0F1F526AF4A0602D6ADA063C471F9F1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation and vesting of restricted units</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9" xlink:type="arc" />
    <link:label id="lab_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98_terseLabel_en-US" xlink:label="lab_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash stock-based compensation and vesting restricted units (in shares)</link:label>
    <link:label id="lab_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98_label_en-US" xlink:label="lab_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Shares</link:label>
    <link:label id="lab_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98_documentation_en-US" xlink:label="lab_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Shares</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="loc_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:to="lab_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_C229D94E8CEFE17CCE5F063C471F42D1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_C229D94E8CEFE17CCE5F063C471F42D1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C229D94E8CEFE17CCE5F063C471F42D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_C229D94E8CEFE17CCE5F063C471F42D1" xlink:to="lab_us-gaap_StockholdersEquity_C229D94E8CEFE17CCE5F063C471F42D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesOutstanding_83A76705A97A7EF1A672063C471FD41A_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding_83A76705A97A7EF1A672063C471FD41A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_83A76705A97A7EF1A672063C471FD41A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding_83A76705A97A7EF1A672063C471FD41A" xlink:to="lab_us-gaap_SharesOutstanding_83A76705A97A7EF1A672063C471FD41A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D114AE088CADD402640194CAF21F027F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4CB5366EA2225EF3A6E2BCD58DC13F57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D114AE088CADD402640194CAF21F027F_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_4CB5366EA2225EF3A6E2BCD58DC13F57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4CB5366EA2225EF3A6E2BCD58DC13F57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_4CB5366EA2225EF3A6E2BCD58DC13F57" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_4CB5366EA2225EF3A6E2BCD58DC13F57" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_25B2E4F2A2B8565B63BC94CAF2AC4B0D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7CD01E6FAD1D5C3EAFEF63331806FE5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of changes in fair value of liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_25B2E4F2A2B8565B63BC94CAF2AC4B0D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7CD01E6FAD1D5C3EAFEF63331806FE5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7CD01E6FAD1D5C3EAFEF63331806FE5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7CD01E6FAD1D5C3EAFEF63331806FE5B" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7CD01E6FAD1D5C3EAFEF63331806FE5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_75994241DE771C045E90E79B5477E5BC_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_75994241DE771C045E90E79B5477E5BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_75994241DE771C045E90E79B5477E5BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_75994241DE771C045E90E79B5477E5BC" xlink:to="lab_us-gaap_SubsequentEventsAbstract_75994241DE771C045E90E79B5477E5BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_B8B858E14E3B9D0B6838E79B547835B1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_B8B858E14E3B9D0B6838E79B547835B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_B8B858E14E3B9D0B6838E79B547835B1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_B8B858E14E3B9D0B6838E79B547835B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_B8B858E14E3B9D0B6838E79B547835B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_B8B858E14E3B9D0B6838E79B547835B1" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_B8B858E14E3B9D0B6838E79B547835B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9C8D0505F701A2AF7B2394CAF21D64E1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_9FB64EA310AF5343A833BC2D12FB808E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9FB64EA310AF5343A833BC2D12FB808E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9FB64EA310AF5343A833BC2D12FB808E" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_9FB64EA310AF5343A833BC2D12FB808E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_89EDFF8913372F82AB5194CAF21EE675_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_09FC8A80F7FC5BA5B5E4F5BA9B2FEC52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_89EDFF8913372F82AB5194CAF21EE675_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_09FC8A80F7FC5BA5B5E4F5BA9B2FEC52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_09FC8A80F7FC5BA5B5E4F5BA9B2FEC52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_09FC8A80F7FC5BA5B5E4F5BA9B2FEC52" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_09FC8A80F7FC5BA5B5E4F5BA9B2FEC52" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:to="lab_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:to="lab_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9543BE17502BAAFFBE0F069A16AB4341_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9543BE17502BAAFFBE0F069A16AB4341" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9543BE17502BAAFFBE0F069A16AB4341" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9543BE17502BAAFFBE0F069A16AB4341" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9543BE17502BAAFFBE0F069A16AB4341" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6418D7F71AEBF3E0538A069A16AB177D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_6418D7F71AEBF3E0538A069A16AB177D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_6418D7F71AEBF3E0538A069A16AB177D_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_6418D7F71AEBF3E0538A069A16AB177D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6418D7F71AEBF3E0538A069A16AB177D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_6418D7F71AEBF3E0538A069A16AB177D" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_6418D7F71AEBF3E0538A069A16AB177D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_4038CF243F3A0B834135069A16AB9A68_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_4038CF243F3A0B834135069A16AB9A68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_4038CF243F3A0B834135069A16AB9A68_label_en-US" xlink:label="lab_us-gaap_InventoryNet_4038CF243F3A0B834135069A16AB9A68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4038CF243F3A0B834135069A16AB9A68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_4038CF243F3A0B834135069A16AB9A68" xlink:to="lab_us-gaap_InventoryNet_4038CF243F3A0B834135069A16AB9A68" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_5266332FA7DC88401B8A069A16AB273F_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_5266332FA7DC88401B8A069A16AB273F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_5266332FA7DC88401B8A069A16AB273F_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_5266332FA7DC88401B8A069A16AB273F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5266332FA7DC88401B8A069A16AB273F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_5266332FA7DC88401B8A069A16AB273F" xlink:to="lab_us-gaap_AssetsCurrent_5266332FA7DC88401B8A069A16AB273F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4D6B2F56E0AD54CA0D75069A16AB51CD_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_4D6B2F56E0AD54CA0D75069A16AB51CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4D6B2F56E0AD54CA0D75069A16AB51CD_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_4D6B2F56E0AD54CA0D75069A16AB51CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4D6B2F56E0AD54CA0D75069A16AB51CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4D6B2F56E0AD54CA0D75069A16AB51CD" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_4D6B2F56E0AD54CA0D75069A16AB51CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OTHER ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_7AC713FE02BBAC2A2250069A16AB0A5D_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_7AC713FE02BBAC2A2250069A16AB0A5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_7AC713FE02BBAC2A2250069A16AB0A5D_label_en-US" xlink:label="lab_us-gaap_Goodwill_7AC713FE02BBAC2A2250069A16AB0A5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_7AC713FE02BBAC2A2250069A16AB0A5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_7AC713FE02BBAC2A2250069A16AB0A5D" xlink:to="lab_us-gaap_Goodwill_7AC713FE02BBAC2A2250069A16AB0A5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_67DE6FF6CA66FF0BB453069A16AC752E_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_67DE6FF6CA66FF0BB453069A16AC752E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_67DE6FF6CA66FF0BB453069A16AC752E_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_67DE6FF6CA66FF0BB453069A16AC752E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_67DE6FF6CA66FF0BB453069A16AC752E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_67DE6FF6CA66FF0BB453069A16AC752E" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_67DE6FF6CA66FF0BB453069A16AC752E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_BFC118C1A2D9CED07044069A16AC9212_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_BFC118C1A2D9CED07044069A16AC9212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_BFC118C1A2D9CED07044069A16AC9212_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_BFC118C1A2D9CED07044069A16AC9212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_BFC118C1A2D9CED07044069A16AC9212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_BFC118C1A2D9CED07044069A16AC9212" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_BFC118C1A2D9CED07044069A16AC9212" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_8471DC0F26577D84CA0D069A16ACEFF2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_8471DC0F26577D84CA0D069A16ACEFF2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_8471DC0F26577D84CA0D069A16ACEFF2_label_en-US" xlink:label="lab_us-gaap_Assets_8471DC0F26577D84CA0D069A16ACEFF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8471DC0F26577D84CA0D069A16ACEFF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_8471DC0F26577D84CA0D069A16ACEFF2" xlink:to="lab_us-gaap_Assets_8471DC0F26577D84CA0D069A16ACEFF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_E636B88AEB29584072BE069A16AC1C1A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_E636B88AEB29584072BE069A16AC1C1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current maturities of long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_E636B88AEB29584072BE069A16AC1C1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_E636B88AEB29584072BE069A16AC1C1A" xlink:to="lab_us-gaap_LongTermDebtCurrent_E636B88AEB29584072BE069A16AC1C1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_335D0DC10ECE5B44879E069A16AC6C3A_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_335D0DC10ECE5B44879E069A16AC6C3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible bridge notes, less debt discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_335D0DC10ECE5B44879E069A16AC6C3A_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_335D0DC10ECE5B44879E069A16AC6C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_335D0DC10ECE5B44879E069A16AC6C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_335D0DC10ECE5B44879E069A16AC6C3A" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_335D0DC10ECE5B44879E069A16AC6C3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2B03DE7D7ACB2FE2CFEB069A16ACB419_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2B03DE7D7ACB2FE2CFEB069A16ACB419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2B03DE7D7ACB2FE2CFEB069A16ACB419_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2B03DE7D7ACB2FE2CFEB069A16ACB419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2B03DE7D7ACB2FE2CFEB069A16ACB419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_2B03DE7D7ACB2FE2CFEB069A16ACB419" xlink:to="lab_us-gaap_AccountsPayableCurrent_2B03DE7D7ACB2FE2CFEB069A16ACB419" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_0EA4ED99E394F00FA8C1069A16ACF1D1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent_0EA4ED99E394F00FA8C1069A16ACF1D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current maturities of capital leases</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsCurrent_0EA4ED99E394F00FA8C1069A16ACF1D1_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent_0EA4ED99E394F00FA8C1069A16ACF1D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_0EA4ED99E394F00FA8C1069A16ACF1D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsCurrent_0EA4ED99E394F00FA8C1069A16ACF1D1" xlink:to="lab_us-gaap_CapitalLeaseObligationsCurrent_0EA4ED99E394F00FA8C1069A16ACF1D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_B23297D99247BD3B66F4069A16AC7BAD_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_B23297D99247BD3B66F4069A16AC7BAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B23297D99247BD3B66F4069A16AC7BAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_B23297D99247BD3B66F4069A16AC7BAD" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_B23297D99247BD3B66F4069A16AC7BAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_B94FC9CD7ADD3AA5AA1F069A16AC78DE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_B94FC9CD7ADD3AA5AA1F069A16AC78DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_B94FC9CD7ADD3AA5AA1F069A16AC78DE_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_B94FC9CD7ADD3AA5AA1F069A16AC78DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_B94FC9CD7ADD3AA5AA1F069A16AC78DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_B94FC9CD7ADD3AA5AA1F069A16AC78DE" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_B94FC9CD7ADD3AA5AA1F069A16AC78DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_07508BBD3EAE42283E92069A16ACA843_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_07508BBD3EAE42283E92069A16ACA843" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_07508BBD3EAE42283E92069A16ACA843_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_07508BBD3EAE42283E92069A16ACA843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_07508BBD3EAE42283E92069A16ACA843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_07508BBD3EAE42283E92069A16ACA843" xlink:to="lab_us-gaap_LiabilitiesCurrent_07508BBD3EAE42283E92069A16ACA843" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_DD447F6A6F4DBBA361B1069A16ACC83D_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_DD447F6A6F4DBBA361B1069A16ACC83D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, less current maturities and discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_DD447F6A6F4DBBA361B1069A16ACC83D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_DD447F6A6F4DBBA361B1069A16ACC83D" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_DD447F6A6F4DBBA361B1069A16ACC83D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_E2A3610A64A818D43BAC069A16AC3576_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_E2A3610A64A818D43BAC069A16AC3576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_E2A3610A64A818D43BAC069A16AC3576_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_E2A3610A64A818D43BAC069A16AC3576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_E2A3610A64A818D43BAC069A16AC3576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_E2A3610A64A818D43BAC069A16AC3576" xlink:to="lab_us-gaap_DerivativeLiabilities_E2A3610A64A818D43BAC069A16AC3576" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalLeaseObligationsNoncurrent_607AFE10F82DDE5EA1D6069A16ADEE84_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent_607AFE10F82DDE5EA1D6069A16ADEE84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital leases, less current maturities</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsNoncurrent_607AFE10F82DDE5EA1D6069A16ADEE84_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsNoncurrent_607AFE10F82DDE5EA1D6069A16ADEE84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Lease Obligations, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_607AFE10F82DDE5EA1D6069A16ADEE84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsNoncurrent_607AFE10F82DDE5EA1D6069A16ADEE84" xlink:to="lab_us-gaap_CapitalLeaseObligationsNoncurrent_607AFE10F82DDE5EA1D6069A16ADEE84" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_69C42E01CB0939456C65069A16ADDA33_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_69C42E01CB0939456C65069A16ADDA33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_69C42E01CB0939456C65069A16ADDA33_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_69C42E01CB0939456C65069A16ADDA33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_69C42E01CB0939456C65069A16ADDA33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_69C42E01CB0939456C65069A16ADDA33" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_69C42E01CB0939456C65069A16ADDA33" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_E79E8787807595E20D05069A16AD6585_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_E79E8787807595E20D05069A16AD6585" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_E79E8787807595E20D05069A16AD6585_label_en-US" xlink:label="lab_us-gaap_Liabilities_E79E8787807595E20D05069A16AD6585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E79E8787807595E20D05069A16AD6585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_E79E8787807595E20D05069A16AD6585" xlink:to="lab_us-gaap_Liabilities_E79E8787807595E20D05069A16AD6585" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:to="lab_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_031A210B39EED14596D1069A16AD067C_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_031A210B39EED14596D1069A16AD067C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_031A210B39EED14596D1069A16AD067C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_031A210B39EED14596D1069A16AD067C" xlink:to="lab_us-gaap_PreferredStockValue_031A210B39EED14596D1069A16AD067C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_BBCC2B24C159E55B4730069A16ADBA0D_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_BBCC2B24C159E55B4730069A16ADBA0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value, 150,000,000 and 1,806,850 shares authorized at June 30, 2017 and December 31, 2016, respectively, 6,407,860 and 449,175 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_BBCC2B24C159E55B4730069A16ADBA0D_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_BBCC2B24C159E55B4730069A16ADBA0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_BBCC2B24C159E55B4730069A16ADBA0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_BBCC2B24C159E55B4730069A16ADBA0D" xlink:to="lab_us-gaap_CommonStockValue_BBCC2B24C159E55B4730069A16ADBA0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_25954DF1703DE8EF63DC069A16ADA105_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_25954DF1703DE8EF63DC069A16ADA105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_25954DF1703DE8EF63DC069A16ADA105_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_25954DF1703DE8EF63DC069A16ADA105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_25954DF1703DE8EF63DC069A16ADA105" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_25954DF1703DE8EF63DC069A16ADA105" xlink:to="lab_us-gaap_AdditionalPaidInCapital_25954DF1703DE8EF63DC069A16ADA105" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DF2C68E956958BC96AC3069A16AD0B1D_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DF2C68E956958BC96AC3069A16AD0B1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DF2C68E956958BC96AC3069A16AD0B1D_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DF2C68E956958BC96AC3069A16AD0B1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DF2C68E956958BC96AC3069A16AD0B1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DF2C68E956958BC96AC3069A16AD0B1D" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_DF2C68E956958BC96AC3069A16AD0B1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_8566C7B4D6C37AD04674069A16ADD0C3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_8566C7B4D6C37AD04674069A16ADD0C3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8566C7B4D6C37AD04674069A16ADD0C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_8566C7B4D6C37AD04674069A16ADD0C3" xlink:to="lab_us-gaap_StockholdersEquity_8566C7B4D6C37AD04674069A16ADD0C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_751B69C8592B682C67E3069A16ADB0EC_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_751B69C8592B682C67E3069A16ADB0EC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_751B69C8592B682C67E3069A16ADB0EC_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_751B69C8592B682C67E3069A16ADB0EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_751B69C8592B682C67E3069A16ADB0EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_751B69C8592B682C67E3069A16ADB0EC" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_751B69C8592B682C67E3069A16ADB0EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66812A255541C57D75F8063C4618B4A1_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66812A255541C57D75F8063C4618B4A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66812A255541C57D75F8063C4618B4A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66812A255541C57D75F8063C4618B4A1" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66812A255541C57D75F8063C4618B4A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:to="lab_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5_label_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:to="lab_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3_label_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="lab_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:type="arc" />
    <link:label id="lab_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80_terseLabel_en-US" xlink:label="lab_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNMC</link:label>
    <link:label id="lab_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80_label_en-US" xlink:label="lab_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNMC [Member]</link:label>
    <link:label id="lab_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80_documentation_en-US" xlink:label="lab_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UNMC [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UNMCMember" xlink:label="loc_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:to="lab_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:type="arc" />
    <link:label id="lab_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5_terseLabel_en-US" xlink:label="lab_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fox Chase</link:label>
    <link:label id="lab_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5_label_en-US" xlink:label="lab_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fox Chase [Member]</link:label>
    <link:label id="lab_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5_documentation_en-US" xlink:label="lab_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fox Chase [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_FoxChaseMember" xlink:label="loc_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:to="lab_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:type="arc" />
    <link:label id="lab_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A_terseLabel_en-US" xlink:label="lab_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IDT</link:label>
    <link:label id="lab_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A_label_en-US" xlink:label="lab_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IDT [Member]</link:label>
    <link:label id="lab_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A_documentation_en-US" xlink:label="lab_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IDT [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_IDTMember" xlink:label="loc_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:to="lab_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:type="arc" />
    <link:label id="lab_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818_terseLabel_en-US" xlink:label="lab_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mount Sinai</link:label>
    <link:label id="lab_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818_label_en-US" xlink:label="lab_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mount Sinai [Member]</link:label>
    <link:label id="lab_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818_documentation_en-US" xlink:label="lab_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mount Sinai [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_MountSinaiMember" xlink:label="loc_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:to="lab_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:type="arc" />
    <link:label id="lab_prpo_SmithMember_45F5C70D228486C531AF063C4619E660_terseLabel_en-US" xlink:label="lab_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Smith</link:label>
    <link:label id="lab_prpo_SmithMember_45F5C70D228486C531AF063C4619E660_label_en-US" xlink:label="lab_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Smith [Member]</link:label>
    <link:label id="lab_prpo_SmithMember_45F5C70D228486C531AF063C4619E660_documentation_en-US" xlink:label="lab_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Smith [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SmithMember" xlink:label="loc_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:to="lab_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:type="arc" />
    <link:label id="lab_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881_terseLabel_en-US" xlink:label="lab_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">XIFIN, Inc.</link:label>
    <link:label id="lab_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881_label_en-US" xlink:label="lab_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">XIFIN, Inc. [Member]</link:label>
    <link:label id="lab_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881_documentation_en-US" xlink:label="lab_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">XIFIN, Inc. [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_XIFINInc.Member" xlink:label="loc_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:to="lab_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:type="arc" />
    <link:label id="lab_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907_terseLabel_en-US" xlink:label="lab_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPDC</link:label>
    <link:label id="lab_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907_label_en-US" xlink:label="lab_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Science Park Development Corporation [Member]</link:label>
    <link:label id="lab_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907_documentation_en-US" xlink:label="lab_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Science Park Development Corporation [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ScienceParkDevelopmentCorporationMember" xlink:label="loc_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:to="lab_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:type="arc" />
    <link:label id="lab_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1_terseLabel_en-US" xlink:label="lab_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CPA Global</link:label>
    <link:label id="lab_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1_label_en-US" xlink:label="lab_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CPA Global [Member]</link:label>
    <link:label id="lab_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1_documentation_en-US" xlink:label="lab_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CPA Global [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_CPAGlobalMember" xlink:label="loc_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:to="lab_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:type="arc" />
    <link:label id="lab_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973_terseLabel_en-US" xlink:label="lab_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Edge Bio</link:label>
    <link:label id="lab_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973_label_en-US" xlink:label="lab_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Edge BioSystems, Inc. [Member]</link:label>
    <link:label id="lab_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973_documentation_en-US" xlink:label="lab_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Edge BioSystems, Inc. [Member]</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_EdgeBioSystemsInc.Member" xlink:label="loc_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:to="lab_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="lab_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, amount</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB" xlink:to="lab_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A" xlink:type="arc" />
    <link:label id="lab_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5_terseLabel_en-US" xlink:label="lab_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, installment period</link:label>
    <link:label id="lab_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5_label_en-US" xlink:label="lab_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Payments</link:label>
    <link:label id="lab_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5_documentation_en-US" xlink:label="lab_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Payments</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_LitigationSettlementPayments" xlink:label="loc_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:to="lab_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:type="arc" />
    <link:label id="lab_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF_terseLabel_en-US" xlink:label="lab_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement, installment payment amount</link:label>
    <link:label id="lab_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF_label_en-US" xlink:label="lab_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Installment Payment Amount</link:label>
    <link:label id="lab_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF_documentation_en-US" xlink:label="lab_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Installment Payment Amount</link:label>
    <link:loc xlink:href="prpo-20170630.xsd#prpo_LitigationSettlementInstallmentPaymentAmount" xlink:label="loc_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:to="lab_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_704B7A149C3D5A6AB3F6E46AA9337E1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_56D4BD3AB392CF77AD28FDB27F22D93A_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_704B7A149C3D5A6AB3F6E46AA9337E1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_704B7A149C3D5A6AB3F6E46AA9337E1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_704B7A149C3D5A6AB3F6E46AA9337E1D" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_704B7A149C3D5A6AB3F6E46AA9337E1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_57B81A48280740010921FF7C6E306ED2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_57B81A48280740010921FF7C6E306ED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_57B81A48280740010921FF7C6E306ED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_57B81A48280740010921FF7C6E306ED2" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_57B81A48280740010921FF7C6E306ED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_B8EC1FB220FEB16362EF94CAF206E187_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_045C315782BC5E02B2C081771B477395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_B8EC1FB220FEB16362EF94CAF206E187_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_045C315782BC5E02B2C081771B477395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_045C315782BC5E02B2C081771B477395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_045C315782BC5E02B2C081771B477395" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_045C315782BC5E02B2C081771B477395" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0E4BE3A5E22A533B84C946E2F2EF2ABC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_116DB9A01C41AF73684EFDF1A0186076_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0E4BE3A5E22A533B84C946E2F2EF2ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0E4BE3A5E22A533B84C946E2F2EF2ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0E4BE3A5E22A533B84C946E2F2EF2ABC" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0E4BE3A5E22A533B84C946E2F2EF2ABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_98C2D206C097D6F2509EF57E27074086_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_98C2D206C097D6F2509EF57E27074086" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVERSE MERGER</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_98C2D206C097D6F2509EF57E27074086_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_98C2D206C097D6F2509EF57E27074086" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_98C2D206C097D6F2509EF57E27074086" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_98C2D206C097D6F2509EF57E27074086" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_98C2D206C097D6F2509EF57E27074086" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>prpo-20170630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.precipiodx.com/role/AccruedExpenses" xlink:href="prpo-20170630.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/AccruedExpensesDetails" xlink:href="prpo-20170630.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/AccruedExpensesTables" xlink:href="prpo-20170630.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/BusinessDescription" xlink:href="prpo-20170630.xsd#BusinessDescription" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/BusinessDescriptionDetails" xlink:href="prpo-20170630.xsd#BusinessDescriptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheets" xlink:href="prpo-20170630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:href="prpo-20170630.xsd#CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/Contingencies" xlink:href="prpo-20170630.xsd#Contingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ContingenciesDetails" xlink:href="prpo-20170630.xsd#ContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIDetails" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoan2017NewBridgeNotesIDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ConvertibleBridgeLoanConvertibleBridgeNotesDetails" xlink:href="prpo-20170630.xsd#ConvertibleBridgeLoanConvertibleBridgeNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/Debt" xlink:href="prpo-20170630.xsd#Debt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtConnecticutInnovationsIncorporatedDetails" xlink:href="prpo-20170630.xsd#DebtConnecticutInnovationsIncorporatedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtConvertiblePromissoryNotesDetails" xlink:href="prpo-20170630.xsd#DebtConvertiblePromissoryNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:href="prpo-20170630.xsd#DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtScheduleOfDebtDetails" xlink:href="prpo-20170630.xsd#DebtScheduleOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtSeniorAndJuniorNotesDetails" xlink:href="prpo-20170630.xsd#DebtSeniorAndJuniorNotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtTables" xlink:href="prpo-20170630.xsd#DebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DebtWebsterBankDetails" xlink:href="prpo-20170630.xsd#DebtWebsterBankDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DocumentAndEntityInformation" xlink:href="prpo-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValue" xlink:href="prpo-20170630.xsd#FairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValueDetails" xlink:href="prpo-20170630.xsd#FairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValueNarrativesDetails" xlink:href="prpo-20170630.xsd#FairValueNarrativesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/FairValueTables" xlink:href="prpo-20170630.xsd#FairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/IncomeTaxes" xlink:href="prpo-20170630.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/IncomeTaxesDetails" xlink:href="prpo-20170630.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMerger" xlink:href="prpo-20170630.xsd#ReverseMerger" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerConsiderationDetails" xlink:href="prpo-20170630.xsd#ReverseMergerConsiderationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerIntangibleAssetsAcquiredDetails" xlink:href="prpo-20170630.xsd#ReverseMergerIntangibleAssetsAcquiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerNarrativesDetails" xlink:href="prpo-20170630.xsd#ReverseMergerNarrativesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerNetAssetsAcquiredDetails" xlink:href="prpo-20170630.xsd#ReverseMergerNetAssetsAcquiredDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerProFormaDisclosuresDetails" xlink:href="prpo-20170630.xsd#ReverseMergerProFormaDisclosuresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/ReverseMergerTables" xlink:href="prpo-20170630.xsd#ReverseMergerTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptions" xlink:href="prpo-20170630.xsd#StockOptions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptionsStockAppreciationRightsDetails" xlink:href="prpo-20170630.xsd#StockOptionsStockAppreciationRightsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptionsStockOptionsDetails" xlink:href="prpo-20170630.xsd#StockOptionsStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockOptionsTables" xlink:href="prpo-20170630.xsd#StockOptionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficit" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitCommonStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockWarrantsDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitCommonStockWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitPreferredStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitSideWarrantsDetails" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitSideWarrantsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StockholdersEquityDeficitTables" xlink:href="prpo-20170630.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SubsequentEvents" xlink:href="prpo-20170630.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesLossPerShareDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:href="prpo-20170630.xsd#SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:href="prpo-20170630.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:href="prpo-20170630.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:href="prpo-20170630.xsd#UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5DE37938492ABCE0D620E7372C80023A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_810D38D3395BE18496B2E7373F2B9830" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5DE37938492ABCE0D620E7372C80023A" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_810D38D3395BE18496B2E7373F2B9830" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8930D8662BD872CF2429F59920672FE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7ABE076676F3B4C43630F5AFB44AA565" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8930D8662BD872CF2429F59920672FE8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7ABE076676F3B4C43630F5AFB44AA565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_162FBCA0EEF8FE910323F5B291F7F49D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8930D8662BD872CF2429F59920672FE8" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_162FBCA0EEF8FE910323F5B291F7F49D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_6316ACEDD1C802DE2A03F5992067E1A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8930D8662BD872CF2429F59920672FE8" xlink:to="loc_us-gaap_InterestPayableCurrent_6316ACEDD1C802DE2A03F5992067E1A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_A3D0DCF44B14A394E616F5992068B3F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8930D8662BD872CF2429F59920672FE8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_A3D0DCF44B14A394E616F5992068B3F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_DB264E11571A34AB979DE7372C86C0D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4FABB41DFCC27048CA25E73AC4D62960" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_DB264E11571A34AB979DE7372C86C0D3" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4FABB41DFCC27048CA25E73AC4D62960" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/BusinessDescription" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89D99D9E919E5662A29A4B722105C0C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_FA25116630AF559DBCED6C6F0EFD1147" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89D99D9E919E5662A29A4B722105C0C5" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_FA25116630AF559DBCED6C6F0EFD1147" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/BusinessDescriptionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A04C229E97307F90E2F104805C33455F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A04C229E97307F90E2F104805C33455F" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E65508C4E45E96C6140604805C36FD5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:to="loc_us-gaap_RangeAxis_E65508C4E45E96C6140604805C36FD5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_E65508C4E45E96C6140604805C36FD5C" xlink:to="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_33E1D5E0D54DF54CC5F004805C360D5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC" xlink:to="loc_us-gaap_MaximumMember_33E1D5E0D54DF54CC5F004805C360D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7689E005B0F5EC1EEA9C04805C36AACC" xlink:to="loc_us-gaap_MinimumMember_9CD4BBFD5704BEB442C804805C3761F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A91CD0779EB2C4F8414E04805C3734F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A91CD0779EB2C4F8414E04805C3734F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_73DACA12CFB77D314F0904805C37F11D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A91CD0779EB2C4F8414E04805C3734F8" xlink:to="loc_us-gaap_ClassOfStockDomain_73DACA12CFB77D314F0904805C37F11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A36A3EC6D96638181C4604805C37AF90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_73DACA12CFB77D314F0904805C37F11D" xlink:to="loc_us-gaap_CommonStockMember_A36A3EC6D96638181C4604805C37AF90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_069E5CAE4C144E3CC11004805C353530" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_642A6662749D16E97CEF048071354777" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_642A6662749D16E97CEF048071354777" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WorkingCapitalDeficiency" xlink:label="loc_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:to="loc_prpo_WorkingCapitalDeficiency_67E0DD77DE193E050E5004805C38520F" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_StockholdersEquityNoteReverseStockSplitConversionRatio" xlink:label="loc_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0F110C34D433C7EDF35904805C37F8B1" xlink:to="loc_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio_B02BF101C006E382EBA904805C38D527" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CC634D5E5E9DAE51B9E9069A16AB15B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CC634D5E5E9DAE51B9E9069A16AB15B4" xlink:to="loc_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:to="loc_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9543BE17502BAAFFBE0F069A16AB4341" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9543BE17502BAAFFBE0F069A16AB4341" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6418D7F71AEBF3E0538A069A16AB177D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6418D7F71AEBF3E0538A069A16AB177D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4038CF243F3A0B834135069A16AB9A68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:to="loc_us-gaap_InventoryNet_4038CF243F3A0B834135069A16AB9A68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_018F6E3A66F9C5EABCD3069A16AB5F3A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:to="loc_us-gaap_OtherAssetsCurrent_018F6E3A66F9C5EABCD3069A16AB5F3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5266332FA7DC88401B8A069A16AB273F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_696361D509DB889AC24C069A16ABE617" xlink:to="loc_us-gaap_AssetsCurrent_5266332FA7DC88401B8A069A16AB273F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4D6B2F56E0AD54CA0D75069A16AB51CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4D6B2F56E0AD54CA0D75069A16AB51CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_7AC713FE02BBAC2A2250069A16AB0A5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:to="loc_us-gaap_Goodwill_7AC713FE02BBAC2A2250069A16AB0A5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_67DE6FF6CA66FF0BB453069A16AC752E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_67DE6FF6CA66FF0BB453069A16AC752E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_BFC118C1A2D9CED07044069A16AC9212" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_456E7D33A3DCC50EB81C069A16AB77F2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_BFC118C1A2D9CED07044069A16AC9212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8471DC0F26577D84CA0D069A16ACEFF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3008BD1D8B86FD7AF7DC069A16AB0F39" xlink:to="loc_us-gaap_Assets_8471DC0F26577D84CA0D069A16ACEFF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CC634D5E5E9DAE51B9E9069A16AB15B4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_E636B88AEB29584072BE069A16AC1C1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:to="loc_us-gaap_LongTermDebtCurrent_E636B88AEB29584072BE069A16AC1C1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_335D0DC10ECE5B44879E069A16AC6C3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_335D0DC10ECE5B44879E069A16AC6C3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2B03DE7D7ACB2FE2CFEB069A16ACB419" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:to="loc_us-gaap_AccountsPayableCurrent_2B03DE7D7ACB2FE2CFEB069A16ACB419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_0EA4ED99E394F00FA8C1069A16ACF1D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_0EA4ED99E394F00FA8C1069A16ACF1D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_B23297D99247BD3B66F4069A16AC7BAD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_B23297D99247BD3B66F4069A16AC7BAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_EB1A54307718C0D1AFEB069A16ACB5C6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:to="loc_us-gaap_DeferredRevenueCurrent_EB1A54307718C0D1AFEB069A16ACB5C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_B94FC9CD7ADD3AA5AA1F069A16AC78DE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_B94FC9CD7ADD3AA5AA1F069A16AC78DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_07508BBD3EAE42283E92069A16ACA843" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_E0803DA84C640EF6415D069A16ACD82D" xlink:to="loc_us-gaap_LiabilitiesCurrent_07508BBD3EAE42283E92069A16ACA843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_DD447F6A6F4DBBA361B1069A16ACC83D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_DD447F6A6F4DBBA361B1069A16ACC83D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_E2A3610A64A818D43BAC069A16AC3576" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:to="loc_us-gaap_DerivativeLiabilities_E2A3610A64A818D43BAC069A16AC3576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsNoncurrent_607AFE10F82DDE5EA1D6069A16ADEE84" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:to="loc_us-gaap_CapitalLeaseObligationsNoncurrent_607AFE10F82DDE5EA1D6069A16ADEE84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_69C42E01CB0939456C65069A16ADDA33" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_557D0DD3EA54012E18D6069A16AC69AA" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_69C42E01CB0939456C65069A16ADDA33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E79E8787807595E20D05069A16AD6585" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:to="loc_us-gaap_Liabilities_E79E8787807595E20D05069A16AD6585" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:to="loc_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_031A210B39EED14596D1069A16AD067C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:to="loc_us-gaap_PreferredStockValue_031A210B39EED14596D1069A16AD067C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_BBCC2B24C159E55B4730069A16ADBA0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:to="loc_us-gaap_CommonStockValue_BBCC2B24C159E55B4730069A16ADBA0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_25954DF1703DE8EF63DC069A16ADA105" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:to="loc_us-gaap_AdditionalPaidInCapital_25954DF1703DE8EF63DC069A16ADA105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DF2C68E956958BC96AC3069A16AD0B1D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DF2C68E956958BC96AC3069A16AD0B1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8566C7B4D6C37AD04674069A16ADD0C3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_E7C238FE84AAF62CE418069A16AD7813" xlink:to="loc_us-gaap_StockholdersEquity_8566C7B4D6C37AD04674069A16ADD0C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_751B69C8592B682C67E3069A16ADB0EC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3334FCB28155FA5A3C69069A16ACC86D" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_751B69C8592B682C67E3069A16ADB0EC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3F5228D45FF19C3C5D140264D47ABA21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3F5228D45FF19C3C5D140264D47ABA21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6169FD8FA08D97F8CD890264D47A67BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6169FD8FA08D97F8CD890264D47A67BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3DEEB6675AA42D7ED7C40264D47A45B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3DEEB6675AA42D7ED7C40264D47A45B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_873217D481CEB06A211B0264D47A47A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_873217D481CEB06A211B0264D47A47A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_3F8ED586EB6F9284865B0264D47A1BFF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_3F8ED586EB6F9284865B0264D47A1BFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B07125D6F26E2DEFCF930264D47A30CE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_B07125D6F26E2DEFCF930264D47A30CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_FB324CC0497D55710DE60264D47A96C2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:to="loc_us-gaap_CommonStockSharesIssued_FB324CC0497D55710DE60264D47A96C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7F8DE9A64589D0580DDF0264D47A9A5C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C5B5541C5498460610930264D479903F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7F8DE9A64589D0580DDF0264D47A9A5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E91992C70145A019B7D8D8FA9359650" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_704B7A149C3D5A6AB3F6E46AA9337E1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E91992C70145A019B7D8D8FA9359650" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_704B7A149C3D5A6AB3F6E46AA9337E1D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66812A255541C57D75F8063C4618B4A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66812A255541C57D75F8063C4618B4A1" xlink:to="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_571ECD3909D6C7410FC5063C461915A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:to="loc_dei_LegalEntityAxis_571ECD3909D6C7410FC5063C461915A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3276B64F62504A35A58A063C46199B9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_571ECD3909D6C7410FC5063C461915A9" xlink:to="loc_dei_EntityDomain_3276B64F62504A35A58A063C46199B9F" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_7739098496F4369AF43B063C46194AB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3276B64F62504A35A58A063C46199B9F" xlink:to="loc_prpo_TransgenomicsMember_7739098496F4369AF43B063C46194AB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:to="loc_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_39931F101D1B74677694063C461903D5" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UNMCMember" xlink:label="loc_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_UNMCMember_3E39605A0D052B007D5D063C4619BE80" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_FoxChaseMember" xlink:label="loc_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_FoxChaseMember_5110897B175D805FD845063C4619D1D5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_IDTMember" xlink:label="loc_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_IDTMember_67A5A3856346F1B5388B063C46193F4A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_MountSinaiMember" xlink:label="loc_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_MountSinaiMember_B34F49DACE8C7275DB8A063C4619E818" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SmithMember" xlink:label="loc_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_SmithMember_45F5C70D228486C531AF063C4619E660" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_XIFINInc.Member" xlink:label="loc_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_XIFINInc.Member_3DE25653F2F934B6961A063C46193881" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ScienceParkDevelopmentCorporationMember" xlink:label="loc_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_ScienceParkDevelopmentCorporationMember_208843160DFED133DBD6063C46198907" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_CPAGlobalMember" xlink:label="loc_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_CPAGlobalMember_474C84BE827D3849BF01063C46197AA1" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_EdgeBioSystemsInc.Member" xlink:label="loc_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_03BC8FA16F2805B1A70F063C461952D3" xlink:to="loc_prpo_EdgeBioSystemsInc.Member_C27E956DE8DA35A70B10063C4619E973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_48C22E65B1C30FD109E2063C461993F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_48C22E65B1C30FD109E2063C461993F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_DCBAAB7FFB9CCD27F100063C46191787" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_48C22E65B1C30FD109E2063C461993F4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_DCBAAB7FFB9CCD27F100063C46191787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_54B764C0A2271C4E431C063C461AC084" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_DCBAAB7FFB9CCD27F100063C46191787" xlink:to="loc_us-gaap_SubsequentEventMember_54B764C0A2271C4E431C063C461AC084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1E52471A8835E5FF5DB1063C46198D97" xlink:to="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_43C93FA8D09CBB729D2F063C461AC380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4B4C38B7AE5A020D9E2A063C461A3003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationSettlementAmount" xlink:label="loc_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_us-gaap_LitigationSettlementAmount_8B6FC72BE6F3A93EDCEB063C461AC1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_9D3EC51A1F227428BDD5063C461A539A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_LitigationSettlementPayments" xlink:label="loc_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_prpo_LitigationSettlementPayments_D161ECAE8653B2C78E7E063C461A9BA5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_LitigationSettlementInstallmentPaymentAmount" xlink:label="loc_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3BBCC950C9D0BAE17878063C461A3247" xlink:to="loc_prpo_LitigationSettlementInstallmentPaymentAmount_29BD33A1FD87EAE9C8AF063C461A8DDF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_71329E231E4A49686386EFA9C8C50B7C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaap_ShortTermDebtTextBlock_0E6DA61C4454718D9968EFA9C8C51678" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_71329E231E4A49686386EFA9C8C50B7C" xlink:to="loc_us-gaap_ShortTermDebtTextBlock_0E6DA61C4454718D9968EFA9C8C51678" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_63E3E0327B30721BD35D04808985E12D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63E3E0327B30721BD35D04808985E12D" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_3CF09EEAFF4B23EC5558048089853189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_3CF09EEAFF4B23EC5558048089853189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_20A23A5079E90EDB079304808985B846" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_3CF09EEAFF4B23EC5558048089853189" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_20A23A5079E90EDB079304808985B846" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AegisWarrantMember" xlink:label="loc_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_20A23A5079E90EDB079304808985B846" xlink:to="loc_prpo_AegisWarrantMember_E450CE3C71EB9DF1D2F704808985A150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_50DC6B5BBB5388D966BF04808985FD26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_StatementClassOfStockAxis_50DC6B5BBB5388D966BF04808985FD26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_EC7C9617186EA3C9B7DF048089857241" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_50DC6B5BBB5388D966BF04808985FD26" xlink:to="loc_us-gaap_ClassOfStockDomain_EC7C9617186EA3C9B7DF048089857241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_8B06DDE305EA2566B410048089855F26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_EC7C9617186EA3C9B7DF048089857241" xlink:to="loc_us-gaap_CommonStockMember_8B06DDE305EA2566B410048089855F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_6E91FF93C2E0B4F5BF8A048089857AEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_dei_LegalEntityAxis_6E91FF93C2E0B4F5BF8A048089857AEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_B7DF555CC23F6355061004808986685F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6E91FF93C2E0B4F5BF8A048089857AEB" xlink:to="loc_dei_EntityDomain_B7DF555CC23F6355061004808986685F" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_B73FE8306D6028B138E3048089868D3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_B7DF555CC23F6355061004808986685F" xlink:to="loc_prpo_TransgenomicsMember_B73FE8306D6028B138E3048089868D3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_C9B437F9621CC8296BE5048089864CA6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_C9B437F9621CC8296BE5048089864CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8D4EE147DB8F5132079F04808986DA32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_C9B437F9621CC8296BE5048089864CA6" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8D4EE147DB8F5132079F04808986DA32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_0492876F711B8C9D84390480898603CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8D4EE147DB8F5132079F04808986DA32" xlink:to="loc_us-gaap_BridgeLoanMember_0492876F711B8C9D84390480898603CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_FB7E07FF366366A2C7CA0480898625B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_DebtInstrumentAxis_FB7E07FF366366A2C7CA0480898625B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_FB7E07FF366366A2C7CA0480898625B1" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017BridgeNotesMember" xlink:label="loc_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9" xlink:to="loc_prpo_A2017BridgeNotesMember_E6339B6643B86E0B5875048089861247" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_NewBridgeNotesIMember" xlink:label="loc_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7B65DC899E4F0D678CAF0480898656A9" xlink:to="loc_prpo_NewBridgeNotesIMember_227C5181C531BEE9ED7F04B75357EC4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6F0A208903B8143A0BFC0480898618C5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_RangeAxis_6F0A208903B8143A0BFC0480898618C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_EF9B658EBB89D02BAE51048089864520" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6F0A208903B8143A0BFC0480898618C5" xlink:to="loc_us-gaap_RangeMember_EF9B658EBB89D02BAE51048089864520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_DB2D22D2091E1B6A635C048089866E8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_EF9B658EBB89D02BAE51048089864520" xlink:to="loc_us-gaap_MinimumMember_DB2D22D2091E1B6A635C048089866E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_C78B0F465B7D052464EC048089853EAF" xlink:to="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_B0F42A440C39063ABF48048089860A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D182107B8D67A97D1B9704808986EBD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D182107B8D67A97D1B9704808986EBD4" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="loc_prpo_ConversionofStockPerShareConversionPrice_93E8A4E076756751A33504BCE04A485A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_ConversionofStockPerShareConversionPrice_93E8A4E076756751A33504BCE04A485A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_193EAB8D243F2CDD34B10480898600E2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_DebtInstrumentTerm_193EAB8D243F2CDD34B10480898600E2" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlement" xlink:label="loc_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_PremiumRateonDebtSettlement_F396BE45B0CBE91EAA180480898734B7" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlementAmount" xlink:label="loc_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_PremiumRateonDebtSettlementAmount_552E0B4C4713514A8574049059155736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_5B9432A8F11492617027049473C293CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2B0622CF511255AADB3004808987A38B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2B0622CF511255AADB3004808987A38B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D437D4FAAF02663699B0048089874373" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D437D4FAAF02663699B0048089874373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1FB0B4BAA73202292ADF049768920148" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1FB0B4BAA73202292ADF049768920148" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PercentageofPerShareOfferingPrice" xlink:label="loc_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_PercentageofPerShareOfferingPrice_ECFEE84F00B61D11EA220480898749F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_122CFA787884E5635D1F04808987C077" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_122CFA787884E5635D1F04808987C077" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AgentFees" xlink:label="loc_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_53E6DA56E2F0528897BF0480898608AE" xlink:to="loc_prpo_AgentFees_2E37946E9050215AD4A704808987FA9D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIiDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D359BEB09737432B93CE069A1522F84A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D359BEB09737432B93CE069A1522F84A" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_68FE91D421DB2C40C744069A1522D805" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_68FE91D421DB2C40C744069A1522D805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_CA277B9DA94B65714542069A1522468E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_68FE91D421DB2C40C744069A1522D805" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_CA277B9DA94B65714542069A1522468E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_519300BB3DFBF780698B069A152267B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_CA277B9DA94B65714542069A1522468E" xlink:to="loc_us-gaap_BridgeLoanMember_519300BB3DFBF780698B069A152267B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8BF43F9B683DB30C5843069A1522546A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_DebtInstrumentAxis_8BF43F9B683DB30C5843069A1522546A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8BF43F9B683DB30C5843069A1522546A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017NewBridgeNotesMember" xlink:label="loc_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D" xlink:to="loc_prpo_A2017NewBridgeNotesMember_10B6D26C4C373D9A9C4E069A1523BAC1" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConvertibleBridgeLoanMember" xlink:label="loc_prpo_ConvertibleBridgeLoanMember_484F48E8F081153B8600069A1523A657" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_053A8FB158474490D004069A1523F58D" xlink:to="loc_prpo_ConvertibleBridgeLoanMember_484F48E8F081153B8600069A1523A657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_540219E2B87F51B19CE4069A15236318" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_540219E2B87F51B19CE4069A15236318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_7890896F0C62B029B200069A1523FC25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_540219E2B87F51B19CE4069A15236318" xlink:to="loc_us-gaap_ClassOfStockDomain_7890896F0C62B029B200069A1523FC25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3D679CB68BEB1A845DA7069A1523F17F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7890896F0C62B029B200069A1523FC25" xlink:to="loc_us-gaap_CommonStockMember_3D679CB68BEB1A845DA7069A1523F17F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_69B4EC098F32AAA4A0DB069A15238657" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_69B4EC098F32AAA4A0DB069A15238657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6827027171DD5B58D728069A1523F3BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_69B4EC098F32AAA4A0DB069A15238657" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6827027171DD5B58D728069A1523F3BF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SideWarrantMember" xlink:label="loc_prpo_SideWarrantMember_4FFCB11DE1E4FAF06963069A152360DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6827027171DD5B58D728069A1523F3BF" xlink:to="loc_prpo_SideWarrantMember_4FFCB11DE1E4FAF06963069A152360DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A6EF7003E0509DFB9B9A069A1523E7E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_AwardTypeAxis_A6EF7003E0509DFB9B9A069A1523E7E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A6EF7003E0509DFB9B9A069A1523E7E8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UponExecutionMember" xlink:label="loc_prpo_UponExecutionMember_B2F83C544D5753DF27FA069A15238673" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68" xlink:to="loc_prpo_UponExecutionMember_B2F83C544D5753DF27FA069A15238673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BCD1D252351D8665212E069A1523E33B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AFF651898F4D7F022DE8069A15232D68" xlink:to="loc_us-gaap_PerformanceSharesMember_BCD1D252351D8665212E069A1523E33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_F487DBF6CA9D4AE85424069A1523B47B" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_86FB1169D039A24A18A5069A1524A417" xlink:to="loc_us-gaap_SubsequentEventMember_09A29395DC4B22F88CAC069A15243969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_6EDF5685E08EC61666D5069A1522656A" xlink:to="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_58D110A1A11B8E095863069A1524A3AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_58D110A1A11B8E095863069A1524A3AB" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ProceedsFromtheSalesofDebtInstrument" xlink:label="loc_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_ProceedsFromtheSalesofDebtInstrument_251CFB696B1C41509FE9069A1529A918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_56518594C7D304367B58069A1529BCDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_56518594C7D304367B58069A1529BCDA" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="loc_prpo_ConversionofStockPerShareConversionPrice_65D9C62F5262C4BA875E069A15299C24" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_ConversionofStockPerShareConversionPrice_65D9C62F5262C4BA875E069A15299C24" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlement" xlink:label="loc_prpo_PremiumRateonDebtSettlement_F7A4E8968518221A9567069A1529DEEA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_PremiumRateonDebtSettlement_F7A4E8968518221A9567069A1529DEEA" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PremiumRateonDebtSettlementAmount" xlink:label="loc_prpo_PremiumRateonDebtSettlementAmount_D1B16C1CADC35261F372069A152AFBF1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_PremiumRateonDebtSettlementAmount_D1B16C1CADC35261F372069A152AFBF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_ED15132D161F84AB9DCE069A152AA92C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_ED15132D161F84AB9DCE069A152AA92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3BC232CDB268AD3BBDD8069A152A983D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3BC232CDB268AD3BBDD8069A152A983D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_44BAE5BA0823A33DE1D3069A152A96B6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_44BAE5BA0823A33DE1D3069A152A96B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_FBCA14B216189F92E9B9069A152A0C80" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_FBCA14B216189F92E9B9069A152A0C80" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassofWarrantorRightTerm" xlink:label="loc_prpo_ClassofWarrantorRightTerm_4B62A759990396FEC778069A152A055C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_prpo_ClassofWarrantorRightTerm_4B62A759990396FEC778069A152A055C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_633DC465337BE2B0865A069A152AFA90" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_633DC465337BE2B0865A069A152AFA90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B8AF2CC4DCB1B2988E9C069A152A3C77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_679C9AEEA5B4BEDDFFD8069A152AAF10" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_679C9AEEA5B4BEDDFFD8069A152AAF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_A4DDCD58CDA7EEAA0943069A152ACCFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_963366FF2953728B6239069A152A3C91" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A51F4D726F0215583220069A15247EAD" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_963366FF2953728B6239069A152A3C91" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ConvertibleBridgeLoanConvertibleBridgeNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9DB6A20D03EFA885EBFFF5BF01622821" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9DB6A20D03EFA885EBFFF5BF01622821" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_8D00CEA3784FED94BB08F5BF0162736C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_8D00CEA3784FED94BB08F5BF0162736C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4890D087732E43F5E5D0F5BF01625E9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8D00CEA3784FED94BB08F5BF0162736C" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4890D087732E43F5E5D0F5BF01625E9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_140A7CAFF607A2890EC5F5BF0163E77F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4890D087732E43F5E5D0F5BF01625E9C" xlink:to="loc_us-gaap_BridgeLoanMember_140A7CAFF607A2890EC5F5BF0163E77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_29003CA271993C509FF5F5BF0163FA62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:to="loc_us-gaap_DebtInstrumentAxis_29003CA271993C509FF5F5BF0163FA62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_29003CA271993C509FF5F5BF0163FA62" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConvertibleBridgeLoanMember" xlink:label="loc_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B" xlink:to="loc_prpo_ConvertibleBridgeLoanMember_4A1D6A405F1586AD3705F5BF016359F3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UnsecuredConvertibleBridgeLoanMember" xlink:label="loc_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_690D9B944520DD87E8FAF5BF0163188B" xlink:to="loc_prpo_UnsecuredConvertibleBridgeLoanMember_10D98428FD703D7022BCF5BF016323D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EFF95FF84E0B6BCCFB85F5BF01635673" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:to="loc_us-gaap_StatementClassOfStockAxis_EFF95FF84E0B6BCCFB85F5BF01635673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EFF95FF84E0B6BCCFB85F5BF01635673" xlink:to="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_694763C9AD362D27B648F5BF016399E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_D367BB04A98BBF6B31DDF5BF01641F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_918D4222D55F7903B18AF5BF01642BDD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_CBFB8C737ABBC721AD14F5BF0163ACAF" xlink:to="loc_us-gaap_CommonStockMember_918D4222D55F7903B18AF5BF01642BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_7F966F7A25C03F943A2FF5BF01621F10" xlink:to="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_95AAA294C8B7D41EAD38F601A4149B31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_95AAA294C8B7D41EAD38F601A4149B31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52FB3CE3D28749CE6D14F5BF01649837" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52FB3CE3D28749CE6D14F5BF01649837" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockDiscountRate" xlink:label="loc_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_prpo_ConversionofStockDiscountRate_2D1330E88EB5A3005DAEF5BF0164040E" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DebtInstrumentDebtConvertedRate" xlink:label="loc_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_prpo_DebtInstrumentDebtConvertedRate_C531585BBBDC19B339EFF5BF01649919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7F350E0467C8717FEAC9F5BF0165FDE1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_7F350E0467C8717FEAC9F5BF0165FDE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_528CD03A69DC1CB41BCFF5BF016446C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4E0AA7E3B814709F25DAF60C2FD0890F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_A931EEF7A17E2DD37E63F5BF01642D4B" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_4E0AA7E3B814709F25DAF60C2FD0890F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/Debt" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E996C1F82E5B52CBAB0A9A468E7AA037" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4CB5366EA2225EF3A6E2BCD58DC13F57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E996C1F82E5B52CBAB0A9A468E7AA037" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4CB5366EA2225EF3A6E2BCD58DC13F57" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/DebtConnecticutInnovationsIncorporatedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_21A9DC50CA84D56D1879F5BF01876138" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_EE83D97E3C7ADB87F45BF5BF0187AC72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_21A9DC50CA84D56D1879F5BF01876138" xlink:to="loc_us-gaap_DebtInstrumentTable_EE83D97E3C7ADB87F45BF5BF0187AC72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_765BF370137350922BCCF5BF0187B5D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EE83D97E3C7ADB87F45BF5BF0187AC72" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_765BF370137350922BCCF5BF0187B5D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_0B72EC3C240A4012F432F5BF01874BFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_765BF370137350922BCCF5BF0187B5D1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_0B72EC3C240A4012F432F5BF01874BFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_7B7F2061EA6F866038F6F5BF0187F361" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_0B72EC3C240A4012F432F5BF01874BFD" xlink:to="loc_us-gaap_LineOfCreditMember_7B7F2061EA6F866038F6F5BF0187F361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B6E72B73F5F47D318665F5BF018743B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EE83D97E3C7ADB87F45BF5BF0187AC72" xlink:to="loc_us-gaap_RangeAxis_B6E72B73F5F47D318665F5BF018743B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_B6E72B73F5F47D318665F5BF018743B6" xlink:to="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_047DE1F2593F10E0BD4CF5BF0187D336" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E" xlink:to="loc_us-gaap_MinimumMember_047DE1F2593F10E0BD4CF5BF0187D336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_D9BA7B80C9BCE5AE4DCBF5BF01878164" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_534AB34C81391F79F67CF5BF0187D38E" xlink:to="loc_us-gaap_MaximumMember_D9BA7B80C9BCE5AE4DCBF5BF01878164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_EE83D97E3C7ADB87F45BF5BF0187AC72" xlink:to="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_280FD6DD648B710E778DF5BF01882E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD019C65BC8EC468E7D0F5BF01888A7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_BD019C65BC8EC468E7D0F5BF01888A7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_F5C5D6743CD8A4E7F171F5BF01883FB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_F5C5D6743CD8A4E7F171F5BF01883FB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_239F6305BFE82F725457F5BF018872FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentInterest_1D03CA598CF3370C3A5DF5BF0188B4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_94FBD998D22D97AFF6E9F5BF0188FA74" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_95288FF3A7ECE5B97135F5BF018889B4" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_94FBD998D22D97AFF6E9F5BF0188FA74" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/DebtConvertiblePromissoryNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7FBADD4C9095EE0180E4EC9413B1A793" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7FBADD4C9095EE0180E4EC9413B1A793" xlink:to="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_07CE7C8C230E2BC3B357EC9413B1BE80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_07CE7C8C230E2BC3B357EC9413B1BE80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_ABD534F4A8683D41023FEC9413B191A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_07CE7C8C230E2BC3B357EC9413B1BE80" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_ABD534F4A8683D41023FEC9413B191A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_CEF8C9D6A9A6F543161BEC9413B13567" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_ABD534F4A8683D41023FEC9413B191A5" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_CEF8C9D6A9A6F543161BEC9413B13567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_ADB47F666D7DF7FC58FAEC9413B15DEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:to="loc_us-gaap_DebtInstrumentAxis_ADB47F666D7DF7FC58FAEC9413B15DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_60575600E99D1185877DEC9413B157BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ADB47F666D7DF7FC58FAEC9413B15DEA" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_60575600E99D1185877DEC9413B157BF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AdditionalNotesMember" xlink:label="loc_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_60575600E99D1185877DEC9413B157BF" xlink:to="loc_prpo_AdditionalNotesMember_2E797336A64A18099D52EC9413B17CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_B4D2F099C916445273D5EC9413B1AC67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_B4D2F099C916445273D5EC9413B1AC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_880E227DC8B5FB679346EC9413B21F68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_B4D2F099C916445273D5EC9413B1AC67" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_880E227DC8B5FB679346EC9413B21F68" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_880E227DC8B5FB679346EC9413B21F68" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_CEF8C9D6A9A6F543161BEC9413B13567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B557553DB5747337386DEC9413B1D2BD" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent" xlink:label="loc_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent_EF49C2566188CBEC6F7DEC9413B27ECF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent" xlink:label="loc_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent_129845EBC8EC98FCEEA8EC9413B28DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_48401F79AB01FC12145EEC9413B26123" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_48401F79AB01FC12145EEC9413B26123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9EB557F00D03221833BAEC9413B26D47" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9EB557F00D03221833BAEC9413B26D47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_613AD1002A2B06FADC54EC9413B226AD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_613AD1002A2B06FADC54EC9413B226AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_EB918F2379674DE49DEBEC9413B21593" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_EB918F2379674DE49DEBEC9413B21593" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_D723FBAB806FB5801941EC9413B27D15" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_D723FBAB806FB5801941EC9413B27D15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E151005CB31DDD4C987BEC9413B27377" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6810BBCAD72145B3A27EEC9413B264FA" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E151005CB31DDD4C987BEC9413B27377" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/DebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6E928B9520FF9D0A2952E6F69494A8B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1F1002DC1175BE439E3FE6F697DA919C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6E928B9520FF9D0A2952E6F69494A8B8" xlink:to="loc_us-gaap_DebtInstrumentTable_1F1002DC1175BE439E3FE6F697DA919C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_F874295D93BCD9957A42E6F697DA2319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1F1002DC1175BE439E3FE6F697DA919C" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_F874295D93BCD9957A42E6F697DA2319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0E0EC0B7250618F21E06E6F697DA988A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_F874295D93BCD9957A42E6F697DA2319" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0E0EC0B7250618F21E06E6F697DA988A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TermLoanMember" xlink:label="loc_prpo_TermLoanMember_D8960907B2C5934726EEE6F7294AA871" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0E0EC0B7250618F21E06E6F697DA988A" xlink:to="loc_prpo_TermLoanMember_D8960907B2C5934726EEE6F7294AA871" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_36585DDDDE22C1DF2305E6F697DA9C33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1F1002DC1175BE439E3FE6F697DA919C" xlink:to="loc_us-gaap_DebtInstrumentAxis_36585DDDDE22C1DF2305E6F697DA9C33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4D20F68EC2EBA27DC237E6F697DA2657" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_36585DDDDE22C1DF2305E6F697DA9C33" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4D20F68EC2EBA27DC237E6F697DA2657" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_45274D27B202FE3F1CA3E6F727F6F395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4D20F68EC2EBA27DC237E6F697DA2657" xlink:to="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_45274D27B202FE3F1CA3E6F727F6F395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1F1002DC1175BE439E3FE6F697DA919C" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_5BB3A5229C8977A3CF46E6F6DA50EC1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtInstrumentTerm_5BB3A5229C8977A3CF46E6F6DA50EC1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9C5DCB5800D43D310420E6FCA13DB6E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9C5DCB5800D43D310420E6FCA13DB6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16C5C890DEB6CF2D99C2E6FCA14BA078" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16C5C890DEB6CF2D99C2E6FCA14BA078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_F0CE403E58AE548D5A9AE6FCA157BB9F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_F0CE403E58AE548D5A9AE6FCA157BB9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_1EF258E7F1502E1AFDF5E6FCA1649A90" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6F1E47F349049E91DAF9E6F697DA0830" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_1EF258E7F1502E1AFDF5E6FCA1649A90" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_66F1D71B06AE746B7E2FF5BF0197DC54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_66F1D71B06AE746B7E2FF5BF0197DC54" xlink:to="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ED017C37A7C7A566A918F5BF0197A510" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:to="loc_us-gaap_SeniorNotesMember_F73056180DEAA8CA2AD4F5BF0198C362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_JuniorNotesMember" xlink:label="loc_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:to="loc_us-gaap_JuniorNotesMember_91E5AD60E2ABD090BC93F5BF0198F0B2" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TermLoanMember" xlink:label="loc_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:to="loc_prpo_TermLoanMember_4C6350EE45BB6876ACC4F5BF019895E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D6B336D23DC8DCC2FB38F5BF019810ED" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_BAD920F9EDF7C93A0BD3F5BF01986734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_BD779D3D58BB17796CBCF5BF0198C9D4" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:to="loc_us-gaap_LineOfCreditMember_F4AF65ECDD60C4794BE6F5BF01989A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1B1E5B88069FF98F1158F5BF019816B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_329FB3BED7F0375BA41EF5BF01982C71" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1B1E5B88069FF98F1158F5BF019816B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:to="loc_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_57BB41A7C978B38DB1A6F5BF019843CF" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:to="loc_prpo_DepartmentofEconomicandCommunityDevelopmentMember_4FEE51B270CC82185261F5BF0199F4E3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WebsterBankMember" xlink:label="loc_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A37631F2A9691C471EB3F5BF019956A6" xlink:to="loc_prpo_WebsterBankMember_2621249BFA40A49D0D27F5BF01994796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_768C4083EC425D52E32CF5BF01970067" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_ACDE5B4582152E9F601BF5BF019990BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_ABD713B27A4C4533B009F5BF0199B6F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="loc_us-gaap_LongTermDebtCurrent_0CAF97D9713E559CAE1AF5BF01999498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1C824DDA1E61899E2F4BF5BF0199FE08" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_B66C79BB7643CB20D2C7F5BF019973CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/DebtSeniorAndJuniorNotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7E90354718A47777B2E0FF96A93A23B2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7E90354718A47777B2E0FF96A93A23B2" xlink:to="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_15041FF23EDED5462730FF96A93AF199" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_15041FF23EDED5462730FF96A93AF199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_15041FF23EDED5462730FF96A93AF199" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_340B0030271951180D6AFF96A93A5720" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:to="loc_us-gaap_SeniorNotesMember_340B0030271951180D6AFF96A93A5720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_JuniorNotesMember" xlink:label="loc_us-gaap_JuniorNotesMember_970899DE34EDD2C2B4D5FF96A93D8663" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:to="loc_us-gaap_JuniorNotesMember_970899DE34EDD2C2B4D5FF96A93D8663" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SeniorandJuniorNotesMember" xlink:label="loc_prpo_SeniorandJuniorNotesMember_1C925BC4E5F8982E882BFFA10DE4BAB6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_841C2196792BB2EDE6FCFF96A93A2A2D" xlink:to="loc_prpo_SeniorandJuniorNotesMember_1C925BC4E5F8982E882BFFA10DE4BAB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_B3F0C925F2E1CA6C6C4EFF96A93D61CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_B3F0C925F2E1CA6C6C4EFF96A93D61CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_2D5DC3AA79FF9F9FAEFAFF96A93DF99B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_B3F0C925F2E1CA6C6C4EFF96A93D61CA" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_2D5DC3AA79FF9F9FAEFAFF96A93DF99B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_72C6D46BCB5B21731E32FF96A93D223F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_2D5DC3AA79FF9F9FAEFAFF96A93DF99B" xlink:to="loc_us-gaap_BridgeLoanMember_72C6D46BCB5B21731E32FF96A93D223F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8662E8CC15EBFC709E3CFF96A93DFBF8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8662E8CC15EBFC709E3CFF96A93DFBF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8662E8CC15EBFC709E3CFF96A93DFBF8" xlink:to="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_4FACF93829E2C2395E3DFF96A93DBEAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_6393F5BF470B84C4C101FFAA4A7E1AF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:to="loc_us-gaap_PreferredStockMember_6393F5BF470B84C4C101FFAA4A7E1AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A2869161FC7A743C524EFFA9586680B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_CF31A16253EE82143F35FF96A93D5601" xlink:to="loc_us-gaap_CommonStockMember_A2869161FC7A743C524EFFA9586680B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1E57F5262267F07025ECFF96A93A7986" xlink:to="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_412CEEE5CAAE32F9D54DFF96A93D3D52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_412CEEE5CAAE32F9D54DFF96A93D3D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_398D9570CB97CCCCE23BFF96A93D620F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_398D9570CB97CCCCE23BFF96A93D620F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityFairValueDisclosure" xlink:label="loc_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_EquityFairValueDisclosure_07819359268F5F7A951DFF96A93D025A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_606DC94E70D3F4B48A6FFF96A93D8BC7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_PreferredStockValue_606DC94E70D3F4B48A6FFF96A93D8BC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockDividend_CCE33CC68AFC9F5A5494FF96A93D564A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_ConvertibleDebt_E3B22BA1FB07C0CDCAB9FF96A93D367C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_46A30FFB3B9E126EC800FF96A93D566D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_InterestPayableCurrentAndNoncurrent_46A30FFB3B9E126EC800FF96A93D566D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_DC015E4899D6AF54AB0DFF96A93DA0A1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_DC015E4899D6AF54AB0DFF96A93DA0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_266E557633192A6C3D48FF96A93D6415" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_266E557633192A6C3D48FF96A93D6415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_54DFDD167E4EAF18CE24FFA2F02B05A5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_75998EF319A1183DCE1EFF96A93DE01F" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_54DFDD167E4EAF18CE24FFA2F02B05A5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_11BE8F3CA7E5354218C3E5D971D12526" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_5E10168AB7CB2730657AE5D971D10BDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_11BE8F3CA7E5354218C3E5D971D12526" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_5E10168AB7CB2730657AE5D971D10BDC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/DebtWebsterBankDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_507AA40C5606D0C587FA0480899DDDA2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_507AA40C5606D0C587FA0480899DDDA2" xlink:to="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_AF03D50B795EE5950DF40480899D7EB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_AF03D50B795EE5950DF40480899D7EB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_506E2A43A81EE5238CFB0480899DF9F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_AF03D50B795EE5950DF40480899D7EB1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_506E2A43A81EE5238CFB0480899DF9F8" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TermLoanMember" xlink:label="loc_prpo_TermLoanMember_50D55973A4FF5EEF67F10480899DC530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_506E2A43A81EE5238CFB0480899DF9F8" xlink:to="loc_prpo_TermLoanMember_50D55973A4FF5EEF67F10480899DC530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_19F959BA6BC7CC14A3B60480899E1FBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:to="loc_us-gaap_DebtInstrumentAxis_19F959BA6BC7CC14A3B60480899E1FBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_945AAADF063E7E54E5020480899ED4BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_19F959BA6BC7CC14A3B60480899E1FBE" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_945AAADF063E7E54E5020480899ED4BF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WebsterBankMember" xlink:label="loc_prpo_WebsterBankMember_6AE9FC411DB3B8D103750480899E6410" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_945AAADF063E7E54E5020480899ED4BF" xlink:to="loc_prpo_WebsterBankMember_6AE9FC411DB3B8D103750480899E6410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:to="loc_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_3D02466C428E7B1DA9F90480899EA8E9" xlink:to="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_4DF1B9E685DCC8849C1B0480899EA9C8" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_27947BE3EFB30955262B0480899E4136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_41F479DC0716D208BDB40480899DC375" xlink:to="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentTerm_215E3704B78638F74AC50480899E3130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_7E56BD0658969C7BDB720480899E2A87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_7E56BD0658969C7BDB720480899E2A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_89398735957A9022BCB70480899E09E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_0FE68FAFAF840F8EF0820480899E2C76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_FD60DD9BBD475642BDB20480899E8F32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_52170F87AFA6E7BF3E6E0480899E9418" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_52170F87AFA6E7BF3E6E0480899E9418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_196075C04A176954E1A00480899E064A" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0A895B28E6EFB4E4253804870E70EA34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DocumentAndEntityInformationAbstract" xlink:label="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_30B8BDAA15EA55C5812CAC37E29930EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_EntityRegistrantName_30B8BDAA15EA55C5812CAC37E29930EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1764033C55315753A7E5FF086D95C4DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_EntityCentralIndexKey_1764033C55315753A7E5FF086D95C4DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_10042B2587C25DA48E7C7E4838F051DB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_CurrentFiscalYearEndDate_10042B2587C25DA48E7C7E4838F051DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_19A05152F83B587DB487503A88FD92D5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_EntityFilerCategory_19A05152F83B587DB487503A88FD92D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5A1DBCEA2F22584D85B693C82D4F382D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_DocumentType_5A1DBCEA2F22584D85B693C82D4F382D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_EE0BA25D60E25AB89755289BA18384E5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_DocumentPeriodEndDate_EE0BA25D60E25AB89755289BA18384E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_78856E616CD15EBB93C4A9C2C3C57041" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_DocumentFiscalYearFocus_78856E616CD15EBB93C4A9C2C3C57041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_95333E7419BD5B9FB881699052E65B75" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_DocumentFiscalPeriodFocus_95333E7419BD5B9FB881699052E65B75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_522BCA79216F50EBB02E4BF9DCE7263F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_AmendmentFlag_522BCA79216F50EBB02E4BF9DCE7263F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_031712F0EE0A5AE3BD3F73298CE7544E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_1003CC61DCF75BF99EB8CCCAB57DE54B" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_031712F0EE0A5AE3BD3F73298CE7544E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9A6D9564C49F58DF8537CFB4497DA289" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_87AE62A93B4C53D590749C60CB15C1A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9A6D9564C49F58DF8537CFB4497DA289" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_87AE62A93B4C53D590749C60CB15C1A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/FairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_AA0AB12948B3D67480BBE79B54D9E52E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_AA0AB12948B3D67480BBE79B54D9E52E" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_657233ACB3CAD3EF2A02E79B54D9E719" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_657233ACB3CAD3EF2A02E79B54D9E719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CE4A99326A6F3C721586E79B54D92255" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_657233ACB3CAD3EF2A02E79B54D9E719" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CE4A99326A6F3C721586E79B54D92255" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="loc_prpo_A2016WarrantLiabilityMember_BE8138DA57D309D414DFE79B54D90D1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_CE4A99326A6F3C721586E79B54D92255" xlink:to="loc_prpo_A2016WarrantLiabilityMember_BE8138DA57D309D414DFE79B54D90D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_482E40B57E76E164C515E79B54D9D757" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_F49D36C95B3D19FC22ECE79B54D95075" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7C61151A4B8935867A3BE79B54DAD37C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_D62969A6F64D6066B922E79B54DAD67A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TotalGainsOrLossesAbstract" xlink:label="loc_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:to="loc_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_TotalGainsOrLossesAbstract_0AAFDF89A89E7CB5A67FE79B54DA733B" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_F0A0651AAB06EBEAC7A1E79B54DA1228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7DF55E30EA9C7D1B59A1E79B54DA0C47" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1B008DDF90D1F3106C7EE79B54DA8127" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7DF55E30EA9C7D1B59A1E79B54DA0C47" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/FairValueNarrativesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89E2BFB4B02BA6FC36BCF5BF00C07994" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89E2BFB4B02BA6FC36BCF5BF00C07994" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3EB190BCB2C2FD31B67BF5BF00C092D1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="loc_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_5DFE7102C8865F2FDE25F5BF00C0938D" xlink:to="loc_prpo_A2016WarrantLiabilityMember_E5F54F7A765795AD0F70F5BF00C078AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7D82E1E618D35E8FE553F5BF00C0A299" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4F23A1A81BEA495F0C2CF5BF00C0ED83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_452E0DF6396EC5E87C93F5BF00C0DA0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="loc_us-gaap_SharePrice_452E0DF6396EC5E87C93F5BF00C0DA0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_B02D9BCAAF086D6EFAA7F5BF00C0BF3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4004DF44730136417666F5BF00C01BE8" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_950A7131DC68C43CEB2EF5BF00C0125C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3AD46FE7B9AB59B4A3722EF8A7E854CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7CD01E6FAD1D5C3EAFEF63331806FE5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3AD46FE7B9AB59B4A3722EF8A7E854CB" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7CD01E6FAD1D5C3EAFEF63331806FE5B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9FB64EA310AF5343A833BC2D12FB808E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_09FC8A80F7FC5BA5B5E4F5BA9B2FEC52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9FB64EA310AF5343A833BC2D12FB808E" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_09FC8A80F7FC5BA5B5E4F5BA9B2FEC52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ReverseMerger" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_DEEF782154C99A3C785BF57E27064694" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_98C2D206C097D6F2509EF57E27074086" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_DEEF782154C99A3C785BF57E27064694" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_98C2D206C097D6F2509EF57E27074086" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerConsiderationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1775CD3EDF6AD56E36CA069A1620C397" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_751BE69082ED8B8EF8C2069A16206FB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1775CD3EDF6AD56E36CA069A1620C397" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_751BE69082ED8B8EF8C2069A16206FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_751BE69082ED8B8EF8C2069A16206FB3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_CE81C3C5164EBD798046069A1620405D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_8F8E77EE100DBEF07FE5069A16209A78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_05AA20017269B9F37ADD069A1620A944" xlink:to="loc_prpo_TransgenomicsMember_8F8E77EE100DBEF07FE5069A16209A78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_751BE69082ED8B8EF8C2069A16206FB3" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationAcquiredEntitiesCommonStock" xlink:label="loc_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_prpo_BusinessCombinationAcquiredEntitiesCommonStock_9416DA0A9B25D24FDCFF069A16218C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_6025196AA065D462EC4F069A16215621" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock_26FE50BB32B137FBAC18069A1621ACC6" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock_B0E3FA384E919E224570069A162640CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_8785C72D16CCE70D5BDC069A1626DE8D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BusinessCombinationFairValueofDebtConverted" xlink:label="loc_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_prpo_BusinessCombinationFairValueofDebtConverted_55E79E77871CDDD71976069A16263ED8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_23F8B8E24BF82E168FC4069A162143F8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_CDB679F3D68E1C6FA072069A16262B93" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerIntangibleAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_FB775E53D9766DF5DCCBEC78C33E3491" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_FB775E53D9766DF5DCCBEC78C33E3491" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_45FC32A378EA9515D2C5EC78C33ED9C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_45FC32A378EA9515D2C5EC78C33ED9C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F3A66F26F00678A941ACEC78C33E1E2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_45FC32A378EA9515D2C5EC78C33ED9C9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F3A66F26F00678A941ACEC78C33E1E2A" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_8F0875B6FAB8B7E69AE2EC78C33E0648" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_F3A66F26F00678A941ACEC78C33E1E2A" xlink:to="loc_prpo_TransgenomicsMember_8F0875B6FAB8B7E69AE2EC78C33E0648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_DBEC0F7A0D520F48710FEC78C33E5E2A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_07EFC1E045FF6A9C1227EC78C33E691E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_us-gaap_CustomerRelationshipsMember_D0B4F4C426D2FE505FD5EC78C33E731F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_593EE08C5440CCB04173EC78C33EAF77" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BacklogMember" xlink:label="loc_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_prpo_BacklogMember_E1F0D096130B0403B505EC78C33EA82A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_745CDEE7401B12389428EC78C33E37EF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_3599E5AF5CE5620B4EB0EC78C33F796C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8CDC0736A17ADB7DBABFEC78C33F0164" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_23A4030DE1465B373CFEEC78C33F89F2" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_51BE7323AA2998286C3DEC78C33FD719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_17603C8DC3C9F0940BCAEC78C33FCA7C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_17035B1ADE980D6B8DF1EC78C33E6AB2" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_17603C8DC3C9F0940BCAEC78C33FCA7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_17603C8DC3C9F0940BCAEC78C33FCA7C" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_F8402EFCC3FD30FE6AB1EC78C33FC949" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerNarrativesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_92E17FF1A4C6564033370268AE201889" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationTable" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_92E17FF1A4C6564033370268AE201889" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_67A6693C04D97F84F1680268AE20C3BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="loc_us-gaap_StatementClassOfStockAxis_67A6693C04D97F84F1680268AE20C3BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_67A6693C04D97F84F1680268AE20C3BE" xlink:to="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_85BD3A014825E8CBAA310268AE21BCED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15" xlink:to="loc_us-gaap_CommonStockMember_85BD3A014825E8CBAA310268AE21BCED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_E8A9B48C64BB009414790268AE21B12C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_E1770DDCEEA9F15FA4F40268AE20DE15" xlink:to="loc_us-gaap_PreferredStockMember_E8A9B48C64BB009414790268AE21B12C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="loc_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_453D6B37172187ABF5250268AE2115FD" xlink:to="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PrecipioDiagnosticMember" xlink:label="loc_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:to="loc_prpo_PrecipioDiagnosticMember_07D05E07BF58BA08CF630268AE210EB9" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_F9A0DB9331BA0E9FD9740268AE2161FF" xlink:to="loc_prpo_TransgenomicsMember_DF2FE80D9AE91159FB790268AE210DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_E9DDF48C1E3138B1BFDF0268AE2173B7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3EC8295D7BD12631B0810268AE22F1B3" xlink:to="loc_us-gaap_PrivatePlacementMember_D6B2A2AA7A35D128D2B10268AE225ACE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_FFC9FED3FFB0581626CC0268AE22F6EE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_FFC9FED3FFB0581626CC0268AE22F6EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6DBB2BE0E8F8E2A2C33B0268AE227558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_FFC9FED3FFB0581626CC0268AE22F6EE" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6DBB2BE0E8F8E2A2C33B0268AE227558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6DBB2BE0E8F8E2A2C33B0268AE227558" xlink:to="loc_us-gaap_ConvertibleDebtMember_A32409895AFB1398843B0268AE2261B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSegmentAllocationLineItems" xlink:label="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationTable_B33E05FD907128FEC8990268AE20ADBF" xlink:to="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_3618A71446C76543D1D00268AE23B5FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_A3B7DC7117E525E9BD290268AE230E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_3B22F1215C82E3F2544F0268AE2326FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0BD5BCED68E59F1FF48D0268AE238D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_AABD9A89FE60A3A76A770268AE235337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_363FD20C1DB277E25BE80268AE237BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0438F195BDB79069C8C90268AE237E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_4411AD762DC2837012520268AE234EBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1B08E9859621B5B502810268AE23DBEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_8F8CEC805790DAA2DB440268AE2417B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSegmentAllocationLineItems_8BCEB4B6B676FCF62FF30268AE22912C" xlink:to="loc_us-gaap_SharePrice_4A7A1A36E412E2DC90DB0268AE24F2E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerNetAssetsAcquiredDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_416D0629F48E2F72E985FF7C6E2DDE28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635670A14D167F32A7CBFF7C6E2DD977" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_416D0629F48E2F72E985FF7C6E2DDE28" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635670A14D167F32A7CBFF7C6E2DD977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3F6DA8D4331E5F897C09FF7C6E2DAD57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635670A14D167F32A7CBFF7C6E2DD977" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3F6DA8D4331E5F897C09FF7C6E2DAD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_245CEE9F4E1A56A7DA8BFF7C6E2DE491" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3F6DA8D4331E5F897C09FF7C6E2DAD57" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_245CEE9F4E1A56A7DA8BFF7C6E2DE491" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_3B6AA8D81E648A7C1D9CFF7C6E308A04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_245CEE9F4E1A56A7DA8BFF7C6E2DE491" xlink:to="loc_prpo_TransgenomicsMember_3B6AA8D81E648A7C1D9CFF7C6E308A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635670A14D167F32A7CBFF7C6E2DD977" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0E13A0CB1C8BBC1FA3D0FF7C6E3048B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_AFB3F88F08F5D0BA376EFF7C6E30B890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8026077D3CE84A4061DFFF7C6E30A30B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_Goodwill_8026077D3CE84A4061DFFF7C6E30A30B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_57B81A48280740010921FF7C6E306ED2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_57B81A48280740010921FF7C6E306ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_DAD59CDE6C8D189DE4ABFF7C6E304EB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_033EDCCE26D57EA561BAFF7C6E30BA96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_E5FC91E8A9CC31B5EED7FF7C6E302902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_E4CED8BBAE318F04EE3FFF7C6E30BC11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_CCA996E3D25C36128AC2FF7C6E30718B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_D3C94BA6C9F632202934FF7C6E30E038" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerProFormaDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_84FBA38152E7697EB5F4063C46A6E576" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C4128BA9B94A48BE24063C46A63459" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_84FBA38152E7697EB5F4063C46A6E576" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C4128BA9B94A48BE24063C46A63459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_A60233223DD6F94CBC0F063C46A733C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C4128BA9B94A48BE24063C46A63459" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_A60233223DD6F94CBC0F063C46A733C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64980A0BE70AB99E369F063C46A7587D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_A60233223DD6F94CBC0F063C46A733C4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64980A0BE70AB99E369F063C46A7587D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_319D86BCE4AAF0DF107D063C46A760D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_64980A0BE70AB99E369F063C46A7587D" xlink:to="loc_prpo_TransgenomicsMember_319D86BCE4AAF0DF107D063C46A760D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B3C4128BA9B94A48BE24063C46A63459" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_5FF84F3E6D92C3BC79B2063C46A77A8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_AA120D1667AB8390B7CE063C46A705A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95D9874016E6EC492964063C46A7983D" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_A9EEE63D84FE6ED500E7063C46A739D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/ReverseMergerTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_FD118CFB4C100947A6EEEC78C234AEEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_F3EC345614FBD0A37FF6EC78C234A4E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_FD118CFB4C100947A6EEEC78C234AEEC" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_F3EC345614FBD0A37FF6EC78C234A4E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_BEBFA508647B7BFCFD00EC78C2346326" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_FD118CFB4C100947A6EEEC78C234AEEC" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_BEBFA508647B7BFCFD00EC78C2346326" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockOptions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FFBB116E1DF85A008C9F53455CE51438" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_18EBA6BCDA7753CE9F8B98F2246A64C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FFBB116E1DF85A008C9F53455CE51438" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_18EBA6BCDA7753CE9F8B98F2246A64C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockOptionsStockAppreciationRightsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49275ADA91F8ABEDF68905B0CA22B452" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3706FD1ED9BF02FD85FC05B0CA22D5B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49275ADA91F8ABEDF68905B0CA22B452" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3706FD1ED9BF02FD85FC05B0CA22D5B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_64238DE8F5411BE9EA6F05B0CA223B8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3706FD1ED9BF02FD85FC05B0CA22D5B1" xlink:to="loc_us-gaap_AwardTypeAxis_64238DE8F5411BE9EA6F05B0CA223B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDDACE316AC95966898505B0CA22F264" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_64238DE8F5411BE9EA6F05B0CA223B8D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDDACE316AC95966898505B0CA22F264" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAppreciationRightsSARSMember" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_DDDACE316AC95966898505B0CA22F264" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_F913E4E02A5F6DF1E36E05B0CA224C47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3706FD1ED9BF02FD85FC05B0CA22D5B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_4B9084AF8B077942417005B0CA221930" xlink:to="loc_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_779F905B856065964D8205B0CA2366E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_38D7801325780E493CE905B0CA2379B6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_811AA79AA4E64229791605B0CA2391C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_9149B5D7A0EDD0CC69EF05B0CA23D21D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7AD5CF02B91767CF1C4E05B0CA23BC96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7AD5CF02B91767CF1C4E05B0CA23BC96" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ChangeinStockAppreciationRightsLiability" xlink:label="loc_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_prpo_ChangeinStockAppreciationRightsLiability_499F9B6E99B6C742810805B0CA23DA44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3145D04DC7ADE379148A05B0CA23FBCB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_25E4675EFE027405C8FC05B0CA229870" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3145D04DC7ADE379148A05B0CA23FBCB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockOptionsStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DBD93CB6EE93660957A05B0CA28752E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DBD93CB6EE93660957A05B0CA28752E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B8D8185619178778CE9C05B0CA29BB8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:to="loc_us-gaap_AwardTypeAxis_B8D8185619178778CE9C05B0CA29BB8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CCC55095E63A8A313AF805B0CA2914E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B8D8185619178778CE9C05B0CA29BB8B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CCC55095E63A8A313AF805B0CA2914E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CCC55095E63A8A313AF805B0CA2914E9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_79CC00BA85D446881A9605B0CA29B963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:to="loc_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_AFF7E82AB6AE18171D1905B0CA291BBA" xlink:to="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_EquityIncentivePlan2006Member" xlink:label="loc_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_B805D995CD9A6684383D05B0CA29F9E1" xlink:to="loc_prpo_EquityIncentivePlan2006Member_81146884841E19E1211C05B0CA296583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FCF2C262B046A717F12005B0CA29B0ED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_69DF5D4E9F555E2C2B8E05B0CA29C644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5FB88A443AAB683B713C05B0CA29D010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3B2579E4FEF5DC52088E05B0CA29D9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_552E4DB972A8218D6EDA05B0CA292D93" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_EE2D67A6CF06A01D438705B0CA2947C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_552E4DB972A8218D6EDA05B0CA292D93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BE5B5CCFBA5D8D95600305B0CA29EF76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F538383C93E65E5DDA9405B0CA2A81F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24DD28AB8E388F36A8A705B0CA2A2150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1623C22FBDA37C95A1A405B0CA2A160D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5F0FA9FA941D9211DAF305B0CA2AD94E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_739C3BB9A499534C40C305B0CA2A0741" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5F0FA9FA941D9211DAF305B0CA2AD94E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5D1F20F53A2668FB34DC05B0CA2ADF7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_FFB760E0FFD6C4CDF65005B0CA2A9278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F90CF2A2B89B71F4DD4F05B0CA2A7CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65E7AE072DE6C3C20D3205B0CA297D0D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58E229FCBFD822FD76DC05B0CA2A5CB4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockOptionsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B54011D3562A520C8BA259183EC7681D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0E4BE3A5E22A533B84C946E2F2EF2ABC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B54011D3562A520C8BA259183EC7681D" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0E4BE3A5E22A533B84C946E2F2EF2ABC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_E5D4286138377957508EEB341EFF3429" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95D2B6EE35519FFD3279EB341EFF3CD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_E5D4286138377957508EEB341EFF3429" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_95D2B6EE35519FFD3279EB341EFF3CD8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_024E10B28E2E22CD9C3D0666A5AFDFD8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9C97674701C15EF4E0F90666A5AF2ABC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_024E10B28E2E22CD9C3D0666A5AFDFD8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9C97674701C15EF4E0F90666A5AF2ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EC6A08413C698B8AFDB00666A5AF3E68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9C97674701C15EF4E0F90666A5AF2ABC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_EC6A08413C698B8AFDB00666A5AF3E68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EC6A08413C698B8AFDB00666A5AF3E68" xlink:to="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_075477B840E845267F3E0666A5AFFE60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76" xlink:to="loc_us-gaap_CommonStockMember_075477B840E845267F3E0666A5AFFE60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_57A194FB782CADCB19C40666A5AF5F27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B1A993ADD691582CC02C0666A5AFEE76" xlink:to="loc_us-gaap_PreferredStockMember_57A194FB782CADCB19C40666A5AF5F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_475183C31F217FF1BB930666A5B0074F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9C97674701C15EF4E0F90666A5AF2ABC" xlink:to="loc_us-gaap_AwardTypeAxis_475183C31F217FF1BB930666A5B0074F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3D9ADC7D1FC8CB6FA080666A5B08D29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_475183C31F217FF1BB930666A5B0074F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3D9ADC7D1FC8CB6FA080666A5B08D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_08161DF256E5238879EA0666A5B00CA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D3D9ADC7D1FC8CB6FA080666A5B08D29" xlink:to="loc_us-gaap_PerformanceSharesMember_08161DF256E5238879EA0666A5B00CA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9C97674701C15EF4E0F90666A5AF2ABC" xlink:to="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0A179094F83779BEBB930666A5B06739" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0A179094F83779BEBB930666A5B06739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_C42C98CE314FCFA42F360666A5B0B8E4" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="loc_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_prpo_ConversionofStockPerShareConversionPrice_0DA6C5F51E4967DC5D850666A5B050E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_F46DDBD08CA5948CD1BA0666A5B080D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_F46DDBD08CA5948CD1BA0666A5B080D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_FEF993E450E234FB9A010666A5B0B58D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_TreasuryStockCommonShares_FE02971771F0D2924E610666A5B06790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_RestrictedStockExpense_C7A04DF808DE8E202CDB0666A5B0281D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_2831BAA1A844A56167720666A5B0FB8F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_2831BAA1A844A56167720666A5B0FB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7AA9A9E23FA80F91E64A0666A5B0CC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_7F45D30EF2899478C6E10666A5B024BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D2FB8C2D3D258194F6140666A5B0FE31" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D2FB8C2D3D258194F6140666A5B0FE31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_AC78402ED8C570B8C9F10666A5B035D4" xlink:to="loc_us-gaap_SharesOutstanding_F5B1F3A84DB14CF30EE90666A5B09FD9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5CC191FAB9D3D3051ACC0664AD7A1A0E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5CC191FAB9D3D3051ACC0664AD7A1A0E" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_3460ADD7A273AE70C32E0664AD7FBE6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_3460ADD7A273AE70C32E0664AD7FBE6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3460ADD7A273AE70C32E0664AD7FBE6D" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_17DCA36E995323171D7D0664AD7FFF89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8" xlink:to="loc_us-gaap_LineOfCreditMember_17DCA36E995323171D7D0664AD7FFF89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_13A1A4E95A2B283C8E070664AD7F3D32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_243A634BA761DEF2A0FB0664AD7FD0C8" xlink:to="loc_us-gaap_BridgeLoanMember_13A1A4E95A2B283C8E070664AD7F3D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6F4CCEBADFDE3E0E45CB0664AD7FB94F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6F4CCEBADFDE3E0E45CB0664AD7FB94F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6BFC15D9FE0E2BA5EB2B0664AD80E4C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6F4CCEBADFDE3E0E45CB0664AD7FB94F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6BFC15D9FE0E2BA5EB2B0664AD80E4C5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TermLoanMember" xlink:label="loc_prpo_TermLoanMember_56D1F3D8487DEE26930D0664AD80F237" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6BFC15D9FE0E2BA5EB2B0664AD80E4C5" xlink:to="loc_prpo_TermLoanMember_56D1F3D8487DEE26930D0664AD80F237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7C900DB30991F3EFD7150664AD80E229" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_DebtInstrumentAxis_7C900DB30991F3EFD7150664AD80E229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7C900DB30991F3EFD7150664AD80E229" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_WebsterBankMember" xlink:label="loc_prpo_WebsterBankMember_BA3C2551CFAAE1EE08640664AD80A886" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3" xlink:to="loc_prpo_WebsterBankMember_BA3C2551CFAAE1EE08640664AD80A886" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017BridgeNotesMember" xlink:label="loc_prpo_A2017BridgeNotesMember_E4643FFD68712C7E659A0664AD801EA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1CD3D824942B8986EE3C0664AD8058F3" xlink:to="loc_prpo_A2017BridgeNotesMember_E4643FFD68712C7E659A0664AD801EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3E69E335BEF6551FA05D0664AD806B91" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3E69E335BEF6551FA05D0664AD806B91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3E69E335BEF6551FA05D0664AD806B91" xlink:to="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3686C7F4A8BBCD9B66880664AD80D92B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:to="loc_us-gaap_CommonStockMember_3686C7F4A8BBCD9B66880664AD80D92B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_B2232359EBAE05978E010664AD802374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_E137EC93234C0127C3890664AD8024AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_32D35AA31508281ADAC50664AD800CB5" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_E137EC93234C0127C3890664AD8024AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12FA90F745F0FD15BB670664AD80E106" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_dei_LegalEntityAxis_12FA90F745F0FD15BB670664AD80E106" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_59035BA3BDE4CB8DDA870664AD80DDB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_12FA90F745F0FD15BB670664AD80E106" xlink:to="loc_dei_EntityDomain_59035BA3BDE4CB8DDA870664AD80DDB8" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_93836301921BAFB80B140664AD8033D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_59035BA3BDE4CB8DDA870664AD80DDB8" xlink:to="loc_prpo_TransgenomicsMember_93836301921BAFB80B140664AD8033D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7B81A434E31A36C923FB0664AD80D04D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7B81A434E31A36C923FB0664AD80D04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5BE2901E77C3ECAC67300664AD80CF82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7B81A434E31A36C923FB0664AD80D04D" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5BE2901E77C3ECAC67300664AD80CF82" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AegisWarrantMember" xlink:label="loc_prpo_AegisWarrantMember_FA1E626E1136A6C2D3BA0664AD81DB26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5BE2901E77C3ECAC67300664AD80CF82" xlink:to="loc_prpo_AegisWarrantMember_FA1E626E1136A6C2D3BA0664AD81DB26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_DCC1D4CB634F6CF17C3D0664AD81BF02" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_RangeAxis_DCC1D4CB634F6CF17C3D0664AD81BF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_F5B8C60D77AD5D1125620664AD814288" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_DCC1D4CB634F6CF17C3D0664AD81BF02" xlink:to="loc_us-gaap_RangeMember_F5B8C60D77AD5D1125620664AD814288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8D712D39D161F0AB64750664AD81C4B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_F5B8C60D77AD5D1125620664AD814288" xlink:to="loc_us-gaap_MinimumMember_8D712D39D161F0AB64750664AD81C4B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9621DCCF8444B957886A0664AD7E5C5B" xlink:to="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8C8A948225A2DC1D5E040664AD810664" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_8C8A948225A2DC1D5E040664AD810664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_32D9E52519EBA01843E50664AD813313" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_32D9E52519EBA01843E50664AD813313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ECF381BA761DB00E0BF80664AD81B96D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_ECF381BA761DB00E0BF80664AD81B96D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1CC3858E7B49E6D22DF80664AD81B632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_C5F1A9833FE36A4787170664AD81D8FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_DC8A25212AF77CE3B3460664AD81BF55" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassofWarrantorRightTerm" xlink:label="loc_prpo_ClassofWarrantorRightTerm_73F8ACA7BBD8D4A75A0E0664AD81B217" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_prpo_ClassofWarrantorRightTerm_73F8ACA7BBD8D4A75A0E0664AD81B217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_CD565C5817DA1AF8027406668D9AE653" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_CD565C5817DA1AF8027406668D9AE653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_PreferredStockValue_6DE6479354A9A36152AE066A1CFCF75F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_9CDB58B370EB2F93D948066C7F893A1C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_9CDB58B370EB2F93D948066C7F893A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_DividendsPreferredStockCash_F260A15DC3DEA0CB1ADE066FB0352726" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised" xlink:label="loc_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised_28A4E3B5B8ADD7AC9619067236D93335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_107F2F32E5C6A9E82C050664AD813E49" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_107F2F32E5C6A9E82C050664AD813E49" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PercentageofPerShareOfferingPrice" xlink:label="loc_prpo_PercentageofPerShareOfferingPrice_6892ADDAABA753EE0DF80664AD810AE4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_FAFB195B680F2C37AD280664AD81CFD2" xlink:to="loc_prpo_PercentageofPerShareOfferingPrice_6892ADDAABA753EE0DF80664AD810AE4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_079336573A5EE066E9CFF5BF00FD8AF9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_079336573A5EE066E9CFF5BF00FD8AF9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_128F20EAF23A4E43FC99F5BF00FD6AC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_128F20EAF23A4E43FC99F5BF00FD6AC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B6A6368FA60AD3CAD0BBF5BF00FDF531" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_128F20EAF23A4E43FC99F5BF00FD6AC9" xlink:to="loc_us-gaap_ClassOfStockDomain_B6A6368FA60AD3CAD0BBF5BF00FDF531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B6A6368FA60AD3CAD0BBF5BF00FDF531" xlink:to="loc_us-gaap_PreferredStockMember_750DEF29EDE3923532B5F5BF00FD16CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_C22D2081F72DEC83CF04F5BF00FD9EDC" xlink:to="loc_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73495DB37594326E0471F5BF00FDCC32" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_A0DC3C2748DBAFF73FF9F5BF00FD76AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B7988B57D842BFDD3F73EC4386435643" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_DAA5EDEF9EC5631DC1B9EC438A5AB121" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B7988B57D842BFDD3F73EC4386435643" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_DAA5EDEF9EC5631DC1B9EC438A5AB121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2B8367016725FE24AE71EC438A5A9010" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_DAA5EDEF9EC5631DC1B9EC438A5AB121" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2B8367016725FE24AE71EC438A5A9010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2B8367016725FE24AE71EC438A5A9010" xlink:to="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_AC74218D5706957BD402EC438A69D83F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_AC74218D5706957BD402EC438A69D83F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_01B2CAC552CAE945ACD4EC438A79C7FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9BCBC202988F72F4C28FEC438A5A3532" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_01B2CAC552CAE945ACD4EC438A79C7FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_5222D1AC493432CFBEC8EC438A5A8EA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_DAA5EDEF9EC5631DC1B9EC438A5AB121" xlink:to="loc_us-gaap_ClassOfStockLineItems_5222D1AC493432CFBEC8EC438A5A8EA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9FB7ED58692C4454610CEC438A5A1E1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5222D1AC493432CFBEC8EC438A5A8EA9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9FB7ED58692C4454610CEC438A5A1E1A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesSeniorPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_886BABD5A8C7C2B807B1048088A5095B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_886BABD5A8C7C2B807B1048088A5095B" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_662E1B3493C4874C23AE048088AA846E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:to="loc_us-gaap_StatementClassOfStockAxis_662E1B3493C4874C23AE048088AA846E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_662E1B3493C4874C23AE048088AA846E" xlink:to="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PreferredStockSeriesASeniorMember" xlink:label="loc_prpo_PreferredStockSeriesASeniorMember_A7494ED8C9C2D897116C048088ABA2B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF" xlink:to="loc_prpo_PreferredStockSeriesASeniorMember_A7494ED8C9C2D897116C048088ABA2B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_892F66CEC7EB1FA5C5A5048088ABC9E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D86506B5A195A21EF3D9048088AB30DF" xlink:to="loc_us-gaap_PreferredStockMember_892F66CEC7EB1FA5C5A5048088ABC9E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5A8833A9F236E0202F3C048088ABC4C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:to="loc_dei_LegalEntityAxis_5A8833A9F236E0202F3C048088ABC4C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DE88A2D186A6C8390AF8048088AB9418" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5A8833A9F236E0202F3C048088ABC4C9" xlink:to="loc_dei_EntityDomain_DE88A2D186A6C8390AF8048088AB9418" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_TransgenomicsMember" xlink:label="loc_prpo_TransgenomicsMember_48078963FC911F3CBBA8048088AB6319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_DE88A2D186A6C8390AF8048088AB9418" xlink:to="loc_prpo_TransgenomicsMember_48078963FC911F3CBBA8048088AB6319" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_B6D76E7AF6292110BFCD048088AB52F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_B6D76E7AF6292110BFCD048088AB52F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38C98358D94099B4A629048088AB6FFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B6D76E7AF6292110BFCD048088AB52F9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38C98358D94099B4A629048088AB6FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_02524F2EE12212889191048088AB267A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38C98358D94099B4A629048088AB6FFA" xlink:to="loc_us-gaap_PrivatePlacementMember_02524F2EE12212889191048088AB267A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_237085DF2375AF528D00048088A5F20F" xlink:to="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_46C72747180B668771C1048088ABBEC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_46C72747180B668771C1048088ABBEC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_312F7AF8A9EE593762C8048088ABDD2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_312F7AF8A9EE593762C8048088ABDD2E" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="loc_prpo_ConversionofStockPerShareConversionPrice_7C5873851B30477BB105048088ABC7F2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_prpo_ConversionofStockPerShareConversionPrice_7C5873851B30477BB105048088ABC7F2" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConversionofStockDiscountRate" xlink:label="loc_prpo_ConversionofStockDiscountRate_2A1D7EDE2477FBAC75FF048088ACEABD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_prpo_ConversionofStockDiscountRate_2A1D7EDE2477FBAC75FF048088ACEABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_0C0D8AF8D14E00A0FF87048088AC5415" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_0C0D8AF8D14E00A0FF87048088AC5415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_D313FAF92788BD218B06048088ACB478" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_D313FAF92788BD218B06048088ACB478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6FA8FD4247A5873D0FB9048088ACF413" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6FA8FD4247A5873D0FB9048088ACF413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_2636F956824FBF581648048088AC334D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_2636F956824FBF581648048088AC334D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_088F415DF3D3A3C417DD048088AC30C4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_088F415DF3D3A3C417DD048088AC30C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_04C0EEDEA861AABA82C9048088ACEBCB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_04C0EEDEA861AABA82C9048088ACEBCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_668B96FFDA75571ACA96048088AC4206" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_668B96FFDA75571ACA96048088AC4206" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_AC11BB0216FA7358E8A8048088AC83C5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_AC11BB0216FA7358E8A8048088AC83C5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_DeemedDividend" xlink:label="loc_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6B259E8CC486FAA5D543048088AB22C5" xlink:to="loc_prpo_DeemedDividend_8A691B2D4F43AD2F9A0B04F98E4BADFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitSideWarrantsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3C268E9C018DAFB74A7B048088E9D2AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3C268E9C018DAFB74A7B048088E9D2AC" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7CABAC9E855D9EBE617E048088EA8038" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SideWarrantMember" xlink:label="loc_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_SideWarrantMember_3F349BBE6805ADC729F5048088EA4A2C" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJanuary2018Member" xlink:label="loc_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJanuary2018Member_D412DACF600620872A08048088EA9064" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersApril2020Member" xlink:label="loc_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersApril2020Member_B87DCF92F8D03BF5812D048088EA7514" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersFebruary2020Member" xlink:label="loc_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersFebruary2020Member_D9AD3F7500468C22A88B048088EAF9D4" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersDecember2020OneMember" xlink:label="loc_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersDecember2020OneMember_A6DFD96361517A4EB70E048088EBAC27" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJanuary2021OneMember" xlink:label="loc_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJanuary2021OneMember_7B6C03E567F191BF35C1048088EB1F4D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJanuary2021TwoMember" xlink:label="loc_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJanuary2021TwoMember_B3720B30C0EBD0548752048088EB44E5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJune2022Member" xlink:label="loc_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJune2022Member_9E87083AEF91EECBF311048088EBFEF3" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_VariousInstitutionalHoldersJune2022BMember" xlink:label="loc_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E6872F178E34BE99A647048088EA6099" xlink:to="loc_prpo_VariousInstitutionalHoldersJune2022BMember_ED098364BF703352A865048088EBF2DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:to="loc_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_F5EF464A5FCCE6699986048088EB3AE6" xlink:to="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1067364E650C5A9BC3C8048088EB485B" xlink:to="loc_us-gaap_CommonStockMember_502DA456996FACA5C59E048088EB9A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:to="loc_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8DA24C334C40B4D24A46048088EBC557" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_UponExecutionMember" xlink:label="loc_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:to="loc_prpo_UponExecutionMember_15B2DA48FE22AC87379B048088ECF9BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2540FC7FDA82A8A9F2B3048088EBFBC5" xlink:to="loc_us-gaap_PerformanceSharesMember_22914B88B167D0325CC2048088EC7B31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0C058834D2F47E03DDF2048088EAC998" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4D37AD1EFD5EE647488A048088EC126B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_439E4E1DA8CC4ADFF71C048088EC3A06" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassofWarrantorRightTerm" xlink:label="loc_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_prpo_ClassofWarrantorRightTerm_1E91F87C589616C1818C048088F1B2DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_A4A726E03A1B05F9545B04F0BC6356ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_51DBC923B753A1163A3E048088ECEA89" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_191AF402F3C69D131AAE04F3EC7F805A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/StockholdersEquityDeficitTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_DBA62B88C091130E435CEB3421511F00" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3E215995EDAF1D32F776EB342151BA39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_DBA62B88C091130E435CEB3421511F00" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_3E215995EDAF1D32F776EB342151BA39" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_75994241DE771C045E90E79B5477E5BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_B8B858E14E3B9D0B6838E79B547835B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_75994241DE771C045E90E79B5477E5BC" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_B8B858E14E3B9D0B6838E79B547835B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7B1F774058E25894B4DBB07554C7E728" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_045C315782BC5E02B2C081771B477395" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7B1F774058E25894B4DBB07554C7E728" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_045C315782BC5E02B2C081771B477395" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_DCCBA8C9E647E17EA504E158D49FA52A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_EB478E47FC6EA898FC73E158D4A0C667" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DCCBA8C9E647E17EA504E158D49FA52A" xlink:to="loc_us-gaap_OtherAssetsCurrent_EB478E47FC6EA898FC73E158D4A0C667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2A6783523A1DDBBAC47AE158D4A0BE79" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DCCBA8C9E647E17EA504E158D49FA52A" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2A6783523A1DDBBAC47AE158D4A0BE79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_48DF9AF03D0F5D7DFDCAE158D4A53E8D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DCCBA8C9E647E17EA504E158D49FA52A" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_48DF9AF03D0F5D7DFDCAE158D4A53E8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4C4BC46DC6E3569AE809E158D47CA4FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_D927D851B9AB66767F34E1E14B1A7362" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4C4BC46DC6E3569AE809E158D47CA4FF" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_D927D851B9AB66767F34E1E14B1A7362" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5874C6F2796DFC254FAAE1D872663825" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41DC293A8D3E0CE1427EE1D87270031C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5874C6F2796DFC254FAAE1D872663825" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_41DC293A8D3E0CE1427EE1D87270031C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8273406695111E802581E1D61E82B8D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_83E96B4C625FCEFF8586E1D620E677A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8273406695111E802581E1D61E82B8D5" xlink:to="loc_us-gaap_DeferredRevenueCurrent_83E96B4C625FCEFF8586E1D620E677A2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_640A59ECBD6C4A2328D404808A06C427" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_640A59ECBD6C4A2328D404808A06C427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_96927A07B2337BB29E5204808A06E7BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_96927A07B2337BB29E5204808A06E7BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_F6D6BC6A9109D08FEA2804808A0632F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_UseOfEstimates_F6D6BC6A9109D08FEA2804808A0632F9" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_prpo_RisksAndUncertaintiesPolicyTextBlock_C0456F6342240E9BDC1004808A06AFF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_53D56113312890A3087304808A065837" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_53D56113312890A3087304808A065837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1A8A0C102FA8D831744304808A06F3B2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1A8A0C102FA8D831744304808A06F3B2" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ConcentrationOfCashPolicyPolicyTextBlock" xlink:label="loc_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_prpo_ConcentrationOfCashPolicyPolicyTextBlock_C045351EDF81324EC45B04808A06AE45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_89C8CE050922DA0B90F604808A0631DE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_89C8CE050922DA0B90F604808A0631DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_237410658643A65D5E8D04808A067191" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_237410658643A65D5E8D04808A067191" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_F8EB23C54815A4526F4304808A066650" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_F8EB23C54815A4526F4304808A066650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1893C0C4D87276C529AA04808A0629DF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1893C0C4D87276C529AA04808A0629DF" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BeneficialConversionFeaturePolicyTextBlock" xlink:label="loc_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_prpo_BeneficialConversionFeaturePolicyTextBlock_E6AA7F416FD328E4B94A0483218F0091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_C12B5FBA3D98FCD8116604808A06E50D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_C12B5FBA3D98FCD8116604808A06E50D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_03EB306186CA4F324F9E04808A06FD12" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E09D4A50EF3E28B545C204808A062A66" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_03EB306186CA4F324F9E04808A06FD12" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39D67B29DB02A2C97E76E158D48ACE63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_B70437748421A65FA875E158D48A6629" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39D67B29DB02A2C97E76E158D48ACE63" xlink:to="loc_us-gaap_Depreciation_B70437748421A65FA875E158D48A6629" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_106B433D1C9C78C3A47205ABC096EDAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E7A05C451C2F21EE62A005ABC0969866" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_106B433D1C9C78C3A47205ABC096EDAE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E7A05C451C2F21EE62A005ABC0969866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E7A05C451C2F21EE62A005ABC0969866" xlink:to="loc_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_8F62F26DF012B3A837E005ABC096D763" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:label="loc_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_D2EC26029E995E3955AC05ABC096A367" xlink:to="loc_us-gaap_ExecutiveOfficerMember_4FE37AEB6E5881A07ED105ABC096478C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E7A05C451C2F21EE62A005ABC0969866" xlink:to="loc_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_B7DA124C064EABC2F0A405ABC096D864" xlink:to="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_A55DA9B4FEAB434840F105ABC096E91E" xlink:to="loc_us-gaap_MaximumMember_6C7289A1367A8B11997505ABC0961E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E7A05C451C2F21EE62A005ABC0969866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_12E1C3960C300AA3C28905ABC09664BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7776B767E3FCD43CB4C805ABC0968FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED490F34FAB5B29B907805B4EAEC7C9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_C19857F65B0F7A07F80305ABC096DB96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_241807C228409EEBC13205ABC096FAAC" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="loc_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_75DCB5D66CA71CA0FC0B05ABC0961040" xlink:to="loc_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_82188F2AD4FFC02BC3B005ABC0963B06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_28B60D7EEA65D62EB0EA02770668021A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28B60D7EEA65D62EB0EA02770668021A" xlink:to="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_35D9D243B232BF4C601D027706693EC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_35D9D243B232BF4C601D027706693EC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_50145C2DB3B1526F98E602770669513B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_35D9D243B232BF4C601D027706693EC1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_50145C2DB3B1526F98E602770669513B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_50145C2DB3B1526F98E602770669513B" xlink:to="loc_us-gaap_BridgeLoanMember_36874653B8A66FA9C36C02770669B36C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_97CEE60B224F53E5D4A0027706697998" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_97CEE60B224F53E5D4A0027706697998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_361AE87FE3C84E2DC52F027706696C89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_97CEE60B224F53E5D4A0027706697998" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_361AE87FE3C84E2DC52F027706696C89" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SeniorandJuniorNotesMember" xlink:label="loc_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_361AE87FE3C84E2DC52F027706696C89" xlink:to="loc_prpo_SeniorandJuniorNotesMember_84B644C99532E66ABFB302770669BDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92AD8AB0C6508DE1D7BD0277066981CE" xlink:to="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_33986DDF167F05DF322F027706699AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8B3E22BAF1136717C10B0277066F0978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7F7CAB4D46286C64DA620277066F1165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_AEBD17905F110BA22A200277066FF706" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_AEBD17905F110BA22A200277066FF706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_ShareBasedCompensation_7BB4BB3B115A58BC39F20277066FC504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_F40D90A8E4F23AE301700277066FF54A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_F40D90A8E4F23AE301700277066FF54A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_B1F1EDE565CD5CA80F420277066FD4A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_5E9FF8106F40BB5401F60277066FBBC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_9303F78839FF12CD4E7D0277066FDE6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3C6610FCBBA546E304010277066FAF30" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AE85B7EA87B2A4BFEC4402770670AA60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3023576A2D678575284E02770670EE13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_C6533D15396E2530CBB3027706704836" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0EA9CBFB2E855563397A027706707581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_DDB2CB51E62136BD359F0277066FF196" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_060631A6B6E62196E45602770670AC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_21625E83AE54E8F94938027706692ABB" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E58901EFE1CE6FEE14E002770670AB1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_52B22E81295B3272EE2402770670E899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_97A45B3BB7B2A50C3053027706703E51" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F02B63E11D6322761E8F027706700247" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_7A754B10D2E375A68A6B0277067066EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_9204B10830E9E84013C60277067028BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_5386F68938163F96448D027706718D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_B4ABA673E8C1104717CF02770671249D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_AD7A6F66460DE556EA2E027706719CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_6694BC67CC0AE8302FF0027706718047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_9220BEE6807E6CE90343027706710000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93D122F8EAC4D825E4FF02770670AB3F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2E00649199475249F4B80277067155EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7868E2B33C069F188E910277067191DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_392CD6A0D98E22ACE40D027706712624" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3D511417FDAB28CB2AAB02770671AA23" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3D511417FDAB28CB2AAB02770671AA23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_74A02D0E08A0C2F804D2027706715980" xlink:to="loc_us-gaap_InterestPaid_AF3DC230E7DD6CA892A102770671E4FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A4D5602359C87D3DC9C202770669F073" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_0D2E62172F6E99E1C70702770672D8A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_819E6A99DB79FB69D55E027706722A94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_819E6A99DB79FB69D55E027706722A94" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_ShortTermDebtConvertedtoLongTermDebt" xlink:label="loc_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_prpo_ShortTermDebtConvertedtoLongTermDebt_4DD171BF87820B26F19B02770672E461" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_EquitySecuritiesTransferedtoDebt" xlink:label="loc_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_prpo_EquitySecuritiesTransferedtoDebt_0EA3B884E10D61F1B8BF027926C04F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_062A869CA03F98B40A43027706721D41" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_062A869CA03F98B40A43027706721D41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4CC9C002ED77EB057DC502770672F83D" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BeneficialConversionFeatureonIssuanceofDebt" xlink:label="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_7040AD7151CAEFC198D5027A3314B2C2" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_NoncashAccruedMergerCost" xlink:label="loc_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_prpo_NoncashAccruedMergerCost_56D7EEA81080319B146E02770672FC93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_046243CDB61BA8BF5C5D02770672AECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92FDEC2E91B9C79B492F02770672F05D" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_A379A01DB027643A2E7F027D0353139F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_5EBC434A36CC4134302CFF640D931982" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D5E73C11F6F835CE3AE8FF640D93C0FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5EBC434A36CC4134302CFF640D931982" xlink:to="loc_us-gaap_StatementTable_D5E73C11F6F835CE3AE8FF640D93C0FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_D0AC128347F0375E2FB8FF640D93A8E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D5E73C11F6F835CE3AE8FF640D93C0FC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_D0AC128347F0375E2FB8FF640D93A8E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D0AC128347F0375E2FB8FF640D93A8E5" xlink:to="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_PreferredStockSeriesASeniorMember" xlink:label="loc_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA" xlink:to="loc_prpo_PreferredStockSeriesASeniorMember_02320D7CE45D658CDADAFF640D9310E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_A8095C6F597A422AFE8AFF640D93325E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2BAAB7FFAEC3D8C6CC83FF640D9307FA" xlink:to="loc_us-gaap_PreferredStockMember_A8095C6F597A422AFE8AFF640D93325E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D5E73C11F6F835CE3AE8FF640D93C0FC" xlink:to="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_Revenues_B83594B6FEA0D9FF06B5FF640D937433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="loc_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_SalesAllowancesServices_9CE1AFD69B6853A03FD0FF640D936895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="loc_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_SalesRevenueServicesNet_8B8CB023FC40A8BC4FB4FF640D93BC96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1907D3E33A55332E5EE2FF640D931534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_GrossProfit_BF7572DF3C8015AD643DFF640D938DEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_OperatingExpenses_686B7EB0DA5D1D56DB87FF640D9334EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_OperatingIncomeLoss_BBE2893A02FAE0B74453FF640D9336F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_InterestIncomeAndExpenseNet" xlink:label="loc_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_prpo_InterestIncomeAndExpenseNet_CB838A10C9841820E944FF640D9301A8" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_GainLossOnStockWarrantsRevaluation" xlink:label="loc_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_prpo_GainLossOnStockWarrantsRevaluation_0FF7B07A6D2CE4146CF2FF640D931007" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F78051A9CDAFD28EBA81FF640D93637A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_F78051A9CDAFD28EBA81FF640D93637A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1AAC0A96EE717FF49B4BFF640D93043B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed_1AAC0A96EE717FF49B4BFF640D93043B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_AA2F043B2B1FEC4EC9DAFF640D935771" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_OtherIncomeExpense" xlink:label="loc_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_2E23A98F9B69AA69045EFF640D93EC37" xlink:to="loc_prpo_OtherIncomeExpense_2685A3D802BC6245CD60FF640D93C882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BFF01E7767C68745494BFF640D957733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11E6907627CA0F41221CFF640D952179" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_NetIncomeLoss_7D202ADD88AAEC95F270FF640D959811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_1266D3E413A10D65AA8FFF640D956CBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_D8C9F37EC28DFC8EA9A2FF640D95F804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_4B3E18D047FC42D323ADFF640D95F8B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6FDC713797074C56CBF5FF640D93D702" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_E5B896658D75BEAC9B67FF640D957963" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4C8B51BEACA7113C8D44063C471D0679" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4C8B51BEACA7113C8D44063C471D0679" xlink:to="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_CED738A3CCF3BB977DCB063C471DB136" xlink:to="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_D86EA77130D3FD2F6AEC063C471D4067" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:to="loc_us-gaap_PreferredStockMember_D86EA77130D3FD2F6AEC063C471D4067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AA20D02A4E39C1FA65C4063C471DEAD8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:to="loc_us-gaap_CommonStockMember_AA20D02A4E39C1FA65C4063C471DEAD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_60618D87472A5595851E063C471D8023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25BDF745F2A45D4F9AF7063C471D00C2" xlink:to="loc_us-gaap_RetainedEarningsMember_AD41D1BC079E2D42E43B063C471D5A26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_02D0EAA1CB60FE342F57063C471D5DAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_02D0EAA1CB60FE342F57063C471D5DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_209EB2CA80B200F42EF3063C471D1BED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_02D0EAA1CB60FE342F57063C471D5DAC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_209EB2CA80B200F42EF3063C471D1BED" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_SeniorandJuniorNotesMember" xlink:label="loc_prpo_SeniorandJuniorNotesMember_A7046B15EC183495349B063C471D565A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_209EB2CA80B200F42EF3063C471D1BED" xlink:to="loc_prpo_SeniorandJuniorNotesMember_A7046B15EC183495349B063C471D565A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_817D4076D42EC55CD894063C471D173E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:to="loc_us-gaap_DebtInstrumentAxis_817D4076D42EC55CD894063C471D173E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E63D21C3D7B79C8BBB22063C471D858B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_817D4076D42EC55CD894063C471D173E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E63D21C3D7B79C8BBB22063C471D858B" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_A2017BridgeNotesMember" xlink:label="loc_prpo_A2017BridgeNotesMember_2BB15C819DAFCB133DB1063C471D377A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E63D21C3D7B79C8BBB22063C471D858B" xlink:to="loc_prpo_A2017BridgeNotesMember_2BB15C819DAFCB133DB1063C471D377A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2C5BE80C6DDCE112D1CE063C471D5186" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2C5BE80C6DDCE112D1CE063C471D5186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2C5BE80C6DDCE112D1CE063C471D5186" xlink:to="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06" xlink:to="loc_us-gaap_CommonStockMember_AA20D02A4E39C1FA65C4063C471DEAD8" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_E6B138C6FFEAEA293F62063C471ECD06" xlink:to="loc_us-gaap_PreferredStockMember_D86EA77130D3FD2F6AEC063C471D4067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D0EAA53BB018C222338D063C471EE8FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_19F9563994BDC6B28F71063C471D035B" xlink:to="loc_us-gaap_StatementLineItems_D0EAA53BB018C222338D063C471EE8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D0EAA53BB018C222338D063C471EE8FB" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockholdersEquity_54E9319C39D8D9132C4D063C471EDD47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_0F89CFFBD9FD1AD3C067063C471E86FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_SharesOutstanding_0F89CFFBD9FD1AD3C067063C471E86FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B0E52458BAB399FE3941063C471EE29F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_NetIncomeLoss_B0E52458BAB399FE3941063C471EE29F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_63866789A4CA4675BAAE063C471ED0B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_B5D83C2A072B0F95564C063C471E6865" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_B5D83C2A072B0F95564C063C471E6865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_2C9893F978A55922FBEE063C471E82B8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_2C9893F978A55922FBEE063C471E82B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_DCA18445FD084AE33A68063C471EBC70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_9A8F50405EEACF2E4CB7063C471E4B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_E2504DB862AE6BB1EB9A063C471E000D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_E2504DB862AE6BB1EB9A063C471E000D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_05C9F300265D54349445063C471E0003" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_05C9F300265D54349445063C471E0003" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8ED54A73E497799FC5EC063C471E2FAD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_8ED54A73E497799FC5EC063C471E2FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25EF3A4BDCF7D47FB124063C471E7A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_608D581B288CA9368420063C471F534F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_608D581B288CA9368420063C471F534F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_D706030D0307C8D98D89063C471F6491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0F1F526AF4A0602D6ADA063C471F9F1F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0F1F526AF4A0602D6ADA063C471F9F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0D62D3E66414471C8C52063C471F0339" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_0D62D3E66414471C8C52063C471F0339" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_BeneficialConversionFeatureonIssuanceofDebt" xlink:label="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_3913C74DDE5870613D88063C471F612C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_prpo_BeneficialConversionFeatureonIssuanceofDebt_3913C74DDE5870613D88063C471F612C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_B2B3DFB4953D40598B28063C471FB9C9" xlink:type="arc" />
    <link:loc xlink:href="prpo-20170630.xsd#prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="loc_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_019E159081BAC8BEAAE3063C471F1E98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_C229D94E8CEFE17CCE5F063C471F42D1" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_StockholdersEquity_C229D94E8CEFE17CCE5F063C471F42D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_83A76705A97A7EF1A672063C471FD41A" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8C40A619DC60957242C0063C471ECCB9" xlink:to="loc_us-gaap_SharesOutstanding_83A76705A97A7EF1A672063C471FD41A" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767907792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Aug. 16, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PRECIPIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001043961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,407,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769731744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 967<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="nump">552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">21,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">37,010<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long-term debt</a></td>
<td class="nump">513<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible bridge notes, less debt discounts and debt issuance costs</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,328<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Current maturities of capital leases</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,521<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,314<span></span>
</td>
<td class="nump">3,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current maturities and discounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Common stock warrant liability</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital leases, less current maturities</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,241<span></span>
</td>
<td class="nump">7,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 150,000,000 and 1,806,850 shares authorized at June 30, 2017 and December 31, 2016, respectively, 6,407,860 and 449,175 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">34,975<span></span>
</td>
<td class="nump">4,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(15,287)<span></span>
</td>
<td class="num">(10,848)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">19,769<span></span>
</td>
<td class="num">(6,460)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and stockholders' equity</a></td>
<td class="nump">$ 37,010<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769140928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">1,294,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,712,901<span></span>
</td>
<td class="nump">780,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,712,901<span></span>
</td>
<td class="nump">780,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">1,806,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,407,860<span></span>
</td>
<td class="nump">449,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">6,407,860<span></span>
</td>
<td class="nump">449,175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767752912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Patient service revenue, net</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">$ 619<span></span>
</td>
<td class="nump">$ 1,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">less provision for bad debts</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Net sales</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">504<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">COST OF DIAGNOSTIC SERVICES</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">466<span></span>
</td>
<td class="nump">479<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">OPERATING EXPENSES</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(801)<span></span>
</td>
<td class="num">(285)<span></span>
</td>
<td class="num">(1,398)<span></span>
</td>
<td class="num">(513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_InterestIncomeAndExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(220)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(382)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_GainLossOnStockWarrantsRevaluation', window );">Warrant revaluation</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(53)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Merger advisory fees</a></td>
<td class="num">(2,603)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,603)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_OtherIncomeExpense', window );">Other Income (Expense)</a></td>
<td class="num">(2,879)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
<td class="num">(3,041)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(3,680)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
<td class="num">(4,439)<span></span>
</td>
<td class="num">(752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX EXPENSE</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(3,680)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
<td class="num">(4,439)<span></span>
</td>
<td class="num">(752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">TOTAL DIVIDENDS</a></td>
<td class="num">(5,248)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,248)<span></span>
</td>
<td class="num">(1,855)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (8,928)<span></span>
</td>
<td class="num">$ (444)<span></span>
</td>
<td class="num">$ (9,687)<span></span>
</td>
<td class="num">$ (2,607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)</a></td>
<td class="num">$ (15.35)<span></span>
</td>
<td class="num">$ (1.03)<span></span>
</td>
<td class="num">$ (18.77)<span></span>
</td>
<td class="num">$ (6.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)</a></td>
<td class="nump">581,481<span></span>
</td>
<td class="nump">429,819<span></span>
</td>
<td class="nump">515,968<span></span>
</td>
<td class="nump">427,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prpo_PreferredStockSeriesASeniorMember', window );">Preferred stock - series A senior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">TOTAL DIVIDENDS</a></td>
<td class="num">$ (5,248)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (5,248)<span></span>
</td>
<td class="num">$ (1,422)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">TOTAL DIVIDENDS</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (433)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_GainLossOnStockWarrantsRevaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_GainLossOnStockWarrantsRevaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_InterestIncomeAndExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income and (expense), net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_InterestIncomeAndExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_OtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_OtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAllowancesServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate selling price reductions recognized during an accounting period due to the rendering of deficient or nonconforming services. Allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAllowancesServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prpo_PreferredStockSeriesASeniorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prpo_PreferredStockSeriesASeniorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771413072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - 6 months ended Jun. 30, 2017 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>2017 Bridge Notes</div></th>
<th class="th"><div>Senior and Junior Notes</div></th>
<th class="th">
<div>Senior and Junior Notes </div>
<div>Common Stock</div>
</th>
<th class="th"><div>Preferred stock</div></th>
<th class="th">
<div>Preferred stock </div>
<div>Preferred stock</div>
</th>
<th class="th">
<div>Preferred stock </div>
<div>Senior and Junior Notes</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>2017 Bridge Notes</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Senior and Junior Notes</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Preferred stock</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>2017 Bridge Notes</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Senior and Junior Notes</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2016</a></td>
<td class="num">$ (6,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,848)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock and preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred stock into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(788,647)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Shares converted, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock and preferred stock dividends (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,958,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Conversion of bridge notes into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 4,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 885<span></span>
</td>
<td class="nump">$ 4,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of bridge notes into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,414,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">802,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,639<span></span>
</td>
<td class="nump">1,414,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for consulting services in connection with the merger</a></td>
<td class="nump">2,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of stock for consulting services in connection with the merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued in connection with business combination</a></td>
<td class="nump">20,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">802,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,255,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Issuance of warrants in conjunction with issuance of side agreement</a></td>
<td class="nump">414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_BeneficialConversionFeatureonIssuanceofDebt', window );">Recorded beneficial conversion feature on debt</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash stock-based compensation and vesting of restricted units</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares', window );">Non-cash stock-based compensation and vesting restricted units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2017</a></td>
<td class="nump">$ 19,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,287)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Jun. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,712,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,407,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_AdjustmentstoAdditionalPaidinCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_BeneficialConversionFeatureonIssuanceofDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Conversion Feature on Issuance of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_BeneficialConversionFeatureonIssuanceofDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_A2017BridgeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_A2017BridgeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorandJuniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_SeniorandJuniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769442528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS USED IN OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss</a></td>
<td class="num">$ (4,439)<span></span>
</td>
<td class="num">$ (752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs and debt discount</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation and change in liability of stock appreciation rights</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Merger advisory fees</a></td>
<td class="nump">2,603<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses on doubtful accounts</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Capitalized PIK interest on convertible bridge notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant revaluation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(136)<span></span>
</td>
<td class="num">(340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">484<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(897)<span></span>
</td>
<td class="num">(390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS PROVIDED BY INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired in business combination</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments on capital lease obligations</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Issuance of preferred stock</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing costs</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from long-term debt</a></td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on long-term</a></td>
<td class="num">(345)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">916<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">967<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Purchases of equipment financed through capital lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Preferred unit dividend financed through exchange agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ShortTermDebtConvertedtoLongTermDebt', window );">Convertible bridge notes exchanged for long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_EquitySecuritiesTransferedtoDebt', window );">Series A and B preferred exchanged for long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred debt issuance cost</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_BeneficialConversionFeatureonIssuanceofDebt', window );">Recorded beneficial conversion feature on debt</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_NoncashAccruedMergerCost', window );">Accrued merger cost</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for merger advisory fees</a></td>
<td class="nump">2,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Issuance of warrants in conjunction with issuance of side agreement</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorandJuniorNotesMember', window );">Senior and Junior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes to equity</a></td>
<td class="nump">4,771<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes to equity</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_BeneficialConversionFeatureonIssuanceofDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Conversion Feature on Issuance of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_BeneficialConversionFeatureonIssuanceofDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_EquitySecuritiesTransferedtoDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Transfered to Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_EquitySecuritiesTransferedtoDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_NoncashAccruedMergerCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash Accrued Merger Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_NoncashAccruedMergerCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ShortTermDebtConvertedtoLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short Term Debt Converted to Long Term Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ShortTermDebtConvertedtoLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorandJuniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_SeniorandJuniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754389360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS DESCRIPTION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BUSINESS DESCRIPTION</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS DESCRIPTION</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Description</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio, Inc., and Subsidiary, (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221; or &#8220;Precipio&#8221;) is a cancer diagnostics company providing diagnostic products and services to the oncology market. We have built and continue to develop a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory located in New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and technologies developed within academia so that we can provide a better standard of cancer diagnostics and solve the growing problem of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development of ICE-COLD-PCR (&#8220;ICP&#8221;), the patented technology which was exclusively licensed by us from Dana-Farber Cancer Institute, Inc. (&#8220;Dana-Farber&#8221;) at Harvard University (&#8220;Harvard&#8221;). The research and development center will focus on the development of this technology, which we believe will enable us to commercialize other technologies developed by our current and future academic partners. Our platform connects patients, physicians and diagnostic experts residing within academic institutions. Launched in 2017, the platform facilitates the following relationships:</font></div><div style="line-height:120%;text-align:justify;text-indent:41px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients: patients may search for physicians in their area and consult directly with academic experts that are on the platform. Patients may also have access to new academic discoveries as they become commercially available.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Physicians: physicians can connect with academic experts to seek consultations on behalf of their patients and may also provide consultations for patients in their area seeking medical expertise in that physician&#8217;s relevant specialty. Physicians will also have access to new diagnostic solutions to help improve diagnostic accuracy.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Academic Experts: academic experts on the platform can make themselves available for patients or physicians seeking access to their expertise. Additionally, these experts have a platform available to commercialize their research discoveries.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to continue updating our platform to allow for patient-to-patient communications and allow individuals to share stories and provide support for one another, to allow physicians to consult with their peers to discuss and share challenges and solutions, and to allow academic experts to interact with others in academia on the platform to discuss their research and cross-collaborate.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ICP was developed at Harvard and is licensed exclusively by us from Dana-Farber. The technology enables the detection of genetic mutations in liquid biopsies, such as blood samples. The field of liquid biopsies is a rapidly growing market, aimed at solving the challenge of obtaining genetic information on disease progression and changes from sources other than a tumor biopsy.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gene sequencing is performed on tissue biopsies taken surgically from the tumor site in order to identify potential therapies that will be more effective in treating the patient. There are several limitations to this process. First, surgical procedures have several limitations, including:</font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost: surgical procedures are usually performed in a costly hospital environment. For example, according to a recent study the mean cost of lung biopsies is greater than $14,000; surgery also involves hospitalization and recovery time.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Surgical access: various tumor sites are not always accessible (e.g. brain tumors), in which cases no biopsy is available for diagnosis.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk: patient health may not permit undergoing an invasive surgery; therefore a biopsy cannot be obtained at all.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Time: the process of scheduling and coordinating a surgical procedure often takes time, delaying the start of patient treatment.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second, there are several tumor-related limitations that provide a challenge to obtaining such genetic information from a tumor:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tumors are heterogeneous by nature: a tissue sample from one area of the tumor may not properly represent the tumor&#8217;s entire genetic composition; thus, the diagnostic results from a tumor may be incomplete and non-representative.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Metastases: in order to accurately test a patient with metastatic disease, ideally an individual biopsy sample should be taken from each site (if those sites are even known). These biopsies are very difficult to obtain; therefore physicians often rely on biopsies taken from the primary tumor site.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The advent of technologies enabling liquid biopsies as an alternative to tumor biopsy and analysis is based on the fact that tumors (both primary and metastatic) shed cells and fragments of DNA into the blood stream. These blood samples are called &#8220;liquid biopsies&#8221; that contain circulating tumor DNA, or ctDNA, which hold the same genetic information found in the tumor(s). That tumor DNA is the target of genetic analysis. However, since the quantity of tumor DNA is very small in proportion to the &#8220;normal&#8221; (or &#8220;healthy&#8221;) DNA within the blood stream, there is a need to identify and separate the tumor DNA from the normal DNA.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ICP is an enrichment technology that enables the laboratory to focus its analysis on the tumor DNA by enriching, and thereby &#8220;multiplying&#8221; the presence of, tumor DNA, while maintaining the normal DNA at its same level. Once the enrichment process has been completed, the laboratory genetic testing equipment is able to identify genetic abnormalities presented in the ctDNA, and an analysis can be conducted at a higher level of sensitivity, to enable the detection of such genetic abnormalities. The technology is encapsulated into a chemical that is provided in the form of a kit and sold to other laboratories who wish to conduct these tests in-house. The chemical within the kit is added to the specimen preparation process, enriching the sample for the tumor DNA so that the analysis will detect those genetic abnormalities.</font></div><div style="line-height:174%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Merger Transaction</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;29, 2017, the Company (then known as &#8220;Transgenomic, Inc.&#8221;, or &#8220;Transgenomic&#8221;), completed a reverse merger (the &#8220;Merger&#8221;) with Precipio Diagnostics, LLC, a privately held Delaware limited liability company (&#8220;Precipio Diagnostics&#8221;) in accordance with the terms of the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated October&#160;12, 2016, as amended on February&#160;2, 2017 and June&#160;29, 2017, by and among Transgenomic, Precipio Diagnostics and New Haven Labs Inc. (&#8220;Merger Sub&#8221;) a wholly-owned subsidiary of Transgenomic. Pursuant to the Merger Agreement, Merger Sub merged with and into Precipio Diagnostics, with Precipio Diagnostics surviving the Merger as a wholly-owned subsidiary of the combined company (See Note 3 - Reverse Merger). In connection with the Merger, the Company changed its name from Transgenomic, Inc. to Precipio, Inc., relisted its common stock under Precipio, Inc. on the National Association of Securities Dealers Automated Quotations (&#8220;NASDAQ&#8221;), and effected a 1-for-30 reverse stock split of its common stock. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements. Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods. As a result of the Merger, historical preferred stock, common stock, restricted units, warrants and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the effect of the Merger exchange ratio. Pursuant to the Merger Agreement, each outstanding share of capital stock of Precipio Diagnostic was exchanged for 10.2502 pre-reverse stock split shares of Company Common Stock (the &#8220;Exchange Ratio&#8221;). See Note 3 - Reverse Merger for additional discussion of the Merger.</font></div><div style="line-height:120%;text-align:justify;text-indent:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Going Concern</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. As of June 30, 2017, the Company had a net loss of </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> and negative working capital of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">. The Company&#8217;s ability to continue as a going concern is dependent upon a combination of achieving its business plan, including generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio is currently in discussions with certain investors to raise additional capital.  There can be no assurance such capital is or will be available at terms favorable or agreeable to management, if at all, or that the Company will successfully complete the proposed capital raise. Since the outcome of these matters cannot be predicted with any certainty at this time, there is substantial doubt that the Company will be able to continue as a going concern. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company&#8217;s ability to continue as a going concern.  There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern. The accompanying financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of the outcome of this uncertainty.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754414768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to June 30, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than what is disclosed in Note 12 - Subsequent Events, there were no other subsequent events that required recognition or disclosure. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto of Precipio Diagnostics for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> contained in our current report on Form 8-K/A, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 31, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Precipio, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in the healthcare industry which is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse.  Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.  Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.  See Note 10 - Fair Value for additional information.</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less. Other current assets as of June 30, 2017 of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> includes prepaid assets of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and other receivables of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and consisted of primarily prepaid assets as of December 31, 2016.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Risk.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed Federal Deposit Insurance Corporation insured limits.  We have not experienced any losses on such accounts as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Service companies in the health care industry typically grant credit without collateral to patients.  The majority of these patients are insured under third-party insurance agreements. The services provided by the Company are routinely billed utilizing the Current Procedural Terminology (CPT) code set designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial, and analytical purposes. CPT codes are currently identified by the Centers for Medicare and Medicaid Services and third-party payors. The Company utilizes CPT codes for Pathology and Laboratory Services contained within codes 80000-89398.</font></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property and Equipment.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense related to property and equipment was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the six months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Depreciation expense during each period includes depreciation related to equipment acquired under capital leases. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Merger, the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration. See Note 3 - Reverse Merger for the amounts recorded.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Goodwill</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may impact goodwill. Impairment occurs when the carrying value is determined to be not recoverable, thereby causing the carrying value of the goodwill to exceed its fair value. If impaired, the asset&#8217;s carrying value is reduced to its fair value. No events have transpired in the six months ended June 30, 2017 that would require an impairment analysis prior to our scheduled review.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Intangibles</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group). There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment charges during the six months ended June 30, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development (&#8220;IPR&amp;D&#8221;) represents the fair value assigned to research and development assets that were not fully developed at the date of the Merger. Until the IPR&amp;D projects are completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. For the six months ended June 30, 2017, there was no impairment of IPR&amp;D. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended both </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, we recorded compensation expense for all stock awards of less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> within operating expense.  As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the unrecognized compensation expense related to unvested stock awards was less than </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in our stock awards outstanding as of June 30, 2017 were fully vested stock appreciation rights (&#8220;SARs&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">to purchase </font><font style="font-family:inherit;font-size:10pt;">2,777</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. The SARs were issued solely to a former executive officer and vested over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. </font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our New Haven, Connecticut laboratory, we primarily recognize revenue for services rendered upon completion of the testing process.  Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payors.  Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At each of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and December 31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, deferred net sales included in the balance sheet in deferred revenue were </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Presentation of Insurance Claims and Related Insurance Recoveries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its insurance claims and related insurance recoveries at their gross values as standards for health care entities do not allow the Company to net insurance recoveries against the related claim liabilities.  There were no insurance claims or insurance recoveries recorded during the three and six months ended June 30, 2017 and 2016.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent that it is more likely than not that they will not be realized. </font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Beneficial Conversion Features.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The intrinsic value of a beneficial conversion feature (&#8220;BCF&#8221;) inherent to a convertible note payable, which is not bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of issuance to the first conversion date using the effective interest method. If the note payable is retired prior to the end of its contractual term, the unamortized discount is expensed in the period of retirement to interest expense. In general, the BCF is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the common shares at the commitment date to be received upon conversion.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">         Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares. When the preferred shares are non-redeemable the BCF is fully amortized into additional paid-in capital and preferred discount. If the preferred shares are redeemable, the discount is amortized from the commitment date to the first conversion date.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to </font><font style="font-family:inherit;font-size:10pt;">2,545,463</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2,771,149</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock have been excluded from the computation of diluted loss per share at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, because the effect is anti-dilutive due to the net loss.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&#8217;s financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2016, FASB issued ASU No.&#160;2016-15</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">Classification of Certain Cash Receipts and Cash Payments.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">ASU No.&#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&#160;2016-15 is effective for fiscal years beginning after December&#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&#160;2016-15 will have a material effect on our financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, FASB issued ASU No.&#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01 adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January&#160;2017, FASB issued ASU No. 2017-04, Intangibles &#8212; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which removes Step 2 from the goodwill impairment test.&#160;It is effective for annual and interim periods beginning after December&#160;15, 2019.&#160;Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after January&#160;1, 2017. The Company has adopted this standard and there was no impact on its consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, FASB issued ASU No. 2017-11, Earning Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815), which was issued in two parts, Part I, Accounting for Certain Financial Instruments with Down Round Features and Part II, Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of ASC No. 2017-11 addresses the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in Part II of ASU 2017-11 recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the codification, to a scope exception. Part II amendments do not have an accounting effect. The ASU 2017-11 is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company has early adopted this standard as of January 1, 2017 with the only impact being that the warrants with down round provisions entered into in June 2017 were treated as equity classification. (See Note 5 - Convertible Bridge Notes).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760023584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE MERGER<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">REVERSE MERGER</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REVERSE MERGER</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June&#160;29, 2017 (the &#8220;Closing Date&#8221;), the Company completed the Merger with Precipio Diagnostics, in accordance with the terms of the Merger Agreement. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements. Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods.</font></div><div style="line-height:120%;padding-top:9px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Closing Date, the outstanding common and preferred units of Precipio Diagnostics and certain debt of Precipio Diagnostics were converted into (i) </font><font style="font-family:inherit;font-size:10pt;">5,352,847</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock, together with cash in lieu of fractional units, and (ii) </font><font style="font-family:inherit;font-size:10pt;">802,920</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio preferred stock with an aggregate face amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:11px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, on the Closing Date, Precipio also issued promissory notes and shares of Precipio preferred and common stock in a number of transactions, whereby:</font></div><div style="line-height:120%;padding-top:11px;text-align:left;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of certain secured indebtedness of Transgenomic received in exchange for such indebtedness </font><font style="font-family:inherit;font-size:10pt;">802,925</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio preferred stock in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> stated value, and </font><font style="font-family:inherit;font-size:10pt;">352,630</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders of Transgenomic preferred stock converted it into </font><font style="font-family:inherit;font-size:10pt;">7,155</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Precipio issued </font><font style="font-family:inherit;font-size:10pt;">107,056</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio preferred stock to certain investors in exchange for </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> in a private placement. Precipio also completed the sale of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$800,000</font><font style="font-family:inherit;font-size:10pt;"> of promissory notes pursuant to a securities purchase agreement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:61px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Consideration</font></div><div style="line-height:120%;padding-top:9px;text-align:left;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preliminary estimated purchase consideration based on the value of the equity of Transgenomic, the accounting acquiree, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.2265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legacy Transgenomic common stock</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of preferred stock converted to common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of debt converted to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of debt converted to preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,796</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of existing bridge notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase consideration</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,602</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:5px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In estimating the preliminary purchase consideration above, Transgenomic used its closing stock price of </font><font style="font-family:inherit;font-size:10pt;">$6.80</font><font style="font-family:inherit;font-size:10pt;"> as of the Closing Date. Transgenomic had </font><font style="font-family:inherit;font-size:10pt;">895,334</font><font style="font-family:inherit;font-size:10pt;"> common shares outstanding prior to the Merger. In connection with the Merger, Transgenomic preferred stock converted into </font><font style="font-family:inherit;font-size:10pt;">7,155</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock and certain of Transgenomic debt and accrued interest converted into </font><font style="font-family:inherit;font-size:10pt;">352,630</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock and </font><font style="font-family:inherit;font-size:10pt;">802,925</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio preferred stock, face value </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> with an </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;"> annual dividend. At the Closing Date, the preferred stock had a fair value of </font><font style="font-family:inherit;font-size:10pt;">$12.20</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Allocation of Purchase Consideration</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth an allocation of the purchase consideration to the identifiable tangible and intangible assets of Transgenomic, the accounting acquiree, based on fair values as of the Closing Date with the excess recorded as goodwill:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current and other assets  </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets  </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities  </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired  </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,602</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets consist of:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademark and trade name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Backlog</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangibles</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determined the estimated fair value of the acquired technology but using the multi-period excess earnings method of the income approach.  The estimated fair value of the remaining identifiable intangible assets acquired were determined primarily by using the income approach.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unaudited pro forma information</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The operating results of Transgenomic for the period after the Closing Date to June 30, 2017 have been included in the Company's condensed consolidated financial statements as of and for the three and six months ended June 30, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollars in thousands, except per share amounts</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss available to common stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,864</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1497-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1490-128463<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1486-128463<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1524-128463<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4922-128472<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4934-128472<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4926-128472<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=SL65897772-128472<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1383-128463<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754456608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DEBT</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Note debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Junior Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Connecticut Innovations - line of credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Department of Economic and Community Development (DECD)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DECD debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Webster Bank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Webster Bank debt discounts and issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible promissory notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,522</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(513</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Senior and Junior Notes</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2016, the Company raised </font><font style="font-family:inherit;font-size:10pt;">$525,000</font><font style="font-family:inherit;font-size:10pt;"> from members through the issuance of senior notes which accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;"> and are payable at the sooner of the closing of a qualified public offering, as outlined in the note agreement, or five years from date of issuance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also during 2016, the Company restructured equity through a redemption and exchange agreement by exchanging Member Equity comprised of Series A and Series B Convertible Preferred Units in the amount of </font><font style="font-family:inherit;font-size:10pt;">$2,147,716</font><font style="font-family:inherit;font-size:10pt;"> (members&#8217; initial investment of $</font><font style="font-family:inherit;font-size:10pt;">1,715,000</font><font style="font-family:inherit;font-size:10pt;">, plus declared dividends on these preferred units of </font><font style="font-family:inherit;font-size:10pt;">$432,716</font><font style="font-family:inherit;font-size:10pt;">), and Convertible Bridge Notes of </font><font style="font-family:inherit;font-size:10pt;">$1,120,000</font><font style="font-family:inherit;font-size:10pt;">, plus accrued interest of </font><font style="font-family:inherit;font-size:10pt;">$61,073</font><font style="font-family:inherit;font-size:10pt;"> for new senior notes of </font><font style="font-family:inherit;font-size:10pt;">$2,744,968</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;Senior Notes&#8221;) and new junior notes of </font><font style="font-family:inherit;font-size:10pt;">$583,821</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;Junior Notes&#8221;). The Senior and Junior Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">, respectively, and have maturity dates ranging from March 2021 to September 2021, or earlier based on certain qualifying events as outlined in the note agreements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six months ended June 30, 2017, the Company raised </font><font style="font-family:inherit;font-size:10pt;">$315,000</font><font style="font-family:inherit;font-size:10pt;"> from members through the issuance of Senior Notes at a rate of </font><font style="font-family:inherit;font-size:10pt;">12%</font><font style="font-family:inherit;font-size:10pt;"> interest that are payable at the sooner of the closing of a qualified public offering, as outlined in the note agreement, or five years from date of issuance.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Closing Date of the Merger, the outstanding balance of </font><font style="font-family:inherit;font-size:10pt;">$3,584,968</font><font style="font-family:inherit;font-size:10pt;"> in Senior Notes and </font><font style="font-family:inherit;font-size:10pt;">$583,821</font><font style="font-family:inherit;font-size:10pt;"> in Junior Notes, plus accrued interest of </font><font style="font-family:inherit;font-size:10pt;">$602,373</font><font style="font-family:inherit;font-size:10pt;">, were converted into </font><font style="font-family:inherit;font-size:10pt;">802,920</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio preferred stock and </font><font style="font-family:inherit;font-size:10pt;">1,414,700</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> Senior or Junior Notes outstanding as June 30, 2017. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, the outstanding balance of Senior and Junior Notes was </font><font style="font-family:inherit;font-size:10pt;">$3,269,968</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$583,821</font><font style="font-family:inherit;font-size:10pt;">, respectively, with accrued interest included within the accrued expenses on the accompanying condensed consolidated balance sheet of </font><font style="font-family:inherit;font-size:10pt;">$279,740</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$71,258</font><font style="font-family:inherit;font-size:10pt;">, respectively.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Connecticut Innovations, Incorporated</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a line of credit on April 1, 2012 with Connecticut Innovations, Incorporated (Connecticut Innovations), an entity affiliated with a director of the Company, for up to </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;"> with interest paid monthly at </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;">, due on </font><font style="font-family:inherit;font-size:10pt;">September&#160;1, 2018</font><font style="font-family:inherit;font-size:10pt;">. Principal and interest payments began February 1, 2013 and ranged from </font><font style="font-family:inherit;font-size:10pt;">$7,436</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$12,206</font><font style="font-family:inherit;font-size:10pt;"> until September 2016, when the Company entered into a forbearance agreement to 1) defer monthly principal payments until October 2017 and 2) make interest-only payments totaling </font><font style="font-family:inherit;font-size:10pt;">$1,041</font><font style="font-family:inherit;font-size:10pt;"> per month through October 2017. Pursuant to the forbearance agreement, the Company was also restricted from any additional borrowings under the line of credit. The line was secured by substantially all of the Company&#8217;s assets.  </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company was to pay in full its loan obligations with Connecticut Innovations. The outstanding balance was </font><font style="font-family:inherit;font-size:10pt;">$162,066</font><font style="font-family:inherit;font-size:10pt;"> at both June 30, 2017 and December 31, 2016.  The outstanding principal and accrued interest balance was paid in full in July 2017. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Department of Economic and Community Development.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;">-year term loan with the Department of Economic and Community Development (&#8220;DECD&#8221;) on May 1, 2013 for </font><font style="font-family:inherit;font-size:10pt;">$300,000</font><font style="font-family:inherit;font-size:10pt;">, with interest paid monthly at </font><font style="font-family:inherit;font-size:10pt;">3%</font><font style="font-family:inherit;font-size:10pt;">, due on </font><font style="font-family:inherit;font-size:10pt;">April&#160;23, 2023</font><font style="font-family:inherit;font-size:10pt;">. The loan was secured by substantially all of the Company&#8217;s assets but was subordinate to the term loan with Webster Bank and the Connecticut Innovations line of credit.  In connection with the Merger, the Company was to pay in full its loan obligations with DECD. The outstanding balance was </font><font style="font-family:inherit;font-size:10pt;">$225,714</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$243,287</font><font style="font-family:inherit;font-size:10pt;"> as of June 30, 2017 and December 31, 2016, respectively.  The outstanding principal and accrued interest balance was paid in full in July 2017. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Webster Bank.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a </font><font style="font-family:inherit;font-size:10pt;">3.5</font><font style="font-family:inherit;font-size:10pt;">-year term loan with Webster Bank on December 1, 2014 for </font><font style="font-family:inherit;font-size:10pt;">$500,000</font><font style="font-family:inherit;font-size:10pt;">, with interest paid monthly at the one month LIBOR rate (</font><font style="font-family:inherit;font-size:10pt;">1.16%</font><font style="font-family:inherit;font-size:10pt;"> at June 30, 2017) plus 500 basis points, due on </font><font style="font-family:inherit;font-size:10pt;">May&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. The line was secured by substantially all of the Company&#8217;s assets and had first priority over all other outstanding debt. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term loan with Webster Bank was subject to financial covenants relating to maintaining adequate cash runway, as defined in the term loan agreement. As of December 31, 2016 the Company was not in compliance with these covenants and, as such, the Webster Bank debt has all been presented as current in the accompanying condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 29, 2017, the closing date of the Merger, the Company paid in full its loan obligations (including principal and interest) with Webster Bank. The outstanding balance was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$328,000</font><font style="font-family:inherit;font-size:10pt;"> as of June 30, 2017 and December 31, 2016, respectively.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and six months ended June 30, 2017, the Company incurred a loss on extinguishment of debt in the approximate amount of </font><font style="font-family:inherit;font-size:10pt;">$53,000</font><font style="font-family:inherit;font-size:10pt;">, related to the extinguishment of the Connecticut Innovations, DECD and Webster Bank loans.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Promissory Notes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company, as part of the merger, assumed an Unsecured Convertible Promissory Note (the &#8220;Note&#8221;) with an accredited investor (the &#8220;Investor&#8221;) in the aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">$125,000</font><font style="font-family:inherit;font-size:10pt;"> and interest accrues at a rate of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> per year. The Note provided that two-thirds of the outstanding principal amount of the Note was due upon the earlier to occur of the close of the Merger or </font><font style="font-family:inherit;font-size:10pt;">June&#160;17, 2017</font><font style="font-family:inherit;font-size:10pt;"> (such applicable date, the &#8220;Maturity Date&#8221;).&#160; The remaining one-third of the principal amount outstanding on the Note was to be paid on the six month anniversary of the Maturity Date.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Maturity Date, the then outstanding aggregate amount owed on the Note of $</font><font style="font-family:inherit;font-size:10pt;">143,041</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(</font><font style="font-family:inherit;font-size:10pt;">$125,000</font><font style="font-family:inherit;font-size:10pt;"> in principal amount and </font><font style="font-family:inherit;font-size:10pt;">$18,041</font><font style="font-family:inherit;font-size:10pt;"> of accrued interest which is included within accrued expenses on the accompanying consolidated condensed balance sheet) became due. Pursuant to the terms of the Note, the Company&#8217;s failure to pay any principal or interest within 10 days of the date such payment is due will constitute an event of default (the &#8220;Prospective Event of Default&#8221;). On June 21, 2017, the Investor agreed to waive the Prospective Event of Default and agreed to further extend the Maturity Date of the Note pursuant to a side letter to the Note (the &#8220;Side Letter&#8221;). The Side Letter provides that two-thirds of the outstanding principal amount of the Note must be paid upon the earlier to occur of (1) the closing of a public offering by the Company of either common stock, convertible preferred stock or convertible preferred notes or (2) August 16, 2017 (such applicable date, the &#8220;Deferred Maturity Date&#8221;). As of August 21, 2017, the Company has not made any payment related to amounts that were due on August 16, 2017. Pursuant to the terms of the Notes, the Company&#8217;s failure to pay any principal or interest within 10 days of the date such payment is due will constitute an event of default. The Company is attempting to negotiate a resolution with the Investor so that the Company will not default on such payment; however, there is no guarantee that the Company will be able to work out a satisfactory resolution. The remaining one-third of the principal amount outstanding on the Note must be paid on the six month anniversary of the Deferred Maturity Date (the &#8220;Extended Maturity Date&#8221;). All accrued and unpaid interest on the outstanding principal amount of the Note will be due and immediately payable on the Extended Maturity Date, unless the Note is converted in which case such interest will be payable in shares of the Company&#8217;s common stock as part of the conversion.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754498624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE BRIDGE LOAN<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">CONVERTIBLE BRIDGE LOAN</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;CONVERTIBLE BRIDGE NOTES.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Bridge Notes.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2016, the Company had outstanding </font><font style="font-family:inherit;font-size:10pt;">$695,000</font><font style="font-family:inherit;font-size:10pt;"> of unsecured convertible bridge notes.  The notes accrued interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">14%</font><font style="font-family:inherit;font-size:10pt;"> and were payable on the extended maturity date of December 31, 2016. During January 2017, the holders of the convertible bridge notes agreed to waive the maturity date of December 31, 2016 and change it to payable on demand and accrue interest until paid.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The convertible bridge notes had conversion terms of (i) convertible into Series C Preferred Units of the Company (at a </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;"> discount) upon a Qualified Series C Financing (as defined in the note agreement), (ii) at the option of the holders of a majority of the then-outstanding principal amount of the notes, convertible into Series C Preferred Units of the Company (at a </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;"> discount) upon any other Series C Financing, or (iii) if no such Qualified Series C Financing occurs, or no such optional conversion takes place by the maturity date (as hereinafter defined), the convertible notes will be fully repaid by Company or the notes and accrued and unpaid interest shall convert into Preferred Series B Units (at a </font><font style="font-family:inherit;font-size:10pt;">30%</font><font style="font-family:inherit;font-size:10pt;"> discount) of the Preferred Series B conversion Price as defined in the operating agreement provided that notice is given to the Company at least one day prior to maturity.&#160; In the event a Deemed Liquidity Event (merger, sale, IPO, or transaction with exchange of 50% or more of voting power) the holders of the notes at their sole discretion can (a) require the Company to pay an amount equal to two times the principal and accrued and unpaid interest or (b) convert all unpaid principal and interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">70%</font><font style="font-family:inherit;font-size:10pt;"> of the applicable security.&#160; These notes were subordinated to Connecticut Innovations, DECD and Webster Bank.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, on the Closing Date, convertible bridge notes of </font><font style="font-family:inherit;font-size:10pt;">$695,000</font><font style="font-family:inherit;font-size:10pt;">, plus </font><font style="font-family:inherit;font-size:10pt;">$192,000</font><font style="font-family:inherit;font-size:10pt;"> of accrued interest, were converted into </font><font style="font-family:inherit;font-size:10pt;">155,639</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 New Bridge Notes I.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the Merger, the Company (then Transgenomic) completed the sale of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> of non-convertible promissory notes (the &#8220;2017 Bridge Notes&#8221;) in a bridge financing pursuant to a securities purchase agreement (the &#8220;Purchase Agreement&#8221;), for which $561,500 was then given to Precipio Diagnostics through the issuance of a promissory note and is eliminated in consolidation. The financing was intended to help facilitate the completion of the Merger. The 2017 Bridge Notes had an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">4%</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">-day maturity. The 2017 Bridge Notes may be repaid by the Company at any time in cash upon payment of a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> premium. In connection with the issuance of the 2017 Bridge Notes, the Company issued warrants (the &#8220;2017 Bridge Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">40,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to anti-dilution protection. The Purchase Agreement provides certain piggyback registration rights for the holders of the 2017 Bridge Warrants for a period of six months after the closing of the bridge financing. Aegis Capital Corp. acted as placement agent for the bridge financing and received a placement agent fee of </font><font style="font-family:inherit;font-size:10pt;">$84,000</font><font style="font-family:inherit;font-size:10pt;"> and warrants (the &#8220;Aegis Warrants&#8221;) to acquire </font><font style="font-family:inherit;font-size:10pt;">5,600</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The Aegis Warrants are identical to the 2017 Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the time of the Merger, the 2017 Bridge Notes were extinguished and replaced with convertible promissory notes (the &#8220;2017 New Bridge Notes I&#8221;) with an original principal amount of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate pursuant to an Exchange Agreement (the &#8220;Exchange Agreement&#8221;) entered into on the Closing Date. The 2017 New Bridge Notes I have an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;"> and are due and payable upon the earlier to occur of (i) October 1, 2017 or (ii) the closing of a Qualified Offering (as defined in the 2017 New Bridge Notes I). The 2017 New Bridge Notes I are convertible into shares of our common stock at an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$3.736329</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment, and may be convertible into shares of our preferred stock at the holder&#8217;s option if the Company does not complete a Qualified Offering (as defined in the 2017 New Bridge Notes I) by October 1, 2017. The Company may redeem the 2017 New Bridge Notes I at any time in cash upon payment of a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> premium, or </font><font style="font-family:inherit;font-size:10pt;">$240,000</font><font style="font-family:inherit;font-size:10pt;">. As the convertible promissory notes were convertible into the Company's common stock at a conversion rate lower than the fair market value of the common stock at the time of issuance, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$989,000</font><font style="font-family:inherit;font-size:10pt;"> as a beneficial conversion feature, which was recorded as a debt discount in the balance sheet. The discount will be amortized using the effective interest method through the first conversion date of the 2017 New Bridge Notes I.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Exchange Agreement, the 2017 Bridge Warrants were canceled and replaced with new warrants to acquire </font><font style="font-family:inherit;font-size:10pt;">45,600</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock (the &#8220;2017 New Bridge Warrants&#8221;). The initial exercise price of the 2017 New Bridge Warrants is </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;"> (subject to adjustments). If the Company completes a Qualified Offering (as defined in the 2017 New Bridge warrants), the exercise price of the 2017 New Bridge Warrants will become the lower of (i) </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;">, or (ii) </font><font style="font-family:inherit;font-size:10pt;">110%</font><font style="font-family:inherit;font-size:10pt;"> of the per share offering price in the Qualified Offering, but in no event lower than </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;"> per share, which has been considered a down round provision. At issuance, the 2017 New Bridge Warrants had a fair value of </font><font style="font-family:inherit;font-size:10pt;">$211,000</font><font style="font-family:inherit;font-size:10pt;"> and were recorded as a debt discount to the related 2017 New Bridge Notes I, with the corresponding entry to additional paid in capital as the warrants were considered classified as equity in accordance with GAAP. As discussed in Note 2 of the accompanying unaudited condensed consolidated financial statements, the Company early adopted ASU 2017-11, which allowed the Company to treat the warrants as equity classified, despite the down round provision.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 New Bridge Note II.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, on the Closing Date and pursuant to a Securities Purchase Agreement (the &#8220;Bridge Purchase Agreement&#8221;), the Company completed the sale of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$800,000</font><font style="font-family:inherit;font-size:10pt;"> of a convertible promissory note (the &#8220;2017 New Bridge Note II&#8221;). The Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$721,000</font><font style="font-family:inherit;font-size:10pt;"> from the sale of the 2017 New Bridge Note II, which will be used for working capital purposes. The 2017 New Bridge Note II has an annual interest rate of </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;"> and are due and payable upon the earlier to occur of (i) October 1, 2017 or (ii) the closing of a Qualified Offering (as defined in the 2017 New Bridge Note II). The 2017 New Bridge Note II is convertible into shares of our common stock at an initial conversion price of </font><font style="font-family:inherit;font-size:10pt;">$3.736329</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to adjustment, and may be convertible into shares of our preferred stock at the holder&#8217;s option if the Company does not complete a Qualified Offering (as defined in the 2017 New Bridge Note II) by October 1, 2017. The Company may redeem the 2017 New Bridge Note II at any time in cash upon payment of a </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> premium, or </font><font style="font-family:inherit;font-size:10pt;">$160,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the 2017 New Bridge Note II was convertible into the Company's common stock at a conversion rate lower than the fair market value of the common stock at the time of issuance, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$656,000</font><font style="font-family:inherit;font-size:10pt;"> as a beneficial conversion feature, which was recorded as a debt discount in the balance sheet. The discount will be amortized using the effective interest method through the first conversion date of the 2017 New Bridge Note II.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the bridge financing and the assumption of certain obligations by an entity controlled by Mark Rimer (a director of the Company), the Company issued to that entity warrants (the &#8220;Side Warrants&#8221;) to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">91,429</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$7.00</font><font style="font-family:inherit;font-size:10pt;"> per share (subject to adjustment), with a fair value of </font><font style="font-family:inherit;font-size:10pt;">$487,000</font><font style="font-family:inherit;font-size:10pt;"> at the date of issuance. The Side Warrants have a term of </font><font style="font-family:inherit;font-size:10pt;">5 years</font><font style="font-family:inherit;font-size:10pt;"> and are exercisable as to </font><font style="font-family:inherit;font-size:10pt;">22,857</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock upon grant and as to </font><font style="font-family:inherit;font-size:10pt;">68,572</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock upon the entity&#8217;s performance of the assumed obligations. The Company has recorded merger advisory expense of </font><font style="font-family:inherit;font-size:10pt;">$414,000</font><font style="font-family:inherit;font-size:10pt;"> related to the Side Warrants during the three and six months ended June 30, 2017. The remaining fair value of </font><font style="font-family:inherit;font-size:10pt;">$73,000</font><font style="font-family:inherit;font-size:10pt;"> will be recorded as expense at the time the performance obligations are met.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, upon the Company consummating one or more rounds of equity financing following July 1, 2017, with aggregate gross proceeds of at least </font><font style="font-family:inherit;font-size:10pt;">$7 million</font><font style="font-family:inherit;font-size:10pt;">, the Company will use a portion of the proceeds from such financing to repay the principal amount of the 2017 New Bridge Notes, together with any premium and interest.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 30, 2017, the outstanding convertible notes balance was </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of debt discounts of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> and debt issuance cost of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.  Accrued interest of approximately </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> is included within accrued expenses on the accompanying condensed consolidated balance sheet.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760103696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;ACCRUED EXPENSES.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following:</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.5859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6598022832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENCIES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTINGENCIES</font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is involved in legal proceedings related to matters, which are incidental to its business. The Company has also assumed a number of claims as a result of the Merger. See below for a discussion on these matters. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The healthcare industry is subject to numerous laws and regulations of federal, state and local governments.  These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed.  Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations.  While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The outcome of legal proceedings and claims brought against us are subject to significant uncertainty.  Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management&#8217;s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Claims assumed in the Merger</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assumed a number of claims as a result of the Merger. In addition to the claims described below, we are delinquent on the payment of outstanding accounts payable certain of our vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 25, 2016, the Board of Regents of the University of Nebraska (&#8220;UNMC&#8221;) filed a lawsuit against us in the District Court of Douglas County, Nebraska, for breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to UNMC.  A </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at March 31, 2017 and December 31, 2016. We and UNMC entered into a settlement agreement dated February 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay $0.4 million to UNMC in installments over a period of time. As of March 15, 2017, the initial payment due to UNMC under the settlement agreement is delinquent. We and UNMC are currently in discussions to extend the date of the initial payment due to UNMC. A </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 13, 2016, Fox Chase Cancer Center (&#8220;Fox Chase&#8221;) filed a lawsuit against Transgenomic in the Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania Civil Trial Division (the &#8220;Court of Common Pleas&#8221;), alleging, among other things, breach of contract, tortious interference with present and prospective contractual relations, unjust enrichment, fraudulent conversion and conspiracy and seeking punitive damages in addition to damages and other relief. This lawsuit relates to a license agreement Transgenomic entered into with Fox Chase in August 2000, as amended (the &#8220;License Agreement&#8221;), as well as the assignment of certain of Transgenomic's rights under the License Agreement to Integrated DNA Technologies, Inc. (&#8220;IDT&#8221;) pursuant to the Surveyor Kit Patent, Technology and Inventory Purchase Agreement Transgenomic entered into with IDT effective as of July 1, 2014 (the &#8220;IDT Agreement&#8221;). Pursuant to the terms of the IDT Agreement, Transgenomic agreed to indemnify IDT with respect to certain of the claims asserted in the Fox Chase proceeding. On July 8, 2016, the Court of Common Pleas sustained Transgenomic's preliminary objections to several of Fox Chase&#8217;s claims and dismissed the claims for tortious interference, fraudulent conversion, conspiracy, punitive damages and attorney&#8217;s fees.&#160; Accordingly, the case has been narrowed so that only certain contract claims and an unjust enrichment claim remained pending against Transgenomic. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During June 2017, prior to the Merger, Transgenomic entered into a settlement agreement with Fox Chase (the &#8220;Agreement&#8221;) which will resolve all outstanding claims in the litigation brought in April 2016 by Fox Chase against Transgenomic in the Court of Common Pleas of Philadelphia County (the &#8220;Action&#8221;). The case will remain pending with the Court until all settlement payments to Fox Chase have been made. Under the Agreement the Company will make three (</font><font style="font-family:inherit;font-size:10pt;">3</font><font style="font-family:inherit;font-size:10pt;">) payments to Fox Chase totaling </font><font style="font-family:inherit;font-size:10pt;">$175,000</font><font style="font-family:inherit;font-size:10pt;">. The last payment is to be made on or before September 30, 2017, and once received Fox Chase is obligated to cause the Action to be formally dismissed with prejudice. Also, on July 13, 2017 the Company entered into an agreement with its co-Defendant, IDT, regarding the Company&#8217;s indemnity obligations to IDT for legal fees and expenses incurred in the Action pursuant to the terms of the IDT Agreement. The IDT Agreement provides for monthly payments of </font><font style="font-family:inherit;font-size:10pt;">$27,800</font><font style="font-family:inherit;font-size:10pt;"> from the Company to IDT, in the total amount of </font><font style="font-family:inherit;font-size:10pt;">$139,000</font><font style="font-family:inherit;font-size:10pt;">, commencing on August 15, 2017 and concluding on December 15, 2017. A </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&#8220;Mount Sinai&#8221;) filed a lawsuit against us in the Supreme Court of the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> to Mount Sinai in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at June 30, 2017.  Effective as of February 1, 2017, we and Mount Sinai agreed to amend the terms of our settlement agreement to extend the date of the initial payment due to Mount Sinai.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 19, 2016, Todd Smith (&#8220;Smith&#8221;) filed a lawsuit against us in the District Court of Douglas County Nebraska, alleging breach of contract and seeking recovery of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to Smith for costs and damages arising from a breach of our obligations pursuant to a lease agreement between the parties.  On April 7, 2017, we entered into a settlement agreement with Smith related to the early termination of our lease for our Omaha, Nebraska facility. The agreement included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> to Smith in installments over a period of time. A </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at June 30, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 21, 2017, XIFIN, Inc. (&#8220;XIFIN&#8221;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.27 million</font><font style="font-family:inherit;font-size:10pt;"> owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against us. On May 5, 2017, XIFIN filed an application for entry of default judgment against us. A </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> liability has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and Science Park Development Corporation (&#8220;SPDC&#8221;) entered into that certain Lease dated as of December 31, 2011, as modified by the First Amendment to Lease dated as of June 18, 2013, as further modified by a letter agreement dated as of February 2, 2015, as modified by the Second Amendment to Lease dated as of June 26, 2015 (the &#8220; SPDC Lease&#8221;).   In November 2016, SPDC alleged that we defaulted on our obligations under the SPDC Lease.  Specifically, SPDC alleges that we failed to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> in rental payments due under the SPDC Lease and that we vacated a portion of the leased premises in violation of the terms of the SPDC Lease.  We and SPDC entered into a settlement agreement dated March 6, 2017, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> to SPDC in installments over a period of time. This liability has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CPA Global provides us with certain patent management services.  On February 6, 2017, CPA Global claimed that we owe approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for certain patent maintenance services rendered.  CPA Global has not filed claims against us in connection with this allegation.  A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 9, 2016, counsel for Edge BioSystems, Inc. (&#8220;EdgeBio&#8221;) sent a demand letter on behalf of EdgeBio to us in connection with the terms of that certain Asset Purchase Agreement dated September 8, 2015 (the &#8220;EdgeBio Agreement&#8221;). EdgeBio alleges, among other things, that certain customers of EdgeBio erroneously remitted payments to us, that such payments should have been paid to EdgeBio and that we failed to remit these funds to EdgeBio in violation of the terms of the EdgeBio Agreement.  On September 13, 2016, we received a demand for payment letter from EdgeBio&#8217;s counsel alleging that the balance due to EdgeBio is approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.  A liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> has been recorded and is reflected in accrued expenses at June 30, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 17, 2017, Jesse Campbell (&#8220;Campbell&#8221;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we have a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&#8217;s deal protection provisions deter superior offers.&#160; As a result, he alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&#160; Although we intend to defend the lawsuit, there can be no assurance regarding the ultimate outcome of this case.  Given the uncertainty of litigation, the legal standards that must be met for, among other things, class certification and success on the merits, we are unable to estimate the amount of loss, or range of possible loss, at this time that may result from this action. In the event that a settlement is reached related to these matters, the amount of such settlement may be material to our results of operations and financial condition and may have a material adverse impact on our liquidity.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759992208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INCOME TAXES </font></div><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We file a US federal consolidated income tax return and state income tax returns in various jurisdictions. We have statutes of limitation open for federal &amp; state income tax returns related to tax years 2014 through 2016.</font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense for both the three months and six months ended June&#160;30, 2017 was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> as a result of recording a full valuation allowance against the deferred tax asset generated predominantly by net operating losses. For the three and six months ended June 30, 2016, the Company was organized as a limited liability company and operated under the default classification as a partnership until July 31, 2016. Consequently, prior to August 1, 2016, income tax expense or benefits were calculated at the members&#8217; level.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had no material interest or penalties during fiscal 2017 or fiscal 2016, and we do not anticipate any such items during the next twelve months.  Our policy is to record interest and penalties directly related to uncertain tax positions as income tax expense in the condensed consolidated statements of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the merger, there was a change in ownership as defined in IRS &#167; 382. Because of this change, use of a portion of the accumulated net operating losses and tax credit carryforwards will be limited in future periods. Further, a portion of the carryforwards will expire before being applied to reduce future income tax liabilities. Since the net deferred tax assets have a full valuation allowance recorded, any limitation generated from this calculation would not effect the current financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754377264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock.</font></div><div style="line-height:120%;padding-left:36px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">150,000,000</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">shares of common stock authorized for issuance.</font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company effected a 1-for-30 reverse stock split of its common stock. This reverse stock split became effective on June 13, 2017 and, unless otherwise indicated, all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying unaudited condensed consolidated financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split. Additionally, as a result of the Merger, the Company has recapitalized its stock. All historical preferred stock, common stock, restricted units, warrants and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the effect of the Merger exchange ratio. Pursuant to the Merger Agreement, each outstanding share of capital stock of Precipio Diagnostics was exchanged for </font><font style="font-family:inherit;font-size:10pt;">10.2502</font><font style="font-family:inherit;font-size:10pt;"> pre-reverse stock split shares of the Company's common stock.</font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2016, there were </font><font style="font-family:inherit;font-size:10pt;">449,175</font><font style="font-family:inherit;font-size:10pt;"> share of common stock outstanding. </font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2017, restricted stock of </font><font style="font-family:inherit;font-size:10pt;">59,563</font><font style="font-family:inherit;font-size:10pt;"> shares were granted during the three and six months ended June 30, 2017, none of which vested prior to the merger, upon closing of the merger, all shares fully vested. During 2017, </font><font style="font-family:inherit;font-size:10pt;">64,593</font><font style="font-family:inherit;font-size:10pt;"> shares were released to common stock. We recorded stock compensation expense of approximately </font><font style="font-family:inherit;font-size:10pt;">$28,000</font><font style="font-family:inherit;font-size:10pt;"> related to restricted stock that vested during the six months ended June 30, 2017. </font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Closing Date, Precipio Diagnostics received </font><font style="font-family:inherit;font-size:10pt;">4,317,152</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock from the conversion of preferred stock, senior and junior debt, bridge notes and warrants. Also, certain advisors of Precipio Diagnostics received </font><font style="font-family:inherit;font-size:10pt;">321,821</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock related to services performed in connection with the Merger. The fair value of these advisory shares was </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> at the date of the Merger and is included as a merger advisory fee expense in the accompanying financial statements.</font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the Merger, Precipio Diagnostics also received </font><font style="font-family:inherit;font-size:10pt;">200,081</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock that have not been issued yet. </font><font style="font-family:inherit;font-size:10pt;">135,000</font><font style="font-family:inherit;font-size:10pt;"> of these shares are being held for future issuance to advisors pending completion of certain performance obligations. If these performance obligations are not met, the shares will remain with Precipio Diagnostics as part of the unissued pool. For any shares that remain unissued, it is the intent of the Company to allocate these to Precipio Diagnostics shareholders on a pro rata basis. </font></div><div style="line-height:120%;padding-top:9px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also, upon completion of the Merger, Transgenomic legacy stockholders had </font><font style="font-family:inherit;font-size:10pt;">1,255,119</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock outstanding.</font></div><div style="line-height:120%;padding-top:11px;text-align:justify;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June 30, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">6,407,860</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock outstanding.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrants.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the merger, in connection with the line of credit with Connecticut Innovations, the Company issued warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">8,542</font><font style="font-family:inherit;font-size:10pt;"> Series A Preferred shares of the Company, which were classified as an equity warrant, at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$2.93</font><font style="font-family:inherit;font-size:10pt;"> per unit, subject to adjustments as defined in the warrant agreement. The warrants were valued at </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;"> at the date of the grant utilizing the Black-Sholes model (volatility </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;">, expected life </font><font style="font-family:inherit;font-size:10pt;">7 years</font><font style="font-family:inherit;font-size:10pt;">, and risk free rate </font><font style="font-family:inherit;font-size:10pt;">.36%</font><font style="font-family:inherit;font-size:10pt;">). The value of the warrants were treated as a debt discount. At the Merger date, the warrants were exercised and then converted into shares of Precipio common stock.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Webster Bank agreement, the Company issued </font><font style="font-family:inherit;font-size:10pt;">7 years</font><font style="font-family:inherit;font-size:10pt;"> warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">20,000</font><font style="font-family:inherit;font-size:10pt;"> Series B Preferred shares of the Company. At the Merger date, Webster Bank declined to exercise their warrants and, per the terms of the warrant agreement, the warrants were retired.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Company entered into a redemption and exchange agreement with certain member's relating to their </font><font style="font-family:inherit;font-size:10pt;">275,237</font><font style="font-family:inherit;font-size:10pt;"> Preferred A Units and </font><font style="font-family:inherit;font-size:10pt;">208,087</font><font style="font-family:inherit;font-size:10pt;"> Preferred B Units. Under the terms of the agreement, the unit holders would exchange their units in the Company for the issuance of debt. The aggregate purchase price per the agreement was the member's initial investment of </font><font style="font-family:inherit;font-size:10pt;">$750,000</font><font style="font-family:inherit;font-size:10pt;"> for Preferred A Units and </font><font style="font-family:inherit;font-size:10pt;">$965,000</font><font style="font-family:inherit;font-size:10pt;"> for Preferred B Units, along with a preferred return of </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;">, recorded as a dividend in the amount of </font><font style="font-family:inherit;font-size:10pt;">$432,716</font><font style="font-family:inherit;font-size:10pt;">. In addition to the debt issued as consideration for the member's preferred units, the Company also issued common warrant units, which allows the holders to collectively purchase common units of the Company, representing approximately </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;"> of the Company at the time of exercise. At the time of issuance, this represented approximately </font><font style="font-family:inherit;font-size:10pt;">1,958,204</font><font style="font-family:inherit;font-size:10pt;"> common units. The common warrant units had a $0.00 exercise price with a </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> year expiration date. The common warrant units were classified as equity awards and the fair value upon issuance was calculated utilizing a discounted cash flow analysis to value the Company's equity and an option pricing method to allocate the value of the equity. The fair value of the warrants was determined directly utilizing the option pricing method as the exercise price was $0.00. The aggregate value of the common warrant units was </font><font style="font-family:inherit;font-size:10pt;">$1,421,738</font><font style="font-family:inherit;font-size:10pt;">, which was considered a deemed dividend. At the time of the Merger, these warrants were converted into </font><font style="font-family:inherit;font-size:10pt;">1,958,204</font><font style="font-family:inherit;font-size:10pt;"> shares of Precipio common stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Warrants Assumed in Merger</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the time of the Merger, Transgenomic had a number of outstanding warrants related to various financing transactions that occurred between 2013-2016. Details related to year issued, expiration date, amount of underlying common shares and exercise price are included in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 New Bridge Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the six months ended June 30, 2017, prior to the Merger, Transgenomic completed the sale of the 2017 Bridge Notes in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> and the issuance of the 2017 Bridge Warrants to acquire </font><font style="font-family:inherit;font-size:10pt;">40,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share, subject to anti-dilution protection. Aegis Capital Corp. acted as placement agent for the bridge financing and received Aegis Warrants to acquire </font><font style="font-family:inherit;font-size:10pt;">5,600</font><font style="font-family:inherit;font-size:10pt;"> shares of Transgenomic common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$15.00</font><font style="font-family:inherit;font-size:10pt;"> per share. The Aegis Warrants are identical to the 2017 Bridge Warrants except that the Aegis Warrants do not have anti-dilution protection. (See Note 5 - Convertible Bridge Notes).</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the holders of the 2017 Bridge Notes, the 2017 Bridge Warrants and the Aegis Warrants agreed to exchange the 2017 Bridge Notes, the 2017 Bridge Warrants and the Aegis Warrants for 2017 New Bridge Notes and the 2017 New Bridge Warrants to acquire </font><font style="font-family:inherit;font-size:10pt;">45,600</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. (See Note 5 - Convertible Bridge Notes). The initial exercise price of the 2017 New Bridge Warrants is </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;"> (subject to adjustments). If the Company completes a Qualified Offering (as defined in the 2017 New Bridge Warrants), the exercise price of the 2017 New Bridge Warrants will become the lower of (i) </font><font style="font-family:inherit;font-size:10pt;">$7.50</font><font style="font-family:inherit;font-size:10pt;"> or (ii) </font><font style="font-family:inherit;font-size:10pt;">110%</font><font style="font-family:inherit;font-size:10pt;"> of the per share offering price in the Qualified Offering, but in no event lower than </font><font style="font-family:inherit;font-size:10pt;">$1.50</font><font style="font-family:inherit;font-size:10pt;"> per share. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At issuance, the 2017 New Bridge Warrants had a fair value of </font><font style="font-family:inherit;font-size:10pt;">$211,000</font><font style="font-family:inherit;font-size:10pt;"> and were recorded as a debt discount to the related 2017 New Bridge Notes I, with the corresponding entry to additional paid in capital as the warrants were considered classified as equity in accordance with GAAP.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Side Warrants</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the bridge financing and the assumption of certain obligations by an entity controlled by Mark Rimer (a director of the Company), the Company issued to that entity Side Warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">91,429</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$7.00</font><font style="font-family:inherit;font-size:10pt;"> per share (subject to adjustment), with a fair value of $487,000 at the date of issuance. The Side Warrants have a term of </font><font style="font-family:inherit;font-size:10pt;">5 years</font><font style="font-family:inherit;font-size:10pt;"> and are exercisable as to </font><font style="font-family:inherit;font-size:10pt;">22,857</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock upon grant and as to </font><font style="font-family:inherit;font-size:10pt;">68,572</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock upon the entity&#8217;s performance of the assumed obligations. The Company has recorded merger advisory expense of </font><font style="font-family:inherit;font-size:10pt;">$414,000</font><font style="font-family:inherit;font-size:10pt;"> related to the Side Warrants during the three and six months ended June 30, 2017. The remaining fair value of </font><font style="font-family:inherit;font-size:10pt;">$73,000</font><font style="font-family:inherit;font-size:10pt;"> will be recorded as expense at the time the performance obligations are met. </font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a summary of the warrants outstanding as of June 30, 2017:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Warrants Assumed in Merger</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,055</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$270.00</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$120.00</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,826</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$67.20</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$49.80</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,733</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$36.30</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$36.30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Warrants</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,600</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.50</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,379</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with an offering in July 2015, and were amended in connection with an offering which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These are the 2017 New Bridge Warrants which were issued in connection with the Merger. See discussion above for additional information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(8)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These are the Side Warrants which were issued in connection with the Merger. See discussion above for additional information</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series A and Series B Preferred Stock.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company had outstanding preferred units of </font><font style="font-family:inherit;font-size:10pt;">367,299</font><font style="font-family:inherit;font-size:10pt;"> for Series A and </font><font style="font-family:inherit;font-size:10pt;">412,806</font><font style="font-family:inherit;font-size:10pt;"> for Series B as of December 31, 2016.  These shares have been recapitalized and are included in preferred stock. On the Closing Date, the outstanding preferred units for Series A and Series B, along with the related accumulated dividends, were converted into common shares of the Company.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Board of Directors is authorized to issue up to </font><font style="font-family:inherit;font-size:10pt;">15,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i)&#160;the number of shares; (ii)&#160;the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii)&#160;whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv)&#160;whether shares shall be convertible and, if so, the terms and provisions thereof; (v)&#160;what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi)&#160;whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends.  We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Series A Senior Preferred Stock.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware on June 29, 2017, designating </font><font style="font-family:inherit;font-size:10pt;">4,100,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s Preferred Stock, par value </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share, as Series A Senior Convertible Preferred Stock ("Series A Senior") and establishing the rights, preferences and privileges of the new preferred stock. Generally, the holders of the Series A Senior stock are entitled to vote as a single voting group with the holders of the Company's common stock, and the holders of the Series A Senior stock are generally entitled to that number of votes as is equal to the number of whole shares of the Company's common stock into which the Series A Senior stock may be converted as of the record date of such vote or consent.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">So long as the shares of Series A Senior stock are outstanding certain actions will require the separate approval of at least two-thirds of the Series A Senior stock, including: changes to the terms (requires three-fourths approval) of the Series A Senior stock, changes to the number of authorized shares of Series A Senior stock, issuing a series of preferred stock that is senior to the Series A Senior stock, changing the size of the board of directors, certain changes to the capital stock of the Company, bankruptcy proceedings and granting security interests in the Company&#8217;s assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series A Senior stock will be convertible into the Company's common stock at any time at the then applicable conversion price. The initial conversion price for the Series A Senior stock issued in connection with the Merger and the other transactions described herein is </font><font style="font-family:inherit;font-size:10pt;">$3.736329</font><font style="font-family:inherit;font-size:10pt;">, but will be subject to anti-dilution protections including adjustments for stock splits, stock dividends, other distributions, recapitalizations and the like. Additionally, each holder of the Series A Senior stock will have a right to convert such holder's Series A Senior stock into securities issued in any future private offering of the Company's securities at a </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> discount to the proposed price in such private offering.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series A Senior stock will be entitled to an annual </font><font style="font-family:inherit;font-size:10pt;">8%</font><font style="font-family:inherit;font-size:10pt;"> cumulative payment in lieu of interest or dividends, payable in-kind for the first two years and in cash or in-kind thereafter, at the option of the Company. The Series A Senior stock also will be entitled to share in any dividends paid on the Company's common stock.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 3 - Reverse Merger, in connection with the Merger, the Company issued 1) to holders of certain Transgenomic secured indebtedness, </font><font style="font-family:inherit;font-size:10pt;">802,925</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Senior stock in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;">, 2) to holders of certain Precipio Diagnostic indebtedness, </font><font style="font-family:inherit;font-size:10pt;">802,920</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Senior stock in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;"> and 3) to certain investors, </font><font style="font-family:inherit;font-size:10pt;">107,056</font><font style="font-family:inherit;font-size:10pt;"> shares of Series A Senior stock in exchange for </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;"> in a private placement. The Company had outstanding Series A Senior shares of </font><font style="font-family:inherit;font-size:10pt;">1,712,901</font><font style="font-family:inherit;font-size:10pt;"> as of June 30, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determined that there was a beneficial conversion feature in connection with the issuances of the Series A Senior stock since the conversion price of  </font><font style="font-family:inherit;font-size:10pt;">$3.736329</font><font style="font-family:inherit;font-size:10pt;"> was at a discount to the fair market value of the Company's common stock at issuance date. The Series A Senior stock is non-redeemable and as a result, the Company recognized the full beneficial conversion feature in the amount of </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;"> as a deemed dividend at the time of issuance.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759980976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FAIR VALUE</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FAIR VALUE</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our condensed consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;1&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;2&#8212;Observable inputs other than those included in Level&#160;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&#160;and</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level&#160;3&#8212;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrant Liabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 Warrant Liability</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assumed the 2016 Warrant Liability in the merger and it represents the fair value of Transgenomic warrants issued in January 2016, of which, </font><font style="font-family:inherit;font-size:10pt;">25,584</font><font style="font-family:inherit;font-size:10pt;"> warrants remain outstanding as of June 30, 2017. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our condensed consolidated Statement of Operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Warrant Liability is considered a Level 3 financial instrument and is valued using a binomial lattice simulation model.  This method is well suited to valuing options with non-standard features.  Assumptions and inputs used in the valuation of the common stock warrants include: our equity value, which was estimated using our stock price of </font><font style="font-family:inherit;font-size:10pt;">$9.00</font><font style="font-family:inherit;font-size:10pt;"> as of June 30, 2017; volatility of </font><font style="font-family:inherit;font-size:10pt;">121%</font><font style="font-family:inherit;font-size:10pt;">; and a risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">1.64%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended June 30, 2017, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:72.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at April 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions - liability assumed in the Merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760030112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTIONS</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK OPTIONS </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options.</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's 2006 Equity Incentive Plan (the "2006 Plan") was terminated as to future awards on July 12, 2016. The Company's 2017 Stock Option and Incentive Plan (the "2017 Plan") was adopted by the Company's stockholders on June 5, 2017 and will expire on June 5, 2027. The following table summarizes stock option activity under our plans during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,908</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">21,713</font><font style="font-family:inherit;font-size:10pt;"> options that were vested or expected to vest with an aggregate intrinsic value of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">6.9</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Appreciation Rights (</font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">SARs</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2,777</font><font style="font-family:inherit;font-size:10pt;"> outstanding and exercisable SARs shares were vested or expected to vest. All outstanding SARs were issued solely to a former chief executive officer. The weighted-average exercise price of these SARs was </font><font style="font-family:inherit;font-size:10pt;">$129.60</font><font style="font-family:inherit;font-size:10pt;"> per share and the aggregate intrinsic value was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> with a remaining weighted average contractual life of </font><font style="font-family:inherit;font-size:10pt;">6.25</font><font style="font-family:inherit;font-size:10pt;"> years. During the six months ended June 30, 2017, the SARs liability decreased approximately </font><font style="font-family:inherit;font-size:10pt;">$5,000</font><font style="font-family:inherit;font-size:10pt;"> and at June 30, 2017, a liability of approximately </font><font style="font-family:inherit;font-size:10pt;">$7,000</font><font style="font-family:inherit;font-size:10pt;"> was recorded in accrued expenses.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759981520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-left:30px;text-indent:-30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENTS </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 1, 2017, the Company announced that it was planning a public offering of common stock and warrants in an underwritten public offering. There can be no assurances as to whether the offering will be completed, or as to the size or terms of the offering. Even if the offering is completed, the Company will need to raise additional funding.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770296864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to June 30, 2017 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than what is disclosed in Note 12 - Subsequent Events, there were no other subsequent events that required recognition or disclosure. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2016. The accompanying condensed consolidated financial statements as of and for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;"> are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto of Precipio Diagnostics for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> contained in our current report on Form 8-K/A, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 31, 2017. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2017.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements include the accounts of Precipio, Inc. and our wholly owned subsidiary. All inter-company balances and transactions have been eliminated in consolidation.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. In addition, estimates and assumptions associated with the determination of the fair value of certain assets and related impairments require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risks and Uncertainties.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements.  The more significant of those risks are presented below and throughout the notes to the unaudited condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise specified, book value approximates fair value. The common stock warrant liability is recorded at fair value.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents and Other Current Asssets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents and Other Current Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents include cash and investments with original maturities at the date of acquisition of three months or less.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConcentrationOfCashPolicyPolicyTextBlock', window );">Concentrations of Cash</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Risk.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may maintain a cash position with financial institutions in amounts that exceed Federal Deposit Insurance Corporation insured limits.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Intangible Assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Merger, the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration. See Note 3 - Reverse Merger for the amounts recorded.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Goodwill</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may impact goodwill. Impairment occurs when the carrying value is determined to be not recoverable, thereby causing the carrying value of the goodwill to exceed its fair value. If impaired, the asset&#8217;s carrying value is reduced to its fair value. No events have transpired in the six months ended June 30, 2017 that would require an impairment analysis prior to our scheduled review.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Intangibles</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair market value of the asset to the carrying amount of the asset (group). There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment charges during the six months ended June 30, 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development (&#8220;IPR&amp;D&#8221;) represents the fair value assigned to research and development assets that were not fully developed at the date of the Merger. Until the IPR&amp;D projects are completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. For the six months ended June 30, 2017, there was no impairment of IPR&amp;D. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation. </font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year contractual terms. Unvested awards as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> had vesting periods of up to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. None of the awards outstanding at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are subject to performance or market-based vesting conditions.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Net Sales Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Sales Recognition.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;padding-left:66px;text-indent:-36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue is realized and earned when all of the following criteria are met:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Persuasive evidence of an arrangement exists;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delivery has occurred or services have been rendered;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The seller&#8217;s price to the buyer is fixed or determinable; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collectability is reasonably assured.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our New Haven, Connecticut laboratory, we primarily recognize revenue for services rendered upon completion of the testing process.  Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payors.  Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our Omaha, Nebraska laboratory, we perform services on a project by project basis. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. These projects typically do not extend beyond one year.  </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ncome Taxes.</font></div><div style="line-height:120%;padding-top:18px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent that it is more likely than not that they will not be realized. </font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_BeneficialConversionFeaturePolicyTextBlock', window );">Beneficial Conversion Feature</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Beneficial Conversion Features.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Per Share.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.  Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements. </font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers. This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to a customer. ASU No. 2014-09 will replace most existing revenue recognition guidance in generally accepted accounting principles in the U.S. when it becomes effective. In July 2015, the FASB decided to defer the effective date of this new accounting guidance by one year.  As a result, ASU No. 2014-09 will be effective for us for all annual and interim reporting periods beginning after December 15, 2017 and early adoption would be permitted as of the original effective date. The new standard permits the use of either the retrospective or cumulative effect transition method. We do not expect to early adopt this guidance and we have not selected a transition method. We are currently evaluating the impact this guidance will have on our financial condition, results of operations and cash flows. </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard simplifies several aspects related to the accounting for share-based payment transactions, including the accounting for income taxes, statutory tax withholding requirements, forfeitures and classification on the statement of cash flows. This guidance is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. The Company adopted ASU No. 2016-09 as of January&#160;1, 2017. The adoption of this guidance does not have a material effect on the Company&#8217;s financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August&#160;2016, FASB issued ASU No.&#160;2016-15</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">Classification of Certain Cash Receipts and Cash Payments.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">ASU No.&#160;2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments in the statement of cash flows by adding or clarifying guidance on eight specific cash flow issues. ASU No.&#160;2016-15 is effective for fiscal years beginning after December&#160;15, 2017, and for interim periods within that fiscal year. We do not believe ASU No.&#160;2016-15 will have a material effect on our financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, FASB issued ASU No.&#160;2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business.  ASU No. 2017-01 adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&#160;15, 2017, and interim periods within those fiscal years. The Company does not believe ASU No. 2017-01 will have a material effect on its financial position and results of operations.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January&#160;2017, FASB issued ASU No. 2017-04, Intangibles &#8212; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which removes Step 2 from the goodwill impairment test.&#160;It is effective for annual and interim periods beginning after December&#160;15, 2019.&#160;Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after January&#160;1, 2017. The Company has adopted this standard and there was no impact on its consolidated financial statements because a goodwill impairment has not occurred after January 1, 2017.</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, FASB issued ASU No. 2017-11, Earning Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815), which was issued in two parts, Part I, Accounting for Certain Financial Instruments with Down Round Features and Part II, Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. Part I of ASC No. 2017-11 addresses the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in Part II of ASU 2017-11 recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the codification, to a scope exception. Part II amendments do not have an accounting effect. The ASU 2017-11 is effective for annual and interim periods beginning after December 15, 2018, with early adoption permitted. The Company has early adopted this standard as of January 1, 2017 with the only impact being that the warrants with down round provisions entered into in June 2017 were treated as equity classification. (See Note 5 - Convertible Bridge Notes).</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_BeneficialConversionFeaturePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Conversion Feature [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_BeneficialConversionFeaturePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConcentrationOfCashPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of Cash Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConcentrationOfCashPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6603906608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE MERGER (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:9px;text-align:left;padding-left:9px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preliminary estimated purchase consideration based on the value of the equity of Transgenomic, the accounting acquiree, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:82.2265625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legacy Transgenomic common stock</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,088</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of preferred stock converted to common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of debt converted to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of debt converted to preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,796</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of existing bridge notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,996</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase consideration</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,602</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth an allocation of the purchase consideration to the identifiable tangible and intangible assets of Transgenomic, the accounting acquiree, based on fair values as of the Closing Date with the excess recorded as goodwill:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current and other assets  </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">419</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets  </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,604</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities  </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net assets acquired  </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,602</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets consist of:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:69.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired technology</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete agreements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trademark and trade name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Backlog</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangibles</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2016:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.1015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dollars in thousands, except per share amounts</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Six months ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss available to common stockholders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,864</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,266</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1486-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759995728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.51219512195122%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Dollars&#160;in&#160;Thousands</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Note debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Junior Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Connecticut Innovations - line of credit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Department of Economic and Community Development (DECD)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DECD debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Webster Bank</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Webster Bank debt discounts and issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible promissory notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">513</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,522</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(513</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760143120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses consist of the following:</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:75.5859375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:54%;" rowspan="1" colspan="1"></td><td style="width:3%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">791</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754363712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of stockholders' equity, including warrants and rights</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:60.9375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Issue&#160;Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Warrants Assumed in Merger</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,055</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$270.00</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$120.00</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,826</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$67.20</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2020</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$49.80</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,733</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$36.30</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(6)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$36.30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Warrants</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,600</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.50</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(8)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June 2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$7.00</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,379</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;padding-top:8px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2013. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in February 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in July 2015.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(5)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were originally issued in connection with an offering in July 2015, and were amended in connection with an offering which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(6)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These warrants were issued in connection with an offering which was completed in January 2016.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(7)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These are the 2017 New Bridge Warrants which were issued in connection with the Merger. See discussion above for additional information.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(8)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These are the Side Warrants which were issued in connection with the Merger. See discussion above for additional information</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760143120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in fair value of liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three months ended June 30, 2017, the changes in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:  &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:72.4609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Dollars in Thousands</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Three Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance at April 1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions - liability assumed in the Merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total (gains) or losses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognized in earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at June 30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">618</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754363712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity under our plans during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at January&#160;1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,140</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">111.39</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,908</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119.13</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769729472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS DESCRIPTION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 12, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss</a></td>
<td class="nump">$ 4,439<span></span>
</td>
<td class="nump">$ 752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_WorkingCapitalDeficiency', window );">Working deficiency</a></td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_StockholdersEquityNoteReverseStockSplitConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity Note, Reverse Stock Split, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_StockholdersEquityNoteReverseStockSplitConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_WorkingCapitalDeficiency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital (Deficiency)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_WorkingCapitalDeficiency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756774224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cash and Cash Equivalents and Other Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Current prepaid expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other current receivables</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6648510720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6648377872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757304192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Stock-based Compensation) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation arrangement by share-based payment award, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock awards, not yet recognized</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested stock options, unrecognized compensation expense weighted average recognition period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, unvested options, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember', window );">Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, unvested options, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Common stock rights issued (in shares)</a></td>
<td class="nump">2,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Issued Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760053536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Net Sales Recognition) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754411360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Loss Per Share) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options, warrants and conversion rights, common stock callable and antidilutive (in shares)</a></td>
<td class="nump">2,545,463<span></span>
</td>
<td class="nump">2,771,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769209280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE MERGER (Narratives) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Shares converted, value</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,407,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prpo_TransgenomicsMember', window );">Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes to equity</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 6.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">895,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (percentage)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">4,317,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued (in shares)</a></td>
<td class="nump">200,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Precipio Diagnostic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">5,352,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted from debt instrument (shares)</a></td>
<td class="nump">352,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted from debt instrument (shares)</a></td>
<td class="nump">802,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 12.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued (in shares)</a></td>
<td class="nump">107,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSegmentAllocationLineItems', window );"><strong>Business Combination Segment Allocation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">7,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted from debt instrument (shares)</a></td>
<td class="nump">802,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSegmentAllocationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSegmentAllocationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prpo_PrecipioDiagnosticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prpo_PrecipioDiagnosticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769212256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVERSE MERGER (Consideration) (Details) - Transgenomics<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 29, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_BusinessCombinationAcquiredEntitiesCommonStock', window );">Legacy Transgenomic common stock</a></td>
<td class="nump">$ 6,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of preferred stock converted to common stock</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock', window );">Fair value of debt converted to common stock</a></td>
<td class="nump">2,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock', window );">Fair value of debt converted to preferred stock</a></td>
<td class="nump">9,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of existing bridge notes</a></td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_BusinessCombinationFairValueofDebtConverted', window );">Fair value of warrants</a></td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase consideration</a></td>
<td class="nump">$ 21,602<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_BusinessCombinationAcquiredEntitiesCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquired Entities Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_BusinessCombinationAcquiredEntitiesCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_BusinessCombinationFairValueofDebtConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Debt Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_BusinessCombinationFairValueofDebtConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Debt Converted to Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_BusinessCombinationFairValueofDebtConvertedtoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Fair Value of Debt Converted to Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_BusinessCombinationFairValueofDebtConvertedtoPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756790832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVERSE MERGER (Net Assets Acquired) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 13,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember', window );">Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=73531372&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756902192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVERSE MERGER (Intangible Assets Acquired) (Details) - Transgenomics<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 29, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangibles</a></td>
<td class="nump">$ 21,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember', window );">Trademark and trade name</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangibles</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember', window );">Acquired technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangibles</a></td>
<td class="nump">18,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangibles</a></td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember', window );">Non-compete agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangibles</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember', window );">Backlog</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangibles</a></td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total intangibles</a></td>
<td class="nump">$ 1,590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=73530397&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=prpo_BacklogMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=prpo_BacklogMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769127360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE MERGER (Pro-forma Disclosures) (Details) - Transgenomics - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net sales</a></td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="nump">$ 1,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (13,864)<span></span>
</td>
<td class="num">$ (13,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Loss per common share (usd per share)</a></td>
<td class="num">$ (2.16)<span></span>
</td>
<td class="num">$ (2.07)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770463648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Schedule of Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Jun. 17, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,522,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="num">(513,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(395,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current maturities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,127,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">162,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143,041<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,584,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,269,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt issuance cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_JuniorNotesMember', window );">Junior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 583,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember', window );">Term loan | Department of Economic and Community Development (DECD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">225,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt issuance cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember', window );">Term loan | Webster Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt issuance cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_JuniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_JuniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_WebsterBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_WebsterBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771005376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Senior and Junior Notes) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,522,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityFairValueDisclosure', window );">Equity instrument fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,147,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockDividend', window );">Stock dividend, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of bridge notes into common stock (in shares)</a></td>
<td class="nump">802,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,744,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 3,584,968<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,269,968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_JuniorNotesMember', window );">Junior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">583,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">583,821<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 583,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorandJuniorNotesMember', window );">Senior and Junior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">$ 602,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorandJuniorNotesMember', window );">Senior and Junior Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of bridge notes into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,414,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the entity's equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued to shareholders as a dividend during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_JuniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_JuniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorandJuniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_SeniorandJuniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757299296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Connecticut Innovations, Incorporated) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 01, 2012</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513,000<span></span>
</td>
<td class="nump">$ 4,522,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">Sep.  01,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,066<span></span>
</td>
<td class="nump">$ 162,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument, scheduled periodic payments</a></td>
<td class="nump">$ 7,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument, scheduled periodic payments</a></td>
<td class="nump">12,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Debt instrument, scheduled payment, interest</a></td>
<td class="nump">$ 1,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769592896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Department of Economic and Community Development) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>May 01, 2013</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513,000<span></span>
</td>
<td class="nump">$ 4,522,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember', window );">Term loan | Department of Economic and Community Development (DECD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">Apr. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,714<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770458080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Webster Bank) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2014</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,522,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember', window );">Term loan | Webster Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">May 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember', window );">Term loan | Webster Bank | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate on interest</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_WebsterBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_WebsterBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757738368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Convertible Promissory Notes) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 17, 2017</div></th>
<th class="th"><div>Jan. 17, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,522,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">Jun. 17,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">143,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible promissory notes | Additional Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent', window );">Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent', window );">Required Cumulative Payment on Principal Per Amendment, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of Principal Required to Be Paid Prior to Deferred Maturity Date, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_PortionofPrincipalRequiredtoBePaidPriortoDeferredMaturityDatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Required Cumulative Payment on Principal Per Amendment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_RequiredCumulativePaymentonPrincipalPerAmendmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_AdditionalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_AdditionalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757019136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE BRIDGE LOAN (Convertible Bridge Notes) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">877,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Convertible Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Convertible Bridge Loan | Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockDiscountRate', window );">Conversion of stock, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Convertible Bridge Loan | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockDiscountRate', window );">Conversion of stock, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DebtInstrumentDebtConvertedRate', window );">Debt instrument, debt converted into new debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Convertible Bridge Loan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes to equity</a></td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">$ 192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of bridge notes into common stock (in shares)</a></td>
<td class="nump">155,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Unsecured Convertible Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConversionofStockDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConversionofStockDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_DebtInstrumentDebtConvertedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Converted Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_DebtInstrumentDebtConvertedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_ConvertibleBridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_ConvertibleBridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_UnsecuredConvertibleBridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_UnsecuredConvertibleBridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770975760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE BRIDGE LOAN (2017 New  Bridge Notes I) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Jun. 28, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 13, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,958,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,421,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | New Bridge Notes I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (usd per share)</a></td>
<td class="nump">$ 3.736329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_PremiumRateonDebtSettlement', window );">Premium rate changed upon settlement of debt</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_PremiumRateonDebtSettlementAmount', window );">Premium on debt settlement</a></td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Discount on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prpo_TransgenomicsMember', window );">Transgenomics | Bridge Loan | 2017 Bridge Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Sale of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_PremiumRateonDebtSettlement', window );">Premium rate changed upon settlement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_PercentageofPerShareOfferingPrice', window );">Percentage of per share offering price</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_AgentFees', window );">Agent Fees</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_AegisWarrantMember', window );">Aegis Warrants | Common Stock | Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_AgentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agent Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_AgentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConversionofStockPerShareConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Per Share Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConversionofStockPerShareConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_PercentageofPerShareOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Per Share Offering Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_PercentageofPerShareOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_PremiumRateonDebtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium Rate on Debt Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_PremiumRateonDebtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_PremiumRateonDebtSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on Debt Settlement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_PremiumRateonDebtSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_NewBridgeNotesIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_NewBridgeNotesIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_A2017BridgeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_A2017BridgeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_AegisWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_AegisWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773284320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE BRIDGE LOAN (2017 New Bridge Notes II) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 13, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,958,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="nump">$ 1,421,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassofWarrantorRightTerm', window );">Class of warrant or right, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Merger advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,603,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,603,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from equity financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember', window );">Side Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Merger advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember', window );">Side Warrants | Upon Execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Side Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassofWarrantorRightTerm', window );">Class of warrant or right, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Merger advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Side Warrants | Upon Execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Side Warrants | Performance Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | 2017 New Bridge Notes II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Sale of debt</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ProceedsFromtheSalesofDebtInstrument', window );">Proceeds from sale of debt instrument</a></td>
<td class="nump">$ 721,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (usd per share)</a></td>
<td class="nump">$ 3.736329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_PremiumRateonDebtSettlement', window );">Premium rate changed upon settlement of debt</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_PremiumRateonDebtSettlementAmount', window );">Premium on debt settlement</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Discount on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Convertible Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Discount on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Convertible Bridge Loan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="nump">$ 192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConversionofStockPerShareConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Per Share Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConversionofStockPerShareConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_PremiumRateonDebtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium Rate on Debt Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_PremiumRateonDebtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_PremiumRateonDebtSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on Debt Settlement, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_PremiumRateonDebtSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ProceedsFromtheSalesofDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From the Sales of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ProceedsFromtheSalesofDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=prpo_UponExecutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=prpo_UponExecutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_A2017NewBridgeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_A2017NewBridgeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_ConvertibleBridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_ConvertibleBridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649314720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 2,560<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 3,521<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769839968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 13, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 07, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 21, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 19, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 27, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 13, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 23, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_UNMCMember', window );">UNMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_FoxChaseMember', window );">Fox Chase | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmount', window );">Litigation settlement, amount</a></td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_IDTMember', window );">IDT | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_LitigationSettlementInstallmentPaymentAmount', window );">Litigation settlement, installment payment amount</a></td>
<td class="nump">$ 27,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_MountSinaiMember', window );">Mount Sinai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_SmithMember', window );">Smith</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_XIFINInc.Member', window );">XIFIN, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_ScienceParkDevelopmentCorporationMember', window );">SPDC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Loss contingency, damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_CPAGlobalMember', window );">CPA Global</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_EdgeBioSystemsInc.Member', window );">Edge Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prpo_TransgenomicsMember', window );">Transgenomics | Fox Chase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_LitigationSettlementPayments', window );">Litigation settlement, installment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prpo_TransgenomicsMember', window );">Transgenomics | IDT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_LitigationSettlementInstallmentPaymentAmount', window );">Litigation settlement, installment payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_LitigationSettlementInstallmentPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Installment Payment Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_LitigationSettlementInstallmentPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_LitigationSettlementPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_LitigationSettlementPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of judgment or settlement awarded to (against) the entity in respect of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_UNMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_UNMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_FoxChaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_FoxChaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_IDTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_IDTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_MountSinaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_MountSinaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_SmithMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_SmithMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_XIFINInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_XIFINInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_ScienceParkDevelopmentCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_ScienceParkDevelopmentCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_CPAGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_CPAGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_EdgeBioSystemsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_EdgeBioSystemsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757969680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Common Stock) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 29, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 13, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">1,806,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,407,860<span></span>
</td>
<td class="nump">6,407,860<span></span>
</td>
<td class="nump">449,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Restricted shares, (shares)</a></td>
<td class="nump">64,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.2502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted shares issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,563<span></span>
</td>
<td class="nump">59,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">4,317,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of stock for consulting services in connection with the merger (in shares)</a></td>
<td class="nump">321,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with business combination (in shares)</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued (in shares)</a></td>
<td class="nump">200,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Performance Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued (in shares)</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConversionofStockPerShareConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Per Share Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConversionofStockPerShareConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Stock Split<br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769317840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Common Stock Warrants) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Jun. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,958,204<span></span>
</td>
<td class="nump">268,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,421,738<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassofWarrantorRightTerm', window );">Class of warrant or right, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,712,901<span></span>
</td>
<td class="nump">780,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Dividends, preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 432,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised', window );">Stock warrant potential Entity ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prpo_TransgenomicsMember', window );">Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (percentage)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_PercentageofPerShareOfferingPrice', window );">Percentage of per share offering price</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Transgenomics | Aegis Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember', window );">Term loan | Webster Bank | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassofWarrantorRightTerm', window );">Class of warrant or right, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of credit | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | 2017 Bridge Notes | Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Sale of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_PercentageofPerShareOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Per Share Offering Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_PercentageofPerShareOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Warrant Potential Entity Ownership Percentage if Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_StockWarrantPotentialEntityOwnershipPercentageifExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_AegisWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_AegisWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_WebsterBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_WebsterBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_A2017BridgeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_A2017BridgeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770171088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Side Warrants) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="nump">1,958,204<span></span>
</td>
<td class="nump">268,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassofWarrantorRightTerm', window );">Class of warrant or right, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Merger advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,603,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,603,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="nump">$ 1,421,738<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember', window );">Side Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Merger advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember', window );">Side Warrants | Upon Execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember', window );">Side Warrants | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassofWarrantorRightTerm', window );">Class of warrant or right, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed', window );">Merger advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember', window );">Side Warrants | Common Stock | Upon Execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember', window );">Side Warrants | Common Stock | Performance Based</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJanuary2018Member', window );">Various Institutional Holders; January 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersApril2020Member', window );">Various Institutional Holders; April 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersFebruary2020Member', window );">Various Institutional Holders; February 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersDecember2020OneMember', window );">Various Institutional Holders; December 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJanuary2021OneMember', window );">Various Institutional Holders; January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJanuary2021TwoMember', window );">Various Institutional Holders; January 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJune2022Member', window );">Various Institutional Holders; June 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJune2022BMember', window );">Various Institutional Holders; June 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassofWarrantorRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassofWarrantorRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_SideWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=prpo_UponExecutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=prpo_UponExecutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJanuary2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJanuary2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersApril2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersApril2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersFebruary2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersFebruary2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersDecember2020OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersDecember2020OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJanuary2021OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJanuary2021OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJanuary2021TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJanuary2021TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJune2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJune2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJune2022BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_VariousInstitutionalHoldersJune2022BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770795968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Series A and Series B Preferred Stock) (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,712,901<span></span>
</td>
<td class="nump">780,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,299<span></span>
</td>
<td class="nump">275,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,806<span></span>
</td>
<td class="nump">208,087<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760135584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Preferred Stock) (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">1,294,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773471152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (DEFICIT) (Series A Senior Preferred Stock) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Shares converted, value</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 433,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,712,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prpo_TransgenomicsMember', window );">Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (percentage)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible promissory notes to equity</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prpo_PreferredStockSeriesASeniorMember', window );">Preferred stock - series A senior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.736329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockDiscountRate', window );">Conversion of stock, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,712,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted from debt instrument (shares)</a></td>
<td class="nump">802,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued (in shares)</a></td>
<td class="nump">107,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock | Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted from debt instrument (shares)</a></td>
<td class="nump">802,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted, shares</a></td>
<td class="nump">7,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConversionofStockDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConversionofStockDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConversionofStockPerShareConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Per Share Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConversionofStockPerShareConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prpo_PreferredStockSeriesASeniorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prpo_PreferredStockSeriesASeniorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769735904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Narratives) (Details) - 2016 Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (shares) | shares</a></td>
<td class="nump">25,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">121.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">1.64%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6702995232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Details) - 2016 Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_TotalGainsOrLossesAbstract', window );"><strong>Total (gains) or losses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Recognized in earnings</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of period</a></td>
<td class="nump">$ 618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_TotalGainsOrLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total gains or losses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_TotalGainsOrLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754481648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS (Stock Options) (Details) - Employee Stock Option - Equity Incentive Plan 2006<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">24,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">22,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">19,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 107.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">75.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">111.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 119.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options, expected to vest, outstanding (in shares)</a></td>
<td class="nump">21,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Stock options, expected to vest, outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Stock options, expected to vest remaining contractual term</a></td>
<td class="text">6 years 11 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prpo_EquityIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prpo_EquityIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759081440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS (Stock Appreciation Rights) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested stock options, unrecognized compensation expense weighted average recognition period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 2,560,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">SARs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of SARs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">$ 129.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Stock appreciation rights, aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested stock options, unrecognized compensation expense weighted average recognition period</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ChangeinStockAppreciationRightsLiability', window );">Decrease in SAR liability</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ChangeinStockAppreciationRightsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Stock Appreciation Rights Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ChangeinStockAppreciationRightsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercisable, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MZP^_F[#UVNS-/S:^"K8-_+J+]@M02P,$%     @ )HT52YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M-9Z-#<F (P2<Y8 C1%?,D2)H?!M.&6^$>./[EAT)W#)98KD7E!E*/!]$\FR
M,2.TL /&5._#2'X8)$DWY J^D9)Q28A+RW%)R$*5); ?%F0?8A-[UB3)S"1D
MIN7,G#7+ P I9Q9DF#.'BP.8\43L[[Q]+NIN]=3T?5--)RZGING=4&#T<2CP
M[/+C_:%TIWZ\38;[]G82=7OHF\M\RA;>C_JV_P-02P,$%     @ )HT52PAB
M'4]+ @  O0<  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6R-E6^OFR 4
MQK^*\0,4_*^--5F[+%NR)<U=MKVF+:WFHCB@]>[;#]!K+'#O;5]4P.<YYW<
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M^#&2W$6F:GCW!FK?"MLW,'[*K12#,2O%4G2E&&QVI03OX<*FVO#+ZL!,\['
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M S_V *@*LSU&-IA-@SD)>8A0<Q>%V-ZX")3?!P(12)2\!4%'9X9'=-P!'7=
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M,"YX;6Q]4V%OVR 0_2N('U <DBU99%MJ.DV=M$E1I[6?B7VV4<&X@./NW^_
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M^+*Q_Y4Q'E!*<H,CU. 'FPT%E0_'/9[M.&:CX4TW_2 V?^/\-U!+ P04
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M <D".,0\;$H4E7_FGI>Y-2.Q4^]['IYX?TRP-U5PQE;$.Q3OT'LM]X<T9]=
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M?#C>X-E.8S89WO3S#V++-RY_ 5!+ P04    "  FC15+*>YA.+4!  #2 P
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M#9[M.&:CX4TW_2 V?^/B#U!+ P04    "  FC15+'^-J7+4!  #2 P  &0
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MU-9O#VZOI[<\&5;U\YB2Y5]1_ %02P,$%     @ )HT52U71R#.W 0  T@,
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M7#CN_=E,8S893O?S#R++-R[_ 5!+ P04    "  FC15+#CI<N;8!  #2 P
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M_.S/9AJSR7#8SS^(+=^X^ M02P,$%     @ )HT52R]7>5BX 0  T@,  !D
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MWOBS&<=L-!QVTP]B\S?._P)02P,$%     @ )HT52^4B]HJX 0  T@,  !D
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M''?^;,8Q&PVGN^D'D?D;%^]02P,$%     @ )HT52T@[?"^U 0  T@,  !D
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M<]S<H6B$T&#TP@<CV)IK8BH8--INMV8OQX]E++3H_3V I\NH_ M02P,$%
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M5?;NGSE7H$U&*WUFC9Z&4T#AK,RVT'OA9H(+%._'<8>FF5O]!5!+ P04
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MQUKF=?/KK8^UDD7'HJ44Z6M[S<KF>F[?1$D7A@= %P"7 ,+>#:!= )T:P+H
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M+W-H965T,SDN>&ULE5C;;IM $/T5Q <$=G:7A<BVU#BN6JF5HE1MGXF]CE&
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MYNUMHYU(UMB;5-1=YY;_ %!+ P04    "  FC15+"S?TR:@"  "W"0  &0
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M,&&/J08OHX3'J1&,#8,T3'!2@ID_@O1'$/XD1@T'3#SU!X Q9KA]'NS6AH%
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M<VAE970T-RYX;6R%5-V.G" 8?17C RPJHC,3->G:-&W2)I-MVEXS^CF:1;'
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M8]T7X^\_#A3OIY<-S<]K]A=02P,$%     @ )HT52[=JBZ0"!   )18  !D
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ME)B"\H'N)C&]Y,]GU(WDS8V".+ 'G"W *4%QX!A0)&:KO&-,W4@^@2:A=J<
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M9_6RRPH\K6DX?%@HGJ\4R5=7&=8&U)T'\TI]W374"[,)X8E-D<1V!61M0%8
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MPLRS R(K('H\D-@*B-\-9!NO&@WB!&?9XN6N93B)<)#8W216-XDE#]\.2*V
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M9^\R.S/K\SJ;N'B5+8#RWAGM9>ZW2@U'A&39 B/RC@_0ZR\U%XPH'8H&R4$
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M"?T#S!C12J9_H)7Y\^EGY)J=%];U8'1Z%WVX^'1Y=877!KP6F.3E]?F;WK^
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M]P_":I7B*]/T*9T72]C%<I[4F&L#?ZJRAQP)#U"A3*;9!.#/'*4$*9,N\'H
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M+<U+ #"Y((R:2'=D=47C2H/OLA<C(]-0$+'(&]^]?Y&UX6IC]>.5*?Q9#K_
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MVH#_C]5KBPVB4[7AQ67YBS^/+(==$$:$XCY*UHZ!3:$;DC(E\+L5QZ]0L6\
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MD'_G=1U?T.*%%I=IY%Q*WTZNJDVD6>:[U>Z/&6N7=(/.BDS)(]/ /F0/Z8)
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MK:O"\[MATXD,=\;D"LW/5_G$OD.Y*#^ Q#I.#O:$]!OU8NW%UC#VF%V5>(8
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M$E'A*0C[PO0'NDXYQH*RU07VSK_!G^/213RB@9UIEF?V'MKVV&5>N9WA<LU
M K7BX]#,5H2=FKO7-EWYC@XD^(S'F">^.R'--"S8 )M2228JQF1+F\:#/C!
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M_87)1V2*SO+T._9/3S%.S-<$&@36$P.]35XD8LFH9+HKVLQQJ9F<OU@*<.*
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M6(VC*B5U2A'C(BA2UZF\HJRE<1&1\B<<S6^L'Q1!ZTQ-.Q6N))F ['RG!5-
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MCJ@2)L(^,;2=[P$>XL)E5IPXD=M9+<%.D!'GGO8D?KLN%(C(8BX]Z%.B%"W
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M)3\)8<W7.@*N(]_K",".?+$C(#ORS8X [<A7.P*V(]_M".".?+DCH#OR[8X
M[\C76X#>PM=;@-YRA6=M]+#-UUN WL+76X#>PM=;@-["UUN WL+76X#>PM=;
M@-["UUN WL+76X'>RM=;@=[*UUN!WGJ%LQ)T6,+76X'>RM=;@=[*UUN!WLK7
M6X'>RM=;@=[*UUN!WLK7VX#>QM?;@-[&U]N WL;7VX#>=H6S;G38S=?;@-[&
MU]N WL;7VX#>QM?;@-[&U]N WL;7VX'>SM?;@=[.U]N!WL[7VX'>SM?;@=Y^
MA;M*=%G)U]N!WL[7VX'>SM?;@=[.U]LG>N>F'M+VI0R'=I\O7?)I^+>7WA.X
M<WD_ILMGG*=^NW^B=!FWI'!^O;C-YZD?$>'3?V0>_P)02P,$%     @ )HT5
M2YOHY>3? 0  T"(  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=I=3\(P% ;@
MOT)V:UCI%WX$N%%OU43_0-T.;&%;F[8@_GN[H28:3#1"\MXPMM.=\VXTSQ6S
MIU='8;1KFR[,LRI&=\58*"IJ3<BMHRY5EM:W)J93OV+.%&NS(B8FDRDK;!>I
MB^/8]\@6LQM:FDT31]?[ZWWK>6:<:^K"Q-IV;-N5WYJ.WQOFGIIA3:AJ%\[2
M@FQTNTM=0KHVSU(U9.P7$[[?V)^G^^ZWY'U=TI^BV>6R+JBTQ:9-M^3!>3)E
MJ(ABV^2A,I[*Q^CK;O6>]\'X>&?:U)CM&O9E07ZZ'/&UH<,!ALHQ)\>T+>C0
MJ*&P_^3_&OBQ&PKK:>Q\JOI8'WB\%.DA50/K%Q[S$:G?.B65OQJ>6I_NAWVQ
M?CU\/_3"/XN!#8?_O?7CY1 @.21(#@620X/DF(+D. ?)<0&2XQ(D!Y^@!$$1
ME:.0RE%,Y2BH<A15.0JK',55C@(K1Y%5H,@J4&05*+(*%%D%BJP"15:!(JM
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M+GAM;%!+ 0(4 Q0    ( ":-%4M$HMG0[P   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ":-%4N97)PC$ 8
M )PG   3              "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ )HT52YHLA;U5 @  K@<  !@              ( !^ @  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ":-%4L]5*<H"00
M /83   8              "  8,+  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  FC15+"&(=3TL"  "]!P  &               @ '"
M#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ )HT52ZEG
M%VVL!   )!@  !@              ( !0Q(  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( ":-%4L3L=W+P@0  /H6   8
M  "  247  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  F
MC15+8Y*T4"$%   0'   &               @ $='   >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ )HT52_*)Z/6Q 0  T@,  !@
M         ( !="$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( ":-%4M957D?LP$  -(#   8              "  5LC  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  FC15+I)RFRK0!  #2 P
M&               @ %$)0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ )HT52[Q/_*NU 0  T@,  !D              ( !+B<  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  FC15+/M"CHK0!
M  #2 P  &0              @ $:*0  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( ":-%4M>$/!RM@$  -(#   9              "
M 04K  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ )HT5
M2QB"'?&T 0  T@,  !D              ( !\BP  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  FC15+?1U+B[,!  #2 P  &0
M        @ '=+@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( ":-%4OW\?ZSM0$  -(#   9              "  <<P  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ )HT52RGN83BU 0  T@,
M !D              ( !LS(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  FC15+'^-J7+4!  #2 P  &0              @ &?-
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ":-%4L","^^
MM@$  -(#   9              "  8LV  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ )HT52V@9I0!G @  # D  !D
M ( !>#@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  F
MC15+6-Y#0L8!   W!   &0              @ $6.P  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ":-%4M5T<@SMP$  -(#   9
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M970R-2YX;6Q02P$"% ,4    "  FC15+"SS"V$,"  #Z!@  &0
M    @ &X1@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M ":-%4M@?K,/S $  )@$   9              "  3))  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ )HT52^VO3_X% @  D 4  !D
M             ( !-4L  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  FC15+.6\5]KT!  #2 P  &0              @ %Q30  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ":-%4M[@)>"4@(
M -8'   9              "  65/  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ )HT52_@RJP:P 0  S@,  !D              ( !
M[E$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  FC15+
M8,@+Q. !  !J!   &0              @ '54P  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( ":-%4NGAL@YB0,  -80   9
M      "  >Q5  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ )HT52[=R>5'^ 0  O@4  !D              ( !K%D  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  FC15+0+>:+F8"  !-"
M&0              @ 'A6P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( ":-%4MLJQ6,3P(  .0(   9              "  7Y>  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ )HT52S/EC*T.
M @  ?P4  !D              ( !!&$  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    "  FC15+J8?CJRH#   Y#@  &0
M@ %)8P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ":-
M%4L@@*JQI0,  #(1   9              "  :IF  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ )HT52S#AC)%L @  N @  !D
M         ( !AFH  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    "  FC15+;Y>&5"X"  #9!@  &0              @ $I;0  >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ":-%4M<X#QQC0(  -H)
M   9              "  8YO  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ )HT52PLW],FH @  MPD  !D              ( !4G(
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  FC15+6STO
MR D#   J#0  &0              @ $Q=0  >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    ( ":-%4M[UAQ?D ,  .00   9
M  "  7%X  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M)HT52X[2W! ?!0  T!P  !D              ( !.'P  'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    "  FC15+Z5]%9/4!  !J!0  &0
M            @ &.@0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( ":-%4NW:HND @0  "46   9              "  ;J#  !X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ )HT52_8UO7?= @
M$0L  !D              ( !\X<  'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    "  FC15+EPV<C&($  #5%@  &0              @ $'
MBP  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ":-%4OC
MR+K!5P4  .D>   9              "  :"/  !X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ )HT52T,X5J\5 @  2P8  !D
M     ( !+I4  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ":-%4N7DLFSE0(   <)   9              "
M 6RA  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ )HT5
M2Z-!MCMB @  YP<  !D              ( !.*0  'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    "  FC15+MK!P^0B%   T_0$ %
M        @ '1I@  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    "  F
MC15+$+\H*7H"  #M#@  #0              @ $++ $ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( ":-%4LK):1ICP0  *\E   /              "  ; N
M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  FC15+-0-- 0D"   S(P
M&@              @ %L,P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  FC15+F^CEY-\!  #0(@  $P              @ &M-0$
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0P!# $<2  "]-P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>188</ContextCount>
  <ElementCount>255</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICALS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - BUSINESS DESCRIPTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/BusinessDescription</Role>
      <ShortName>BUSINESS DESCRIPTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - REVERSE MERGER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/ReverseMerger</Role>
      <ShortName>REVERSE MERGER</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - CONVERTIBLE BRIDGE LOAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/ConvertibleBridgeLoan</Role>
      <ShortName>CONVERTIBLE BRIDGE LOAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/AccruedExpenses</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/Contingencies</Role>
      <ShortName>CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockholdersEquityDeficit</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/FairValue</Role>
      <ShortName>FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - STOCK OPTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockOptions</Role>
      <ShortName>STOCK OPTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - REVERSE MERGER (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/ReverseMergerTables</Role>
      <ShortName>REVERSE MERGER (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/ReverseMerger</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/Debt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/AccruedExpensesTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/AccruedExpenses</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/FairValueTables</Role>
      <ShortName>FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/FairValue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - STOCK OPTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockOptionsTables</Role>
      <ShortName>STOCK OPTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockOptions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - BUSINESS DESCRIPTION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/BusinessDescriptionDetails</Role>
      <ShortName>BUSINESS DESCRIPTION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/BusinessDescription</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cash and Cash Equivalents and Other Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsAndOtherAssetsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cash and Cash Equivalents and Other Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Property, Plant and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesIntangibleAssetsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Stock-based Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesStockBasedCompensationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Stock-based Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Net Sales Recognition) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesNetSalesRecognitionDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Net Sales Recognition) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Loss Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesLossPerShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Loss Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - REVERSE MERGER (Narratives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/ReverseMergerNarrativesDetails</Role>
      <ShortName>REVERSE MERGER (Narratives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/ReverseMergerTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - REVERSE MERGER (Consideration) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/ReverseMergerConsiderationDetails</Role>
      <ShortName>REVERSE MERGER (Consideration) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/ReverseMergerTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - REVERSE MERGER (Net Assets Acquired) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/ReverseMergerNetAssetsAcquiredDetails</Role>
      <ShortName>REVERSE MERGER (Net Assets Acquired) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/ReverseMergerTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - REVERSE MERGER (Intangible Assets Acquired) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/ReverseMergerIntangibleAssetsAcquiredDetails</Role>
      <ShortName>REVERSE MERGER (Intangible Assets Acquired) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/ReverseMergerTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407406 - Disclosure - REVERSE MERGER (Pro-forma Disclosures) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/ReverseMergerProFormaDisclosuresDetails</Role>
      <ShortName>REVERSE MERGER (Pro-forma Disclosures) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/ReverseMergerTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - DEBT (Schedule of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DebtScheduleOfDebtDetails</Role>
      <ShortName>DEBT (Schedule of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DebtTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - DEBT (Senior and Junior Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.precipiodx.com/role/DebtSeniorAndJuniorNotesDetails</Role>
      <ShortName>DEBT (Senior and Junior Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DebtTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - DEBT (Connecticut Innovations, Incorporated) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DebtConnecticutInnovationsIncorporatedDetails</Role>
      <ShortName>DEBT (Connecticut Innovations, Incorporated) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DebtTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - DEBT (Department of Economic and Community Development) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DebtDepartmentOfEconomicAndCommunityDevelopmentDetails</Role>
      <ShortName>DEBT (Department of Economic and Community Development) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DebtTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408406 - Disclosure - DEBT (Webster Bank) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DebtWebsterBankDetails</Role>
      <ShortName>DEBT (Webster Bank) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DebtTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2408407 - Disclosure - DEBT (Convertible Promissory Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.precipiodx.com/role/DebtConvertiblePromissoryNotesDetails</Role>
      <ShortName>DEBT (Convertible Promissory Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DebtTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - CONVERTIBLE BRIDGE LOAN (Convertible Bridge Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.precipiodx.com/role/ConvertibleBridgeLoanConvertibleBridgeNotesDetails</Role>
      <ShortName>CONVERTIBLE BRIDGE LOAN (Convertible Bridge Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/ConvertibleBridgeLoan</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - CONVERTIBLE BRIDGE LOAN (2017 New  Bridge Notes I) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIDetails</Role>
      <ShortName>CONVERTIBLE BRIDGE LOAN (2017 New  Bridge Notes I) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/ConvertibleBridgeLoan</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - CONVERTIBLE BRIDGE LOAN (2017 New Bridge Notes II) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.precipiodx.com/role/ConvertibleBridgeLoan2017NewBridgeNotesIiDetails</Role>
      <ShortName>CONVERTIBLE BRIDGE LOAN (2017 New Bridge Notes II) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/ConvertibleBridgeLoan</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/AccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/AccruedExpensesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2411401 - Disclosure - CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/ContingenciesDetails</Role>
      <ShortName>CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/Contingencies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Common Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Common Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Common Stock Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockholdersEquityDeficitCommonStockWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Common Stock Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Side Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockholdersEquityDeficitSideWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Side Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Series A and Series B Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesAndSeriesBPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Series A and Series B Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockholdersEquityDeficitPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - STOCKHOLDERS' EQUITY (DEFICIT) (Series A Senior Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockholdersEquityDeficitSeriesSeniorPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (DEFICIT) (Series A Senior Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - FAIR VALUE (Narratives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/FairValueNarrativesDetails</Role>
      <ShortName>FAIR VALUE (Narratives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/FairValueTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/FairValueDetails</Role>
      <ShortName>FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/FairValueTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - STOCK OPTIONS (Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockOptionsStockOptionsDetails</Role>
      <ShortName>STOCK OPTIONS (Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockOptionsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="prpo-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - STOCK OPTIONS (Stock Appreciation Rights) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StockOptionsStockAppreciationRightsDetails</Role>
      <ShortName>STOCK OPTIONS (Stock Appreciation Rights) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/StockOptionsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>prpo-20170630.xml</File>
    <File>prpo-20170630.xsd</File>
    <File>prpo-20170630_cal.xml</File>
    <File>prpo-20170630_def.xml</File>
    <File>prpo-20170630_lab.xml</File>
    <File>prpo-20170630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001043961-17-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001043961-17-000018-xbrl.zip
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MQSQ,^A@B=PX&TT2E=*-A<4W_]N-^$'G&_B8YO*R"T7Q;@JVZT6^S@5F"$Y7
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M1--_@2P#6U3$@BNQUEON [:V)<FO0*I1-@:OVAW>9F;0"]_3_F'V/FOV(\O
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MQYO[6J&1DQ(C0ZVAU!(M&61@(BB+%3(X+B(/BP380L(5'LMB'7TD2!%!)0E
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MN[720":9/@]'JQX%I ,)$2%.1HQMVM-&Q1"0@+0FM2' [#P :PS JJ,$\]/
M&J\U3CV8(+8"@T[Y,XP!]U1)SVICH X^!%NVZ2F.[V_>MR6"TU8B4$*M%%$Q
MQPAP/^4T#D&'6G%)-2O>L3['@-U>O#42RCM.&.1WD&E0K%&P0F/"8SH0Z6J5
MNV1S_OW&QF%]-^V$B,9)'86!($@$\\I-YX"@QC:XZ<-!W^\/NZ!\K_A 6_W
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M$=4)P!OS+R^Y>7)1DT0;C<#* >_R2L/_P(T[Q S65#@=?*TL]NV9ZW&Y%Z2
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MF-),HX!J2P3@1(\(N)?7<"QNFT.B=U(B!4FHC0 13,8@$8.(9PGUM6A'B3H
M,(UJSEZ$#"(?CMX/)TU7,91W*0/D0<9*9:APE-B8UN.",$  #4KW!==Z-BFJ
M"#X=7>>9@=3$)>_ O*($!ABF #A5'!73SM=O1>:5N'4$RG[.UAQ8X5V(UGC)
M#)@M$+;BB($1@<%X<UT+()0(K<O5A\>N[#Q!37TH&&6(RT!":A$%(3^-+$=2
MJVH7A:2M1 <8VN4AKQ0T"YT_=AY29_M55V.A8#"BU&L7E00BQBR0ADC2\1(A
MXK(N@\>@=+VX:V%?6TA2.00I >8+Q-,%*BS$*P81S"<24$]"(&$1IZ3M_$(P
MT&GB),/"LQB%)."?"Y.&;('J6,]<Q;X(X+),,4;@J@X#5Y4J0@X6B',%;X4$
MEUI=(Q4<[XM4K%,8NF/:RLO^F5,/V71JE6,"ME0ZQX.+GJ8;SV2=9)#J!M-A
MD3H@;V44@K<UD,TY'](R#D.XF!C&1J_K=P$2(MXL<'.,(%VY(@,#0H"%\)%%
MP$]$ZR'-5*H^-4EJ),:.!;<=\OV K$WUHY)CR9% D8E0&%3P$MABK4WFT=A2
MNYC,KPY30[E200.34I 4% NH11*$F&,<U=IS[QV4EG("3+U"AE.!M9?6J&C0
ME#F"-3AC:[/BA/2L;/QH*4VT!*@#1Q"906-(]PTW'$@5H'#<BBY-!2JE=0Q4
M%*XH6-8L,*G :H4AR"LFE*WQQ!-2=+[MM?)I71M;QS6BH+*EM+!<!L1X?NOW
M,'KN(MMQW*=#=9#F(1Y2H:W"TVR'>*<)K:U78+*OU;[U-5\_Y:%:"A(H,\YY
M3J1TEG$(V52F-2DE:NO6^TMYVM)V?D4R3<^@!4T)#Y \K^+C^DQ$4HJ:+]Y+
MRE.J)L2R;=LN#W9,A0G N+!BA'KG8$Z#B9.TI&&-Q?7;CAE%;-=+<<W')-I9
M>X3,+UWJC0C2D ))B03&0>AT/Y 5GM3[Q>]C[7$+A==>DXM(1T2!5T<@W!9T
MUM(FA0UC,.JB-L+ P-@+UN2>-^>?]N-+++*HBVJK6F?) 2*,T[421FM'G/!.
M,1<#>"EF*8F,U6Z8JQ52KJM)R]KO?ZF@K7J?^0L-@.=!2/  ?Y N[?&0&%QP
MP/^4T[86+YMVQ_:"?FFC?(TL9CKE(&]>G^@'A80Q&L'W4*TQU12E;D<8*:D)
M4ZNRO(.!T-(V:70B>NFIXL 7/4KAE4[5YT984IN'!U-?[M &++51,PD#3UU@
M!/[GT0P$%ZIM;U.EA<0'G [5(K!V+ $2>X<<L.AT82I1P0DDIR (K2%+JE48
M2[E[#,HG; Y00KI)\6"PD%I:&BU$KX#3A0\& AJ+'CM(2)KJ1RDG@FZ"X!P:
MIX3C9A6(G@/!33="1Z*YU>"=>0&EU-91%9OZ5BI$-.%'!>7I,H7* A'\ S0A
M77(:&<$0'XJ^ZMHKQ*T1C5U$.1=4'^5HM&VK8)BIM"@U\4) VR%1)3[@:+W4
MD>#&:5_8ZJ&G?5,@662IZ1"WG!I;*9KNK@[;!B^#5\X2K#QC+M6<1.X=AU]0
MU]C&ZR@LKBV>LIMYC(VBV#K(KC 5TFG%28C12"D5%]PUG<G$+%WC<8RFV@ZL
M;1ELC("GC QL%$N%!?;"@<%Z##'+L6C/T+[D0$(TC 9.E$AMZ(( ?R!L0I=;
M,&5DF]Q!NR[V^3';&>?CSW>CK-/[,$@]M]+RW2=0N1YZV&_,9]U+O,^N4V6)
MYA=;AX/><' %$HZ^P/=\N ;XLUYZ[)<K^^'3RK-1W&A,.+ADSG'$+)WH3OUH
M PN*HKEK8@=%'Y*B"02J\+%U8%P,/0B233.(7=4$5KM?6"8)88PHZZURD40)
MQI?.WFLI3*T0HVD5LDGZ'6NXP8:88"8HEGHC<>R!9EL2:-*0R;1G4J\D(I+5
MEQW;4W$'6T056A&QY,#*D+242QX,#B*Y9Z(X!_WKA6(->T2MJ)NTI;^17SL/
M:[B'_1:&5!=IG8,)[Y00B!,<I*<BB*AT$((WW*!+&]9H6T-LCPYU"8GR"@.#
MHEJG'C_$ GE*G;FQD=I3INMUT;M$9&?;3U4_@2/D-$1$H."8:F5$"))@&W5@
MG-<*JW8Z;];/K]]G?Y5REJO=E.M9%:(*PG*3;G$RE'N$@50'#910,UNOQB1[
M,(ARNKNN0:375U[9@!5B2%-&T]W?X$2M3T>F;80 $F2L7;&K7JQKP5BR\21Q
M@VGCJ(_9J LO=&Z:+P,_<"EGQ7UZSJGBTB!KA .OB5A(9_*53&7WJ)DV54OK
MU@.C+0C7.6+SQV"<FLQEO7UBR67@EEH=++?(,9Y:>P?GH]-!<CG74^T8L6R+
ME1J&TW8I0"$\0IIHEO;&&6<**RGG&L"68%A(Q(\*A@VHJY>4&*P\Y*\"II61
M5@$,6!A'9#3>-L- #@G#+DK:,"8^"H<L5MA#6@Q^F( U>*IC(&%N2><88=@)
M6XG6,D4"48)[X/C<,F,5!X[F,8+_JN9<51P(DP0)^8V9NU&)V+ZD<*KB+G#J
ME ,3Q!)+$87,/1D(I#U2$>4I:@9C88JW!S!.(B^*:;V?!$2,=I8[R2QX(1&U
MHPSY8)N#$:('A/4HDB?C4M]%9 S3/D1/%:)I&8E((H7P<T6:)=@P/N3D?&Y*
MOM76Z+9;*BVQ)D(!72.=HZ@X$!-IH,%))X$P1!P6&.JA6--F^5T!X7R2MR,4
M/3=<F*A3T90'>XTPVX,SBF$>,)(+EC\/Z44/GR57,L=T<$(++5)PEM'*F*KO
M(8N, K)(1?>"X*^=26J-_>#A#;7E^A2$/[XL"#^'!VG2K>V*(LZL\UA'#N$A
MI.8XFI)(TZD]K"Z0OD +%XS+PFZITE&%TE(7A2")-3:$:  %:CA*[26,,T(S
M;E0"A] +Q,!Y[1"<O0;$TAXLXS08R/X-!#VBF%&)E&HCTQH;83/+X!=T5Y:Q
M>079"B)>4LX0$](Y#.:BLE%@2H/$ 29\@  D"^7D!1(76+Y,.9CM^;"7=T&2
M]./JR=QP-W/G>]/=S"T=T&!<* @:V#ED(-QB1A@"#V B10;%>NLF3,CB%*2B
M[6YA:;ZRNB58 E5*(2O2%8+2,ZF,8P4L)%@-W+ *BV2T=51FL>/XC$81(0(6
MD- ;%GS4P9"$3D@)',206K,*7#OFL5+IQ2@E^4\D@AB#=-KYYY!,*,6))YA"
M!!'>8F\19/@_?\3HGXN021^[(0R'B164JV@15QB8.H)$$Z8)3EM-'&BHA?03
MU*3_%+^VJ.=IY#K/-"MPS@F6DL-$X1H<B].0W 0@Y:G/! 33CQKY[?#Y8]"Y
M!;'2C0D^'W>+7L%+.B0>-%F9;WN&I8Z*<*J1%%@(R/T08EI!S@T,O'YH7?!Z
M%X1U8-@?=+O=99C;S0M1<DH(!.P0O<=!8R41 W]C8G2BX:"A7+K#=0SH[6P7
M=.X,C6& %C<&)EYR4MY3!T9';,! ?4RM3D KW0YLX_%]ND ]]6$<7PVZZ:F>
M!P(YN'D_''0[XZ\?1A\A,.6=_N//A?\"D?/A8.-^G#9*0; %DFN) 3[+P!O'
M*!C'FA',:N<2JPJ^1-@=:[ZB3Z:,46)/@@&&CZE!@@HZU1SR%VMK%0"BWA^M
M1>VGI8,Q'SQ]WJ-YO,^.W\402(^L<-([%ZWP'/Y+P<5(9K652-7VT''-PRQ3
M?Q50"=HE6!UY9TKL+(^8":HBN!H?+.73<^ ^$HWJ39OI:NCF -D#>KML5\,1
M\IC*X+EFB#$!*$U;(*"(**JYIUK[H_VATU*G"XVUMI%;Q8A+5[#0=/-@L@=A
M/!6\=F*M&G1VJ_#Q=7VJ=)=6&,(VP=HQX[PC:6,P@>>4E[YN+D>&W XG$O64
MP01*ZY.0:6J+%5A7FDC(<Q+=\M8_^T.FI4D$@ZZLL5+8Z-,]>9'C:;L8R#,C
MA*>VM?T$)CVXS];NBC\7/-/Y,TTM#YISRH42:MJ:2Z!$.^O+:@N"Y[P,;4@Y
MUWDS2",44.!T^XK&3 46M#;>B>B\];5U'%WM5M*6D,L:,J( F2(-D.(P!FDT
M5I8[A!VUTJ3V&S4>0O"NH*Q*61YP'"ED]30H+C0GU-AT,PEE4B(93:3U$O4M
M!OPN7<S369@15!O>E\5+E; B*J>(]41925!0 3O-L;#*AEK>4[?'YR_?2*@J
M62\+E>X[1L;CU(8_+2'A8&P2RDD!@US'K!VA&JX&F&MK210ES)KH)<P)XHS#
M,*8N4(:=]VIW0BU#"G*YQ!XB-U'PU Y81\HB@7="JJ/U&EQ\M5#P]WZ6_F(&
M/3--:]<?UKE&#5['H(7V F'.(#!!^$X#+(AAPL=Z5YQJ$?9JF5ZNPXH\,@3&
MF/2IA2#CJ=6-"3; _T605IM0O[V@VD!]4QU&^3?X[;=L=O5PGFUXWX*-.GJ+
M1+ .<C4?K<56<&2PU1P1L;P[7L.W;R'>,B^N+4$@'N;@(SGS::83%J6!L*B,
MHC5 !:XBNDK&_%O>RP:]\?R1/0?Y>6WY6/R&?^V,\ 7%BW8X#,.:<6D#\@K8
M.A -[Y&0"%'.P*!KZPB,$CE7_;-8FK+0H3,:Y(.;\>Q^X73<K MVXO/^_:1Z
M9VRSFR=S5HL1#I M\51J'*DIKGVD!,(D%3$LO ?Y L_5?*V0ZJ4*_'.Q I +
M!1LML1$8'1!^$\'[:F(@9\8,1[-0 7&)T7X4J(</,N>HI61,*: #D@='C?#@
M,X@P''Z+JJU]RR/ +RG?FP9+AB"D&ZA3J7*@GN, <U9;ZDG$6G"FJFUVRAJH
M2RFWT^#VKC]\R+)/63]5R)0F^%:LUA((U4@1'2B"5)N"!P>WS8#]"$6 GM6"
M924 K13GA;(O<Y,J&@93%Z63CE9&(01C4]FE3\6'M7UGC5\N^^-U0+-A2L<E
M;N^RP;@(4^_3BB,DL#WS5V?4&_\^G'3ZY==3+@79VS\SD*H[O!FDQ?#"UWVX
M6[/[>IGHT!BM4SJ=7 .NKX Q>"%U L!#7%,K>>I>5)K#L#@]'COYJ+C5-VT#
M](?C^P57V&_4+^%II7?5(?2YP*6Q9%1)G"J6!-@^EA 1B 8J0TT,]9NM<&H1
M58I<"Q6:T_K[!.;V?3[^FG3X<)TR^X:37J>S5;O('#FE 4PP&N.%\$Q:"*U6
M6*ZTBD#'5QZ:6PS4"^$\;-7I?,84F++>!X;358 , C=$<6>H5VFSB=9 JAZV
M6P^C)XLTO?^^'T^FC_ZC,P+;F8PWSE$\I)G C20%:L1-8)!3:>0<901H$\&U
ME8^2N$L%>8'$*S(2)@V600,+#91;)ZU4$+B4DA3,,N :OY^_E6(+H<?C^]NI
MOPO?[[(NN,O_&$)02>'DX=,ZM7I/'V4?9G'HH7!W\S8J'L5X>J9N;F5^$H7D
M1J9;!5WDB$-()PY8N26IM1&5Y?Q\5J"++\OM#M;7<!4NG_+QGW&49>4BWSVB
M4KXEU% ,8% (GS#AP/-K =0?!26=X%+.;3"4#RP(MAR7)@T;4?DUZZ08D>SJ
M'_GDZQ^#X9<QA.!4?7DUN+N?C%,D'71!DR+"?DK',M..:M%?XTG'?^_D@U^&
MX[3KVK_OI:XG,Q:Y1UCG9QUG1AE-+%!Y2*J, 7+&B(8<$$.N50^G%PNFW:[Q
MV>&@?+P?=;\"A3K8&,BT<!YH4(@K#E$8IGKJH2XB6#FUK-;?1&"^RT%XPJ,-
MS,<+OJ3XK.5;DSM"6PDO@Y$J2$L@O%!CB?*>&1-(@'2PECVU /12$ Z <IFH
M[\JF%>!)%(D*.6X84^FXDT\7(#"6&IZM6@[;.=3)U8R3K\G&'P9-#&WC6XV%
MD!$2.A)2?Q9J/$0K%:+1QN)(8_T*YI*V*X5YN>3+J)=@2@FGN$+41TQ92&7/
MA>3(1Z"X!Y1\Q3W'!+FT"$P5I-#">V)"E(^82V9T;1OR@L_'KSV(O[2:"QR/
MMY9"W'61B4@B\X_B0ZI1[^KS,O&'P]Y?>;_?V*UCL6U@ZPGVDHLH>6H#JZV-
MRE*8KE@[6D.X+-WC%ZXGQ+)5(V^IY4Q8C!1X$ZH-51@2,0DS2TN-:JM&.%U
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MT%9J:2D(J[E#6@D/E ,27!<]-FS9LDF;4JZ8<=Y;P3CP(*4,1TA#--;)9YF
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M,A5^9JN:U\@E$IP8;ZWPD;+4YCR%8(09$]+51&.56U*;9=A&RF4V""R>2HN
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MKAG,,2Q#9=9&&T V+ZT>;8 ]<7D6VW=&)IS!F ]6-0YWUG1'#L'>]GT=TTR
MP2S3VVS"*9>J_:JW[V\40L2,1N$_?TWQJP8DSNUM%M^"'P8^69;,\V1\=#3V
M&86FB:, #45E.$A*-L'/#75%"5S%=37FF-LJ EX,I<^[KZ]"]X58U*B[KFEZ
MCF[C89GJ,M<P/;#75:?5J;76?3C Y3EW\PB5F!_N(NPO7,_#OF_*5SGT%4<%
M,P:G7X*4=4,+=*.K:KIM!7X0;I*OIGYI'A)IZAFMO6YIV\=XS;MIN8&M.0JV
MML;&%:&KV0ZS?4]3@Y!9]L;=Q,!ACYNY/T([^[B'15(')]W':NS (X5>E\C#
M1AB&*+BHK]DET RP&4S?47S91+GF.YA=H_NZX3B^X3%M$_+L+O+V7=NA+866
M27G;(\E-FF"V:UF.ZZB:%H:R8?D!>(JAY5J*Y6N.;V\^+KUD^ZWK>K<(OS[X
M6&B#(MZ[64,/A\XK9DM@*(ZFRZ$>@LMMR9;M8B$ZN.' ;H'=2;9;Q=T+8:F?
MW?JV2'@:YO908JOM@<:,0%/\P+;T()!MQ6$*8SA0W<%L=3P=EE?3(_J K9<%
M;SO&PC,BY8P/E!KA5%UF*M-D<']EUV<X60TK!&TY -D6VK %9A\[L!-9O6S)
MWD;?GJ?(N_.#GDV9+V5U0$U/F>8:AJXPSPI :VNN:6E*:!BJ0<?RBK)Z+G\6
MZ.QL\A%]D;8.S&Z,U=T9E[,#SPQ\AQF6J=NF; 6AYN.0=UWV9::LZZ>C:;9B
MZBN(W=1 YR3K._!X& "V0ITQ<)M!OKJV9IN8?6:C9QVL[9.XVOCKJ4M<VQBE
MKRW49+!9'1E;(N$ ,@U4K!/J'F,Z;*W*UFVAH<E8=W:V"VP6>.' .B_47%WW
M%; P?<MS+1::O@]_RRQ8=WI\!LL[C$0Q$FXKMJK;&!LW'!9Z/M_"4,><R7VZ
M6FU?HVB,("Q]T7#1+[,Z4Y(WBLU6&BE4UQ]>?8H];?'X&!;E^$[@A0&3F>DK
MGFM;:K>DI[E93X3UM.O>D14=R(RI&$,'&>F /:>!.Q&&IALP'\L?NK,(E)5"
M@U>P^ -9P9E,:%)X-/T<)9,/<U%SN[/%2V@YFJUZ-O-IKH\6R *1!C9T>G9$
M=A_ .:XQ"SW?:.L>XK)NE8RM-E/@>>.(.89UI(II6(:)O0IUT_4#4]5:0V67
MAVJK563[KNWI"#F>A/96%JJJV([.3%7W/+ /L0P8=*&O.)[K8.GGVD;4NJXH
M]BO#R(%)CDPV@9D<+)L/#,LU,.1%:'$LWP_E-6BQ9&8S_918X?W?L$L">'?+
M7G!7\1@NQ?F8/8P.Z!#.Z<PP$E6FX<BF8:N!QL*0R3BU0D4][;2B'LLL-QU3
MP_=$\DY\G17FUQ'H26E<!59W_9"!7<0<'8<&*R'@7P63/S0-<]TI"ZAG]NS(
MY]^':;:V[O(D2J,E(0W7LKW -#U0J;)BR[YE@LXP[%!UW%!9)PI4IEA,V1-1
MG>7UA)AG4!XFPZI;YMNZY]N&9SBJZH&4- !7,BC4=9[&,Z'F8_Q /^U#*^MC
M,?"TFS2;8:$M?^3!D;0#1*%G!@X.9PUTTW0,5S-MQP,:L["MF6JR=32FJ/K^
M9DF-CI,@L%=46*JN69JO6H;F^V"]NK+! !6:J@+#6:ZUSD0#1%C[TM1+HV*[
MF.^]9P(@+C1\U6-@SF'S<LO$H:>:KC)F6JJQ=@"!;,KZOCJV+W2>SK!K"BRF
MR9:E.YIEN7K(#,_4'8S\!"'-BU/690&?&!LK[71(%GV,BT\WC5/K'J:B'1+@
M=' RM,O4$.Q<*V @S,$NP,Y+2F#ZVKH\4-W6#75/%.VSX--C[XE&\6;L,56V
M3$UQ3>RW!4B3 ^RNA)%W1U85E:W'GOK,V.-'*GLX65N:;C!%EC4YL&P=.X_K
MELI ]:M6$(:*KG1:F8",MJU]%%8'M#Z7\RR!&#NP3!5$BQ%BS#Q47#F4"36A
M@CU<.Q-F 37FJT/-]IA+JXN;Z?BF'02^JODX7,XRF<71P61=]KJMO=EKP\5A
MDPD"8)D@=$)?\VW35<CQY>@P/*W;M/BTE/$:0@K'<2'H*D77#-UVS9!YV#M9
MQ1,"T/@VN&]^IRO,!=LKS+<?UMX2^O?G=)^!M6DPPP*3TS("S3=\6:#<MM75
MA#]NM[]%C!\D#Y@*RA.$([,L4W9M2Y/1A_8P-<P";=KMJKN7V_<VD/8L@H+A
M[#M7,>S ]_'<S9%#DV^ :P26UVW+\P(;L'>D9S-O!H9J82=;#&8;NF[:>H 9
MB%X GK;9;9K.%,O>>YW'Q&D.6]>S4 *8:8JFA9:"!6^*XL@!IN01CICBVUV;
M5K&,UXNC_>6ZJ2J &"N45=G30]VVP/87>-%,3>OT@E=/CY2=080MC0U-RU--
M#>>MVJ;JR+Z"\M9S319JBM+MPK_?\5\;JMZ6\2QTK[NN#JH'>X?*EFOY!K,9
M1XEJ&%IKS!W?7WM_T?#B*#E(&5N:*@/_*V8@.X82V++I* (3BJO[W:D'I\,#
M_5:-U-XYWZ?7X5&MTP_? 5VHR KP>Z!KH1DH'J@2YFAVX!IJ1SMJ*C.5W>&R
M[A([>+E+IQ-0GNM&C.SJ&"T'INL&L#>JX^M6P)R :2Q0 QL[UAC=YJ47AK;:
M9[$#P1'P/0OS.I[IZ+)C.3)XU2'XD:IO*BYV+ ,D!-U C*:::Y36,R]U?]T#
M/K%M85D?)K39G@]LR9BFL,!V7 QCKQ/7+[NV T>S!9H9>H9OP>ZI/@AB WL!
M:YHO!PKS.];_FFC ,R]OM1/Y3C<<5*VC !^:LAXHH<4<V#PYL+'GI=_MV;RF
M>?O35[FM.;LN&T%H!]A;T<)V%"[V.0J8&JJZYKI.1U8HMFFL47]/A>]Y%+T&
M>^#)KJE98/JH"LY6 /6F^)Z!Z:&=7#M5L\TUWLXSKW5_8<$"@RG80L333=V1
MP9E6#;$^13:Z4P2-OJ5%_VFO[?5IKJ?8 7,M,\#F-:Y)KBJNSV=*T!&&*Q,K
M7V)]!XH+V[(,Q0E#W_$T4W4#S7&K%3H^>+![C$HX=)4X;8.^O5I,DV+ILG_!
M<H>-Q3B*>J+C[Q#,3A \N@^6%\Z(!Y<]<#79U$+;-^0F AJMV5:/CPY88!,Y
M7V/8PRS*'OF-SGB<Q2AEOJ9?XDG,RV]XJ'GRSS(O<,V'=^MV59P%:YBAJ^B.
M+SO@3[JRJ5N>J>KN:N,LT'AM&_L($'M?X:[A#(YN8/F>KJB*;JBAK6N@[E0;
MY_6%2G>.4(^KR^(H+[-'VFU!='1LN+DR=)/=[WLX;,/W-!F\_)"9GNJ8P);,
M5A2F:_KZ&@G=;A#B1F":$%?)PT"C5W%13&-L9(;J++^K2[_\)!]/4WC4^AG+
M&\_Z346U/=MW#<4S-,^U#264#5-G<@CR4^Z.I-*88JJ-'GJ'P=;GJK;9*VC9
MAQ[:B*;EAZZC8>\2#8T2%1RSH'NZN#)#X$57M2'GB@K9?@/U(1IC=\K>A&05
M$'S*J+1V>>L5>)#BMQWZ!;Q3U0;+SM-\U#&R#):IK#E,#UTC ">_TRI>/7OD
MU9;$CH2U0W'86P)^*\1J6+9L&V$( M\%/>\&82!K(0@7U5=MJV-MGR7^>Z/&
M$.C.<&5?5TT&VM!5 T<!7O8\5?5T5>D.M%DQ=5X$'4WU\?(5R9MT,'B78"X&
M@>&IH0DN):@Q6?-=VV3@@'9'QQGGA5=[<RS>DGU%!3(  @E<1_4#106M9B@V
M<[Q@S0"1_L1_NUB7][^!_4)9TRBB<Z,\&3OSB9],2[AZG\$S3:T-'HZ!,P[<
M, AUW79<59%5UP,K,/0LRUI7V*<QVVJ6HQP'Z(F6NF40G\Y"/S <.S!#6==]
MV[9=VW%4E=FA@AE5:Y=J@I%RCDOMSKUIE:2&GA.ZID4-G0)?<5'LJ9:M!PZV
M8%V7=ZE;BM9,ZCVKI6[9U3"TK5 SF2V'.$/"QCG$JNOC9%G3=;UUNZHKNFU8
M?2P5]<][-Y[32,!HNO3UPCC"W,#/Z309/WZ%Y;C3=-LT\D;%G*L[EF'KBNPR
M!>MU9"9KEFK:"I"M:_[PEW^;%C]-DGLI+QZG\7_^< ./O+B)9LGT\?W79 :^
MQ\?X0?J2@F'R$_V6)_\;OU?D1?'3#_]V6_RT<OL4-,7%'2'@O<+D/_V$\%U$
MT^1V_GX:WQ2-9]C-1^#7ZT!(YG>@/C;>=IU)8Y"!&7C3Z3S^X<_5]W_&Z^L/
M -_30&TO=W]8Z3[^$2]_CS&^9,R?M-QF:;G/DMCH_/+<5G%RE*-#G-P\\J^2
M^01,BO?,7GSK?0$; :W^_H\_'\B'->O"A=C'@_>< 8,)M#*_]'#&=0(68F(N
MF >J#HQJ@2ABBA7*@>YHJG=ZQEU$$Y12%T6Z>*]8L ]K]NJT'-+"9BZE-Q(.
M&CB>,UHK8NM7U*0^U>B9^G#6NU3 WDA%2O\=20^Q-(L>)6R<@H%6*9+&0#32
M(N6)H-)#4MQ)-\D<W$*4%,D<P"Q*CA"\?,;G?1=W42'%WW"B/(@0'(PYE?R8
MGB)]F(,IB&XER)D,PU/TX 2_A:NGR2PI=HB;%<;8E\IKML!MRT'3_0;W9;A,
MS)TZG"5"SP9'TU0\Q?1T%Q2UPP)'-FQ?50S#\MWO@"4(DQ+8#U(+E\_($ZQG
MGO#X*J2L7EG97)D$-I-$]V,H%ZY+RTR:1(\ \ 7\1TH7<24?\%ZXH+B+I466
MCN.<1,8BBQ<1)B[0G4M.RBN_-;^4I*]PSRR%-^6P[@2$/KA8>'-QE^9Q!5J&
MSXUSN 78YCJ>I@_TRN(N2\O;N[0LZ-5S'/Y-_ T?RGE4@LO,K= )#MJFOW(@
M_0G.?EX/SR&\N ]K-8UH9SPFB2'&D\.=&*0NXTG5"Q%N7_J/AW"GZBE:8)F:
MI[J*;YMJZ"O@&N$$:M5@OAN>G#O[Y+P'_MSK=#H1#XIFBY_^H!CR3X[G??DM
M\*7@_WT./EX%5\?SWFNVS%2Y9SD@R!"4& VDIR.//,D%&\;238IS<X&/W[^:
M)9UR3U !Q]D^?%))>'0&WLN5A!=KQL_-U\PQ CUM:P6\IGYP@5)#&L?3J;B&
MO&?\G"^B<?7Y< Z?1=EM,N= 1F615E]D!!9]\Y!,BKOWIGZI6[JMFOJ??KI.
M,S!U+L9 &M$BC]]7?W1\H"7X6?T72F($>OZ?/]@_2%GZP/]6EGY",5G^F:U]
M@E@GATS7_O13ZT'+%ZQ]Z.K]ZM-N5YYXN_VBKV<ONWCK65^_@YPHSW,<304%
M7Z=%D<Y^:O$Q6F%-)FU^YM>WON)<A-_L!+,A.5( Y :$[ON[9 +2HE_96.O3
M[=;..IP/^-F GQI<]8=GQ]4:_.ROKH[!T%_+>2RI\DA"8W0@HH&(CL&0'X_I
M(%)2%2(D8U]$'27"KZ/Q[[?@+<XG:+.DV?L_C,=Q?'/S F1WRBCQJBG?%W.>
M$?K.CFM[Y]2-R#X7*OOCLY'5%BP=B0PBNEZQP4:Z(9\<(^>R]T=YUH.D&23-
M(&F>C U]$#,G-1+?IBTX;HR@&)RU_ITU=@)G[0#7K'\Q8]I*7W1R+KQP:JME
MX(<WS ^*K@_\,,1@#M6["8;,XKP8/*,S$CZ](O%EI9(Y> ,#:PVL=0+6TNS>
M%/Z;9ZU7XFB?'5L-^'D*5_'L([%Z=?%-FJ0E9D?]@5K.R<<%0_E#*?$*GDB9
MHO4#SX5=^PN([HO"9\98_])<'>FLMX#&3K2]"BH:PB&#_!KDURN17Z;<GZ,W
M2*^VR?IG2JI>>_W:PH\GUG(TRT&P!CG_=".>A.T]CRQ7U&E&BADJ'K6%<AW%
M#7Q+\SSF:J8F!]]!;1;A$LL5/O,J(3KKZJDR:\."3EJ^@$51T1@/[J+Y8\*G
M1.];P[12+97,\19L;X-MZ:BF\6?'^7PI_3V6[J+[6(KOHVE)3XOOZ?YT/"XS
M*MO*R^L\_E>)Y5]%*K6R/B5XHK1("_@-7Y_%X_1VSNLFX8?)LD^'* L[: &\
M:^]X6D[B"=57CJ04'I+AWW/I 0LN8;O%2_@:L5.;I##I0KI: AW0@D8( $#R
M@/^:I^)1C;6)=5,A9P;?)5B<N7%%EU(_=/42%7]?-^_$=32E0M7\+HX+*2)N
MZBSTP'>*B(=0'[2R":"55PV^1\'=3@5=&EH;<T*/6;7T ,L!M9;<(\5A(3#6
M(U;E@>L63J2 >+G$^L0,.267KN-XCO0S!B*\K0F[?3L]O9/92D]Y D,33,@5
MR'3XTN?:F.(NBV-Z<YY\ZV<O9O#E72[%<^3MYUH'BJX&<6W*7#]J08B=YUI'
M?RR!2F)9(HMKR.*;:3P&#IA.I:CND9A+[T0U(-7QWDCI?/HH\5HUE)%"4S1N
M^)%S#[Q@5/%(NDCF)$=O)+ QHENBZY$TC[%2.,H>B:XCZ29*LDIS\4KYJ@"Q
MYHJZ.!\A%@7(\'JXIYP"K!5_T-%;,I,6U#$])_[+CZP)IE?QTN+\+BVG6( ,
M+XPJU?K/<CY>]@O MU<OV?$TTDJ@5[G9,DX622KY270[3P'9X^5B'L',[8E?
MGD7:HL5*C6NKFG$D$M2S6;Q(LT+"5BM /Y)U\=]_=D: I2E<6B.O,1D'415\
M$^(6&^4E.35J>4<BD*"W&)-_N@J\^I/RTX_X@K^60*5B6287OQ6-( TO*]<W
M4$S#@(K(:BAJ:H7UP]43<*X*4"@5B38I\ 9L!=ATVC=Z?W\&PVG-Z.T.5,<)
MVL^#:?D\90Y+S)LSW#]G*5)#](%L5-J50YP?YAAR"/\S3(T9OB<;AL\"9BJV
M[GB.X_BOI?2]-L_J8NN&M%IDJ438 <*KL521* D29 \T+?X];TB=BB;!?D@X
ME49+O"/A?LVB>7X;S]-9,@839R),?W@CLE T+U$V"]G02^WW"<J(C@H&#.">
M/[AON([>OL2I, ;KL8[>ZJ6.7GO>8NQ.)?K+UN&_;"'\,R_^E9S;GS*.[".O
M93GW4M(R!WLS'U$KKT6!AJ!$72:K1E\'Q.#/K([W=9V-#6>' _WL>7ISSH+K
MO)#6)"IS5QY?ZY"P>PQXXG2^$UBQ5\FW=MRQ.LH8:.Y,!-DI:.[<&EX,S5(&
MVCHA;0W]4WK X\<8;HFF_35.&:KRGT15KZ$J7QEI)CLY1LYE[X^*" ZE..?I
M-Y\]M0V2IBUI3$L=),W;<MI.;<Y,TSR7HOLHF=*Y1Y%B0Q#PAN%9RW&GQ]C=
M;Z[._YVBCBQ#ZUL@+\GB=+*F=\KY<?!4^_=4WR3',&-OSW/@F,'_WH[$7U!9
MX=%;I:/P!&ZPD <+>5^!Q"[W#X0]&2-O6TZ](I%T=BI_D$/?O1R2>SOL^<[E
MT"OQXU=ED$A'9+V/-GJ#&25GA:N!K@:Z.F76TK$UYP<63ZRKN_#2V74RI^N.
MFS3(#-5CS)55V5)=3?4LS] ")51#PV%6:)Y^-&Y/NT@?.Y,&OP1_"[Y<!=*O
MP9>?@R];M_:Y2D+POE<]7/#37&I77S);5)"OEG%Y0(Y8]^)'1=RLYQHU"URH
MF_4T+J@P/)9^C;/;../58^N*Z*@$$0MOLPE5Z=9E9D6<S?*J>$L\Q;G-8JK2
MNY1^6Z1UW7I>SF:M<D1^.0?K+LF+-$-YM[[<;U-QWW4,"XE72G=V/.Q2<F@E
M@*3IX]->ST>[B@K[ND0?X,AX5=LB2["^7Y1/'DUL32%O[U'O?@+B(PPW*(OC
M+2T+P-(<@:M"35AMN,CBFY@*H,IYL@U]V*% 3,^=Q-?%Q@NIY\"89ICS9@Q%
M*KU+?NRGD%,?J3H;65I/A<P4:VNON7E2!(A+;V/JG4!<1,.R8?W3)"[QIILL
MHCI8($!"WHBP]"[I:[66S$8VZ[;"Z6NMR[VGY?)%1D 7MR 6;H%RI)MH7%4#
M2/&_2E@H[&8O\/Q1E>":Z;H&_<<\KJ>"4^4%./8#U53/XY62ZDKDINL8NM["
M:)JG4I+G):^9Q'KA-'L4Y=;4Q6#;MO.V(TN")]4AS4MJY8"B'ZLE.8T#<3]@
M]?;UX_%ED=M03<YVRV2NI:= /-/Z-FF/,31Z*Z63-H&TN5;-4/9QI-KNRJG*
MHV /#W'I=EF,K9VG)C ]>"M@3!E/=X-AI0=YK]OLS]Y#2O_%DQF062OMG&,[
M =*\J*?CR5S,IF^5/H,LB*DY#-P05PT'L)(_+\=W[5M[5&7='L.G4F4HR.:G
MTER7<J^ZBUNO$PF[4L6C7KJKT'/15#+4TYD/3<WQT_864?N$!0YAH9:X(+$X
M*(9!,0R*8:UB: G^54'9\-0*[JSU(B_,T;H1,J>1/" P!^$S")]!^)R-\*D9
M57BFO0@"139'LMY3QZX]3$A,&Q8F=0(R$J..><=<[L>BU&1Y)*_I>7S4TLB'
M7V3)/09P%M-H+ *\[9A!.ZB,!6"\XV(C^--#.TR^/*O/Y0%4G4#'HLSR,N(]
M6R/N /%^:O #;%8>PZJJ0/?WKBJ>ZZB)+J]ZK=$WG<.GS]7N>-AO<2(ZU/42
M7K)?/+J$G<U I$R363+'IF(@0)(9^7DU48Z;RY:NHYRW(4.&)%^P.GW!!KW%
MXZHI-Q+]S:I6=+S5&9#Y"%L%1[GHJY8?'Z\[:UH=VFK=O;?8)1@3_;;5TGII
MJV4]L;734SM#G7-GJ5DRF4SCMY/&OEZXOYNLZ34UU-B<(!'I%#4V3T]$>EG\
M',61)T[O?A631GX!VW_\V(X9-<,M3V;@ =<])I"? IFO8T20,9(MJR]MLA%_
MKX*,CC*M!^NE>5^(??AKGVMSC'REE'RP9GJS9GHGMK.15)K=%YF<"[>\B, Y
MH]J[YY-$E&EY<O%S1JA]77+I=/._7U)@L9%JG]ZT.A>&&ZRGD\NL%7MJL)H&
MJVDG.NR1:??6UN!<&&4PG)Y+",7?Q/RVZRR9W,;\G'BPEP9[Z20]"IG9S74;
M[*7!7MI+5#U$618=-FUE,(N>(H1./>SA9661W9_9M M3Y\)/@UEUPE3.M<E*
M9VD0G"\2^SOH:W&D"APY24M,0JI8\CL\"63*R)#[ZT9_-(:_M[/"S4U=G@VP
M5YN\V&0^_65JSD4^*OK(Q4JJZH8$U>@:#+U1.S6DS*ER*)?&HCZ=GY@NLF3<
M8P*Y<6GUE#T>U1U0F@7UE]VYP+V\SK+UD:IVVVL?!7JS/VS>:N?!6Y<4::-O
MP*6THZW OD5AK[ BK-6K9+7^C:+3>$$T'F<E7V$,3RM.LNCG+,'MKW#XF8NU
M1[S-"'>(^Q$8O9=H5ZU1^L'OGWH29O,Y%K:#H@$A/9]<2DZQH?G/*H.CA(L
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MGHR32-P+X"29M("?J7KK(<VFDX=D$A-F>"%@O&X3I&ETG<*/:?8H@:RF&CT
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M5Y\N_MOW3@[^R>"?/(=_TB?->FE>O%_+FLC>95Z2B%D*)#2) -X< [MW:;[
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MPCQ$++:;?,P5XN#I5X*\:G>\KA &243"2@29:^CS$\D2I>=VC\\C ?N%>I"
MK8"54@>+_QKGE#$]6UQC?FI3Y%5?;@U;+:>S31]%<DQ#_O%242E/ #H**N<)
M6+[%VFK;#>&N9I2K#C773/4@4JJB9G'LRF!(< ; OI[P_KSIMT>1M,S[?:(3
M@68$GOZ($1&UY,'75]^M"E'B<1Q2A\^LIL^0L<8+(7" "A;TDJV;\<+:=AKD
MLCQO)-W%'8>.EL7%&8E[D?FI:.^B'PE$)N-?E62K6G4[(KKWI9R"6ZU%%S9"
M-2NG(BL)*ZZCFP*[;S=@J8JO'V+*!)V3K)U0[A#WK/AN5]W_UK7E:V<6X8RC
M&1VPK;2.&W-GZ^?D7IQD-"K"J=:\3@D4(XDHVXCR!^'Q5:\[/*['E*V8Z&2]
M[@+S+L])>9'K7%2IYZ(]8%7'2,?[>5WHN.R1ARU+9M7,KF6Z#C81IK+EC/"-
MDYVKIB7\IV;/ @%N]%@58HKD()3U8VY/?N!@\#ILNKSE;Y*$BG H]<HIS;*E
MT&@%0E*TC4>(<:FK5=K5:%5DTV6;6E)S:^JWB9&BQU5NJXJUL1L'!I9%3(./
MG$L.;P]X6!>S=O^SJH$W@'MX1T!941S'=7Q/=1S=\A1'#WW#\MW ,<S0\\SG
M[0C8XV$%_]AI__=YV:F<LF8;R'O%1]U?#^SI7G7_*T1/SW)E9H9P!*IH#!_1
M(JV.:,%\S2E/H;^HIK,((X\S5+$<--5LP")2^X7M,=Y_#];QS6;J;W*)'U\7
MQ[4#5!Q/\753\S77U5TY<)70E[7 <FQ-"X) /CF#],D/G59_?N!^/9KL^Z1@
MO*_7RKP^@?LE1>8&CXIW1Z?^+/FRG/L&N"-]  'P_BR@[1V5#6DVI@CQ/G3<
M:O^XVOT1/S=?P_O'M^6HW)PWW=N$[Q7(9U$&]C0',BJ+M/J""M#X-WS,MVU?
MZ@I3[.I?[$\_75/?Y OLQ! M\OA]]4=GRLER%<T1WO7 :KLUR+K>G+V'@',
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ME!/I)LEPD[,DI6Q*+-;E3X#[LY9FP7X(_1ZS#[)N1=9MDR#"5/PGZ'ZTT6[
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M14F/G]4KWE3F]5X4^^Q'6O9^%)/UVSM0?K(76&=0[CPVFWL;.9RU.:)R44P
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MIHB,X@9YO'Q?EL<M7#0O@P55WMW$>8CU3?@1NA553$67H=_%K9%IQKMA-[[
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M,D8'NYYGM\HDH'H#+5V&;7S^!#S"'1>!\S!W2R57I#5"Z08GRQPCVU/.$UC
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MZ?O7Z-"G92F)R.5F<=.B!(F1G;%6\0U XQNYIL]6!.?Q\7[(MYN*LFM<=KM
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MNM#3$0.Z'8 ]@-X.YQ]@\ 33 ,Y0'.L\B$ _1?IY#R:/+Z9P=>1&R21#8>K
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M&09&QT)Y8MP""@-R5<$&9B)<.%/7"T*@^4Q(TXE01S.553+"5Y4Q5.$%Z)U
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M@I*5A?IRE<1I6O%>%FT0#&&ST;S7JG9'V)TC*CL+M##**K'B0.3XI,8>)6B
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M''48K7&VD;O?-K=%C=M5&2F4&@1(@G(V$>A,01/B'/#'&1[^OS^-&P"E4-7
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M*4U76);\3 $W):@0AU=8V!:',KZ(-H?-RC8AX5&CTM3*.72HWU7UE^^_QHO
M<P;MX<$'[)<**"()"$31V7P1QK="L(=$-LKZ+!-%2_VO!E/3 "?&39'@4XP_
MHF1/6>_2FF30'99Z!44LZ$OLKE IJ7K&CY[$7?.Z3/3),&[-0R1SFF& (4\D
MU%D<ROQO?48CO#D%6<ZC(2*_X#X*T64#584PY"C1!%U50WU.#M*O3G90?&$)
M#U17"#="]E^:MI7Q]"NT5!S(CP6'FHBHW')V8#7'2FZB4B]54ELQ'8=S26KT
MA_VAPKW/_@$V,LZOX$LE+C!#J6$FU4<.V[VG>AW6&.&&$GA/EDAWZJ@AQ#1
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M9.B27"R2^ ?UT@48&-GC3YVA.75;RT5:P7)R!<G[?^YAQSO!!#[)5$J)X:<
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M?,,8]7+%^Q(1NJB4NYZ7SW/^-R Y,-+(3QO,/8%GHEB@#68Q:O)S8(_R< "
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M]H&^KCUDE9%K"XDC (5MP=_B>K:"3"O %CI\]Y[&-1?IQ+1V+M*BE'-_GHY
MI9%K!J/L8>S5KF%L!GHU'->Z,X[^=(4"VJ/XKPPZVY39H]BT/0_&?=<0(,B-
MM=H/\7^MIE/=U0JRE]'<P N"A5D+A]$QU:VVF"S&U,;EKA,IR"][8TK:1BSC
M_NZN,_D7&-T"0_\VU$5;Z<B=T+W>Z%Y=@@'&HX%>LTM(BM5V#_*E/(TF_DC_
M]0AMV5!$RLA9(N:MAI;OX Y>=/;"X&7:%$9AFQ C72&"=TI./D2$48E*'']A
MN*;=92$\MS?$O)+9["HFUT22@5()$TGLQ3E;PFZ(!I3S,6+&$K+R!P2J%Y%K
M <E!40D+D"4"421099[AWXW-$#F&\)]\@DRZ\,I^)2O(*"G7&))S926,06X5
M4B6#2-%GF]B-U&M%BX6BQLN6^)<<:97 .RCF#&P" ._V\)>Q#;V3C")ZJG99
MPH'*RVWXR860,H;@%_]WH 10 >)&A+,#V(V;FBGI0BZO 5W)NZ>K[9\_1&&Y
M%I*<2"]A(:KLIKSB7MVZL2F]GL9Q3Z!K84==_IJ\!79SB2L?S>78Z]:F3R6,
MH0KS#/#;K=:'Y$7!]\/.?5^?>I?+IETS:TS%'WGTVI#VT>L8W\'M8/2S3G,-
MQ8$8K?US*:\"<X1[-LZ7>^,\&FN33MTV6!9'X@";D0Y16+857.]M!77<Y/3'
MQ=:GC_R$V >2U.>1_.^@ CCC#H.F<]-PF+R609J2_*C,OSOR*US^4M0 PQFV
M!79W:#63QQKEYYYN&ME9L&W+]9" ,7=%2=AQI13?&'77-PWUI=$OPHQ6#>!]
M:,;[*.H7BZX@)KIX(55K "^C<"#""J<JH^4R_T:/BW(J?8I<5YG4)O7MB2H2
MOV0U19<=&4Y0'<M2M@[M-%5VO#R:&A&Q_\_EZDHW[M!0S#'$%B8]N,8.M-6$
MU&P[VIT@X0FYD,Q [!&;:*R*CDQ7*#(>5L'K%U2E.KT4KE@<WBC0 G/?N6Q9
M1-J;$S"'A?RN-(K %DFH7KTK2L30A+ULRS?SOM)PTS 9LF3??:!Z[T+SP::+
M>)5O)QZ_MKN(J#@"VM[5F?(KX[<(.F)0J$::+U/T['1M$7QL="A#L8>"3L#F
M-76D1.?<E09 Y]ZEP+E*II"<G%6&JOL?_A'.;(:)RA^<^U3W<<DURG##[4;[
MLE1OJ@(VU]!X^/E7QLKO,>_4/H/D/T)UAQ:S@J+T_R&5$M^86*E>$BQ.KFIV
M]F"]<>>;307W>!^63#Y^+]9;0K) F.PXO;@95&UT*)[_Y/ *E;8AYZ.Y'\&-
MF))]Z$I01G/91R$KV +IO]R$5-5(CQ7;QC6F@=C4DVR*V"JFUXX,U:4/9-M?
M?BIP)XZ7TYNQ]4*F':%6B?PG$6B%L1+U)JSD"H-<MYA !T64RLQ421.AAI!6
M5E:6$IAP1]A%.1V"+1CABS$30\"=ZNS.OX=FBF-%U78[^+0ODFPY^\PLQW?\
MLK?5A>K,]=9'(WUOU.;RLQW9ZOI()%A]_(@M1*Q0[*W4D^N,=MI6>$\_W7P2
M *9_$B!N<54(3V\J+NO>XXY/M-&X6-X]>E^'8;(XN(Z:< ==3(T7+CC+K[&\
MCR.9\?[T //65'35W^)')'<^7+9:'[<TRLET?'_H26@@TV5JF#X5<1 7 Q Y
M%(G.;Q3(]W9\S2U]%@&]O,DG"E8B]?CH?!-,Y![+4?Q\\P0]BK&C3^X)7RCG
MVT%([T_CX$03CH^+3AQA^MSQKFZ5?MC[=/P0;1I,=I:30V*CVD T[X7*9B#'
M\=[*2 C:MGP<PQ?5]:QD ![H6I+F%96WT"Q=]R(Q59H:ONP\2]5(GNJJK=WL
M>+U2,[J3-6Y@ G&\-:6DGUX/N_4QR[@&NUX>WS<,Q1A<GN(Q32&!%5QJRS>-
M)>/],1I&(9W4<1_/D_EN+- F]<WI>K>Q-_J""T3GP;A[-!=QC-PH&1VE%\EX
MY"'@F#)'S2((>8B)U]!6J\XJ).LBN4@M7H@\(C[S9I3OY'*4'!&)$:ROWT;=
MP_ Z3HWL]"!C?P=5'\,%$4T,FW$GDO'^]-QA?&' OQ[#NY@@H55NQN.[22'E
M"KLK.9LB=R'+3Y,%_6E$D8PLQVY]NX6+!T=%,A[%81;3DIH(6?R6T97P].IX
MC[=D%<Z.A8H6RGNZG4/@\GKN2NT=% -V+[)3,[*>6Q2^KB.2+!7WQ7UH=?(C
MF_($\P=YQOA>5")S1.-V@D-$R16&@GF/N;JPTX,:)D9"[#%D#Y%)P9[_N5[!
M+>Y'BV<_O<["<_<P]IW'+>VR<AR_>TC?5M>1LQH+E77V$F8)!IA/D%DBO/9N
MS0SFW@+7P[5GT5PPEXIY*Y>;JOAKRGK-U= BS=Q8B@!.KFUN[3@84+((DL,J
M*93WY'SY[@817B.TU0Y27IQ@>UYA9[DE>"SI!%IL9-YQ++R)Z!F@[:U/C)X(
M8GR)U^&H"L_])A)NH]J'P9%[T.1A"^E/_?OBO3!\;6,G7.&=R/J,*5Z%^O5F
MFZJ,MJ1?2"X()U)/KW%-J0-M.8'.1TS.H8OATM:*6V:.DUMG4VLS"Z160K=Z
M_?17IP?)_?"N%Y<\EG*" A,NU\;4>:R\/1(%\YZ@DFL1ZCP+V9/!<OJKTU/A
M!Q0,7"Y#-5\0:'_W7&]GS;!]V;ILQ34K1?&F%.XC4\DM-1@15%CM771O2OE;
M-&.N"$!+ 9Y*]*;4_B<DG@+MWPMKG4;S-I6^;)>Q\QUD;U7UZ1.MHGJ4[&VI
M[A(D;[GI%M<Z0?$F%2ZM[PFK^Q.)-XAU(7F(JY7VXOB#X)^4/8B0WC\;ZIVX
M1\3<G"/(>']BNR)V(O)+O]6'R<U[R>2_#@WOL#TWEV@%O_[V_U!+ P04
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M3D*L[ [1A,X#C /RY6QN9^\;R^BTKL&5/O7_7$RJS@;B/F.-@\C.JJ5;[Y&
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MF!)$%&,J>6X)5\<N#WU95HY!IEPB\."T>1O_OV]:!,&8UE$A[@$A'F4 M\#
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MF;,:HQAY$[=U#"4K#.*>$RJ4-<3V2'%0SU$8!J-4OFVBFGQLZX-T.Z98V;X
M8QF\<![ & +\L'(>66H 728DXP30XSW"D-DWB5[1AJ$HE,UZ;&_U;3(5VP8%
MUBY&C0V*5$7$-:BR8"EX2XU1#+:OXZK3V?4X6/Q7689/D^FF0_G[)@5PDF$-
M5EI2EB$9M$'&4(D8M<E:3'#01Q\@V8<IY6#TR)B%_.CNZ2]Q?O'93Q=-5?L.
M'._2O:#*$<$ 9Z:E1<EHACR!7Q4C ?2 9\GU,&DRY:_WEX:1:)75Q+V#O//9
MR??MBRAMB 2T/2P'@UP ZRT 46%2II7%4=,^29N9LM7[R\)0Q,F7G;GF-BP(
M\<8TS?7="JFC\LP39)P.2/,4$;/"HR"-)R*DJ.S1'Z ,( H#TRBO4=,A#/:P
M71$<$"HE@U+@L!$201 Q(B L&%546T^)/'8S=@">]R5*OMCXRL(<\U>VJK[
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MR/A'V/?#V9??ZN;DX36XS3,/ G;JYY./V^*+W0<IL):$)^R19Y8B[@U%RI.
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M%($0)YQ(/>H?YTGF.8#J&8".A]WD'I:QVGE#>]BYT%)&'!A#T38EM!R7R,)
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M0U90BD(,7'@PO;P__IAOSMUR9.H>6=+./@\NW0'>_'"VCG_[T_\!4$L#!!0
M   ( ":-%4L-\-8@M'8  #D&!@ 5    <')P;RTR,#$W,#8S,%]D968N>&UL
M['U;DQLWLN;[_@JO]]ECW"\GSNP&KA/:D"V%Y!F?MPJ*K.[FNINE(=FR='[]
M FP6N]7-2[$*A2KVS-@C4R10A?PR@4QD)A+_^7^^WMW^\*5<KN;5XJ\_PK^
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MNT)M'""*B.=7Q/>: )27]WW"-,Q"$3%IO"#$QD6\95(%448$>V2LQ43OU"@
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M2W?9^-LW)WA!@&513M?SZ7W0T8OJR\.^Z\UB6@75'8];SH8^%_"]^?"VP<&
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MT[=X?M^JL$(R( '7R(3=)N&(.1?&QI$D2@D^PO)J74&N4H%Q*0F_F%%!PX[
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M&\P5-UQ1QE1,&MO"H2B\J+)-C5G;)+)Z'C"7%E&S3&/,+,+6"&M,O!2\IDY
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MCCQK6"FU'4:O3Q9&N?D:AP@,M.ON>..P)\HSZHP-IJ@A7!+MV,ZZ"9O4\6W
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M110W=M)8QXRP4,BP)U!Z9Q$YW;X27._)7Z,5Y5;(7J*\;FWK)S_DW34]^:$
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M\WKU*UKR3",JG3"&".:CJF\IP8 (((32")U7L.RM6/((<R"H356LJ/(4"0O
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M$#!$/JZR0DGGJ,2<(=/IV=:B_B=HA1-.C$..D6#J;3B:>OF]6J6ML]Y.L!W
M_A='LPR<VSYP0P7'@D(=4>)<:PCV?D7N^T=!%LXD<:G8<Z(TGM13@N64U>)
M-LO3C0)2T')G'8K#]EH93KW?C=RX2-G>\BV<2V(<^0Z YCKK?9[48\  *^(B
M9B%Q "C@O>#MS"F!_16!PJEVQUGK1P&I%#U2IIL]K;<_Q4WJW7*]63TFS7:K
MUKQ;KQ^KNV.9G"_K*%@,L5=>(BZ$M@@*#5B+AB:\O\NX<#K;OI3)"M=DR+/-
MH32(-KLN0D17>$OBXJK2WFF!UZVE9CP94(.C<*[;;(3I!U2QF)QNZ#M$MOSN
MYG&T:,NIM@$QS+RD3$3K6WLJ(".M%FTP'E"$MW &W+[D&!NAJ[%B2^)^K'C>
M-L3)1<)3Z['%"AL"N;7=G('IG_BL<'[<T5@Q$*%B'NTTUNW.9Q^;/&W5:E[?
M;3G]OOJC^=7QN-YS.@B &."BPJX$@RG[FT"F6RF=-@-2+A3.F-L[-#P'3E<X
M]XB,7D>5>]64!/B]NJWFWZN[F^43=^]Y1R"G^PF,"2V9]U9Q2CE41LE.$2,(
MO)V\NKTYDQ&NMW_Q2QD(M08(1DPYIL*)+KH@)3Q[.WEVQ_2)]P>HM^?+5M5]
M7-1VEO@A5]?/3X5T'15J9(DG6%GDI0(:$"^%(UK9 =<W2Z?![>7<&@3&5:_H
MQ0&WU>4F<BGOYTJ)OYU_.^] PT"AU48BK#G%"D(6M;5=#+\S<5^^8L*=5P=^
MZI;>X4;)34:%B!8)\H0[@*WU:#=39:0L&4MXSB6]P0([I]1F'V0F?5GOU5F>
M"'<[V"9P$Y52$Q<\2JUTVC'(6ZSCYH)+4N:B<+<Q9'T.?7J 5/BJUL_C/??.
MUFNM@F."(P^Y<)AH)Z5BA+?S9$#*:<>WC2"_<Q@Q"*M?EQN3#&6;%B5&TL^?
MZ&S'P]A?/!BPQT3J.%L!J+*&(^EI.T*B4,DDZI<IZ</PKD<$I;?8_CY;S>O'
M=3ITF&\>$WZSQ7]M5?*_SI:/L]6/V$8<E^@E?01+(++*> 8 0R!"I8!HYR7!
M\ZKT$XHB&D_8&?'*P0/UL)HO$$"@-PN>]1"TX-9XB;RP #=G%\BV<^(4]N=
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M 3@VH;K#@R11CX=!T<#FSZ<=/)^?[T;NSX?Y-O'S-F?X*;_C&-\1('+08,F
MP0 HA4U$M,60$3W%$I17=*!="?;)Q.0?#?O\>[7>= GOCX66C?DU@7/.-&?<
M86\LP483(UHDA?<33&=V;0)?!_EB]]X6C8RKN]?GNHM?.<+.\SH(SA()/"9>
M::J1U!+P.'L=M1-GN)']]:EL@6]7Y%T63(NY5^X?%O6/JOI8K;[/=T'H+Z;P
M/E6 6<<9-HBM/]6;V>+I[U/LU/MZ\S_59A][U1R8WCPTOHICWIH2WQ\,E()R
MSZ@&/AK$*?P&=PJVEOW/S[(%SEV1SU,4R>25A&TXU;ZZVKH)X/GT;;;<3?A)
M48M_5"D<+4+WO5K-OE:_5XD1\7-3+S>KV>WF<;9(X;59SN9SC#,@ @7@!J%H
MZTCGM($8M;+T2O7WK68+$'R+:LH$1#<L*/_0M91M1:DS;@OU[2H(!(7P2%GB
MHYB0-EAW7M#X8__U/UN>ORL0M!"Z!>)<_[:</=[--PF[Y5T3T9U*3]6+^5VC
MIK6I4>(\F]#=1?W'%4.XVM'\=DY(UHN'@R*6,H PE49PBZV1!@'$X_O'I ?\
MK.",S#,[&2?UTX-!1B8)I8%A% CKH.7:MC,2T)1TYAX/=AH@C$,YM?H@,.D(
MI(_?ZE5S62C5HSTC8\NKSP=,K;2(8(TPTIX8!F '"':F_RWCW!%(/>7Z0F48
M#DHY#?K96,_(7O%JBT !)-0@J[&&%+%42HRU\Z,03SWQVC"9G6+ ((Q^/2Y,
M\H!O&A2XCNCU:G[WM?JMGAW.07+HT8"9X(11K(5BT0B1!C/3SDC'GZ=X;#-0
M-L_O-PZ#I)20?ZN77S?G[^VO/1XD-RZ"HA$BGF)'+5&@G1D?4K\O=XC..%O[
M")A<2]HG%_/7&T0N0^4$]PX;01RRAB+?SHX9,?&*:\,$=D+Z@Q#ZU7@PR3U]
M"N(?R2?WL5K.Z]5L>??7Q_3#^WIS) _4B19!$,T(,5)2C!QC2GN-NPW*JI)W
M1,[<LX>"7^< IM0[_+[:)-?7AU6=RC??Z1]_6U=W[Y8W#TUU]N57=;N9?V\R
M!:G/Z\9C?.3]OKRS@"!#U*6R 90XX2616+2H(*4GF*]I1&]/=KQ*L>C=\K:^
MK]+=:Q_Q2F<+\^5CG,!N)L=/?D\W#AA+P:SUD'$/J/48[=]%J531L,[S6))3
MM'5F_(H%L=S]\W&]:1SPG^IT.KR\G2^JB-Q^1I_J\5:G'%\7L&$, F^T5I0P
MAP$!<(>L5QZ?=;&Y;&!6069. /%27+95<_ZT2P;PL*@:<2[OU'V]VLS_K_G\
M"#?/:1Z$Q@XAK3Q,P<"0&PAT.W,@><ERY6=R[;H$J+-C7&RE?#+$FR]^OIQ%
M(-,A_KK)$9-2#:4T%4<SX)_91> ^E8<FEC DF&'$*M8J,Q$4UC_=<[85;5(L
MRX1S*:;])0+>)-&IUC=+]V<"YW&^_I; O?F2+*0C%#O9-BBG+>02T#A#H!5"
M"K7VL?=\0/A%MG#227%K;("O&TQW<51;X%H3G5SHD"HJM,'2=Z^,H6""A7PG
M19]14"UV;O3+)N_T!%@)E'#$HZA2X^2/Z]Y12B:817%2+)Z6>$J]#@VRR3'M
MZY6M'S]OOCPN=LG)CFE]QYH%#3UTUE%&C:5&">!)]^);HOH'TV0+AIP4$4?$
MME@:ENK^H5[-5C^V(<1QM*O&"DI@WL7?I9^;Y*5[H(^0JT=O@3KIO8" Q==,
M:QJA]NU!N-?:]/>79*NK/"G.Y8>\%!6[/+G[D>YSQ1\AW=%V06* /1<BZC >
M(F.)X[9[[1SK[RC.5K%Y4O0:$]R"9P^K*BJUMMK^_009,WN8;V:+,WS#YW<2
MK-7(: H=0Q S;3&5OM,/X( K9-EJ0D^*8MF0OA[?VDT_0EO-OY^(<3^G>33C
M!=7<*<$U4D1[9PC9SIP#I5C_73*;IS>'6$\R9S!RU^/,NV5*?EZOGN1=/HLL
M3]H%G(Z<.5/(,BXHIT@0U\[5.=@_U"*;I_8J+.D/V16WL'2C;[_\-DG6+]N^
M7ND@&$8QMI!BR1RB&,3%&[>S)P)/T/UZ%<*,@-WU-Z,/LQ^]=Z)=VP"<DD9[
MC>*B2BG#6'+5SIE3T=]!D,W?>M5MJ!]L5UYDG@T^G8=&H_*QNOMM/OL\7S1*
MW^4KSSF]!L  PU QS9(,XGM%*.OV:C/ 6,OF"+W><I0!T.F%&(X26A@<%1)
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M';1V2,BH=Z!HBP#-":&=(8*9[[\]E[SD-5C,O0$I>.^B_GFP.V:>DS#P5-N
M',)*"A]U4*D4DX!0U\XY&JC]$UN4O*G3EP1CP]/;4]9>-]L.(BH-NW&\KG>?
M:A),-">%@L!(0:! P$G2Z9@ J@F6"Q]1$G46D'J+-E7N3:O+S;+QV[0'W]$R
MF"T>#U7#/;-EB.8BUX K9I%Q!!)F_%Z=!&"*N6/S"'ITK(JIWEFK;GLN (5*
M&JN\1<)I)6#G8<"\_Q%(OD1YH_,C%UJE&/+KED.&2AF@)'..PZA1$ZF)[E9@
M@OO;&?G2]&5CY[2P+F;$I (G!T$]9L\<;1B40C[-"FF8ZL Y(_='8)3S"=ZT
MR<>L4:'JK08UHS@EW0-/!L0$5=@*@+1AB%!C6><H-T+TOVV0+_M>'C5G,#;E
MLI"T5G5*"FCJ903B,6*QCYG4U9=Z56V?^S3[LUK'+7DUBW*)J]_J1V/7I6C6
MV#+BOFA@W.KR1U:%C-\:XFH)H..<<<,$)Y3(;@&-K\F <\IL >HC&LK3 ;8L
M@>-,=N_9]B+/:?*]:!$@=/'MY@QQHX G$"%HVODAR >4A\D63CXZ<X:B4LS7
M]K0R\C&_VM/G D\YA92U0B@5]T_J$6^78"H%[*]MP+<0PS $B^L$']EYRBFY
MO%MOQ]UA\>[^X;@[]9)N D2,6>P(Q"K=>*=*"=\B$<$=$'[X%F(>,D)UE<5
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MNCG%+6UZ&_L0P9P\.[L,CK=T($X H #S^ HPB$!44X 7[<RD,U.LW#J>H$=
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MCJQ"?>0](BO+;%T;;%_JC4*74 ;XIU(_ 7[H QQVICR8*IVTTS)@69-Z3,U
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MRFWVC#!@?3M'8'+R'M2%PYE7+#&@PYN<=EDF3$VH:J8N#YCZ/,24%3UZS<>
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MC!W;BBH&\[+%)O+1F\<JWV95)>XAW^1;C3/:HUB5T\RI"%43QYK+#E935?(
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M/)GGC1<6_"EL=3N%>"$VNG=/G[+58UE/Y#^7RVTE"B=QV[5-ER(?QW% /9=
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MDP*/>6K%&\88LGV4IL4F-+I&MW]WP?FM1GCZ/IH%5B6%>"I"%45V!)=VM'.
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ME,*;XFX&&F_,E<)"W])];^9)'+=*1:&&[0YMU^*J5O.710CBE+@^@@FWG.+
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M 4NU8D>KAAU+Y X7N&N!@?EC^;S>ZHFB7:K5A'$TEO7$L<Y)BL5R Q2T2,]
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M]_)AW'4EUE5Q&N.$88^BB/HTBBE.DWT.-Y02H!Z#Z'_=<>AQ><6NT>WYQ:^
M_<<5N[C1C3@,Z%)3 [=,Z6G"'@MHP0RK#&^XZ- '<]ZFH1(]\)>V>I"A8C2'
M8SX+A9IAS((T@\@+.&(>3L(P@GM+,=?*CIA\WW'X<%"-SY<WIHJA0Y>F9CAB
MRE0U=L?@/GWNC+/<2L>!$A7Q,"!P8O)AXL$I 3%F0Z/J9_G2V$ZS]@?L A9
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M3;&\SR_*K=S0EW=!9[Z'8QK$)"0P@303)D/FQ<)B%$",B-(+/SU-.$[<2%Q
M  ,-,E!# ^?G&IF''O0IY&V&84XODGV?M#\;7#I)FQ[4:>1LAJ'0+&7S+I4]
M\S0G_3V5INE/T 2R-!:<**UV&KV@\>993 K_>A8=B'T5_W4K_C'Z7LCCQVE"
M,8\)RFB(6!J%0;BW%B9*R?.^-AQK\ $6J'$!"0S\*:%I'I,U)E$M2S$$?WI*
M;$2=DWCW!#<=$6M?-J<1<_;VHK3;QWJK#BT?Q8)YEL8<^WZ<40]F* B1GZ)H
M9R]$H:]U?<#<RCC*TX#KKSVJ5!JKCP,6K>C/1P0.I4 -#CT-TN1TLBJDZ\?'
M.F3$C*$2[6(M3UC(8!91$N(@X&E*$&EMP2S6>L3%S,+ "M1+<U1),](;!WSU
MU)H/%YQ#R,S)E94=&B<I+[H^=$N+$2-*B:VK3;G(\V7]E-7V(;^9KT3O^D+S
MN^WYNMINZN7Z+(A\PG&<Q=@GH1]Y&6?9SJY8V_FI<H[+BC7'<M-B;!ZLJP1$
MF1]?"HR@V(/42.#885@A#38XN7K:M.=5X@,"(*@12G(E1G ^'KD:B;+!23;+
MF5D@6RV1IL+'J9R:52XGD%ZSZT_IJM?IOMAS,'U>5<]RW_!R(Q%<?F'_>BZV
M/V8X13P@)*0$^SC(TI1E[;2$($FTUL$6S TZ/^0U)O"E6 NDQ?I>]WF>_N2J
M1:H#\VHX-=24MO#D^<R;W?3;0!SZ 9Z/*.L(:2WR/8WXUJ9#;Y[8L<R5JK;1
MW=,^O!Z].2FK;46>-_*1NHM\.T,AI81&*:$H80PA+PMA:Y0(J=71M9ZF'&M:
M'1,4[;A;E!W/+#LA4DW#!N103[^:D*JEK\9U!G;(SH# -JQP=?/4(5J6")Z&
M8-ERIG32"77.GNSN6LY7QUNL\C)2 F&,8IE>]+*,1@$C6>A#["<$<_5S)T:?
M=RQ(!U ?;/=;HTMA@>V>*3W9>4V2T?$2,[9TCI8X9\ULB:S/GN+1DO?\/7FL
MI!<Y$UCS]G2@M-91='*>Y4;:*;]<;0JQ:'N:KZ[E,DZ(^K;$^=6\6(J_$#]3
MMEK_VWS[O!%A*)UO\ZM<=">QVF8\S$@0Q;&?I@0S$O.$[G %"2/J^CL(&M=K
MXL8'N5+;>P%:-^0#@#@'TA-0NR+_H'4&M-X Z<X9V#FDDP(<I#55\J]3:TC-
M1?A?O@UUTKQ3:TO#-/!@;:J8+;9 Z\EL\I!--H&9=UA_R[$&A\:\WJ(@SX]U
MR;RO LL/.6C*]1ZI,(_$'RWE'[=0_"!+PXAAD@H *2=BW9:V4%+*U8_PNP+@
M>/;>"\(!-]@!E_4Z#\HAWZG<@S?1>6<MI# ]3Z%Q]&;DOT"[:$RY4V@?LUG6
M53NIS:F&O)V:1ETWPP1F3N<NE@-V:XWYD>;Y8[ZDQ==B*8S-4A1G/@YHR$.(
M:, SY&$OY%G*0HPH)\K3GN9WG>]E2#1@N8.CH8*Z_"A,.@ZIT=VBJ%FA[EG1
MD'R'[)@IN2I+:LK\TKU3@FM(P@1TU!1YV;\+Z.WSDG+]-1=KEKM5?K79K4EN
MMN7BG[L<8\@1X1E,@XP%)(!9Q"#E/(M1!BEF2&NCMZ\MQ^IX! _L\8$:H.;V
M@35RU39_A^153UI[4>ID _@#KCIV@&VQ/(TM8&O>E&[ZHNYIE>/C?N=K,?KS
M:GL]W^8W6UE(:Q<YSN_S&<Q2^=*T1W"6$/%_+("X!1 ''I\)^'>E^MD5:X9U
M1N$Q1O5=O?7Z6:RTBAU(L!$ P:=Y!>:RQ(F$.? +Q.KD=1[,L-X"TQBA+AQ[
M<V##$7>JX[8YPK8O=4*+:K$J9;63F9>D?@:C+(A3'O$$99&_UPDOB+0JC9M;
M<1QQ-,".[DZ +[+*V]?.]PUL$ZD68PS#H5YTT6 Z X?2>." :U@I.TE/AW+U
MIW0:0F7!C])V9].\/2H#%'E(42RWGF7II*NZY%=MO/Z[_2),"!^$A,0IXB3C
M$8K"+&SM1W&H)4OVK#J6J29>;[-&9R;Z9)%A-;T:AUP]_6IX;4""!B5H8)ZU
ME3Z;']%-NEBZJJI*88?&V6^&:6B> []>7W-UQ)Q!8DB&B3,&<1!@Y'/L)<0C
ME""<M59@G!"]=9/NUYTOCHXS%?)"JW&B1XTL[<2.=9;,$SFTBQ[721MI7"U)
MH\78-%3%&/WI)(P!"\I)EWU8=OF%E(]/^;K:%=)=R<5C??S_YF&^R?&\$FO)
M9FNONLV_;[%P^I\S+T;8)WX2))B3F'MI%)(L)(C[E 4^5KHZ;PN+GS*,8BRO
M)B01)"SC*<Y2'@2A/%U+7%^LO[F])/\.+J]NSR\O;C3O%[EN!36IFE(#:&[_
M[9'+LX#'V,$.?'MMJ<;_RYUTH#W$4($_I0^@=F+@5'9/RKMR:@,UYC14=S!O
M7V??!F59N?QX<UU[OCHD!JL#TH/UF*,D@#3  8H"QH6*)+C1#1\CSO2> E2T
MF2:(Q8&8M7!((A'<9EX29B3V"/8CXB/7AP$Y.K\&?Z#/OS/-]S1L4:HFQ6.P
MJ2>Y>X1'Q3:JH]S=B**J2%Z'>-JF?QHB:=VKU^7.G;"F*GIHO2V6Q>I9GD&[
MD?73ZW?)V??FR0=Y^5X*]'-S9.;R2_L"A%B2UP*-'LOG]786^I0$&40IA<PC
MS ^#A#&?IB*V$HS[2J?&AD7D6# OGW:/.7^;;S9S.<;GZR58U*N32@98F^+^
M0496B_+Q4?RVJK-=B_EJ53]D(W]X?L0#^%2(GY'N5:=W*L=L7S5]GE[3ZJGW
M,7YP< "T'C2E2HY\J*N4[+RH#_K6?IR!QI-A]=T*^1WJ/VSC3F-N&-CG<LSA
MI+NQ)")Y.9==?JESM@_E2K1%U>QO[9_M$[$ZCGSY@!!*?!^2E(:A%T,2)C[U
MXD2YXJ858RZW.W;XI!X<(_RW70TC@[<F;>UT*##7N<MAD_EI#&K+/KW9W;#/
MF/:@;*Q)=2C7,MZL*Z431A.8(D@(AQAG24();FUB'\9Z.[Q]+ US^.0 RNS-
MA'YD:BJ;<QY-#J!H4.A6O=YC1T6U>K$Z,;7JY\LIE;+ D-Z1N+VI7=7T(,*4
M)V'$ Q1&-.09XLE>"3T2Z!^'T[4PL!H9/J-@R)Z:#+DGKI_\C/1RPKNT?'CN
MS93&:>A-3Q_>/>_6CQ'E5->^E)"L1G"^)O.G8CM?[8[GQU[LIV+5$R8!BJ(L
M2B.?M393+X!:*:Q>EASKS5&)*XGNEV(-=O@T,TO]Z%3,& W&I&8FZ"2)(]WN
MZ22J*VMCA>!I2),E7UYG62PRI"I5U_E6Z&"^;%,V.V.(AC[U,?&2C 4T#%@(
M]W%7A *M%9JA"=?BM%@T5^+EN=#\2[$H-,^CF3*G)D<#D*:G0RV@0Y9Y'/EY
MGY@.W>G)Y#0$IZ\3I=7>I2<QY^O%)I]7.<V;_SU?OTU'79>K%2\WW^:;Y2PE
MH8=B/Z,D]K(H"<* >#L4C!"L]:*4;=N.1:F%"SZU@/\&Q(3_7B)73ZRLMX&:
MBHU)OYZ\:3 /_I20P0[SP/*GR6B'+KIJFVD(IC/ORF%ZN,'EJA<V9U'(,NAG
M!&8TI9D/ Q+2UA"E83)[JN\ZW&SGFZUJIEW;B,YX?8U'>>CB^:HN?#_?@KO\
MOEC+&4UN?S4?-+A#I4FD:G[=*7NZVX3OR!K:;C?%W?.V/A>R+<5R<Z-1'LSB
M?:@7+'4FUXTIG89(]7'@O:M,?;A0EIKZ;-#E\[;:SM=+,=1F'D\SPCFF&:<^
MHI!X<9M#8VG,F8'2:-N8@- HG9QR,VA>T]4U9HRIG<B0,<?_>L3T9$)UP%SD
M6Q$DE(_YY[*J9MAC41!&*4889AEG, O]U@8+,LW2*'K?UADD1A?\!!RP$DB&
M[?XO2.CH^F9D3:/;&V(O;707>_?\R?Y4JKR-L;\_=SA1-HMA&L=)FJ&0H#!.
M(HP0V\]9'M;:&W&+Q'$FX "PGF'V=;V:X[ORU.[K/VMK!R@^5C-0>VD$QY-H
M*H,XNKNZP,N&/+[C>_!@.C4'/B3[HW#<>2-.0X\'\E6C7H%MAO5J&#1V:WQ-
M7+6#D"_]&8YH"DF O"3 'L^B* Y):S=.XTB_O&4?:Z/J=K$6Z^H7%S%&6S1\
MR&3'2+?7"M,8S1;]>;=*@#VF>D9AQ]:[I((2Y*=A&''JI2%B$*(X;4%ADG@6
MPC!;4*8;AYE?I7+=>KV"LC$:SEY4UJ#_B<(R1;KUXS+;[3@-*1_*6;7(S W'
MZL<0_\]SM6TJ&I0G#A>].A;Y F!=UR9#*8^\T(L80X0'+"1XGQ0+<:CTT."@
M@ :=$.XVQ?(^!^OZ!<\WT9WN,<<AFDM-^R?74GHSP!%\N9/UZ@PE.)RA/ -O
M#GB_F@Z&K\1E@_O.<Y@#-NTT)H5A77YSJG-POFWD:IL_YN7F)M]\+19BDO(B
MDG'H>4$<T2B$828FK!:#)UK%5FY6W[+K4UD"4+WQ)Z3AQ>+]2[F1E1:JY]56
MQIC5#J_4%_''ZWQ1W\S_5FP?P/8A!X_YYC[?3"*J?)]HP^2>>8--0QX<^::1
MO.O+H(T!CQ9"A*I:G:I9$#$.48@IX0D-$X[]H+T5S!(4:SU)8\VHXV'>!.N@
M:-:-[XSAN^>J6.=5)47@KEC7Q0[L;;;H\=]_7\49]=:W4(Z13D<]CU$9"J=1
M$TQ?,\W<TI#+'KS94,J+_%O]-V+=+H(P#WI4_"<A*<U2FF8[VSP.,Z6G>^U:
M'# 4>I7XM*>$&OSVET$WU%K70 &S^8$)*>">.D/YTZ=^^MIGX).&\)DR9F7;
MZ&#<XSZ/@ACQ$ D4 8T11:WQ3/R=M>TA=9/CZ=Z(YSZ5J#/=&=#G?M*CT]@I
MG4R_*6<V,_HUDKJ ]LN"QTW(E.]6F WJZWQ1WJ_KK]3Z,L,!AI3C,(L@#;TH
M2W'0;D1PG!&MNW>C@W6L"1?E^I?%O'IH9&!7LWQQ7-M<;@]_S:OM[IRX?/AM
M4RSDC>-GX8?F0;W1Z;2X=3"99G>VK7!<Q_[8QS.P]Q+LW-R%>N#(T>EM./1I
ML9Z;$8-TEFG,7=.APV 38\!V^FB^K-_V/L*\?86YZ(FYF>UGGI\Q/\J\U,>(
MI)@AQ& +VF>9TNLJ$X$ZJ;GR]42I?Y)J(JQ^,&5.!.5?8,)L#W;]7+UC62[J
M*OSU5_]*O>2%8S]A;WD59LD6D,&3W'+WZM!IF#9Y)W":6&<8-VR:&AGE) =L
M[U(2) @RFH4L)8PS/R&$1;PU% ;4WUWP9NNE1LI/SX2.^+Q$HZP^1[>[<Q&+
M?%Q 8I(%$%2)G,9ZIX\#'Q= T./"O !""E$2)UZ$L@0EC/LH3H+6#@U]I#T^
MM"V,.#Q^UK('JI1.9*"8X_^P[($>$\HOE^9WV_<>EZ*^'R+FI2E!5*ST@S@4
M\YA\@"WPN1<D6GM'IVR$!$<PCAD*@N9T0,P"3&B44N)#'FD5UC%8[%*&;S4?
M&#4E2RTE.P1/>@M#B6@:C]&=X*9#2_JR.0U%Z>W%ZY<VK;"B_(+FO-C4B<//
MQ?RN6-6W:'[+Y]+T\E)$T(OGC=R;P_.JJ'Y?EW?R:*ZL:W6^?GK>RE!ZO1#_
MJ@ZW#U"#" <LY $*<!K%$8XA;I[I#1 )L4>UGMMT 3 AU/-9S!'U:40@0YSQ
M&$+HIU[,6>3\@.3B(5\^KYIST _B;YJCSE^$J^"K]%7^Q6KGKV:!RG$:5$T^
M)]^6>MHKW6F/%1UY!%J70/TJ\\XI4'MU!H[] K5CX*5G0L+KOQOO55$'K=0Q
M"XS:*:8QA8Q+P>O'3<=O#^45Y+.P_J]G^>;-U_JEF_8MKB3*LC (?<J2Q"=>
M&+',8TF&HS!)A#75QR^-O^_PA.,>$F@PC?<.W0ERNA:/??F<QG#M[\;KI:0=
M7DR'S6&8XE3,[RGS0P9Q1CT<IS#=V4MAA/6.81M;<1U]O1Y"F@>NS=DS4QTW
MQ/66G='BDY/\:"B//J?3E!X#/S[0'E-F-!XQ*!_SV_GWPQIW+W<92:D7>1%/
M/!\%B"<X@+LL#8U#ICJ .DUP++Z$H.\A'L$0HA2*M4Q _8#CU$NUZM_J#:$&
M%1"P7N1K1IJ].SCJ&$8VF)W&0++BR=L2]I;8Z3&8#N,WS1CE/,U\"). IP'"
M49OS9"Q.M,K%=1KR,DY2E'H\X23"*,(1"[GX188#SDCD^C7&\PMR^1L#M^@_
MV(WV8QX]Z#,6(S?,65&CT2;U+IKT!$F?W<DJDH$K'TN2*3_*5RNJ*C]:PD#/
M2[%8]8M@(N8T$9,Z)5Z<(3]&V.-0[R*$WJ<=ZPZZN6&WFHJC2XZ:QCCD14]5
M&B"C!34O>>@Z+6]&V#2$PA3\ZY/H?3C0$P/RO)$OH.QMQ5D,8Y]&7D9QFF:(
M!.'>%HO]1%\3="TXE@;R^_4UN[@%C43\=Q.-T.9,1RI<TF6B&&=@AVADZ7C%
MRX<*8LKCE(3$V(=W]:0?(\JULN?5 UHOY?_((VI?YZLZ;;HE\\WF1[&^;Z["
M9%$(,?.3R LP0IQCYO'6=@A#K6RF'8NN94=>#)'W/^H;(OD!Y\ 5L56XZAA;
M=KF>QEBS[-/KZM@.&%.>XA>+\EE8N\X7>5'O!%[DVYT,S.+03VG"$Q\QS"'S
M(IBBUJ2?)%HG07H9<KT6V&$#FSVX,[#.-5]"[D>E8@ P%(N:<4!+X/41@0+9
M/C(8.!SH8*DK*K!![C0$RXXKKV,$>_RHITCEMD:Y^2$LS4(/IH0'(>00>3@5
MF@>CUD2&8J5[ID8?=IT"W6'IJK5N@1W5C*<C8G0SG#L8M8X,G<T\4-"9O31@
M:AKR8 ;]37;2V'^C!,0L"N(8PH"CA)(T#3T?'R0F2""?;<OM?&60>/CPRUH"
ML >AW-EOY3\!B]TB>EY#ZY%U^)@H@VR#58YZ91E&3"VHIA24R9J&'!AB[THA
M:#*@*@A7F_(IWVQ_7(D.LA5K)KE>>I*W2VL-HC$.>!0S#]$H),BCR5Z#(I]H
M+5=Z&7(<+UQ=7UZQZ]O_!.B" O:_?S^_^HU=W(J)DFG>M^G'IIJ(#$:DGJ:T
ML,Y #:S.N^RAC1!S=-'4H3I6V)V&"-EQI730^TQBE@OA]*MD:B@L)11"!"DA
MD<=PZN^3J4G" _U]$P,CCJ7I\O;O[+K/QHD);SK1C&/*S *; ZB1=U#>LO-A
MQ-.#T&GH3G\WWHV#>O.BJC>_EN7R6[%:S1)$$A]RY@48(Q*@((B\_1XPBK3"
M'^6/.M:3%H>>E*A3HB8=3MC0DXH/B7"B"JW5#A70YF8:HUX?=MFS3^@F/K>B
M^>7#1SLYR;?L^V+U+$L5[$W'"64QYS%!L?@?#^,P@CO3)(D"II<0M6#0>:*T
MQ5@9[,_8H50UBSHPF[K9U18>V,<@^19\VF,$+<B!BYFH\-:9DK5(^S2$RJY+
M;U*XUOE2%;C+[4.^>1TJS3 GOI\2'P4T(XQZB1>&K:TL\+762&867"^0)"BC
M%*\A86IZY9XK/8%J:'J[/AI6C=YEI4-^^K$X#;WIZ4-ILU^9)%YF:9CXE'@\
MB*,DH6F=UVD_SKA,L^CN$GWX2<?;0\AX0^AC,G1R)U9Y,,F4C)$2^3 !HLS*
M-,:W+NAWDQN:/JN.X*.:%6B]?%O*\'#<'<*0$QRD?A1Q%"%(XJPU3])8*]5A
MS:CCR.'S.<+GG\]OS]E-O?%S<WM)_OWOEY\IN[[YK_]/&OC)_Z@W@V[_$WRB
MC)^3\UO%*N'VZ5=3E5&8U].=X\) [1;1]L=H65I5QCI$RSKITY U^VZ5CCNK
ML32^/J3/O-2#% D1CD./\3CTH[T6TS0P%4-=,X[EK[V4<R2#FAM,?2C4%C27
M[!E+V/@7=4XSI"99IK1.3J2,'3DM2_VX41:B<GU_FV\>9:'+]JP/BV&,TQ0Q
M'&11&GI)@%EKR1?+/"T%,OB^:^G9#9K'^?9YT\0"LL*C /J+^-HC6 JH P^C
MMR1UC9\>E$YDX/3QX/6(Z<V&\CVW<OTUWVQE>O78&(1B'%+B>XRP"(=AFF1[
M8S&!6J/%T(3K 7- !>XVQ?(^!^MR*^>?E7PW7HX7L"RJW9T1&5?7?U2TKXLN
MRDHWWV'*M=K$/@#->I/Z,<,2T4B'8]_GI4.*>A(Y#37JZ\3KZW\V.-&][W<U
M_R$O\+3& BQ"!9;0!!%9/B0@G.'6& Y]O3H?9B8<:]+^BMI3 \OL;I\N;8KI
M5?>,::9;6[)VB$:^Q_>2EZZ,;#\BIR$O?9TX<6NO%R?J5_OK%YT^Y_,JO[Q;
M%?=U)>']I0"/H9#1+&,P"[GG<90*?=L9Y3[5O-/?R]0H:X9%@UF$00*T;H33
MDUK%2&<X5C4CGAUU-3)P!&VLT*>3J*X0R [#T] J6\Z\J8A@D2.-T&CSG"_?
M9E1F.(!!E@B#09A@"G$<\_U^=8*1;AT$0RON R0)#.3?Y1-\ZJ]"6IOJWZ>E
M>[;O2>4T!I$%/][.^5:8T3K,]9XU,3Y)1D2002E$*$+(YWMK*=4ZH&IJ8Y #
M7>WUC=4!G\'I+A,&U:;U(<C3F\\;WM[;G!CAC)>6[/3E<AJBT]N+]TYZ]6;%
M?#MTYB61EV*A:0RQ, A2R+*@-832$.J<^S+XO.,S8"]+!!C+C EOIGN?5BGK
MO^<Y]D:GU@:G,G?3$),^#GRXH:G)A8&$O'-7+XH2ZE%I,@H]/V!^2N-]]C5#
M>EN:O2RY/E9V>?$KN&77O]DY66%"I;; .&:QA]9,X"9O)T]J(M2#W\GI41]?
M3DM3;X9,CEL<G:"G- P3'B.Q>J,8(QC[>)\!(2G4._-E9L*U+KTX7K';.6['
MUE%6M=X];O>2QSN%H70_I"?3$QE;/9WH.(YAS(GZ:]R;XNM\6WP]?AYQQ@+Y
M?0_%(4K%J TA1NV]? *C)-9[B]O$@O/S&(^/Y1I4\M J^#;?;.9':PC-%VH-
M*52;X]VSIS>W'_#L,Q6GZ7+T+O<[C'1(3#\&IZ$P/7UX\R)W?T9Z;G\>Z5KL
M)8@SW^-I0"F+&/+W40)E+ TM[(!J6'.M.R^V.T_.X5;V074X[K45ZHA>:[NA
M8UV6_9 N_3U1 ZJGH6 6_5';&35FRG2'Y]A@1L* >3[!7@:S,(I)W)91HQ1!
MV&>31\/,(/L\AT/?UG9Z=)@TV^QQ1&+O_9Y1K_6_RX_&KH\!J=/0)AN.?+#W
M8\R-0>YVQI*,I8GX?R^)LH@%GGR$=F<ACM+(<-_GP^\.LN%C8Z/G8X:T$[!6
MR3%.MXZ65U7+HBJ3- U=,$)^.D.JZ;WJR.^X>,L2$L"4BQ '(1X'A(5^VAI,
M4E\K#NEAQG$<HG+M7W/[I@^G:M(Q$)UZ2G(,ZM_:F_UHN]T4=\];>50:;$MP
M-1]U,\?HBK\%MJ<A238<*:WW1-V*]?F77,1"3<F YBDO#_HH\#T,,\:H'T99
M3-OD-O7BA.@5JM?_OF.)VD-J,LY#%U)_PT?'4.G#WC3&2"\/WE1+[\N&^M58
MN2-Q9 9C0@(<A,2/,A9%.$Q@6T658N1I;6AJ?WS [9<S\/]Z_\WSP=-\ [Y*
M<&? C[PSSZO_4^]F^F="=L[2R /5@YA]*C!_WCZ4F^+_B@$UWX+_];S. ?3.
M@!@ 2?T/:+[('^_$ZAKZ]9_&9T#\LZ=\(9/>JQ]G(#X+O>0LC9OOAV%VYB=1
M^W5YZU9^6?Q-^;RMMN(7L@"HB27=*[NZ?4 Q;^NR^373M$W+WS0M_T?3WN<U
MX4-?U'W)25<NUI2^:>BA.?PWUW)[\:!\ZV2Y+&0*=[ZZFA?+\_4NP3L+Q*(I
MI-Q/Y#6]E/$8[E_TILCW(JT[)X8V'.OB 9:0PV+Y2[%N+\AI7LXUI5!-3X9@
M3T]6CHB3D( @CGQ G)M+.^\STR$N?;F<AL;T]N+U=1TKK*@JSG6^G1?K?,GF
MF[68Z2NT6#P_/J_FVWQ)\R_%HMC.* ](G+(LBK,HQ223F^+[H _[6M&8!7.N
M=>B ""P;2'H"9(-1-2T:F$P]66K!@18=^'1,[0[@P!7E/V:L0ZXLTCT-Y;+I
M4.FL:_9-"<_2*(Y)@D,:$YB(;X=QTMYRI-0C6G>!##X_R-90=82K303G31+S
MTW*4H?:6*:TDI3*MTQA*?1SX,"FIR86M LNS)/)QG)$TR@(<IV*T)FP_0K''
MB.%FJIDQQ\/H=6W?ZL5^0#.4[!90_IA>[9U8]\P:;\\>%4R>5I5DM>W;?LQ.
M0Z/LN:-9#5F3)YVT<;&5[W=*LZ1<;T6DD:\7 @8MJL6JK)XW^7Y#)XY3/T!!
M%$6A3Z*$)A%/O1B2,/93'"+EDCA6C;I--NYPUD/O!5)P@#K:9J86D1]D*.TW
MR#1&K"/?WLEMNF)0_69;5;VP?"OWW&<^BX(P\5&:PHA%G$=47ORIC64IS1*]
MFVU&)ARG&R2J5X/SSQK8Z>%HE4#%&,,]=YJ1A3YMCF[]O4=,5TS1C\EIZ%)?
M)][<^K/ B?JJ9[L[)T_F58Z^%]4,9AGTN>_YU,>)6%LE<1:VACQ(M797##[O
M6F'VB("$)"9\ 4I770Q(4UV]..5+=[VB196C]<IK0CI7*,;L341)>CCP9A72
MDPLS!;D5_Y:6C_-B/?,@)BD7JQH>I%Z$?91XO#47!53KS*FQD:'5I('52T]T
M*#11%4?L]=26CX@;0%T.Q"AKC &74U0:$S<Z]<:8EX]4YVGS5,Y^O_B-_%8?
MMII!!K/8B^03>U& /2^A\B&7YNN8I9Z*R.A^T[&F2"1J^J%-1K=<N.1!3QTD
M"/!G T-12[6Y6):+9[G*K_OL*)R\0&"9FU=R*=V0(I@(K%XM@:\<>T?Q3%T?
M5^",49?]&EQ#OGCYG3P(D=Q9B'S?2[,$^TE$A4)RFH91:X'Z:NLMD^\ZEC&!
M!M1P-,:O+C,*>N:0%#U-V_-A(FRZQ&B(FT."S 1.@R@UE7OIX2FE,^1A FIG
MBKSLWPLT5.^<WNX^'B?RZ<\TBF$8<Q]',$UQ^W'(0Z7ZD9J?=*QU HC&8-9@
M0D'@W)"@IVT"@XFJ:1"A(6AN"#'3,B5BU%1L[]8I =/W>P+:90"Z[-76&HKU
MFZR;>%.LY\7.!H8A#S.*"$M)$@AIQ"EJ;;#43Y6%2_O+CO6KQ@-J0!K#5Y\?
M!3ES2HV>JAVQ8J)N^O1HB)Q3FLRT3HLN-<U[[>4IZ3-F8P(*:(Z]M-$?-/3P
MYK'8/NP^'T8\(HE'@R -TYA$T$?[K!Z+8_6\F\Y'':M@#45C@&OQH2!]KJC0
M4[T:A8G>:=&A(76N:#%3.45ZU/3MR+53TF;B_014S0AVV;/5-;3L/\[Y^<7Y
M>O'?VC0?94$41Y '/(,ACK/8W\NE""657E\T^K!C3:OAG $)2&,H:[.CH&XN
MB=%3N"-.3'1.FQP-K7-)DIG>:9&EIGJOG#RE?*9<3$#]C*&7%OJ"3D2W*'+A
MS=5\\T^:?\U7Y9/L(*04?[>IN\G.=."E:0C]V*.<41]"BF7=U-W9L\Q3.GAJ
MU:#K2/"*ZFS!6J-1)4@<@4'- +)!*,N#_1,<801'((WB2ULLZ\2>([!M&)=:
M85TQ;%5CY61(:YG4"0B^=9=*AYU08X(@5^C757DW7[61>!*2-,0L#1(*TS##
MW-L?0DX04@^3=3_L6/ %'-#@T1 D;7(4Y-TE+WHR?J#$1*RUN=$099<<F8FO
M#E=J$OO*QU-2:DK%!"33&'IIH2MH2"!;WN>X*&]^5-O\L3J*QTF0R'(-E*44
MP0@E'O:]?58B2Y3.-_>SX%@4)2X@@&D,>W.R%+1Q$)[T1+*E:(?)/*E@3IR&
M< Y"H)F"&A*I)J:G_#ZEJKUYFH"\]O>AM-ES>MY__5RL\W-I>@9EJ<$L\DA&
M/8R87U=1;PPB&(3][L"JFW$LO>]=Z)3@0(VN[V58#3:[97E@(O6TV93#86[&
M[AEZ1X0LTCJ1VR86'/GHEJPI-V::](/.'^?W>753/M\_;)LBJ"$D&>0HI5Y&
M,$Z"C ;M-A4B4.TNBCUK0RC4XH#P#"P;C*"J0?:1*"-R393*-:^]!$M0NH,'
M&GR[*LEC"M<[A"GK5Q^RIRACO?SI5+/^3!F*&EHL-L_S%=J2^6;S0_SASC8.
MA0F<(!8A+_!HQ@*T%U3!8P]A,[0XL+B!>0.SEZB9DFLD; /PVD_< /J TB'4
M['V6U!6M)\N35+6^/G4KFQ7&]$L3W.3;[2J7:0GT*$]*SE(<<Y($F,4<H@PR
M2AC>RZE/L5EQ FTSKG7L<,N^VD,[ _,:G&F- GTN%15L&!HU9>O X,T1@ZB;
M0<?%"E[STR58_4F=B$I9<.1DR8*>W/1;0J)O<T'>LA'"C$)&(A_Y/ B2,$@Q
MI>W%.Q3!3.ENG$5SHRTBYPU*&ZM(/7[[+".=46MK';D#.*&%Y#%EVBM)([XG
M(F<6'5):2_;@2FF;]#TQO9K_J.MHSJ@?^XP@EL81Q %)4I:PUEZ&D7J)@UY6
MQ@FVBG6UG:]6]5FLIWQ3E(JB9H%5A3W5P0BU$G:UR 9C4&-S=3 FS39831E5
MVV'M<O[4+JL5PB:PTVK'C])V5^JIW><'V=J9WH7&088IA&+JH&G"$,M(NK^,
M@U)*>2\M-[8Z 6UO\&HMKAVP;ZCY@Q!O90XX0MJJUT?+<=><]YPE!N'>ZJQA
MT ;F\\@I>G3FE=X43W2>Z>_71_..)>:LOF)QFW_?8L'+/V=13$,! V&8!80G
M":)!RBD.$K&PH1G42I=HFDZ\$"?(#S,":81B 8''+(P1RB!,F/.'^<CEQ>WY
MQ:_L@IRS&_W'A6URK)8R&9%>O7E'_:T0B1;4<*?X6LB>RXZ\BJ-&F4:.Q95S
M)@^&F'*HJIOXN2K6N4S\/-X5ZUK#K_-%>;^63Z.?+P6XXDLAWQ% E0A@*[3X
MUW.QR9<"\/%S154E8H0E>=YLI,[7/SGSF ^11[!/4HR)SQ&D'N<)B1GTPA0K
M%3T:'Z5K-6[ -"_%;Q_R#9C7N/2$><1&5-/PGZ/]].2^]0D<.74&#FZ!8[]
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MF;4LMXKJK'53"&!?BH4\N[=8R"NOQ?K^JEP5\F+7X3H73AGQ.19F.<-^#..
M\2PDB =>S/Q4JQZ]HDDOC,1R,DK2 ).(>0$.B)?Z2>+C,$E@YKK.S<WOO_V&
MKO\37')P<_[KQ3D_)^CB%B!"+G^O[Z2"J\O/Y_K74FT1KC9SC,"UWD1P!! <
M$((6XHBW3]6HZY!GR]Q/0VUM.U4Z[:]Z6GBXQWKYY>9AOLGQO,J70L>?\G55
M"SG:;$3GK2L&5/C'X6?:F@&R^M@!I>_'%&?(\TGH(Y[ . T9I]P7?Y+&7J)U
M(L$V-H^%F$$4L2! $80X#<7L$K. "YT)$":NU?7Y\7&^^0'*+Z#:"CR@?*K+
M;\P7V^)KL?VAIZF#-YR:^$ZYS?14^J@<@&BQ&N<O=Q(H./8&'+L#[GZ\^,%]
M 17IDY#U.K ?3=PM-TW'+#!6)YC&=#&:]^4TAF+O%-)[M16RE 14Q('$RQ(:
M\R#R,L:CA 6)/"V>]CWI9F+2\71QS?Y@US<,_,:N?V77O7,[1J0:IVI<\]D_
M\S*-<B]JU.GE0_IP/PT%M>W4Q]F*_IP=].ZX!WT6O_J?_Z7]$_%?,C#XG__E
M_P-02P,$%     @ )HT52Y;'Q0_ZC@  %3\' !4   !P<G!O+3(P,3<P-C,P
M7W!R92YX;6SLO5N7&S>R)OH^O\+'\^PV[I>]IF<6KGMI1E9I2>[=^SSEHEBI
M$H]93#7)DJW]ZP_ 8K)**EXR$V RF9JVVRJQ$DG$%Q\"$4 @\#_^UU_W\Y^^
ME,O5K%K\_6?X-_#S3^5B6MW.%G=___D?[W]1[\VK5S__K__YW_['__/++_^I
MW[W^R5;3A_MRL?[)+,O)NKS]Z<_9^M-/_[PM5W_\]'%9W?_TSVKYQ^S+Y)=?
M'AO]M/EA/EO\\6_Q/Q\FJ_*GOU:S?UM-/Y7WD]?5=++>?/>G]?KSO_WZZY]_
M_OFWOSXLYW^KEG>_(@#PK[M6!Y^(?_NE?NR7^-$O$/V"X=_^6MW^_%.0<+':
M?'>#+ZD?_^O%\W_BS=-02OGKYK>[1U>S?0^&U\)?__.WU^\W<OXR6ZS6D\6T
M_/E__K>??GJ$8UG-RW?EQY_BG_]X]^J;EWQ>EM/9YUEU^]??IM7]K_&17]5T
MNGPH;]U?G\O%JER%[]^\YM.R_/CWGS\O/U=!=,@!PR *_M\//+[^^KG\^\^K
MV?WG>9#VUVS=L>5Z,INW[=5WK<[5N=\G'^:M$?NV4;:NZ8?5;%&N@NBKZ7+V
M.;+_5,>.-#EGMQJJ]'3+;)TTU>(VZN8V_+"JYK/;:('T9!Y'UOM/9;D^V=GF
M;^BQTV\GRV!1/Y7KV71R&N^N[\LIT#I,$&&BF)T>5'L?/D]7&O+U6)N<'0O3
MZGH63(A>SF[ORM?5Y.0X/]KHO%V+_7A3_OGXP9MJ7:Y>-8>SR^MZ%V>669[O
MWW=>@5Y\N.E$BDB-WIA-*%M^6)_JYO-GLGYQ$'513H,U?%B_6BRJ+QN7<_4J
M.+JA#\MH/AL"V>EEN46IM?8V>-NSU:I:?FW#A58OR=IU6WZ>+-<Q=KCYZ*;5
M(GSQ5"W"+'9__["8K;_:\DLYKS['!UK(TOVM686+;O[MP[R\^?C8J<;]/]HP
M;Q?+Q:Q:!FS^]T/\H2UI&C3/VMUF/OO+)[-VXI_EA]6Z7.K)XH\64!UNE:]S
MVS \Z,,%=V;]]=7B8[6\GS0))YJTS=91/YDM_V,R?RA/]>K%@_F[T%"%AY[/
MWZ$WDV68,69?&@_$TRWS=[+90#SP>+;NQ GV/KS\K]-=V?/H.;K14&6'6V3K
MU+LR+N&5OY7+NW)YJC]['SY/5V* .KLMEY,6JPF-7W">+K]:K">+N^@9J=4J
MA-)J^J^'V;*Q@]CE7><1I+5I:=;Z3)TMU^EPGWK)>;H>'&@?)T\[6TWGU>IA
MV0WPTZ\Y3_>;&?<C3;)UZ_VZFOYQLUD^/-F??<^>I2.;G]7GS6,;(_1N=O=I
MW53#[=]T/B&V/W?M^?[F9^EN,TH>;I&W4Y^J>9B 5BZ8E!A,?IQ-9R<7,DXV
M/'\78_Q;+3:_;J/R=J_J58Q_QBEIT6[L=7OE^<5Z&SI=+L,4E45!1]]V?F'>
ME\M9N0K!Y.,/.J]PK=[>E["/:R'G$+3!FWL0,OC<N8;;D7>=7Y 64\GIYOFZ
M^_!A5?[KH5RLW9?PG]/]._!\Q@[=WT^67V\^OI_=+69!]* L-9U6#YN-LK?5
M?-9DIZ_=6WKNO)FL/L5EX?!'5/&7R3PB&3ZY67\JEX]Q0U.JG^L+>X;D^_ T
MJ_@G7MZSJ*^KU>IMN7S_:;)LN@B8_.*>10S1[_O L=6[<EJ%QUJLN.1Z?\\"
MYS5+%S9/(?S_7"[77]_.)X_K\L%DM-D)R_LM/0N_F7_U9)/1<A]SK]JL%V;\
MBFQB_V,Q>;B=K3<9.B]3==ZOPW\CZJN;CW%Z\//JSY-B)KSR F+=?-ZNV6:4
MZ^4[+R!8YR6!C%_12>SGZ:[R4>I%>1>_^_7D0SG_MOO[VLV7RV^:Q3Q;&?-L
M(=L(N.]MF7L:IJ"\G?W^A9G[&QR#P#.WR SQ_M>>I>^!E\O,F!]Z<>;^_Q[7
MJ_/V_.4K<_>Y6D_FF?O\XI7Y^MR!&.N7W6S(@F"V5\$^;B: U^&#[?/QO5T3
MYQ^_J_QK70:+?+M)S*^_;5Y-]XFU$>GC9/5A(]?#ZI>[R>1SP 2R7\OY>E5_
M$BT_^P7 [1&$_[[]N'@[^;I94 B>UZ9+D_E*?5BMEY/ISK;/(QA__SE\?]&@
M54&MPUQB0212VCA@&0*.8XZ,  !A]:VH\WC8HEIN<3VOK%L7;+7M?=WY,$',
M)A]F\Q _E*NGO:[?@Q9TZ,@?1W#H^,9"0&"QL!A+JAT,4#&-(D;8(RT%!DTP
M>LX^M9S^5"W#[/SWG^'//WVN5^I>/_;XX F3#1/7+TS(9#E]P>%O&VZ?^/7S
M)JG[E^FGV?RV;AT/W)R!+=4ED ]RUB/^U[U#_BS&8&\(<-4V04@,K& ,:2N"
M:CTB2'HJ)0*,(^_$Y6S"X\K7"^J8AV5D]A%QCS<LN-(.<,8X\U@30W!PNCU5
M7A.B%&7TQQGAC75?G1'@IX%\7CJYX"147\O@M,PWD4<;1IUL6T"&O#8*..>%
M=Q("C+"G&DGHN2?2)I *_1BDRHUQ7[QZM0AXEZOU%I/39-K?H& 8,F6<M3#,
MK\@ZI "N<7-0H00&X1^#05F [8LV72:VPR9780NL\81H2!26Q#'(MC(*C7V*
MUTI:D^=%$'D-Y,F%[67\TGU;SU?MEEJ-&'$04@X5)DI++NTV^& FQ F7<TN?
M3N"\I,Q&#4VBT^8O*8A76A-HO3&( R*,0C0@H0P) 9ED/U! VI@354]@]S36
M3Y[G[W&DWRSO)HO9?VWD>-J2B+1:W+Y])N/-1S];3!;3V63^M%O1P"9D>7^8
M!*P,_P8?43H:Y@*%I"*:(P0!-< T"O'.@]\>70;)]&0U6]U\?"Y@$RO2_F6%
M#X2&D(6(3'E*I=7!,6*&>>"\A9#P<5F3GME4]:R>R]F?2Z^#78<94H 8A )Q
M. ;<2^"0AV%2":S!F%#JA^#$U,K=G()9;1)U5OKKL[]M9LA&KDRS5Q6 A6%D
ME",&$N*P,1""+2HT_#,RAZ9G)AUT?<ZBG+Z"Y7>3Q5VI_IJMCO!P]TSA&*5
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M=9/E8K:X6ZGI].'^87/;Z6-QMV,>SNG&A?7(,.$D99(*;61<B-B95)U43WB
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M2<G]'F#N2%XMIV'9?1R'^'$Q+=].EG_8\DLYKS;7'YHJ_&ZYD>W$&&_6O$!
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M !6!1 :3VJ=C<\GTN*9*;Y<>UP[=T5;Q0%YCX[!%@A-I''NRZ40*/++[H,[
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M9R:?PV^.5G!L\YH""> MLY81H7DPI)P+6R.!W+@/!'?@PY& )3/48\TTU!9
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M2AID@A/% 4DY7S.@ A_]<"0-VSY8\LCBYCQY]GPA*<;8<0*EME1+KX6 3$I
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MC8+VH]TJO2@)SZ:>2Y+TW6SUAU^6Y?,"ZRTINN\5A:1 <8BA-4P8@HW3R.U
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M<_8R0&_3G$5:8,;C-W%$O4-$.0ZK,4J0SF[OB32=2+NQ.7L9MK=BSDIMM$$
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MHS60CNM&1OE=.#+;,JI#=(?BT=_71=1CUYO9XV1SLJC6SP\&SRS3ABD)(U9
M>*>0J$:#D<]Q>M^6W[(M5[+P;'W3X(_9^K_2P>3?%P_%*NKUBTVE')Q</AJW
M#2GP@WF&"4($.*FM@: :A_)9O!CA_;X.>=$7Q$,M)'5<[G\4DQ24FUQQEVH^
MC=\1*+:408@Q1$("A8'@N,* "GQG&5Y[6'[Z@GHP_>=@R,4%BE"3]@&J.,HX
MO9!7P@H,.2'UV#W6.9;T"%._]J$1]0!S^VMVRT6J0+_:>^]2IYJN4!>U+U=H
M3*&S7D",B#/EC9C]"NW(G25Y[7H3[ GFH5:FZI ITO[E053SY:GY2X*01A@'
M*) (606T!)[5FB.T+H-L(TP(V\,:U1O6U\V9]>YK*<TTJ#2=9M^*E,AD/Z13
M8;&7ORT@S E,Z@ C6#%JJ1.VPH5#F1,"/\*\LCUPL'_0AR+CWF?^[ "I^:IW
MMFWPPFF$#24"4D4H8OY)4V",-KIDUEG-[IMD6M<8#\6K. 66C\6'R??F=#K6
M)$ AL0&&E$>RS% DE:JQDS;'T3G&.MP]L*@C:%NK\KI8E)=I)_.H+7Z+"$8I
M^&*RB99L0V6^^1N"8TIQ3R#S%J-4#EB2-":,H/  9.UN8ZRMW;4^WQO20RT]
M+\,\FJ] 9UH& Y&F7BML4TB\%1"R6I]T%&2E?OPUW.C=(CP4H]X6?S[#8K5<
MQ!\?=AD)+_697OJJ +#3&# H6 JHC':SWZ>$3LX6"[.B0^[;13\0Y.,*'%DM
MOQ:KS8]D>&RB)9*\>%_34.\M+ Q+R[B.*HH&2"$CN>-L%W@LE'&L45V=OL+"
M2O&50CX9#/;T6- <$,PY$03!:!MZ)3BM1L.B(O;+!(<T%NNK$+#6:(YJ_I;I
M,5XY%NYM\D+ -,'80B,-%P8KPA&@2AL@F;.JD0^T)]_<4Z*2ULF(RX1!ISQV
M77U'<%P!:@B%!GD$G8O;(*APE*)95-U=+!N-"74\+\V@HAA*<?TPVZ3!O5E,
M9]]FT^UD?J:"Q\'G@_ L#HI9#Z)VCI7 W-5CL[S97GL[-+L")Y;=2^%J#/OG
M;//ECV)>0K7^,OOZ8>GBG-W\.%O;X\(W!8N<00P@Z5)Z*"PI5:;"0^%[N_>?
MR8ES#.L4Z\$</;MJ$-_B2*(^5:S.EEDXW" 0[S!73C-'A8 *<&=A-3H2MY,[
M9U)7LG_IZND"[,&.P=*2?F9SK)^)!H95$!$#&'&QY\@#1>II)QC)(,P('<S7
MWQ#;(C\H>\ZN/L^>"HI2JZ2.DT%%Q35:JL#7L\!)F!,%,L(EIX7\#C&@%79#
M<> _)M]GC]O'LRSXZ;G #$="*AC7424TA%)R6HT%.G9GCI]64EQVA]]U(WR>
MK9/'ELG?&E3LR7]YX-0:32UC1G%H%/ &Z!HU0'+",D9XC'7]_6MPD0U*](_G
M!_;QY<#<]Z^S7<3H[\5JMCQ5MJ"S[P@0.6BP9,!@ )3")D7([S%D1.?D>A_A
M8CLDZ0[Q_0HB&_WZ7O[QCV)=.C'+$9ZJ0-3EUP3..=.<<8>]L00;38RHD!3>
MWYO-<F7R7T=J0_%?S4M^%-/#8]UG!CQU-M3H!<%9(H''Q"M--9): AY'KZ/I
MX PW,L=*&J.><CW.]B*/P=R CU_GRQ]%\;Y8?9OMJW6^&L+;%,NVCB,L$5M_
M6&Y2?-O3[U.)G+?+S?\K-D\E=LK#V%U0]RF%?)#O#P9*0;EG5 .?[J5[ 7!M
M.6N9<]8WPC"@*\Z%,8IS](K-KI3'F\5ZL]J6AE29Y_/#E\G^4L3ZW7:SWDP6
M*:W?/XM4XR-"]ZU833X7?Q3)S1P_-\M%>9J[G<Q3_;9>;. ^^AD0@0)P@Y @
M0#JG#<3UZ;-7*N?\8(2WFV]1M1J!V-M?@SU5K?7->KTMI@T*\+9]51 ("N&1
MLL1',2%ML*Y]'O''G'WGXCO50U3UNP*]!Y+-0(%N?U],MM/9)N&WF)8E!Y_R
M[*1-,/ZYFX+E56$_7_YYS>)J^]X\ZTRCTFK'FP4D- .6.Y<N^3'D-' *(!YG
M-1, P2M66JB[?39"[:<'@XP,$TH#PR@0UD'+M=V/2 IH[NRPJAOAOMRY<A =
M3OM;KLK2N;;XN/D0O_K,@?C!YP.F5EI$L$88:4\, [ >&W;FWNIKM13L*\TF
M'\JKT>1L:->1%H$"F"YQ6(TU3!=7I7"L&A^%6-\95?)D?(XQK3 =BC-Z-9M^
M+GY;3A9G#\A?/AHP$YPPBG6*WO=*&LQ,-2(=?[YSEEPJUY=I,_/@'(H@ORT7
MGS?-MYY#CP?)C8N@:(2(I]C15'JF&AF7LE'QNQLZXNAFY^D R6MQY.R^<[A!
MG %0.<&]PT80AZRAR%>C8T;<6=!-GH#/L*45HJU=(>^+Q6P93>#IOV_3#ZER
M\/KH?G*F11!$,T*,E!0CQYC27N-Z';3JSFXUY INV0>H@VFLU5+Y6Y/XJE</
M!T4LC9LMIM((;K$UTJ!J5![P'*J,\1RR(Y,F%\?A;O=ORJ1UJ^6WV;28ZA]_
M7Q?3-XMW7XL4BK+XK!XVLV]E99$&KJ'+7Q809(@Z@96CQ DOB<2B0@4I?6]6
M4 8M7EWL[QGK89,EI5)1NYHUZ9+C-@Y@/Y+3Q\_G&P>,I6#6>LBX!]1ZC)Y6
M>:F:W;>]'8;U28N#>94ZQ'ZP")[I?V[7F](/_V&9CJ@7#[-Y$9%[&M&'97>K
M8A]?%[!A# )OM%:4,(<! 7"/K%<>YT0QC]#<&Y#5(Y#64//@>=Z(^/.\V&=P
M5(_+U6;VKTN2>!QK'H3&#B&M/$S7%" W$.AJY$#R'+?$"%??ZY+G1%J0CN0S
MV K]K(OO/OG98A*!3%$(Z[)4O9VMRVP(IS2#IJ\(W'.C-+&$(<$,(U:Q2@&+
MH+"<!-@C7$E'Q=">9#042_\VF2W*&J?%^MW"?4_@;&?K+[OCT^1K.$'/LVV#
M<MI"+@&-(P1:(:10Y:7RGF?%GC2WN^6.EXOB<XI?^'68V;5XKAO#>'$P8>!:
M$YU.6R!55&B#I:\GG*$@Y\+$" -N1T6]3B0RV-'F=CU;%.MU[.K'N'RGGKXO
M(NAQM9C_>(K^_;":Q'$\E$:AFD[+5,Z3>5K?Y\M4T66M'OX[SJ]9%3V\C[D_
M=3.NYV\.G@ K@1*.>!2-")S\\?7\IB3GOMS%<:U#A/Z-:@Z,2[A#3:82V3+C
M\')EE]N/FT_;^3[OURE-]U2SH*&'SCK*J+'4* $\J9<-2U1.0-(H(UA'1>,.
M)3-82JOB\>MR-5G]V$6-Q]ZN2KLQ@3F-OTL_E[6XGH ^0<T6;PO42>\%!"Q.
M4JUIA-I7L1Y>:Y/CV1IC0:(Q\;5_<0U%X[IDW%-/Z_#R4VOIR79!8H ]%R+J
M7AXB8XGCMIZRCMU;^:(Q4;-+P0QXLK4JHB)OB]W?SY QDZ^SS63>X/2@^4N"
MM1H93:%C"&*F+:;2UUH-S+HE.<;*1F.B9V]2NAY7*T4E0EO,OIVY--&D>5!.
M4,V=$EPC1;1WAI#=R#E0BF451&KIT?K0.TW[8,99\F6#?SW:O5E\BZ@N5[.3
M%;Y/M@LXQ5-PII!E7%!.D2"N&JMS,"=DJ;E+?T#7Z54XUA[P*^Z_Z>;KT_I?
MUDV\;.\]\()@&$WIMRF6S"&*0=P]<#5Z(O#=>>JO0K<.D+_^7OK[Y$?KC73?
M-@"GI-%>H[B@4\HPEEQ58^94Y'AT1NB:O^KVV0[R*R]O+SJ?#ORC';^-$IU-
M/L[FI;Y[^9K7Y*T!L%1:5C'-D@SBG"24U3J&R;*/1Y@+XGK+8 _"&%^\<2=Q
MQL%1(0%TWD'CF(^Z2%1,:A0TS+D_=WGT>DJ4<R]Q<KW)X,I,?%/F-NHH\OW$
MRT+<0PC56.MDD-&4XY'6N@MV-&<?'V'<4?^1[]UA/10#TRC*$\HHIA1"_>RT
M\@353K0*%&D4E12(9!PMXL@Y5!OY3L@[N]S7)Q&6?8$^ON6MDV4M1'U&,^P@
MM PCQ!F,FTF% D DIR+-Y<O9M3;:/JC7FPRNS,0ZW+.+C?;$RX+$%B+DA5.I
MU'=4=HCW3^H'SJF@/N8+C+UMM-UA/10#_RB^[G*5K=]]2G>!4X:)O8GV6S*K
MWGV<SSZ?O6MVP5L"5YP2#8%%#G.JF(AV6(4#8VZ8;.M#'W7TR9>7)5%ZD\6
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M#" >Y=@1(XSAN Z1.A;"4%OB$^W795*__01XJFZ]6UU/[8Q-7Q$ 0THP:13
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M=CG9ZD=H(>4)^ Q;6B':.OQPEYAJLIC^^S;]\':Y*8[O+&=:!,4!81I29Z#
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MC_ @;A3J::X4QK!(/DN1W79]?/Z*@*CS6*5S=L\MX5Y#5$6B.*Y85O3M"&\
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M,#$W,#8S,%]D968N>&UL4$L! A0#%     @ )HT52^:5<"3UK0  \^,( !4
M             ( !N,L! '!R<&\M,C Q-S V,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( ":-%4N6Q\4/^HX  !4_!P 5              "  >!Y @!P<G!O+3(P
D,3<P-C,P7W!R92YX;6Q02P4&      8 !@"* 0  #0D#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
